0	Implant-based	_	_	O
1	reconstruction	_	_	O
2	is	_	_	O
3	performed	_	_	O
4	in	_	_	O
5	the	_	_	O
6	majority	_	_	O
7	of	_	_	O
8	women	_	_	O
9	offered	_	_	O
10	primary	_	_	O
11	reconstruction	_	_	O
12	for	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	Two	_	_	O
17	different	_	_	O
18	expander	_	_	O
19	implants	_	_	O
20	were	_	_	O
21	compared	_	_	O
22	prospectively	_	_	O
23	.	_	_	O

24	The	_	_	O
25	primary	_	_	O
26	endpoint	_	_	O
27	was	_	_	O
28	the	_	_	O
29	number	_	_	O
30	of	_	_	O
31	operations	_	_	O
32	needed	_	_	O
33	in	_	_	O
34	each	_	_	O
35	group	_	_	O
36	to	_	_	O
37	obtain	_	_	O
38	patient	_	_	O
39	satisfaction	_	_	O
40	.	_	_	O

41	Secondary	_	_	O
42	endpoints	_	_	O
43	were	_	_	O
44	evaluation	_	_	O
45	of	_	_	O
46	breast	_	_	O
47	volume	_	_	O
48	and	_	_	O
49	shape	_	_	O
50	and	_	_	O
51	aspects	_	_	O
52	of	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	.	_	_	O

57	Seventy	_	_	O
58	consecutive	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	either	_	_	O
66	a	_	_	O
67	one-stage	_	_	O
68	reconstruction	_	_	O
69	with	_	_	O
70	a	_	_	O
71	round	_	_	O
72	permanent	_	_	O
73	expander	_	_	O
74	implant	_	_	O
75	(	_	_	O
76	Becker	_	_	O
77	25	_	_	O
78	;	_	_	O
79	n=35	_	_	O
80	)	_	_	O
81	or	_	_	O
82	a	_	_	O
83	two-stage	_	_	O
84	reconstruction	_	_	O
85	with	_	_	O
86	a	_	_	O
87	crescent-shaped	_	_	O
88	expander	_	_	O
89	(	_	_	O
90	LV	_	_	O
91	133	_	_	O
92	;	_	_	O
93	n=35	_	_	O
94	)	_	_	O
95	,	_	_	O
96	later	_	_	O
97	replaced	_	_	O
98	by	_	_	O
99	a	_	_	O
100	form-stable	_	_	O
101	anatomical	_	_	O
102	implant	_	_	O
103	.	_	_	O

104	Thirty	_	_	O
105	patients	_	_	O
106	had	_	_	O
107	to	_	_	O
108	be	_	_	O
109	excluded	_	_	O
110	and	_	_	O
111	40	_	_	O
112	patients	_	_	O
113	,	_	_	O
114	20	_	_	O
115	in	_	_	O
116	each	_	_	O
117	group	_	_	O
118	,	_	_	O
119	were	_	_	O
120	evaluated	_	_	O
121	.	_	_	O

122	The	_	_	O
123	median	_	_	O
124	follow-up	_	_	O
125	for	_	_	O
126	both	_	_	O
127	groups	_	_	O
128	was	_	_	O
129	3.5	_	_	O
130	years	_	_	O
131	(	_	_	O
132	range	_	_	O
133	,	_	_	O
134	1.5	_	_	O
135	to	_	_	O
136	5	_	_	O
137	years	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Plastic	_	_	O
141	cups	_	_	O
142	,	_	_	O
143	plastic	_	_	O
144	casts	_	_	O
145	,	_	_	O
146	and	_	_	O
147	two	_	_	O
148	-and	_	_	O
149	three-dimensional	_	_	O
150	scanning	_	_	O
151	techniques	_	_	O
152	were	_	_	O
153	used	_	_	O
154	for	_	_	O
155	objective	_	_	O
156	assessment	_	_	O
157	of	_	_	O
158	breast	_	_	O
159	volume	_	_	O
160	and	_	_	O
161	shape	_	_	O
162	.	_	_	O

163	The	_	_	O
164	aesthetic	_	_	O
165	outcome	_	_	O
166	was	_	_	O
167	evaluated	_	_	O
168	by	_	_	O
169	a	_	_	O
170	panel	_	_	O
171	of	_	_	O
172	experts	_	_	O
173	and	_	_	O
174	lay	_	_	O
175	people	_	_	O
176	,	_	_	O
177	and	_	_	O
178	by	_	_	O
179	the	_	_	O
180	patients	_	_	O
181	.	_	_	O

182	Quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	was	_	_	O
186	evaluated	_	_	O
187	with	_	_	O
188	a	_	_	O
189	validated	_	_	O
190	questionnaire	_	_	O
191	(	_	_	O
192	36-Item	_	_	O
193	Short	_	_	O
194	Form	_	_	O
195	Health	_	_	O
196	Survey	_	_	O
197	)	_	_	O
198	.	_	_	O

199	Of	_	_	B-Premise
200	the	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	one-stage	_	_	I-Premise
205	group	_	_	I-Premise
206	,	_	_	I-Premise
207	70	_	_	I-Premise
208	percent	_	_	I-Premise
209	had	_	_	I-Premise
210	revision	_	_	I-Premise
211	surgery	_	_	I-Premise
212	,	_	_	I-Premise
213	mostly	_	_	I-Premise
214	because	_	_	I-Premise
215	of	_	_	I-Premise
216	upper	_	_	I-Premise
217	pole	_	_	I-Premise
218	fullness	_	_	I-Premise
219	and	_	_	I-Premise
220	poor	_	_	I-Premise
221	ptosis	_	_	I-Premise
222	.	_	_	I-Premise

223	These	_	_	O
224	findings	_	_	O
225	agreed	_	_	O
226	with	_	_	O
227	the	_	_	O
228	data	_	_	O
229	from	_	_	O
230	the	_	_	O
231	two-dimensional	_	_	O
232	scanning	_	_	O
233	and	_	_	O
234	from	_	_	O
235	the	_	_	O
236	expert	_	_	O
237	panel	_	_	O
238	and	_	_	O
239	the	_	_	O
240	patients	_	_	O
241	'	_	_	O
242	subjective	_	_	O
243	judgment	_	_	O
244	.	_	_	O

245	Quality	_	_	B-Premise
246	of	_	_	I-Premise
247	life	_	_	I-Premise
248	was	_	_	I-Premise
249	similar	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	two	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Claim
256	permanent	_	_	I-Claim
257	expander	_	_	I-Claim
258	method	_	_	I-Claim
259	failed	_	_	I-Claim
260	significantly	_	_	I-Claim
261	as	_	_	I-Claim
262	a	_	_	I-Claim
263	one-stage	_	_	I-Claim
264	procedure	_	_	I-Claim
265	.	_	_	I-Claim

266	The	_	_	B-Claim
267	crescent	_	_	I-Claim
268	two-stage	_	_	I-Claim
269	method	_	_	I-Claim
270	gave	_	_	I-Claim
271	the	_	_	I-Claim
272	most	_	_	I-Claim
273	acceptable	_	_	I-Claim
274	results	_	_	I-Claim
275	both	_	_	I-Claim
276	objectively	_	_	I-Claim
277	and	_	_	I-Claim
278	subjectively	_	_	I-Claim
279	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	course	_	_	O
5	,	_	_	O
6	treatment	_	_	O
7	,	_	_	O
8	complications	_	_	O
9	,	_	_	O
10	outcome	_	_	O
11	,	_	_	O
12	and	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	perineal/perianal	_	_	O
23	rhabdomyosarcoma	_	_	O
24	(	_	_	O
25	PRMS	_	_	O
26	)	_	_	O
27	treated	_	_	O
28	within	_	_	O
29	the	_	_	O
30	CWS-86	_	_	O
31	,	_	_	O
32	-91	_	_	O
33	,	_	_	O
34	-96	_	_	O
35	,	_	_	O
36	and	_	_	O
37	-2002P	_	_	O
38	trials	_	_	O
39	.	_	_	O

40	Although	_	_	O
41	multiple	_	_	O
42	international	_	_	O
43	study	_	_	O
44	trials	_	_	O
45	exist	_	_	O
46	for	_	_	O
47	the	_	_	O
48	treatment	_	_	O
49	of	_	_	O
50	rhabdomyosarcoma	_	_	O
51	,	_	_	O
52	only	_	_	O
53	very	_	_	O
54	limited	_	_	O
55	information	_	_	O
56	is	_	_	O
57	given	_	_	O
58	on	_	_	O
59	treatment	_	_	O
60	,	_	_	O
61	outcome	_	_	O
62	,	_	_	O
63	and	_	_	O
64	QOL	_	_	O
65	in	_	_	O
66	PRMS	_	_	O
67	.	_	_	O

68	A	_	_	O
69	total	_	_	O
70	of	_	_	O
71	35	_	_	O
72	patients	_	_	O
73	suffering	_	_	O
74	from	_	_	O
75	PRMS	_	_	O
76	were	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	neoadjuvant	_	_	O
80	chemotherapy	_	_	O
81	.	_	_	O

82	Local	_	_	O
83	therapy	_	_	O
84	with	_	_	O
85	radiation	_	_	O
86	and/or	_	_	O
87	surgery	_	_	O
88	was	_	_	O
89	performed	_	_	O
90	,	_	_	O
91	followed	_	_	O
92	by	_	_	O
93	adjuvant	_	_	O
94	chemotherapy	_	_	O
95	.	_	_	O

96	Functional	_	_	O
97	long-term	_	_	O
98	follow-up	_	_	O
99	was	_	_	O
100	evaluated	_	_	O
101	by	_	_	O
102	a	_	_	O
103	gastrointestinal/QOL	_	_	O
104	survey	_	_	O
105	.	_	_	O

106	Thirty-two	_	_	O
107	patients	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	(	_	_	O
111	exclusion	_	_	O
112	n	_	_	O
113	=	_	_	O
114	3	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Eight	_	_	O
118	patients	_	_	O
119	had	_	_	O
120	embryonal	_	_	O
121	histology	_	_	O
122	,	_	_	O
123	and	_	_	O
124	24	_	_	O
125	patients	_	_	O
126	had	_	_	O
127	alveolar	_	_	O
128	histology	_	_	O
129	.	_	_	O

130	The	_	_	O
131	median	_	_	O
132	age	_	_	O
133	was	_	_	O
134	108	_	_	O
135	months	_	_	O
136	(	_	_	O
137	median	_	_	O
138	follow-up	_	_	O
139	:	_	_	O
140	5.8	_	_	O
141	years	_	_	O
142	)	_	_	O
143	.	_	_	O

144	The	_	_	O
145	5-year	_	_	O
146	overall	_	_	O
147	survival	_	_	O
148	was	_	_	O
149	47	_	_	O
150	%	_	_	O
151	(	_	_	O
152	95	_	_	O
153	%	_	_	O
154	confidence	_	_	O
155	interval	_	_	O
156	:	_	_	O
157	29-64	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Sixteen	_	_	O
161	IRS	_	_	O
162	(	_	_	O
163	Intergroup	_	_	O
164	Rhabdomyosarcoma	_	_	O
165	Study	_	_	O
166	)	_	_	O
167	III	_	_	O
168	and	_	_	O
169	IV	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	locoregional	_	_	O
173	lymph	_	_	O
174	node	_	_	O
175	involvement	_	_	O
176	at	_	_	O
177	diagnosis	_	_	O
178	.	_	_	O

179	Seven	_	_	O
180	patients	_	_	O
181	were	_	_	O
182	treated	_	_	O
183	with	_	_	O
184	chemotherapy/surgery	_	_	O
185	alone	_	_	O
186	[	_	_	O
187	5-year	_	_	O
188	event-free	_	_	O
189	survival	_	_	O
190	(	_	_	O
191	EFS	_	_	O
192	)	_	_	O
193	:	_	_	O
194	85.7	_	_	O
195	%	_	_	O
196	]	_	_	O
197	.	_	_	O

198	Eleven	_	_	O
199	patients	_	_	O
200	received	_	_	O
201	only	_	_	O
202	radiochemotherapy	_	_	O
203	(	_	_	O
204	5-year	_	_	O
205	EFS	_	_	O
206	:	_	_	O
207	27.3	_	_	O
208	%	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Combined	_	_	O
212	radiochemotherapy/surgery	_	_	O
213	was	_	_	O
214	used	_	_	O
215	in	_	_	O
216	12	_	_	O
217	patients	_	_	O
218	(	_	_	O
219	5-year	_	_	O
220	EFS	_	_	O
221	:	_	_	O
222	63.6	_	_	O
223	%	_	_	O
224	)	_	_	O
225	.	_	_	O

226	Two	_	_	O
227	patients	_	_	O
228	were	_	_	O
229	treated	_	_	O
230	only	_	_	O
231	with	_	_	O
232	chemotherapy	_	_	O
233	and	_	_	O
234	they	_	_	O
235	died	_	_	O
236	.	_	_	O

237	Patients	_	_	B-Premise
238	with	_	_	I-Premise
239	embryonal	_	_	I-Premise
240	histology	_	_	I-Premise
241	had	_	_	I-Premise
242	a	_	_	I-Premise
243	significantly	_	_	I-Premise
244	better	_	_	I-Premise
245	5-year	_	_	I-Premise
246	EFS	_	_	I-Premise
247	(	_	_	I-Premise
248	87.5	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	than	_	_	I-Premise
252	patients	_	_	I-Premise
253	with	_	_	I-Premise
254	alveolar	_	_	I-Premise
255	histology	_	_	I-Premise
256	(	_	_	I-Premise
257	39.1	_	_	I-Premise
258	%	_	_	I-Premise
259	;	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	0.013	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Some	_	_	B-Premise
266	patients	_	_	I-Premise
267	reported	_	_	I-Premise
268	symptoms	_	_	I-Premise
269	of	_	_	I-Premise
270	fecal	_	_	I-Premise
271	incontinence	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	median	_	_	I-Premise
275	Wexner	_	_	I-Premise
276	fecal	_	_	I-Premise
277	incontinence	_	_	I-Premise
278	score	_	_	I-Premise
279	was	_	_	I-Premise
280	9	_	_	I-Premise
281	(	_	_	I-Premise
282	possible	_	_	I-Premise
283	range	_	_	I-Premise
284	:	_	_	I-Premise
285	0-20	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	the	_	_	I-Premise
290	median	_	_	I-Premise
291	QOL	_	_	I-Premise
292	score	_	_	I-Premise
293	was	_	_	I-Premise
294	90.5	_	_	I-Premise
295	(	_	_	I-Premise
296	applicable	_	_	I-Premise
297	range	_	_	I-Premise
298	:	_	_	I-Premise
299	0-144	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	The	_	_	B-Claim
303	outcome	_	_	I-Claim
304	of	_	_	I-Claim
305	these	_	_	I-Claim
306	patients	_	_	I-Claim
307	remains	_	_	I-Claim
308	unsatisfactory	_	_	I-Claim
309	.	_	_	I-Claim

310	Prognostic	_	_	B-Premise
311	factors	_	_	I-Premise
312	for	_	_	I-Premise
313	a	_	_	I-Premise
314	favorable	_	_	I-Premise
315	outcome	_	_	I-Premise
316	are	_	_	I-Premise
317	tumor	_	_	I-Premise
318	size	_	_	I-Premise
319	of	_	_	I-Premise
320	smaller	_	_	I-Premise
321	than	_	_	I-Premise
322	5	_	_	I-Premise
323	cm	_	_	I-Premise
324	,	_	_	I-Premise
325	negative	_	_	I-Premise
326	locoregional	_	_	I-Premise
327	lymph	_	_	I-Premise
328	nodes	_	_	I-Premise
329	,	_	_	I-Premise
330	age	_	_	I-Premise
331	less	_	_	I-Premise
332	than	_	_	I-Premise
333	10	_	_	I-Premise
334	years	_	_	I-Premise
335	,	_	_	I-Premise
336	low	_	_	I-Premise
337	IRS	_	_	I-Premise
338	group	_	_	I-Premise
339	,	_	_	I-Premise
340	and	_	_	I-Premise
341	embryonal	_	_	I-Premise
342	histology	_	_	I-Premise
343	.	_	_	I-Premise

344	Fecal	_	_	B-Claim
345	incontinence	_	_	I-Claim
346	seems	_	_	I-Claim
347	to	_	_	I-Claim
348	be	_	_	I-Claim
349	a	_	_	I-Claim
350	problem	_	_	I-Claim
351	.	_	_	I-Claim


0	Phase	_	_	B-Claim
1	II	_	_	I-Claim
2	and	_	_	I-Claim
3	III	_	_	I-Claim
4	studies	_	_	I-Claim
5	have	_	_	I-Claim
6	shown	_	_	I-Claim
7	that	_	_	I-Claim
8	the	_	_	I-Claim
9	addition	_	_	I-Claim
10	of	_	_	I-Claim
11	interleukin-2	_	_	I-Claim
12	(	_	_	I-Claim
13	IL-2	_	_	I-Claim
14	)	_	_	I-Claim
15	and	_	_	I-Claim
16	interferon	_	_	I-Claim
17	alpha-2b	_	_	I-Claim
18	(	_	_	I-Claim
19	IFN	_	_	I-Claim
20	alpha-2b	_	_	I-Claim
21	)	_	_	I-Claim
22	in	_	_	I-Claim
23	multiagent	_	_	I-Claim
24	chemotherapy	_	_	I-Claim
25	(	_	_	I-Claim
26	CT	_	_	I-Claim
27	)	_	_	I-Claim
28	for	_	_	I-Claim
29	advanced	_	_	I-Claim
30	melanoma	_	_	I-Claim
31	increases	_	_	I-Claim
32	overall	_	_	I-Claim
33	response	_	_	I-Claim
34	(	_	_	I-Claim
35	OR	_	_	I-Claim
36	)	_	_	I-Claim
37	,	_	_	I-Claim
38	albeit	_	_	I-Claim
39	without	_	_	I-Claim
40	clear	_	_	I-Claim
41	evidence	_	_	I-Claim
42	of	_	_	I-Claim
43	an	_	_	I-Claim
44	improvement	_	_	I-Claim
45	in	_	_	I-Claim
46	overall	_	_	I-Claim
47	survival	_	_	I-Claim
48	(	_	_	I-Claim
49	OS	_	_	I-Claim
50	)	_	_	I-Claim
51	.	_	_	I-Claim

52	Treatment	_	_	B-Claim
53	with	_	_	I-Claim
54	high-dose	_	_	I-Claim
55	IL-2	_	_	I-Claim
56	can	_	_	I-Claim
57	cause	_	_	I-Claim
58	severe	_	_	I-Claim
59	toxicity	_	_	I-Claim
60	and	_	_	I-Claim
61	is	_	_	I-Claim
62	normally	_	_	I-Claim
63	administered	_	_	I-Claim
64	in	_	_	I-Claim
65	an	_	_	I-Claim
66	inpatient	_	_	I-Claim
67	setting	_	_	I-Claim
68	.	_	_	I-Claim

69	We	_	_	O
70	conducted	_	_	O
71	a	_	_	O
72	multicenter	_	_	O
73	prospective	_	_	O
74	randomized	_	_	O
75	clinical	_	_	O
76	trial	_	_	O
77	in	_	_	O
78	outpatients	_	_	O
79	with	_	_	O
80	metastatic	_	_	O
81	melanoma	_	_	O
82	to	_	_	O
83	compare	_	_	O
84	CT	_	_	O
85	with	_	_	O
86	biochemotherapy	_	_	O
87	(	_	_	O
88	bioCT	_	_	O
89	)	_	_	O
90	using	_	_	O
91	immunomodulant	_	_	O
92	doses	_	_	O
93	of	_	_	O
94	IL-2	_	_	O
95	and	_	_	O
96	IFN	_	_	O
97	alpha-2b	_	_	O
98	.	_	_	O

99	One	_	_	O
100	hundred	_	_	O
101	seventy-six	_	_	O
102	eligible	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	advanced	_	_	O
106	melanoma	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	CT	_	_	O
112	(	_	_	O
113	cisplatin	_	_	O
114	and	_	_	O
115	dacarbazine	_	_	O
116	with	_	_	O
117	or	_	_	O
118	without	_	_	O
119	carmustine	_	_	O
120	every	_	_	O
121	21	_	_	O
122	days	_	_	O
123	)	_	_	O
124	or	_	_	O
125	bioCT	_	_	O
126	comprising	_	_	O
127	the	_	_	O
128	same	_	_	O
129	CT	_	_	O
130	regimen	_	_	O
131	followed	_	_	O
132	by	_	_	O
133	low-dose	_	_	O
134	subcutaneous	_	_	O
135	IL-2	_	_	O
136	for	_	_	O
137	8	_	_	O
138	days	_	_	O
139	and	_	_	O
140	IFN	_	_	O
141	alpha-2b	_	_	O
142	three	_	_	O
143	times	_	_	O
144	a	_	_	O
145	week	_	_	O
146	,	_	_	O
147	both	_	_	O
148	for	_	_	O
149	six	_	_	O
150	cycles	_	_	O
151	.	_	_	O

152	At	_	_	B-Premise
153	a	_	_	I-Premise
154	median	_	_	I-Premise
155	follow-up	_	_	I-Premise
156	of	_	_	I-Premise
157	18	_	_	I-Premise
158	(	_	_	I-Premise
159	CT	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	16	_	_	I-Premise
163	(	_	_	I-Premise
164	bioCT	_	_	I-Premise
165	)	_	_	I-Premise
166	months	_	_	I-Premise
167	,	_	_	I-Premise
168	median	_	_	I-Premise
169	OS	_	_	I-Premise
170	was	_	_	I-Premise
171	9.5	_	_	I-Premise
172	versus	_	_	I-Premise
173	11.0	_	_	I-Premise
174	months	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=.51	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	respectively	_	_	I-Premise
181	.	_	_	I-Premise

182	In	_	_	B-Premise
183	the	_	_	I-Premise
184	89	_	_	I-Premise
185	CT-arm	_	_	I-Premise
186	patients	_	_	I-Premise
187	,	_	_	I-Premise
188	18	_	_	I-Premise
189	ORs	_	_	I-Premise
190	(	_	_	I-Premise
191	20.2	_	_	I-Premise
192	%	_	_	I-Premise
193	)	_	_	I-Premise
194	(	_	_	I-Premise
195	three	_	_	I-Premise
196	complete	_	_	I-Premise
197	responders	_	_	I-Premise
198	[	_	_	I-Premise
199	CRs	_	_	I-Premise
200	]	_	_	I-Premise
201	and	_	_	I-Premise
202	15	_	_	I-Premise
203	partial	_	_	I-Premise
204	responders	_	_	I-Premise
205	[	_	_	I-Premise
206	PRs	_	_	I-Premise
207	]	_	_	I-Premise
208	)	_	_	I-Premise
209	were	_	_	I-Premise
210	observed	_	_	I-Premise
211	according	_	_	I-Premise
212	to	_	_	I-Premise
213	World	_	_	I-Premise
214	Health	_	_	I-Premise
215	Organization	_	_	I-Premise
216	criteria	_	_	I-Premise
217	.	_	_	I-Premise

218	In	_	_	B-Premise
219	the	_	_	I-Premise
220	87	_	_	I-Premise
221	bioCT-arm	_	_	I-Premise
222	patients	_	_	I-Premise
223	,	_	_	I-Premise
224	22	_	_	I-Premise
225	ORs	_	_	I-Premise
226	(	_	_	I-Premise
227	25.3	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	(	_	_	I-Premise
231	three	_	_	I-Premise
232	CRs	_	_	I-Premise
233	and	_	_	I-Premise
234	19	_	_	I-Premise
235	PRs	_	_	I-Premise
236	)	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	=.70	_	_	I-Premise
240	)	_	_	I-Premise
241	were	_	_	I-Premise
242	recorded	_	_	I-Premise
243	.	_	_	I-Premise

244	Treatment-related	_	_	B-Premise
245	toxicity	_	_	I-Premise
246	was	_	_	I-Premise
247	fairly	_	_	I-Premise
248	similar	_	_	I-Premise
249	in	_	_	I-Premise
250	both	_	_	I-Premise
251	arms	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Claim
254	addition	_	_	I-Claim
255	of	_	_	I-Claim
256	low-dose	_	_	I-Claim
257	immunotherapy	_	_	I-Claim
258	did	_	_	I-Claim
259	not	_	_	I-Claim
260	produce	_	_	I-Claim
261	a	_	_	I-Claim
262	statistically	_	_	I-Claim
263	significant	_	_	I-Claim
264	advantage	_	_	I-Claim
265	in	_	_	I-Claim
266	OS	_	_	I-Claim
267	,	_	_	I-Claim
268	time	_	_	I-Claim
269	to	_	_	I-Claim
270	progression	_	_	I-Claim
271	,	_	_	I-Claim
272	or	_	_	I-Claim
273	OR	_	_	I-Claim
274	.	_	_	I-Claim

275	However	_	_	B-Claim
276	,	_	_	I-Claim
277	the	_	_	I-Claim
278	11-month	_	_	I-Claim
279	median	_	_	I-Claim
280	OS	_	_	I-Claim
281	in	_	_	I-Claim
282	the	_	_	I-Claim
283	bioCT	_	_	I-Claim
284	arm	_	_	I-Claim
285	does	_	_	I-Claim
286	not	_	_	I-Claim
287	differ	_	_	I-Claim
288	greatly	_	_	I-Claim
289	from	_	_	I-Claim
290	the	_	_	I-Claim
291	best	_	_	I-Claim
292	results	_	_	I-Claim
293	with	_	_	I-Claim
294	high-dose	_	_	I-Claim
295	IL-2-containing	_	_	I-Claim
296	regimens	_	_	I-Claim
297	reported	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	literature	_	_	I-Claim
301	.	_	_	I-Claim

302	Furthermore	_	_	O
303	,	_	_	O
304	our	_	_	B-Claim
305	treatment	_	_	I-Claim
306	schedule	_	_	I-Claim
307	was	_	_	I-Claim
308	carried	_	_	I-Claim
309	out	_	_	I-Claim
310	on	_	_	I-Claim
311	outpatients	_	_	I-Claim
312	and	_	_	I-Claim
313	had	_	_	I-Claim
314	an	_	_	I-Claim
315	acceptable	_	_	I-Claim
316	level	_	_	I-Claim
317	of	_	_	I-Claim
318	toxicity	_	_	I-Claim
319	.	_	_	I-Claim


0	SIR-Spheres	_	_	O
1	are	_	_	O
2	radioactive	_	_	O
3	yttrium90	_	_	O
4	microspheres	_	_	O
5	(	_	_	O
6	SIR-Spheres	_	_	O
7	,	_	_	O
8	Sirtex	_	_	O
9	Medical	_	_	O
10	Limited	_	_	O
11	,	_	_	O
12	Australia	_	_	O
13	)	_	_	O
14	used	_	_	O
15	to	_	_	O
16	selectively	_	_	O
17	target	_	_	O
18	high	_	_	O
19	levels	_	_	O
20	of	_	_	O
21	ionising	_	_	O
22	radiation	_	_	O
23	to	_	_	O
24	tumors	_	_	O
25	within	_	_	O
26	the	_	_	O
27	liver	_	_	O
28	.	_	_	O

29	This	_	_	O
30	trial	_	_	O
31	was	_	_	O
32	designed	_	_	O
33	to	_	_	O
34	measure	_	_	O
35	any	_	_	O
36	increased	_	_	O
37	patient	_	_	O
38	benefit	_	_	O
39	by	_	_	O
40	adding	_	_	O
41	a	_	_	O
42	single	_	_	O
43	administration	_	_	O
44	of	_	_	O
45	SIR-Spheres	_	_	O
46	to	_	_	O
47	a	_	_	O
48	regimen	_	_	O
49	of	_	_	O
50	regional	_	_	O
51	hepatic	_	_	O
52	artery	_	_	O
53	chemotherapy	_	_	O
54	(	_	_	O
55	HAC	_	_	O
56	)	_	_	O
57	administered	_	_	O
58	as	_	_	O
59	a	_	_	O
60	12	_	_	O
61	day	_	_	O
62	infusion	_	_	O
63	of	_	_	O
64	floxuridine	_	_	O
65	and	_	_	O
66	repeated	_	_	O
67	at	_	_	O
68	monthly	_	_	O
69	intervals	_	_	O
70	,	_	_	O
71	vs.	_	_	O
72	the	_	_	O
73	same	_	_	O
74	chemotherapy	_	_	O
75	alone	_	_	O
76	.	_	_	O

77	A	_	_	O
78	phase	_	_	O
79	III	_	_	O
80	randomised	_	_	O
81	clinical	_	_	O
82	trial	_	_	O
83	entering	_	_	O
84	74	_	_	O
85	patients	_	_	O
86	was	_	_	O
87	undertaken	_	_	O
88	on	_	_	O
89	patients	_	_	O
90	with	_	_	O
91	bi-lobar	_	_	O
92	non-resectable	_	_	O
93	liver	_	_	O
94	metastases	_	_	O
95	from	_	_	O
96	primary	_	_	O
97	adenocarcinoma	_	_	O
98	of	_	_	O
99	the	_	_	O
100	large	_	_	O
101	bowel	_	_	O
102	.	_	_	O

103	Patient	_	_	O
104	benefit	_	_	O
105	criteria	_	_	O
106	assessed	_	_	O
107	in	_	_	O
108	the	_	_	O
109	trial	_	_	O
110	were	_	_	O
111	tumor	_	_	O
112	response	_	_	O
113	,	_	_	O
114	time	_	_	O
115	to	_	_	O
116	disease	_	_	O
117	progression	_	_	O
118	in	_	_	O
119	the	_	_	O
120	liver	_	_	O
121	,	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	,	_	_	O
125	quality	_	_	O
126	of	_	_	O
127	life	_	_	O
128	,	_	_	O
129	and	_	_	O
130	treatment	_	_	O
131	related	_	_	O
132	toxicity	_	_	O
133	.	_	_	O

134	Tumor	_	_	O
135	response	_	_	O
136	was	_	_	O
137	measured	_	_	O
138	by	_	_	O
139	serial	_	_	O
140	changes	_	_	O
141	in	_	_	O
142	both	_	_	O
143	cross-sectional	_	_	O
144	tumor	_	_	O
145	areas	_	_	O
146	and	_	_	O
147	total	_	_	O
148	tumor	_	_	O
149	volumes	_	_	O
150	,	_	_	O
151	provided	_	_	O
152	any	_	_	O
153	response	_	_	O
154	lasted	_	_	O
155	not	_	_	O
156	less	_	_	O
157	than	_	_	O
158	three	_	_	O
159	months	_	_	O
160	as	_	_	O
161	well	_	_	O
162	as	_	_	O
163	changes	_	_	O
164	in	_	_	O
165	serum	_	_	O
166	carcino-embryonic	_	_	O
167	antigen	_	_	O
168	(	_	_	O
169	CEA	_	_	O
170	)	_	_	O
171	.	_	_	O

172	The	_	_	B-Premise
173	partial	_	_	I-Premise
174	and	_	_	I-Premise
175	complete	_	_	I-Premise
176	response	_	_	I-Premise
177	rate	_	_	I-Premise
178	(	_	_	I-Premise
179	PR	_	_	I-Premise
180	+	_	_	I-Premise
181	CR	_	_	I-Premise
182	)	_	_	I-Premise
183	was	_	_	I-Premise
184	significantly	_	_	I-Premise
185	greater	_	_	I-Premise
186	for	_	_	I-Premise
187	patients	_	_	I-Premise
188	receiving	_	_	I-Premise
189	SIR-Spheres	_	_	I-Premise
190	when	_	_	I-Premise
191	measured	_	_	I-Premise
192	by	_	_	I-Premise
193	tumor	_	_	I-Premise
194	areas	_	_	I-Premise
195	(	_	_	I-Premise
196	44	_	_	I-Premise
197	%	_	_	I-Premise
198	)	_	_	I-Premise
199	vs.	_	_	I-Premise
200	17.6	_	_	I-Premise
201	%	_	_	I-Premise
202	,	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	0.01	_	_	I-Premise
206	)	_	_	I-Premise
207	tumor	_	_	I-Premise
208	volumes	_	_	I-Premise
209	(	_	_	I-Premise
210	50	_	_	I-Premise
211	%	_	_	I-Premise
212	vs.	_	_	I-Premise
213	24	_	_	I-Premise
214	%	_	_	I-Premise
215	,	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.03	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	CEA	_	_	I-Premise
222	(	_	_	I-Premise
223	72	_	_	I-Premise
224	%	_	_	I-Premise
225	vs.	_	_	I-Premise
226	47	_	_	I-Premise
227	%	_	_	I-Premise
228	,	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	0.004	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	median	_	_	I-Premise
236	time	_	_	I-Premise
237	to	_	_	I-Premise
238	disease	_	_	I-Premise
239	progression	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	liver	_	_	I-Premise
243	was	_	_	I-Premise
244	significantly	_	_	I-Premise
245	longer	_	_	I-Premise
246	for	_	_	I-Premise
247	patients	_	_	I-Premise
248	receiving	_	_	I-Premise
249	SIR-Spheres	_	_	I-Premise
250	in	_	_	I-Premise
251	comparison	_	_	I-Premise
252	to	_	_	I-Premise
253	patients	_	_	I-Premise
254	receiving	_	_	I-Premise
255	HAC	_	_	I-Premise
256	alone	_	_	I-Premise
257	when	_	_	I-Premise
258	measured	_	_	I-Premise
259	by	_	_	I-Premise
260	either	_	_	I-Premise
261	tumor	_	_	I-Premise
262	areas	_	_	I-Premise
263	(	_	_	I-Premise
264	9.7	_	_	I-Premise
265	vs.	_	_	I-Premise
266	15.9	_	_	I-Premise
267	months	_	_	I-Premise
268	,	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.001	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	tumor	_	_	I-Premise
275	volumes	_	_	I-Premise
276	(	_	_	I-Premise
277	7.6	_	_	I-Premise
278	vs.	_	_	I-Premise
279	12.0	_	_	I-Premise
280	months	_	_	I-Premise
281	,	_	_	I-Premise
282	P	_	_	I-Premise
283	=	_	_	I-Premise
284	0.04	_	_	I-Premise
285	)	_	_	I-Premise
286	or	_	_	I-Premise
287	CEA	_	_	I-Premise
288	(	_	_	I-Premise
289	5.7	_	_	I-Premise
290	vs.	_	_	I-Premise
291	6.7	_	_	I-Premise
292	months	_	_	I-Premise
293	,	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	0.06	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	The	_	_	B-Premise
300	one	_	_	I-Premise
301	,	_	_	I-Premise
302	two	_	_	I-Premise
303	,	_	_	I-Premise
304	three	_	_	I-Premise
305	and	_	_	I-Premise
306	five-year	_	_	I-Premise
307	survival	_	_	I-Premise
308	for	_	_	I-Premise
309	patients	_	_	I-Premise
310	receiving	_	_	I-Premise
311	SIR-Spheres	_	_	I-Premise
312	was	_	_	I-Premise
313	72	_	_	I-Premise
314	%	_	_	I-Premise
315	,	_	_	I-Premise
316	39	_	_	I-Premise
317	%	_	_	I-Premise
318	,	_	_	I-Premise
319	17	_	_	I-Premise
320	%	_	_	I-Premise
321	and	_	_	I-Premise
322	3.5	_	_	I-Premise
323	%	_	_	I-Premise
324	,	_	_	I-Premise
325	compared	_	_	I-Premise
326	to	_	_	I-Premise
327	68	_	_	I-Premise
328	%	_	_	I-Premise
329	,	_	_	I-Premise
330	29	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	6.5	_	_	I-Premise
334	%	_	_	I-Premise
335	and	_	_	I-Premise
336	0	_	_	I-Premise
337	%	_	_	I-Premise
338	for	_	_	I-Premise
339	HAC	_	_	I-Premise
340	alone	_	_	I-Premise
341	.	_	_	I-Premise

342	Cox	_	_	B-Premise
343	regression	_	_	I-Premise
344	analysis	_	_	I-Premise
345	suggests	_	_	I-Premise
346	an	_	_	I-Premise
347	improvement	_	_	I-Premise
348	in	_	_	I-Premise
349	survival	_	_	I-Premise
350	for	_	_	I-Premise
351	patients	_	_	I-Premise
352	treated	_	_	I-Premise
353	with	_	_	I-Premise
354	SIR-Spheres	_	_	I-Premise
355	who	_	_	I-Premise
356	survive	_	_	I-Premise
357	more	_	_	I-Premise
358	than	_	_	I-Premise
359	15	_	_	I-Premise
360	months	_	_	I-Premise
361	(	_	_	I-Premise
362	P	_	_	I-Premise
363	=	_	_	I-Premise
364	0.06	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	There	_	_	B-Premise
368	was	_	_	I-Premise
369	no	_	_	I-Premise
370	increase	_	_	I-Premise
371	in	_	_	I-Premise
372	grade	_	_	I-Premise
373	3-4	_	_	I-Premise
374	treatment	_	_	I-Premise
375	related	_	_	I-Premise
376	toxicity	_	_	I-Premise
377	and	_	_	I-Premise
378	no	_	_	I-Premise
379	loss	_	_	I-Premise
380	of	_	_	I-Premise
381	quality	_	_	I-Premise
382	of	_	_	I-Premise
383	life	_	_	I-Premise
384	for	_	_	I-Premise
385	patients	_	_	I-Premise
386	receiving	_	_	I-Premise
387	SIR-Spheres	_	_	I-Premise
388	in	_	_	I-Premise
389	comparison	_	_	I-Premise
390	to	_	_	I-Premise
391	patients	_	_	I-Premise
392	receiving	_	_	I-Premise
393	HAC	_	_	I-Premise
394	alone	_	_	I-Premise
395	.	_	_	I-Premise

396	The	_	_	B-Claim
397	combination	_	_	I-Claim
398	of	_	_	I-Claim
399	a	_	_	I-Claim
400	single	_	_	I-Claim
401	injection	_	_	I-Claim
402	of	_	_	I-Claim
403	SIR-Spheres	_	_	I-Claim
404	plus	_	_	I-Claim
405	HAC	_	_	I-Claim
406	is	_	_	I-Claim
407	substantially	_	_	I-Claim
408	more	_	_	I-Claim
409	effective	_	_	I-Claim
410	in	_	_	I-Claim
411	increasing	_	_	I-Claim
412	tumor	_	_	I-Claim
413	responses	_	_	I-Claim
414	and	_	_	I-Claim
415	progression	_	_	I-Claim
416	free	_	_	I-Claim
417	survival	_	_	I-Claim
418	than	_	_	I-Claim
419	the	_	_	I-Claim
420	same	_	_	I-Claim
421	regimen	_	_	I-Claim
422	of	_	_	I-Claim
423	HAC	_	_	I-Claim
424	alone	_	_	I-Claim
425	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	response	_	_	O
9	rate	_	_	O
10	,	_	_	O
11	clinical	_	_	O
12	outcome	_	_	O
13	,	_	_	O
14	organ/function	_	_	O
15	preservation	_	_	O
16	and	_	_	O
17	toxicity	_	_	O
18	in	_	_	O
19	head	_	_	O
20	and	_	_	O
21	neck	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	treated	_	_	O
25	with	_	_	O
26	induction	_	_	O
27	chemotherapy	_	_	O
28	followed	_	_	O
29	by	_	_	O
30	concomitant	_	_	O
31	chemoradiotherapy	_	_	O
32	and	_	_	O
33	,	_	_	O
34	when	_	_	O
35	necessary	_	_	O
36	,	_	_	O
37	limited	_	_	O
38	surgery	_	_	O
39	.	_	_	O

40	The	_	_	O
41	study	_	_	O
42	design	_	_	O
43	was	_	_	O
44	a	_	_	O
45	phase	_	_	O
46	II	_	_	O
47	non-randomized	_	_	O
48	trial	_	_	O
49	in	_	_	O
50	hospitalized	_	_	O
51	patients	_	_	O
52	setting	_	_	O
53	.	_	_	O

54	The	_	_	O
55	treatment	_	_	O
56	plan	_	_	O
57	consisted	_	_	O
58	of	_	_	O
59	3	_	_	O
60	cycles	_	_	O
61	of	_	_	O
62	induction	_	_	O
63	chemotherapy	_	_	O
64	with	_	_	O
65	cisplatin	_	_	O
66	,	_	_	O
67	fluorouracil	_	_	O
68	(	_	_	O
69	5-FU	_	_	O
70	)	_	_	O
71	,	_	_	O
72	l-leucovorin	_	_	O
73	and	_	_	O
74	interferon	_	_	O
75	alpha2b	_	_	O
76	(	_	_	O
77	PFL-IFN	_	_	O
78	)	_	_	O
79	followed	_	_	O
80	by	_	_	O
81	7	_	_	O
82	cycles	_	_	O
83	of	_	_	O
84	5-FU	_	_	O
85	,	_	_	O
86	hydroxyurea	_	_	O
87	and	_	_	O
88	concomitant	_	_	O
89	radiation	_	_	O
90	for	_	_	O
91	5	_	_	O
92	days	_	_	O
93	(	_	_	O
94	FHX	_	_	O
95	)	_	_	O
96	for	_	_	O
97	a	_	_	O
98	total	_	_	O
99	radiation	_	_	O
100	dose	_	_	O
101	of	_	_	O
102	70	_	_	O
103	Gy	_	_	O
104	.	_	_	O

105	13	_	_	O
106	Cis-retinoic	_	_	O
107	acid	_	_	O
108	was	_	_	O
109	added	_	_	O
110	to	_	_	O
111	treatment	_	_	O
112	regimen	_	_	O
113	for	_	_	O
114	chemoprevention	_	_	O
115	and	_	_	O
116	a	_	_	O
117	systematic	_	_	O
118	prophylaxis	_	_	O
119	of	_	_	O
120	mucositis	_	_	O
121	was	_	_	O
122	administered	_	_	O
123	to	_	_	O
124	all	_	_	O
125	patients	_	_	O
126	during	_	_	O
127	FHX	_	_	O
128	.	_	_	O

129	Conservative	_	_	O
130	surgical	_	_	O
131	resection	_	_	O
132	was	_	_	O
133	reserved	_	_	O
134	to	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	no	_	_	O
138	optimal	_	_	O
139	response	_	_	O
140	(	_	_	O
141	PR	_	_	O
142	>	_	_	O
143	or	_	_	O
144	=70	_	_	O
145	%	_	_	O
146	)	_	_	O
147	,	_	_	O
148	whereas	_	_	O
149	radical	_	_	O
150	surgery	_	_	O
151	was	_	_	O
152	performed	_	_	O
153	as	_	_	O
154	salvage	_	_	O
155	treatment	_	_	O
156	.	_	_	O

157	Twenty-six	_	_	O
158	patients	_	_	O
159	were	_	_	O
160	treated	_	_	O
161	at	_	_	O
162	one	_	_	O
163	institution	_	_	O
164	:	_	_	O
165	more	_	_	O
166	than	_	_	O
167	90	_	_	O
168	%	_	_	O
169	had	_	_	O
170	stage	_	_	O
171	IV	_	_	O
172	disease	_	_	O
173	and	_	_	O
174	only	_	_	O
175	19.2	_	_	O
176	%	_	_	O
177	had	_	_	O
178	laryngeal	_	_	O
179	cancer	_	_	O
180	.	_	_	O

181	Eighty-one	_	_	O
182	percent	_	_	O
183	of	_	_	O
184	patients	_	_	O
185	had	_	_	O
186	performance	_	_	O
187	status	_	_	O
188	0	_	_	O
189	and	_	_	O
190	23.1	_	_	O
191	%	_	_	O
192	of	_	_	O
193	patients	_	_	O
194	had	_	_	O
195	>	_	_	O
196	5	_	_	O
197	%	_	_	O
198	weight	_	_	O
199	loss	_	_	O
200	at	_	_	O
201	the	_	_	O
202	start	_	_	O
203	of	_	_	O
204	treatment	_	_	O
205	.	_	_	O

206	Nineteen	_	_	O
207	patients	_	_	O
208	were	_	_	O
209	analyzed	_	_	O
210	for	_	_	O
211	response	_	_	O
212	to	_	_	O
213	PFL-IFN	_	_	O
214	:	_	_	O
215	3/19	_	_	O
216	(	_	_	O
217	15.8	_	_	O
218	%	_	_	O
219	)	_	_	O
220	patients	_	_	O
221	achieved	_	_	O
222	a	_	_	O
223	CR	_	_	O
224	and	_	_	O
225	7/19	_	_	O
226	(	_	_	O
227	36.8	_	_	O
228	%	_	_	O
229	)	_	_	O
230	achieved	_	_	O
231	a	_	_	O
232	PR	_	_	O
233	for	_	_	O
234	an	_	_	O
235	ORR	_	_	O
236	of	_	_	O
237	52.6	_	_	O
238	%	_	_	O
239	.	_	_	O

240	FHX	_	_	O
241	was	_	_	O
242	administered	_	_	O
243	on	_	_	O
244	protocol	_	_	O
245	to	_	_	O
246	12	_	_	O
247	patients	_	_	O
248	:	_	_	O
249	6	_	_	O
250	patients	_	_	O
251	(	_	_	O
252	50	_	_	O
253	%	_	_	O
254	)	_	_	O
255	had	_	_	O
256	CR	_	_	O
257	,	_	_	O
258	1	_	_	O
259	patient	_	_	O
260	(	_	_	O
261	8.3	_	_	O
262	%	_	_	O
263	)	_	_	O
264	had	_	_	O
265	PR	_	_	O
266	for	_	_	O
267	an	_	_	O
268	ORR	_	_	O
269	of	_	_	O
270	58.3	_	_	O
271	%	_	_	O
272	,	_	_	O
273	2	_	_	O
274	patients	_	_	O
275	(	_	_	O
276	16.7	_	_	O
277	%	_	_	O
278	)	_	_	O
279	had	_	_	O
280	SD	_	_	O
281	and	_	_	O
282	3	_	_	O
283	patients	_	_	O
284	(	_	_	O
285	25	_	_	O
286	%	_	_	O
287	)	_	_	O
288	had	_	_	O
289	PD	_	_	O
290	.	_	_	O

291	At	_	_	O
292	the	_	_	O
293	completion	_	_	O
294	of	_	_	O
295	FHX	_	_	O
296	,	_	_	O
297	no	_	_	O
298	patient	_	_	O
299	underwent	_	_	O
300	local	_	_	O
301	therapy	_	_	O
302	according	_	_	O
303	to	_	_	O
304	treatment	_	_	O
305	plan	_	_	O
306	.	_	_	O

307	At	_	_	B-Premise
308	a	_	_	I-Premise
309	median	_	_	I-Premise
310	follow-up	_	_	I-Premise
311	time	_	_	I-Premise
312	of	_	_	I-Premise
313	13.5	_	_	I-Premise
314	months	_	_	I-Premise
315	(	_	_	I-Premise
316	range	_	_	I-Premise
317	1-28+	_	_	I-Premise
318	)	_	_	I-Premise
319	at	_	_	I-Premise
320	June	_	_	I-Premise
321	2001	_	_	I-Premise
322	,	_	_	I-Premise
323	among	_	_	I-Premise
324	26	_	_	I-Premise
325	patients	_	_	I-Premise
326	enrolled	_	_	I-Premise
327	12	_	_	I-Premise
328	(	_	_	I-Premise
329	46.1	_	_	I-Premise
330	%	_	_	I-Premise
331	)	_	_	I-Premise
332	were	_	_	I-Premise
333	still	_	_	I-Premise
334	alive	_	_	I-Premise
335	and	_	_	I-Premise
336	9	_	_	I-Premise
337	(	_	_	I-Premise
338	75	_	_	I-Premise
339	%	_	_	I-Premise
340	)	_	_	I-Premise
341	of	_	_	I-Premise
342	them	_	_	I-Premise
343	were	_	_	I-Premise
344	progression-free	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	median	_	_	I-Premise
348	duration	_	_	I-Premise
349	of	_	_	I-Premise
350	response	_	_	I-Premise
351	was	_	_	I-Premise
352	9	_	_	I-Premise
353	months	_	_	I-Premise
354	(	_	_	I-Premise
355	range	_	_	I-Premise
356	0-25+	_	_	I-Premise
357	)	_	_	I-Premise
358	,	_	_	I-Premise
359	the	_	_	I-Premise
360	median	_	_	I-Premise
361	progression-free	_	_	I-Premise
362	survival	_	_	I-Premise
363	was	_	_	I-Premise
364	10.5	_	_	I-Premise
365	months	_	_	I-Premise
366	(	_	_	I-Premise
367	range	_	_	I-Premise
368	0-28+	_	_	I-Premise
369	)	_	_	I-Premise
370	,	_	_	I-Premise
371	the	_	_	I-Premise
372	median	_	_	I-Premise
373	overall	_	_	I-Premise
374	survival	_	_	I-Premise
375	time	_	_	I-Premise
376	was	_	_	I-Premise
377	9	_	_	I-Premise
378	months	_	_	I-Premise
379	(	_	_	I-Premise
380	range	_	_	I-Premise
381	1-22	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	The	_	_	B-Premise
385	toxicity	_	_	I-Premise
386	was	_	_	I-Premise
387	significant	_	_	I-Premise
388	and	_	_	I-Premise
389	consisted	_	_	I-Premise
390	mainly	_	_	I-Premise
391	of	_	_	I-Premise
392	mucositis	_	_	I-Premise
393	and	_	_	I-Premise
394	,	_	_	I-Premise
395	to	_	_	I-Premise
396	a	_	_	I-Premise
397	lesser	_	_	I-Premise
398	extent	_	_	I-Premise
399	,	_	_	I-Premise
400	neutropenia/thrombocytopenia	_	_	I-Premise
401	.	_	_	I-Premise

402	In	_	_	O
403	the	_	_	O
404	present	_	_	O
405	study	_	_	O
406	,	_	_	O
407	the	_	_	B-Claim
408	low	_	_	I-Claim
409	serum	_	_	I-Claim
410	levels	_	_	I-Claim
411	of	_	_	I-Claim
412	leptin	_	_	I-Claim
413	and	_	_	I-Claim
414	the	_	_	I-Claim
415	high	_	_	I-Claim
416	serum	_	_	I-Claim
417	levels	_	_	I-Claim
418	of	_	_	I-Claim
419	proinflammatory	_	_	I-Claim
420	cytokines	_	_	I-Claim
421	in	_	_	I-Claim
422	advanced	_	_	I-Claim
423	stage	_	_	I-Claim
424	cancer	_	_	I-Claim
425	patients	_	_	I-Claim
426	were	_	_	I-Claim
427	confirmed	_	_	I-Claim
428	.	_	_	I-Claim

429	In	_	_	O
430	conclusion	_	_	O
431	,	_	_	O
432	this	_	_	B-Claim
433	sequential	_	_	I-Claim
434	induction	_	_	I-Claim
435	chemotherapy	_	_	I-Claim
436	and	_	_	I-Claim
437	chemoradiotherapy	_	_	I-Claim
438	program	_	_	I-Claim
439	has	_	_	I-Claim
440	been	_	_	I-Claim
441	found	_	_	I-Claim
442	moderately	_	_	I-Claim
443	active	_	_	I-Claim
444	and	_	_	I-Claim
445	significantly	_	_	I-Claim
446	toxic	_	_	I-Claim
447	;	_	_	I-Claim
448	moreover	_	_	O
449	,	_	_	O
450	the	_	_	O
451	long	_	_	O
452	overall	_	_	O
453	treatment	_	_	O
454	duration	_	_	O
455	must	_	_	O
456	be	_	_	O
457	taken	_	_	O
458	into	_	_	O
459	consideration	_	_	O
460	.	_	_	O

461	For	_	_	O
462	these	_	_	O
463	reasons	_	_	O
464	,	_	_	O
465	this	_	_	B-Claim
466	regimen	_	_	I-Claim
467	could	_	_	I-Claim
468	not	_	_	I-Claim
469	be	_	_	I-Claim
470	recommended	_	_	I-Claim
471	for	_	_	I-Claim
472	a	_	_	I-Claim
473	phase	_	_	I-Claim
474	III	_	_	I-Claim
475	randomized	_	_	I-Claim
476	study	_	_	I-Claim
477	.	_	_	I-Claim


0	Intermittent	_	_	O
1	dosing	_	_	O
2	may	_	_	O
3	reduce	_	_	O
4	the	_	_	O
5	adverse	_	_	O
6	events	_	_	O
7	(	_	_	O
8	AEs	_	_	O
9	)	_	_	O
10	of	_	_	O
11	androgen-deprivation	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	ADT	_	_	O
15	)	_	_	O
16	.	_	_	O

17	To	_	_	O
18	compare	_	_	O
19	intermittent	_	_	O
20	androgen	_	_	O
21	deprivation	_	_	O
22	(	_	_	O
23	IAD	_	_	O
24	)	_	_	O
25	and	_	_	O
26	continuous	_	_	O
27	androgen	_	_	O
28	deprivation	_	_	O
29	(	_	_	O
30	CAD	_	_	O
31	)	_	_	O
32	with	_	_	O
33	regard	_	_	O
34	to	_	_	O
35	health-related	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	(	_	_	O
40	QoL	_	_	O
41	)	_	_	O
42	.	_	_	O

43	A	_	_	O
44	total	_	_	O
45	of	_	_	O
46	852	_	_	O
47	men	_	_	O
48	with	_	_	O
49	advanced	_	_	O
50	prostate	_	_	O
51	cancer	_	_	O
52	(	_	_	O
53	PCa	_	_	O
54	)	_	_	O
55	were	_	_	O
56	enrolled	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	goserelin	_	_	O
60	acetate	_	_	O
61	3.6	_	_	O
62	mg	_	_	O
63	every	_	_	O
64	28	_	_	O
65	d	_	_	O
66	for	_	_	O
67	24	_	_	O
68	wk	_	_	O
69	.	_	_	O

70	A	_	_	O
71	total	_	_	O
72	of	_	_	O
73	554	_	_	O
74	patients	_	_	O
75	whose	_	_	O
76	prostate-specific	_	_	O
77	antigen	_	_	O
78	(	_	_	O
79	PSA	_	_	O
80	)	_	_	O
81	decreased	_	_	O
82	to	_	_	O
83	<	_	_	O
84	10	_	_	O
85	ng/ml	_	_	O
86	or	_	_	O
87	by	_	_	O
88	â‰¥50	_	_	O
89	%	_	_	O
90	(	_	_	O
91	<	_	_	O
92	20	_	_	O
93	ng/ml	_	_	O
94	at	_	_	O
95	baseline	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomised	_	_	O
99	to	_	_	O
100	IAD	_	_	O
101	or	_	_	O
102	CAD	_	_	O
103	.	_	_	O

104	In	_	_	O
105	the	_	_	O
106	IAD	_	_	O
107	arm	_	_	O
108	,	_	_	O
109	ADT	_	_	O
110	was	_	_	O
111	resumed	_	_	O
112	for	_	_	O
113	at	_	_	O
114	least	_	_	O
115	24	_	_	O
116	wk	_	_	O
117	whenever	_	_	O
118	PSA	_	_	O
119	increased	_	_	O
120	>	_	_	O
121	20	_	_	O
122	ng/ml	_	_	O
123	or	_	_	O
124	above	_	_	O
125	baseline	_	_	O
126	.	_	_	O

127	QoL	_	_	O
128	was	_	_	O
129	monitored	_	_	O
130	with	_	_	O
131	a	_	_	O
132	validated	_	_	O
133	Cleary	_	_	O
134	30-item	_	_	O
135	questionnaire	_	_	O
136	and	_	_	O
137	analysed	_	_	O
138	by	_	_	O
139	the	_	_	O
140	Mann-Whitney	_	_	O
141	U	_	_	O
142	test	_	_	O
143	,	_	_	O
144	0.5	_	_	O
145	standard	_	_	O
146	deviation	_	_	O
147	rule	_	_	O
148	,	_	_	O
149	and	_	_	O
150	repeated	_	_	O
151	measures	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	variance	_	_	O
155	.	_	_	O

156	AEs	_	_	O
157	and	_	_	O
158	adverse	_	_	O
159	drug	_	_	O
160	reactions	_	_	O
161	(	_	_	O
162	ADRs	_	_	O
163	)	_	_	O
164	were	_	_	O
165	analysed	_	_	O
166	by	_	_	O
167	the	_	_	O
168	chi-square	_	_	O
169	test	_	_	O
170	.	_	_	O

171	Median	_	_	O
172	follow-up	_	_	O
173	was	_	_	O
174	65	_	_	O
175	mo	_	_	O
176	.	_	_	O

177	Significant	_	_	B-Premise
178	differences	_	_	I-Premise
179	in	_	_	I-Premise
180	QoL	_	_	I-Premise
181	emerged	_	_	I-Premise
182	in	_	_	I-Premise
183	activity	_	_	I-Premise
184	limitation	_	_	I-Premise
185	,	_	_	I-Premise
186	physical	_	_	I-Premise
187	capacity	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	sexual	_	_	I-Premise
191	functioning	_	_	I-Premise
192	,	_	_	I-Premise
193	favouring	_	_	I-Premise
194	IAD	_	_	I-Premise
195	.	_	_	I-Premise

196	No	_	_	B-Premise
197	significant	_	_	I-Premise
198	differences	_	_	I-Premise
199	emerged	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	prevalence	_	_	I-Premise
203	of	_	_	I-Premise
204	AEs	_	_	I-Premise
205	:	_	_	I-Premise
206	87	_	_	I-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	IAD	_	_	I-Premise
211	arm	_	_	I-Premise
212	(	_	_	I-Premise
213	31.8	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	95	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	CAD	_	_	I-Premise
221	arm	_	_	I-Premise
222	(	_	_	I-Premise
223	33.9	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	had	_	_	I-Premise
227	cardiovascular	_	_	I-Premise
228	(	_	_	I-Premise
229	CV	_	_	I-Premise
230	)	_	_	I-Premise
231	AEs	_	_	I-Premise
232	(	_	_	I-Premise
233	p=0.59	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	with	_	_	I-Premise
237	25	_	_	I-Premise
238	(	_	_	I-Premise
239	9.1	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	and	_	_	I-Premise
243	29	_	_	I-Premise
244	(	_	_	I-Premise
245	10.4	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	withdrawn	_	_	I-Premise
249	(	_	_	I-Premise
250	p=0.62	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	and	_	_	I-Premise
254	21	_	_	I-Premise
255	(	_	_	I-Premise
256	7.7	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	and	_	_	I-Premise
260	24	_	_	I-Premise
261	(	_	_	I-Premise
262	8.6	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	dying	_	_	I-Premise
266	because	_	_	I-Premise
267	of	_	_	I-Premise
268	a	_	_	I-Premise
269	CV	_	_	I-Premise
270	event	_	_	I-Premise
271	(	_	_	I-Premise
272	p=0.70	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	respectively	_	_	I-Premise
276	;	_	_	I-Premise
277	bone	_	_	B-Premise
278	fractures	_	_	I-Premise
279	occurred	_	_	I-Premise
280	in	_	_	I-Premise
281	19	_	_	I-Premise
282	(	_	_	I-Premise
283	6.9	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	and	_	_	I-Premise
287	15	_	_	I-Premise
288	(	_	_	I-Premise
289	5.4	_	_	I-Premise
290	%	_	_	I-Premise
291	)	_	_	I-Premise
292	patients	_	_	I-Premise
293	(	_	_	I-Premise
294	p=0.44	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	respectively	_	_	I-Premise
298	.	_	_	I-Premise

299	Hot	_	_	B-Premise
300	flushes	_	_	I-Premise
301	or	_	_	I-Premise
302	night	_	_	I-Premise
303	sweats	_	_	I-Premise
304	were	_	_	I-Premise
305	the	_	_	I-Premise
306	most	_	_	I-Premise
307	common	_	_	I-Premise
308	ADRs	_	_	I-Premise
309	(	_	_	I-Premise
310	47.1	_	_	I-Premise
311	%	_	_	I-Premise
312	vs	_	_	I-Premise
313	50.4	_	_	I-Premise
314	%	_	_	I-Premise
315	;	_	_	I-Premise
316	p=0.44	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Erectile	_	_	B-Premise
320	dysfunction	_	_	I-Premise
321	(	_	_	I-Premise
322	15.7	_	_	I-Premise
323	%	_	_	I-Premise
324	vs	_	_	I-Premise
325	7.9	_	_	I-Premise
326	%	_	_	I-Premise
327	;	_	_	I-Premise
328	p=0.042	_	_	I-Premise
329	)	_	_	I-Premise
330	and	_	_	I-Premise
331	depressed	_	_	I-Premise
332	mood	_	_	I-Premise
333	(	_	_	I-Premise
334	2.2	_	_	I-Premise
335	vs	_	_	I-Premise
336	0	_	_	I-Premise
337	%	_	_	I-Premise
338	;	_	_	I-Premise
339	p=0.032	_	_	I-Premise
340	)	_	_	I-Premise
341	were	_	_	I-Premise
342	more	_	_	I-Premise
343	common	_	_	I-Premise
344	in	_	_	I-Premise
345	the	_	_	I-Premise
346	IAD	_	_	I-Premise
347	arm	_	_	I-Premise
348	.	_	_	I-Premise

349	IAD	_	_	B-Claim
350	showed	_	_	I-Claim
351	benefits	_	_	I-Claim
352	in	_	_	I-Claim
353	the	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	advanced	_	_	I-Claim
357	PCa	_	_	I-Claim
358	with	_	_	I-Claim
359	respect	_	_	I-Claim
360	to	_	_	I-Claim
361	QoL	_	_	I-Claim
362	.	_	_	I-Claim

363	The	_	_	B-Claim
364	prevalence	_	_	I-Claim
365	of	_	_	I-Claim
366	AEs	_	_	I-Claim
367	was	_	_	I-Claim
368	not	_	_	I-Claim
369	significantly	_	_	I-Claim
370	lower	_	_	I-Claim
371	with	_	_	I-Claim
372	IAD	_	_	I-Claim
373	.	_	_	I-Claim


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	(	_	_	O
4	QoL	_	_	O
5	)	_	_	O
6	after	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	is	_	_	O
10	nowadays	_	_	O
11	a	_	_	O
12	major	_	_	O
13	challenge	_	_	O
14	.	_	_	O

15	Complementary	_	_	O
16	interventions	_	_	O
17	are	_	_	O
18	necessary	_	_	O
19	because	_	_	O
20	of	_	_	O
21	frequent	_	_	O
22	depression	_	_	O
23	symptoms	_	_	O
24	after	_	_	O
25	treatment	_	_	O
26	and	_	_	O
27	also	_	_	O
28	to	_	_	O
29	favour	_	_	O
30	return	_	_	O
31	to	_	_	O
32	activity	_	_	O
33	.	_	_	O

34	Besides	_	_	O
35	,	_	_	O
36	radio-chemotherapy	_	_	O
37	has	_	_	O
38	side-effects	_	_	O
39	like	_	_	O
40	weight	_	_	O
41	gain	_	_	O
42	and	_	_	O
43	fatigue	_	_	O
44	.	_	_	O

45	Several	_	_	O
46	strategies	_	_	O
47	including	_	_	O
48	group	_	_	O
49	behavioural-educational	_	_	O
50	interventions	_	_	O
51	,	_	_	O
52	physical	_	_	O
53	training	_	_	O
54	and/or	_	_	O
55	dietary	_	_	O
56	education	_	_	O
57	,	_	_	O
58	have	_	_	O
59	been	_	_	O
60	tested	_	_	O
61	to	_	_	O
62	answer	_	_	O
63	these	_	_	O
64	difficulties	_	_	O
65	with	_	_	O
66	moderate	_	_	O
67	success	_	_	O
68	in	_	_	O
69	the	_	_	O
70	long	_	_	O
71	run	_	_	O
72	.	_	_	O

73	Two	_	_	O
74	hundred	_	_	O
75	and	_	_	O
76	fifty-one	_	_	O
77	non-metastatic	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	accrued	_	_	O
81	after	_	_	O
82	chemotherapy	_	_	O
83	in	_	_	O
84	a	_	_	O
85	prospective	_	_	O
86	randomised	_	_	O
87	multicenter	_	_	O
88	trial	_	_	O
89	between	_	_	O
90	2008	_	_	O
91	and	_	_	O
92	2010	_	_	O
93	,	_	_	O
94	testing	_	_	O
95	a	_	_	O
96	2-week	_	_	O
97	intervention	_	_	O
98	in	_	_	O
99	SPA	_	_	O
100	centres	_	_	O
101	.	_	_	O

102	Intervention	_	_	O
103	comprised	_	_	O
104	group	_	_	O
105	physical	_	_	O
106	training	_	_	O
107	,	_	_	O
108	dietary	_	_	O
109	education	_	_	O
110	and	_	_	O
111	physiotherapy	_	_	O
112	.	_	_	O

113	Selected	_	_	O
114	patients	_	_	O
115	were	_	_	O
116	in	_	_	O
117	complete	_	_	O
118	remission	_	_	O
119	.	_	_	O

120	QoL	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	with	_	_	O
124	SF36	_	_	O
125	questionnaire	_	_	O
126	,	_	_	O
127	anxiety	_	_	O
128	and	_	_	O
129	depression	_	_	O
130	with	_	_	O
131	the	_	_	O
132	hospital	_	_	O
133	anxiety	_	_	O
134	and	_	_	O
135	depression	_	_	O
136	(	_	_	O
137	HAD	_	_	O
138	)	_	_	O
139	one	_	_	O
140	.	_	_	O

141	Anthropometric	_	_	O
142	measures	_	_	O
143	and	_	_	O
144	QoL	_	_	O
145	evaluations	_	_	O
146	were	_	_	O
147	obtained	_	_	O
148	before	_	_	O
149	randomisation	_	_	O
150	and	_	_	O
151	every	_	_	O
152	6	_	_	O
153	months	_	_	O
154	during	_	_	O
155	3	_	_	O
156	years	_	_	O
157	.	_	_	O

158	Two	_	_	O
159	hundred	_	_	O
160	and	_	_	O
161	twenty	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	evaluable	_	_	O
165	at	_	_	O
166	1	_	_	O
167	year	_	_	O
168	.	_	_	O

169	Intervention	_	_	B-Premise
170	increased	_	_	I-Premise
171	SF36	_	_	I-Premise
172	score	_	_	I-Premise
173	by	_	_	I-Premise
174	9.5	_	_	I-Premise
175	points	_	_	I-Premise
176	(	_	_	I-Premise
177	p=0.000006	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	4.6	_	_	I-Premise
181	(	_	_	I-Premise
182	p=0.032	_	_	I-Premise
183	)	_	_	I-Premise
184	and	_	_	I-Premise
185	6.2	_	_	I-Premise
186	(	_	_	I-Premise
187	p=0.028	_	_	I-Premise
188	)	_	_	I-Premise
189	respectively	_	_	I-Premise
190	at	_	_	I-Premise
191	6	_	_	I-Premise
192	,	_	_	I-Premise
193	12	_	_	I-Premise
194	and	_	_	I-Premise
195	24	_	_	I-Premise
196	months	_	_	I-Premise
197	.	_	_	I-Premise

198	Effect	_	_	B-Premise
199	size	_	_	I-Premise
200	(	_	_	I-Premise
201	ES	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	0.63	_	_	I-Premise
205	[	_	_	I-Premise
206	0.37	_	_	I-Premise
207	;	_	_	I-Premise
208	0.90	_	_	I-Premise
209	]	_	_	I-Premise
210	,	_	_	I-Premise
211	0.29	_	_	I-Premise
212	[	_	_	I-Premise
213	0.03	_	_	I-Premise
214	;	_	_	I-Premise
215	0.55	_	_	I-Premise
216	]	_	_	I-Premise
217	and	_	_	I-Premise
218	0.41	_	_	I-Premise
219	[	_	_	I-Premise
220	0.04	_	_	I-Premise
221	;	_	_	I-Premise
222	0.78	_	_	I-Premise
223	]	_	_	I-Premise
224	.	_	_	I-Premise

225	Anxiety	_	_	B-Premise
226	score	_	_	I-Premise
227	was	_	_	I-Premise
228	shortly	_	_	I-Premise
229	minored	_	_	I-Premise
230	by	_	_	I-Premise
231	intervention	_	_	I-Premise
232	(	_	_	I-Premise
233	6-month	_	_	I-Premise
234	ES=-0.24	_	_	I-Premise
235	[	_	_	I-Premise
236	-0.42	_	_	I-Premise
237	;	_	_	I-Premise
238	-0.05	_	_	I-Premise
239	]	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	depression	_	_	I-Premise
243	score	_	_	I-Premise
244	more	_	_	I-Premise
245	durably	_	_	I-Premise
246	:	_	_	I-Premise
247	ES=-0.45	_	_	I-Premise
248	[	_	_	I-Premise
249	-0.72	_	_	I-Premise
250	;	_	_	I-Premise
251	-0.18	_	_	I-Premise
252	]	_	_	I-Premise
253	,	_	_	I-Premise
254	-0.34	_	_	I-Premise
255	[	_	_	I-Premise
256	-061	_	_	I-Premise
257	;	_	_	I-Premise
258	-0.08	_	_	I-Premise
259	]	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	-0.26	_	_	I-Premise
263	[	_	_	I-Premise
264	-0.63	_	_	I-Premise
265	;	_	_	I-Premise
266	0.11	_	_	I-Premise
267	]	_	_	I-Premise
268	at	_	_	I-Premise
269	6	_	_	I-Premise
270	,	_	_	I-Premise
271	12	_	_	I-Premise
272	and	_	_	I-Premise
273	24	_	_	I-Premise
274	months	_	_	I-Premise
275	.	_	_	I-Premise

276	This	_	_	B-Claim
277	2-week	_	_	I-Claim
278	group	_	_	I-Claim
279	intervention	_	_	I-Claim
280	seemed	_	_	I-Claim
281	to	_	_	I-Claim
282	durably	_	_	I-Claim
283	influence	_	_	I-Claim
284	QoL	_	_	I-Claim
285	of	_	_	I-Claim
286	breast	_	_	I-Claim
287	cancer	_	_	I-Claim
288	patients	_	_	I-Claim
289	treated	_	_	I-Claim
290	by	_	_	I-Claim
291	chemotherapy	_	_	I-Claim
292	.	_	_	I-Claim

293	Differences	_	_	B-Claim
294	,	_	_	I-Claim
295	smaller	_	_	I-Claim
296	at	_	_	I-Claim
297	12	_	_	I-Claim
298	months	_	_	I-Claim
299	than	_	_	I-Claim
300	at	_	_	I-Claim
301	six	_	_	I-Claim
302	,	_	_	I-Claim
303	suggest	_	_	I-Claim
304	that	_	_	I-Claim
305	a	_	_	I-Claim
306	second	_	_	I-Claim
307	but	_	_	I-Claim
308	shorter	_	_	I-Claim
309	intervention	_	_	I-Claim
310	could	_	_	I-Claim
311	help	_	_	I-Claim
312	maintain	_	_	I-Claim
313	the	_	_	I-Claim
314	6-month	_	_	I-Claim
315	benefits	_	_	I-Claim
316	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	toxicities	_	_	O
3	,	_	_	O
4	functional	_	_	O
5	outcomes	_	_	O
6	,	_	_	O
7	and	_	_	O
8	health-related	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	associated	_	_	O
13	with	_	_	O
14	concurrent	_	_	O
15	chemoradiation	_	_	O
16	therapy	_	_	O
17	(	_	_	O
18	CRT	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	head	_	_	O
24	and	_	_	O
25	neck	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	Prospective	_	_	O
29	and	_	_	O
30	retrospective	_	_	O
31	outcomes	_	_	O
32	study	_	_	O
33	.	_	_	O

34	Tertiary	_	_	O
35	care	_	_	O
36	institution	_	_	O
37	.	_	_	O

38	Participants	_	_	O
39	in	_	_	O
40	the	_	_	O
41	longitudinal	_	_	O
42	Outcomes	_	_	O
43	Assessment	_	_	O
44	Project	_	_	O
45	whose	_	_	O
46	head	_	_	O
47	and	_	_	O
48	neck	_	_	O
49	cancer	_	_	O
50	was	_	_	O
51	treated	_	_	O
52	with	_	_	O
53	CRT	_	_	O
54	between	_	_	O
55	February	_	_	O
56	1	_	_	O
57	,	_	_	O
58	2000	_	_	O
59	,	_	_	O
60	and	_	_	O
61	March	_	_	O
62	1	_	_	O
63	,	_	_	O
64	2007	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	104	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	prospectively	_	_	O
73	provided	_	_	O
74	functional	_	_	O
75	and	_	_	O
76	health-related	_	_	O
77	quality	_	_	O
78	of	_	_	O
79	life	_	_	O
80	information	_	_	O
81	,	_	_	O
82	including	_	_	O
83	data	_	_	O
84	from	_	_	O
85	the	_	_	O
86	1-year	_	_	O
87	and	_	_	O
88	most	_	_	O
89	current	_	_	O
90	follow-up	_	_	O
91	visits	_	_	O
92	.	_	_	O

93	Medical	_	_	O
94	records	_	_	O
95	were	_	_	O
96	reviewed	_	_	O
97	to	_	_	O
98	determine	_	_	O
99	toxicity	_	_	O
100	and	_	_	O
101	survival	_	_	O
102	rates	_	_	O
103	.	_	_	O

104	Well-defined	_	_	O
105	acute	_	_	O
106	and	_	_	O
107	late	_	_	O
108	toxicities	_	_	O
109	;	_	_	O
110	functional	_	_	O
111	outcomes	_	_	O
112	(	_	_	O
113	diet	_	_	O
114	,	_	_	O
115	dentition	_	_	O
116	,	_	_	O
117	tracheostomies	_	_	O
118	)	_	_	O
119	;	_	_	O
120	head	_	_	O
121	and	_	_	O
122	neck	_	_	O
123	cancer-specific	_	_	O
124	,	_	_	O
125	general	_	_	O
126	health	_	_	O
127	,	_	_	O
128	and	_	_	O
129	depression	_	_	O
130	outcomes	_	_	O
131	;	_	_	O
132	and	_	_	O
133	survival	_	_	O
134	rates	_	_	O
135	.	_	_	O

136	Most	_	_	O
137	patients	_	_	O
138	had	_	_	O
139	oropharyngeal	_	_	O
140	or	_	_	O
141	laryngeal	_	_	O
142	tumors	_	_	O
143	(	_	_	O
144	87.5	_	_	O
145	%	_	_	O
146	)	_	_	O
147	and	_	_	O
148	advanced-stage	_	_	O
149	disease	_	_	O
150	(	_	_	O
151	75.0	_	_	O
152	%	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Approximately	_	_	B-Premise
156	one-half	_	_	I-Premise
157	had	_	_	I-Premise
158	hematologic	_	_	I-Premise
159	toxicities	_	_	I-Premise
160	and	_	_	I-Premise
161	toxicity-related	_	_	I-Premise
162	treatment	_	_	I-Premise
163	delays	_	_	I-Premise
164	.	_	_	I-Premise

165	Approximately	_	_	B-Premise
166	one-quarter	_	_	I-Premise
167	had	_	_	I-Premise
168	neurotoxicities	_	_	I-Premise
169	and/or	_	_	I-Premise
170	ototoxicites	_	_	I-Premise
171	,	_	_	I-Premise
172	moist	_	_	I-Premise
173	desquamation	_	_	I-Premise
174	,	_	_	I-Premise
175	pneumonia	_	_	I-Premise
176	,	_	_	I-Premise
177	nausea	_	_	I-Premise
178	and	_	_	I-Premise
179	vomiting	_	_	I-Premise
180	requiring	_	_	I-Premise
181	hospitalization	_	_	I-Premise
182	or	_	_	I-Premise
183	intravenous	_	_	I-Premise
184	fluids	_	_	I-Premise
185	,	_	_	I-Premise
186	dehydration	_	_	I-Premise
187	or	_	_	I-Premise
188	malnutrition	_	_	I-Premise
189	requiring	_	_	I-Premise
190	hospitalization	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	mild	_	_	I-Premise
194	or	_	_	I-Premise
195	moderate	_	_	I-Premise
196	fever	_	_	I-Premise
197	.	_	_	I-Premise

198	Although	_	_	B-Premise
199	patients	_	_	I-Premise
200	receiving	_	_	I-Premise
201	the	_	_	I-Premise
202	current	_	_	I-Premise
203	intensity-modulated	_	_	I-Premise
204	radiation	_	_	I-Premise
205	therapy	_	_	I-Premise
206	(	_	_	I-Premise
207	IMRT	_	_	I-Premise
208	)	_	_	I-Premise
209	protocol	_	_	I-Premise
210	using	_	_	I-Premise
211	the	_	_	I-Premise
212	Pinnacle	_	_	I-Premise
213	(	_	_	I-Premise
214	3	_	_	I-Premise
215	)	_	_	I-Premise
216	planning	_	_	I-Premise
217	system	_	_	I-Premise
218	had	_	_	I-Premise
219	more	_	_	I-Premise
220	toxicity-related	_	_	I-Premise
221	treatment	_	_	I-Premise
222	delays	_	_	I-Premise
223	,	_	_	I-Premise
224	they	_	_	B-Premise
225	had	_	_	I-Premise
226	fewer	_	_	I-Premise
227	toxicities	_	_	I-Premise
228	and	_	_	I-Premise
229	better	_	_	I-Premise
230	functional	_	_	I-Premise
231	and	_	_	I-Premise
232	health-related	_	_	I-Premise
233	quality	_	_	I-Premise
234	of	_	_	I-Premise
235	life	_	_	I-Premise
236	outcomes	_	_	I-Premise
237	compared	_	_	I-Premise
238	with	_	_	I-Premise
239	those	_	_	I-Premise
240	receiving	_	_	I-Premise
241	conventional	_	_	I-Premise
242	lateral	_	_	I-Premise
243	opposing-field	_	_	I-Premise
244	radiation	_	_	I-Premise
245	or	_	_	I-Premise
246	the	_	_	I-Premise
247	initial	_	_	I-Premise
248	IMRT	_	_	I-Premise
249	protocol	_	_	I-Premise
250	using	_	_	I-Premise
251	the	_	_	I-Premise
252	Best	_	_	I-Premise
253	nomos	_	_	I-Premise
254	PEACOCK	_	_	I-Premise
255	planning	_	_	I-Premise
256	system	_	_	I-Premise
257	.	_	_	I-Premise

258	Patients	_	_	B-Claim
259	receiving	_	_	I-Claim
260	CRT	_	_	I-Claim
261	experience	_	_	I-Claim
262	a	_	_	I-Claim
263	substantial	_	_	I-Claim
264	number	_	_	I-Claim
265	of	_	_	I-Claim
266	treatment-related	_	_	I-Claim
267	adverse	_	_	I-Claim
268	events	_	_	I-Claim
269	,	_	_	I-Claim
270	primarily	_	_	I-Claim
271	affecting	_	_	I-Claim
272	oropharyngeal	_	_	I-Claim
273	and	_	_	I-Claim
274	laryngeal	_	_	I-Claim
275	function	_	_	I-Claim
276	,	_	_	I-Claim
277	with	_	_	I-Claim
278	improvement	_	_	I-Claim
279	noted	_	_	I-Claim
280	for	_	_	I-Claim
281	the	_	_	I-Claim
282	current	_	_	I-Claim
283	IMRT	_	_	I-Claim
284	protocol	_	_	I-Claim
285	.	_	_	I-Claim

286	Improving	_	_	O
287	dental	_	_	O
288	prosthetic	_	_	O
289	rehabilitation	_	_	O
290	and	_	_	O
291	including	_	_	O
292	evaluations	_	_	O
293	with	_	_	O
294	speech	_	_	O
295	and	_	_	O
296	swallowing	_	_	O
297	pathologists	_	_	O
298	before	_	_	O
299	and	_	_	O
300	during	_	_	O
301	treatment	_	_	O
302	may	_	_	O
303	enhance	_	_	O
304	patient	_	_	O
305	outcomes	_	_	O
306	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	combination	_	_	O
4	of	_	_	O
5	the	_	_	O
6	gastrin	_	_	O
7	antagonist	_	_	O
8	Z-360	_	_	O
9	and	_	_	O
10	gemcitabine	_	_	O
11	for	_	_	O
12	advanced	_	_	O
13	pancreatic	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	Previously	_	_	O
17	untreated	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	PC	_	_	O
21	were	_	_	O
22	randomly	_	_	O
23	allocated	_	_	O
24	to	_	_	O
25	Z-360	_	_	O
26	120	_	_	O
27	mg	_	_	O
28	,	_	_	O
29	240	_	_	O
30	mg	_	_	O
31	or	_	_	O
32	placebo	_	_	O
33	.	_	_	O

34	Z-360/placebo	_	_	O
35	was	_	_	O
36	given	_	_	O
37	on	_	_	O
38	day	_	_	O
39	-3	_	_	O
40	and	_	_	O
41	gemcitabine	_	_	O
42	1000	_	_	O
43	mg/m	_	_	O
44	(	_	_	O
45	2	_	_	O
46	)	_	_	O
47	commenced	_	_	O
48	on	_	_	O
49	day	_	_	O
50	1	_	_	O
51	followed	_	_	O
52	by	_	_	O
53	Z-360	_	_	O
54	on	_	_	O
55	day	_	_	O
56	2	_	_	O
57	.	_	_	O

58	Thereafter	_	_	O
59	Z-360/placebo	_	_	O
60	was	_	_	O
61	given	_	_	O
62	twice	_	_	O
63	daily	_	_	O
64	concurrently	_	_	O
65	with	_	_	O
66	standard	_	_	O
67	dose	_	_	O
68	of	_	_	O
69	gemcitabine	_	_	O
70	.	_	_	O

71	Pharmacokinetics	_	_	O
72	for	_	_	O
73	both	_	_	O
74	drugs	_	_	O
75	was	_	_	O
76	measured	_	_	O
77	alone	_	_	O
78	and	_	_	O
79	in	_	_	O
80	combination	_	_	O
81	.	_	_	O

82	Toxicity	_	_	O
83	,	_	_	O
84	response	_	_	O
85	and	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	were	_	_	O
90	also	_	_	O
91	recorded	_	_	O
92	.	_	_	O

93	Thirty-three	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	a	_	_	O
97	median	_	_	O
98	age	_	_	O
99	of	_	_	O
100	62	_	_	O
101	years	_	_	O
102	were	_	_	O
103	randomised	_	_	O
104	of	_	_	O
105	which	_	_	O
106	six	_	_	O
107	had	_	_	O
108	locally	_	_	O
109	advanced	_	_	O
110	disease	_	_	O
111	and	_	_	O
112	26	_	_	O
113	had	_	_	O
114	metastatic	_	_	O
115	disease	_	_	O
116	.	_	_	O

117	Analysis	_	_	O
118	of	_	_	O
119	the	_	_	O
120	area	_	_	O
121	under	_	_	O
122	the	_	_	O
123	plasma	_	_	O
124	concentration	_	_	O
125	versus	_	_	O
126	time	_	_	O
127	curve	_	_	O
128	(	_	_	O
129	AUC	_	_	O
130	)	_	_	O
131	,	_	_	O
132	the	_	_	O
133	maximum	_	_	O
134	observed	_	_	O
135	concentration	_	_	O
136	(	_	_	O
137	Cmax	_	_	O
138	(	_	_	O
139	obs	_	_	O
140	)	_	_	O
141	)	_	_	O
142	and	_	_	O
143	the	_	_	O
144	time	_	_	O
145	of	_	_	O
146	the	_	_	O
147	maximum	_	_	O
148	observed	_	_	O
149	concentration	_	_	O
150	(	_	_	O
151	Tmax	_	_	O
152	(	_	_	O
153	obs	_	_	O
154	)	_	_	O
155	)	_	_	O
156	for	_	_	O
157	Z-360	_	_	O
158	,	_	_	O
159	gemcitabine	_	_	O
160	and	_	_	O
161	2,2-difluorodeoxyuridine	_	_	O
162	(	_	_	O
163	dFdU	_	_	O
164	)	_	_	O
165	,	_	_	O
166	could	_	_	O
167	not	_	_	O
168	exclude	_	_	O
169	an	_	_	O
170	effect	_	_	O
171	on	_	_	O
172	the	_	_	O
173	systemic	_	_	O
174	exposure	_	_	O
175	to	_	_	O
176	Z-360	_	_	O
177	,	_	_	O
178	gemcitabine	_	_	O
179	and	_	_	O
180	dFdU	_	_	O
181	when	_	_	O
182	co-administration	_	_	O
183	of	_	_	O
184	Z-360	_	_	O
185	and	_	_	O
186	gemcitabine	_	_	O
187	was	_	_	O
188	compared	_	_	O
189	with	_	_	O
190	single	_	_	O
191	agent	_	_	O
192	administration	_	_	O
193	.	_	_	O

194	The	_	_	B-Premise
195	most	_	_	I-Premise
196	commonly	_	_	I-Premise
197	reported	_	_	I-Premise
198	adverse	_	_	I-Premise
199	events	_	_	I-Premise
200	were	_	_	I-Premise
201	nausea	_	_	I-Premise
202	,	_	_	I-Premise
203	abdominal	_	_	I-Premise
204	pain	_	_	I-Premise
205	,	_	_	I-Premise
206	vomiting	_	_	I-Premise
207	and	_	_	I-Premise
208	fatigue	_	_	I-Premise
209	.	_	_	I-Premise

210	At	_	_	B-Premise
211	the	_	_	I-Premise
212	end	_	_	I-Premise
213	of	_	_	I-Premise
214	the	_	_	I-Premise
215	study	_	_	I-Premise
216	,	_	_	I-Premise
217	62.5	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	25	_	_	I-Premise
221	%	_	_	I-Premise
222	and	_	_	I-Premise
223	60	_	_	I-Premise
224	%	_	_	I-Premise
225	had	_	_	I-Premise
226	stable	_	_	I-Premise
227	disease	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	120	_	_	I-Premise
231	mg	_	_	I-Premise
232	,	_	_	I-Premise
233	240	_	_	I-Premise
234	mg	_	_	I-Premise
235	and	_	_	I-Premise
236	placebo	_	_	I-Premise
237	group	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	.	_	_	I-Premise

241	A	_	_	B-Premise
242	higher	_	_	I-Premise
243	proportion	_	_	I-Premise
244	of	_	_	I-Premise
245	patients	_	_	I-Premise
246	in	_	_	I-Premise
247	Z-360	_	_	I-Premise
248	groups	_	_	I-Premise
249	reported	_	_	I-Premise
250	improvement	_	_	I-Premise
251	in	_	_	I-Premise
252	pain	_	_	I-Premise
253	.	_	_	I-Premise

254	Z-360	_	_	B-Claim
255	is	_	_	I-Claim
256	safe	_	_	I-Claim
257	and	_	_	I-Claim
258	well	_	_	I-Claim
259	tolerated	_	_	I-Claim
260	when	_	_	I-Claim
261	combined	_	_	I-Claim
262	with	_	_	I-Claim
263	gemcitabine	_	_	I-Claim
264	.	_	_	I-Claim

265	A	_	_	O
266	Phase	_	_	O
267	III	_	_	O
268	trial	_	_	O
269	is	_	_	O
270	needed	_	_	O
271	to	_	_	O
272	determine	_	_	O
273	whether	_	_	O
274	the	_	_	O
275	combination	_	_	O
276	of	_	_	O
277	Z-360	_	_	O
278	and	_	_	O
279	gemcitabine	_	_	O
280	is	_	_	O
281	superior	_	_	O
282	to	_	_	O
283	gemcitabine	_	_	O
284	alone	_	_	O
285	in	_	_	O
286	advanced	_	_	O
287	PC	_	_	O
288	.	_	_	O


0	Oral	_	_	O
1	etoposide	_	_	O
2	is	_	_	O
3	an	_	_	O
4	active	_	_	O
5	single	_	_	O
6	agent	_	_	O
7	in	_	_	O
8	small-cell	_	_	O
9	lung	_	_	O
10	cancer	_	_	O
11	(	_	_	O
12	SCLC	_	_	O
13	)	_	_	O
14	and	_	_	O
15	is	_	_	O
16	widely	_	_	O
17	prescribed	_	_	O
18	as	_	_	O
19	first-line	_	_	O
20	treatment	_	_	O
21	as	_	_	O
22	an	_	_	O
23	alternative	_	_	O
24	to	_	_	O
25	intravenous	_	_	O
26	combination	_	_	O
27	chemotherapy	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	extensive	_	_	O
32	disease	_	_	O
33	.	_	_	O

34	The	_	_	O
35	intention	_	_	O
36	of	_	_	O
37	this	_	_	O
38	study	_	_	O
39	was	_	_	O
40	to	_	_	O
41	determine	_	_	O
42	if	_	_	O
43	the	_	_	O
44	effects	_	_	O
45	of	_	_	O
46	oral	_	_	O
47	etoposide	_	_	O
48	therapy	_	_	O
49	on	_	_	O
50	survival	_	_	O
51	and	_	_	O
52	quality	_	_	O
53	of	_	_	O
54	life	_	_	O
55	are	_	_	O
56	equivalent	_	_	O
57	to	_	_	O
58	those	_	_	O
59	of	_	_	O
60	intravenous	_	_	O
61	chemotherapy	_	_	O
62	.	_	_	O

63	In	_	_	O
64	a	_	_	O
65	randomized	_	_	O
66	trial	_	_	O
67	of	_	_	O
68	palliative	_	_	O
69	treatment	_	_	O
70	in	_	_	O
71	advanced	_	_	O
72	SCLC	_	_	O
73	,	_	_	O
74	oral	_	_	O
75	etoposide	_	_	O
76	(	_	_	O
77	100	_	_	O
78	mg	_	_	O
79	given	_	_	O
80	twice	_	_	O
81	daily	_	_	O
82	for	_	_	O
83	5	_	_	O
84	days	_	_	O
85	)	_	_	O
86	was	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	intravenous	_	_	O
90	chemotherapy	_	_	O
91	consisting	_	_	O
92	of	_	_	O
93	alternating	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	cisplatin	_	_	O
97	and	_	_	O
98	etoposide	_	_	O
99	(	_	_	O
100	PE	_	_	O
101	)	_	_	O
102	and	_	_	O
103	cyclophosphamide	_	_	O
104	,	_	_	O
105	doxorubicin	_	_	O
106	,	_	_	O
107	and	_	_	O
108	vincristine	_	_	O
109	(	_	_	O
110	CAV	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Six	_	_	O
114	cycles	_	_	O
115	of	_	_	O
116	chemotherapy	_	_	O
117	were	_	_	O
118	administered	_	_	O
119	every	_	_	O
120	21	_	_	O
121	days	_	_	O
122	in	_	_	O
123	both	_	_	O
124	regimens	_	_	O
125	.	_	_	O

126	Symptom	_	_	O
127	control	_	_	O
128	and	_	_	O
129	quality	_	_	O
130	of	_	_	O
131	life	_	_	O
132	were	_	_	O
133	measured	_	_	O
134	with	_	_	O
135	the	_	_	O
136	Rotterdam	_	_	O
137	Symptom	_	_	O
138	Checklist	_	_	O
139	and	_	_	O
140	a	_	_	O
141	daily	_	_	O
142	diary	_	_	O
143	card	_	_	O
144	.	_	_	O

145	In	_	_	O
146	January	_	_	O
147	1996	_	_	O
148	,	_	_	O
149	after	_	_	O
150	155	_	_	O
151	patients	_	_	O
152	had	_	_	O
153	been	_	_	O
154	randomly	_	_	O
155	assigned	_	_	O
156	from	_	_	O
157	a	_	_	O
158	projected	_	_	O
159	intake	_	_	O
160	of	_	_	O
161	365	_	_	O
162	patients	_	_	O
163	,	_	_	O
164	an	_	_	O
165	independent	_	_	O
166	Data	_	_	O
167	Monitoring	_	_	O
168	Committee	_	_	O
169	examined	_	_	O
170	the	_	_	O
171	interim	_	_	O
172	results	_	_	O
173	.	_	_	O

174	Survival	_	_	O
175	was	_	_	O
176	determined	_	_	O
177	by	_	_	O
178	the	_	_	O
179	Kaplan-Meier	_	_	O
180	method	_	_	O
181	,	_	_	O
182	and	_	_	O
183	the	_	_	O
184	logrank	_	_	O
185	test	_	_	O
186	was	_	_	O
187	used	_	_	O
188	to	_	_	O
189	compare	_	_	O
190	treatments	_	_	O
191	.	_	_	O

192	For	_	_	O
193	quality-of-life	_	_	O
194	comparisons	_	_	O
195	,	_	_	O
196	average	_	_	O
197	scores	_	_	O
198	were	_	_	O
199	calculated	_	_	O
200	for	_	_	O
201	each	_	_	O
202	time	_	_	O
203	point	_	_	O
204	.	_	_	O

205	The	_	_	O
206	Mann-Whitney	_	_	O
207	U	_	_	O
208	test	_	_	O
209	was	_	_	O
210	used	_	_	O
211	to	_	_	O
212	determine	_	_	O
213	any	_	_	O
214	significant	_	_	O
215	overall	_	_	O
216	differences	_	_	O
217	between	_	_	O
218	treatments	_	_	O
219	.	_	_	O

220	For	_	_	O
221	the	_	_	O
222	Rotterdam	_	_	O
223	Symptom	_	_	O
224	Checklist	_	_	O
225	,	_	_	O
226	separate	_	_	O
227	analyses	_	_	O
228	were	_	_	O
229	done	_	_	O
230	for	_	_	O
231	each	_	_	O
232	subset	_	_	O
233	(	_	_	O
234	psychological	_	_	O
235	well-being	_	_	O
236	,	_	_	O
237	physical	_	_	O
238	symptoms	_	_	O
239	,	_	_	O
240	lung	_	_	O
241	cancer	_	_	O
242	symptoms	_	_	O
243	,	_	_	O
244	treatment	_	_	O
245	symptoms	_	_	O
246	,	_	_	O
247	activity	_	_	O
248	,	_	_	O
249	and	_	_	O
250	quality	_	_	O
251	of	_	_	O
252	life	_	_	O
253	)	_	_	O
254	.	_	_	O

255	Response	_	_	O
256	rates	_	_	O
257	and	_	_	O
258	toxicity	_	_	O
259	scores	_	_	O
260	were	_	_	O
261	compared	_	_	O
262	by	_	_	O
263	using	_	_	O
264	chi2	_	_	O
265	.	_	_	O

266	All	_	_	O
267	statistical	_	_	O
268	tests	_	_	O
269	were	_	_	O
270	two-sided	_	_	O
271	.	_	_	O

272	Survival	_	_	B-Premise
273	was	_	_	I-Premise
274	inferior	_	_	I-Premise
275	at	_	_	I-Premise
276	1	_	_	I-Premise
277	year	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	oral	_	_	I-Premise
281	etoposide	_	_	I-Premise
282	group	_	_	I-Premise
283	compared	_	_	I-Premise
284	with	_	_	I-Premise
285	intravenous	_	_	I-Premise
286	therapy	_	_	I-Premise
287	(	_	_	I-Premise
288	9.8	_	_	I-Premise
289	%	_	_	I-Premise
290	for	_	_	I-Premise
291	oral	_	_	I-Premise
292	versus	_	_	I-Premise
293	19.3	_	_	I-Premise
294	%	_	_	I-Premise
295	for	_	_	I-Premise
296	intravenous	_	_	I-Premise
297	;	_	_	I-Premise
298	difference	_	_	I-Premise
299	=	_	_	I-Premise
300	9.5	_	_	I-Premise
301	%	_	_	I-Premise
302	;	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	confidence	_	_	I-Premise
306	interval	_	_	I-Premise
307	of	_	_	I-Premise
308	difference	_	_	I-Premise
309	=	_	_	I-Premise
310	0.3	_	_	I-Premise
311	%	_	_	I-Premise
312	-18.7	_	_	I-Premise
313	%	_	_	I-Premise
314	;	_	_	I-Premise
315	P	_	_	I-Premise
316	<	_	_	I-Premise
317	.05	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	there	_	_	I-Premise
322	was	_	_	I-Premise
323	a	_	_	I-Premise
324	trend	_	_	I-Premise
325	toward	_	_	I-Premise
326	inferior	_	_	I-Premise
327	overall	_	_	I-Premise
328	survival	_	_	I-Premise
329	.	_	_	I-Premise

330	Median	_	_	B-Premise
331	survival	_	_	I-Premise
332	was	_	_	I-Premise
333	4.8	_	_	I-Premise
334	months	_	_	I-Premise
335	for	_	_	I-Premise
336	oral	_	_	I-Premise
337	treatment	_	_	I-Premise
338	and	_	_	I-Premise
339	5.9	_	_	I-Premise
340	months	_	_	I-Premise
341	for	_	_	I-Premise
342	intravenous	_	_	I-Premise
343	therapy	_	_	I-Premise
344	.	_	_	I-Premise

345	Progression-free	_	_	B-Premise
346	survival	_	_	I-Premise
347	was	_	_	I-Premise
348	worse	_	_	I-Premise
349	in	_	_	I-Premise
350	the	_	_	I-Premise
351	oral	_	_	I-Premise
352	etoposide	_	_	I-Premise
353	arm	_	_	I-Premise
354	(	_	_	I-Premise
355	median	_	_	I-Premise
356	=	_	_	I-Premise
357	3.6	_	_	I-Premise
358	months	_	_	I-Premise
359	versus	_	_	I-Premise
360	5.6	_	_	I-Premise
361	months	_	_	I-Premise
362	;	_	_	I-Premise
363	P	_	_	I-Premise
364	<	_	_	I-Premise
365	.001	_	_	I-Premise
366	)	_	_	I-Premise
367	,	_	_	I-Premise
368	as	_	_	I-Premise
369	well	_	_	I-Premise
370	as	_	_	I-Premise
371	overall	_	_	I-Premise
372	response	_	_	I-Premise
373	rate	_	_	I-Premise
374	(	_	_	I-Premise
375	32.9	_	_	I-Premise
376	%	_	_	I-Premise
377	versus	_	_	I-Premise
378	46.3	_	_	I-Premise
379	%	_	_	I-Premise
380	;	_	_	I-Premise
381	P	_	_	I-Premise
382	<	_	_	I-Premise
383	.01	_	_	I-Premise
384	)	_	_	I-Premise
385	.	_	_	I-Premise

386	With	_	_	B-Premise
387	the	_	_	I-Premise
388	exception	_	_	I-Premise
389	of	_	_	I-Premise
390	acute	_	_	I-Premise
391	nausea	_	_	I-Premise
392	and	_	_	I-Premise
393	vomiting	_	_	I-Premise
394	associated	_	_	I-Premise
395	with	_	_	I-Premise
396	intravenous	_	_	I-Premise
397	chemotherapy	_	_	I-Premise
398	,	_	_	I-Premise
399	all	_	_	B-Premise
400	aspects	_	_	I-Premise
401	of	_	_	I-Premise
402	symptom	_	_	I-Premise
403	control	_	_	I-Premise
404	and	_	_	I-Premise
405	quality	_	_	I-Premise
406	of	_	_	I-Premise
407	life	_	_	I-Premise
408	were	_	_	I-Premise
409	either	_	_	I-Premise
410	the	_	_	I-Premise
411	same	_	_	I-Premise
412	or	_	_	I-Premise
413	worse	_	_	I-Premise
414	in	_	_	I-Premise
415	the	_	_	I-Premise
416	oral	_	_	I-Premise
417	etoposide	_	_	I-Premise
418	group	_	_	I-Premise
419	.	_	_	I-Premise

420	Study	_	_	O
421	closure	_	_	O
422	was	_	_	O
423	recommended	_	_	O
424	.	_	_	O

425	These	_	_	B-Claim
426	interim	_	_	I-Claim
427	results	_	_	I-Claim
428	show	_	_	I-Claim
429	that	_	_	I-Claim
430	this	_	_	I-Claim
431	schedule	_	_	I-Claim
432	of	_	_	I-Claim
433	oral	_	_	I-Claim
434	etoposide	_	_	I-Claim
435	is	_	_	I-Claim
436	inferior	_	_	I-Claim
437	to	_	_	I-Claim
438	intravenous	_	_	I-Claim
439	chemotherapy	_	_	I-Claim
440	in	_	_	I-Claim
441	the	_	_	I-Claim
442	treatment	_	_	I-Claim
443	of	_	_	I-Claim
444	advanced	_	_	I-Claim
445	SCLC	_	_	I-Claim
446	and	_	_	I-Claim
447	should	_	_	I-Claim
448	not	_	_	I-Claim
449	be	_	_	I-Claim
450	used	_	_	I-Claim
451	as	_	_	I-Claim
452	first-line	_	_	I-Claim
453	treatment	_	_	I-Claim
454	of	_	_	I-Claim
455	this	_	_	I-Claim
456	disease	_	_	I-Claim
457	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Chinese	_	_	O
7	medicine	_	_	O
8	(	_	_	O
9	CM	_	_	O
10	)	_	_	O
11	five-element	_	_	O
12	music	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	for	_	_	O
18	senior	_	_	O
19	and	_	_	O
20	non-senior	_	_	O
21	advanced	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	With	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	,	_	_	O
31	170	_	_	O
32	advanced	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	three	_	_	O
40	groups	_	_	O
41	:	_	_	O
42	the	_	_	O
43	CM	_	_	O
44	five-element	_	_	O
45	music	_	_	O
46	group	_	_	O
47	(	_	_	O
48	68	_	_	O
49	patients	_	_	O
50	)	_	_	O
51	,	_	_	O
52	the	_	_	O
53	Western	_	_	O
54	music	_	_	O
55	therapy	_	_	O
56	group	_	_	O
57	(	_	_	O
58	68	_	_	O
59	cases	_	_	O
60	)	_	_	O
61	,	_	_	O
62	and	_	_	O
63	the	_	_	O
64	no	_	_	O
65	music	_	_	O
66	therapy	_	_	O
67	group	_	_	O
68	(	_	_	O
69	34	_	_	O
70	cases	_	_	O
71	)	_	_	O
72	.	_	_	O

73	All	_	_	O
74	patients	_	_	O
75	of	_	_	O
76	70	_	_	O
77	years	_	_	O
78	old	_	_	O
79	or	_	_	O
80	older	_	_	O
81	were	_	_	O
82	considered	_	_	O
83	seniors	_	_	O
84	and	_	_	O
85	the	_	_	O
86	remaining	_	_	O
87	patients	_	_	O
88	younger	_	_	O
89	than	_	_	O
90	70	_	_	O
91	years	_	_	O
92	were	_	_	O
93	considered	_	_	O
94	nonseniors	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	in	_	_	O
98	the	_	_	O
99	CM	_	_	O
100	five-element	_	_	O
101	music	_	_	O
102	group	_	_	O
103	listened	_	_	O
104	to	_	_	O
105	CM	_	_	O
106	five-element	_	_	O
107	music	_	_	O
108	,	_	_	O
109	the	_	_	O
110	patients	_	_	O
111	in	_	_	O
112	the	_	_	O
113	Western	_	_	O
114	music	_	_	O
115	group	_	_	O
116	listened	_	_	O
117	to	_	_	O
118	Western	_	_	O
119	music	_	_	O
120	,	_	_	O
121	and	_	_	O
122	the	_	_	O
123	patients	_	_	O
124	in	_	_	O
125	the	_	_	O
126	no	_	_	O
127	music	_	_	O
128	group	_	_	O
129	did	_	_	O
130	not	_	_	O
131	listen	_	_	O
132	to	_	_	O
133	music	_	_	O
134	.	_	_	O

135	A	_	_	O
136	course	_	_	O
137	of	_	_	O
138	treatment	_	_	O
139	was	_	_	O
140	3	_	_	O
141	weeks	_	_	O
142	,	_	_	O
143	with	_	_	O
144	30	_	_	O
145	min	_	_	O
146	each	_	_	O
147	day	_	_	O
148	,	_	_	O
149	5	_	_	O
150	days	_	_	O
151	a	_	_	O
152	week	_	_	O
153	.	_	_	O

154	The	_	_	O
155	Hospice	_	_	O
156	Quality	_	_	O
157	of	_	_	O
158	Life	_	_	O
159	Index-Revised	_	_	O
160	(	_	_	O
161	HQOLI-R	_	_	O
162	)	_	_	O
163	and	_	_	O
164	Karnofsky	_	_	O
165	performance	_	_	O
166	score	_	_	O
167	(	_	_	O
168	KPS	_	_	O
169	)	_	_	O
170	were	_	_	O
171	measured	_	_	O
172	in	_	_	O
173	the	_	_	O
174	three	_	_	O
175	groups	_	_	O
176	before	_	_	O
177	and	_	_	O
178	after	_	_	O
179	treatment	_	_	O
180	.	_	_	O

181	The	_	_	O
182	symptom	_	_	O
183	diary	_	_	O
184	score	_	_	O
185	was	_	_	O
186	measured	_	_	O
187	in	_	_	O
188	the	_	_	O
189	three	_	_	O
190	groups	_	_	O
191	every	_	_	O
192	3	_	_	O
193	days	_	_	O
194	,	_	_	O
195	7	_	_	O
196	times	_	_	O
197	in	_	_	O
198	total	_	_	O
199	.	_	_	O

200	CM	_	_	B-Premise
201	five-element	_	_	I-Premise
202	music	_	_	I-Premise
203	group	_	_	I-Premise
204	showed	_	_	I-Premise
205	a	_	_	I-Premise
206	significant	_	_	I-Premise
207	difference	_	_	I-Premise
208	of	_	_	I-Premise
209	HQOLI-R	_	_	I-Premise
210	,	_	_	I-Premise
211	KPS	_	_	I-Premise
212	and	_	_	I-Premise
213	symptom	_	_	I-Premise
214	diary	_	_	I-Premise
215	score	_	_	I-Premise
216	with	_	_	I-Premise
217	other	_	_	I-Premise
218	groups	_	_	I-Premise
219	(	_	_	I-Premise
220	all	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	There	_	_	B-Premise
227	were	_	_	I-Premise
228	significant	_	_	I-Premise
229	differences	_	_	I-Premise
230	of	_	_	I-Premise
231	HQOLI-R	_	_	I-Premise
232	,	_	_	I-Premise
233	symptom	_	_	I-Premise
234	diary	_	_	I-Premise
235	score	_	_	I-Premise
236	,	_	_	I-Premise
237	and	_	_	I-Premise
238	KPS	_	_	I-Premise
239	after	_	_	I-Premise
240	treatment	_	_	I-Premise
241	in	_	_	I-Premise
242	CM	_	_	I-Premise
243	five-element	_	_	I-Premise
244	music	_	_	I-Premise
245	group	_	_	I-Premise
246	and	_	_	I-Premise
247	other	_	_	I-Premise
248	groups	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	non-senior	_	_	I-Premise
252	subgroup	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	<	_	_	I-Premise
256	0.05	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Additionally	_	_	O
260	,	_	_	O
261	there	_	_	B-Premise
262	were	_	_	I-Premise
263	significant	_	_	I-Premise
264	differences	_	_	I-Premise
265	in	_	_	I-Premise
266	HQOLI-R	_	_	I-Premise
267	and	_	_	I-Premise
268	KPS	_	_	I-Premise
269	after	_	_	I-Premise
270	treatment	_	_	I-Premise
271	among	_	_	I-Premise
272	the	_	_	I-Premise
273	three	_	_	I-Premise
274	groups	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	senior	_	_	I-Premise
278	subgroup	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	<	_	_	I-Premise
282	0.05	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	CM	_	_	B-Claim
286	five-element	_	_	I-Claim
287	music	_	_	I-Claim
288	therapy	_	_	I-Claim
289	could	_	_	I-Claim
290	improve	_	_	I-Claim
291	the	_	_	I-Claim
292	quality	_	_	I-Claim
293	of	_	_	I-Claim
294	life	_	_	I-Claim
295	and	_	_	I-Claim
296	KPS	_	_	I-Claim
297	for	_	_	I-Claim
298	senior	_	_	I-Claim
299	and	_	_	I-Claim
300	non	_	_	I-Claim
301	senior	_	_	I-Claim
302	advanced	_	_	I-Claim
303	cancer	_	_	I-Claim
304	patients	_	_	I-Claim
305	,	_	_	I-Claim
306	and	_	_	I-Claim
307	it	_	_	I-Claim
308	could	_	_	I-Claim
309	improve	_	_	I-Claim
310	subjective	_	_	I-Claim
311	symptoms	_	_	I-Claim
312	for	_	_	I-Claim
313	non-senior	_	_	I-Claim
314	advanced	_	_	I-Claim
315	cancer	_	_	I-Claim
316	patients	_	_	I-Claim
317	.	_	_	I-Claim


0	Bacillus	_	_	B-Claim
1	Calmette-GuÃ©rin	_	_	I-Claim
2	and	_	_	I-Claim
3	intravesical	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	represent	_	_	I-Claim
6	viable	_	_	I-Claim
7	adjuvant	_	_	I-Claim
8	options	_	_	I-Claim
9	for	_	_	I-Claim
10	intermediate	_	_	I-Claim
11	risk	_	_	I-Claim
12	nonmuscle	_	_	I-Claim
13	invasive	_	_	I-Claim
14	bladder	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	Although	_	_	O
18	bacillus	_	_	O
19	Calmette-GuÃ©rin	_	_	O
20	is	_	_	O
21	perceived	_	_	O
22	as	_	_	O
23	less	_	_	O
24	tolerable	_	_	O
25	than	_	_	O
26	intravesical	_	_	O
27	chemotherapy	_	_	O
28	,	_	_	O
29	to	_	_	O
30	our	_	_	O
31	knowledge	_	_	O
32	no	_	_	O
33	comparative	_	_	O
34	studies	_	_	O
35	have	_	_	O
36	addressed	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	issues	_	_	O
41	.	_	_	O

42	We	_	_	O
43	compared	_	_	O
44	the	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	of	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	nonmuscle	_	_	O
52	invasive	_	_	O
53	bladder	_	_	O
54	cancer	_	_	O
55	who	_	_	O
56	received	_	_	O
57	adjuvant	_	_	O
58	intravesical	_	_	O
59	gemcitabine	_	_	O
60	or	_	_	O
61	1/3	_	_	O
62	dose	_	_	O
63	bacillus	_	_	O
64	Calmette-GuÃ©rin	_	_	O
65	.	_	_	O

66	Our	_	_	O
67	multicenter	_	_	O
68	,	_	_	O
69	prospective	_	_	O
70	,	_	_	O
71	randomized	_	_	O
72	,	_	_	O
73	phase	_	_	O
74	II	_	_	O
75	study	_	_	O
76	included	_	_	O
77	120	_	_	O
78	patients	_	_	O
79	with	_	_	O
80	intermediate	_	_	O
81	risk	_	_	O
82	nonmuscle	_	_	O
83	invasive	_	_	O
84	bladder	_	_	O
85	cancer	_	_	O
86	.	_	_	O

87	Of	_	_	O
88	these	_	_	O
89	patients	_	_	O
90	88	_	_	O
91	remained	_	_	O
92	assessable	_	_	O
93	at	_	_	O
94	1-year	_	_	O
95	followup	_	_	O
96	.	_	_	O

97	Only	_	_	O
98	1	_	_	O
99	patient	_	_	O
100	was	_	_	O
101	withdrawn	_	_	O
102	because	_	_	O
103	of	_	_	O
104	adverse	_	_	O
105	events	_	_	O
106	.	_	_	O

107	Overall	_	_	O
108	61	_	_	O
109	patients	_	_	O
110	received	_	_	O
111	2,000	_	_	O
112	mg/50	_	_	O
113	cc	_	_	O
114	gemcitabine	_	_	O
115	weekly	_	_	O
116	for	_	_	O
117	6	_	_	O
118	weeks	_	_	O
119	(	_	_	O
120	maintenance	_	_	O
121	monthly	_	_	O
122	for	_	_	O
123	1	_	_	O
124	year	_	_	O
125	)	_	_	O
126	while	_	_	O
127	59	_	_	O
128	received	_	_	O
129	1/3	_	_	O
130	dose	_	_	O
131	bacillus	_	_	O
132	Calmette-GuÃ©rin	_	_	O
133	Connaught	_	_	O
134	weekly	_	_	O
135	for	_	_	O
136	6	_	_	O
137	weeks	_	_	O
138	(	_	_	O
139	maintenance	_	_	O
140	3	_	_	O
141	weekly	_	_	O
142	instillations	_	_	O
143	at	_	_	O
144	3	_	_	O
145	,	_	_	O
146	6	_	_	O
147	and	_	_	O
148	12	_	_	O
149	months	_	_	O
150	)	_	_	O
151	.	_	_	O

152	Quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	was	_	_	O
156	measured	_	_	O
157	by	_	_	O
158	the	_	_	O
159	EORTC	_	_	O
160	QLQ-C30	_	_	O
161	(	_	_	O
162	European	_	_	O
163	Organization	_	_	O
164	for	_	_	O
165	the	_	_	O
166	Research	_	_	O
167	and	_	_	O
168	Treatment	_	_	O
169	of	_	_	O
170	Cancer	_	_	O
171	Quality	_	_	O
172	of	_	_	O
173	Life	_	_	O
174	Questionnaire	_	_	O
175	Core	_	_	O
176	30	_	_	O
177	version	_	_	O
178	3.0	_	_	O
179	)	_	_	O
180	and	_	_	O
181	QLQ-BLS24	_	_	O
182	(	_	_	O
183	Quality	_	_	O
184	of	_	_	O
185	Life	_	_	O
186	Superficial	_	_	O
187	Bladder	_	_	O
188	Cancer-Specific	_	_	O
189	24	_	_	O
190	)	_	_	O
191	questionnaires	_	_	O
192	.	_	_	O

193	Group	_	_	O
194	differences	_	_	O
195	were	_	_	O
196	calculated	_	_	O
197	using	_	_	O
198	ANOVA	_	_	O
199	(	_	_	O
200	ANOVA/MANOVA	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Treatment	_	_	B-Premise
204	was	_	_	I-Premise
205	well	_	_	I-Premise
206	tolerated	_	_	I-Premise
207	in	_	_	I-Premise
208	both	_	_	I-Premise
209	groups	_	_	I-Premise
210	,	_	_	I-Premise
211	although	_	_	B-Premise
212	local	_	_	I-Premise
213	and	_	_	I-Premise
214	systemic	_	_	I-Premise
215	side	_	_	I-Premise
216	effects	_	_	I-Premise
217	were	_	_	I-Premise
218	more	_	_	I-Premise
219	frequently	_	_	I-Premise
220	reported	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	bacillus	_	_	I-Premise
224	Calmette-GuÃ©rin	_	_	I-Premise
225	arm	_	_	I-Premise
226	.	_	_	I-Premise

227	Multivariate	_	_	B-Premise
228	analyses	_	_	I-Premise
229	showed	_	_	I-Premise
230	no	_	_	I-Premise
231	significant	_	_	I-Premise
232	differences	_	_	I-Premise
233	between	_	_	I-Premise
234	the	_	_	I-Premise
235	2	_	_	I-Premise
236	groups	_	_	I-Premise
237	in	_	_	I-Premise
238	all	_	_	I-Premise
239	quality	_	_	I-Premise
240	of	_	_	I-Premise
241	life	_	_	I-Premise
242	dimensions	_	_	I-Premise
243	.	_	_	I-Premise

244	No	_	_	B-Premise
245	significant	_	_	I-Premise
246	changes	_	_	I-Premise
247	over	_	_	I-Premise
248	time	_	_	I-Premise
249	in	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	domains	_	_	I-Premise
254	were	_	_	I-Premise
255	detected	_	_	I-Premise
256	for	_	_	I-Premise
257	patients	_	_	I-Premise
258	on	_	_	I-Premise
259	bacillus	_	_	I-Premise
260	Calmette-GuÃ©rin	_	_	I-Premise
261	and	_	_	I-Premise
262	gemcitabine	_	_	I-Premise
263	except	_	_	I-Premise
264	for	_	_	I-Premise
265	physical	_	_	I-Premise
266	functioning	_	_	I-Premise
267	,	_	_	I-Premise
268	which	_	_	I-Premise
269	decreased	_	_	I-Premise
270	significantly	_	_	I-Premise
271	in	_	_	I-Premise
272	both	_	_	I-Premise
273	groups	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0.002	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	No	_	_	B-Premise
281	significant	_	_	I-Premise
282	differences	_	_	I-Premise
283	were	_	_	I-Premise
284	detected	_	_	I-Premise
285	in	_	_	I-Premise
286	terms	_	_	I-Premise
287	of	_	_	I-Premise
288	recurrence	_	_	I-Premise
289	and	_	_	I-Premise
290	progression	_	_	I-Premise
291	between	_	_	I-Premise
292	the	_	_	I-Premise
293	2	_	_	I-Premise
294	groups	_	_	I-Premise
295	at	_	_	I-Premise
296	1-year	_	_	I-Premise
297	followup	_	_	I-Premise
298	.	_	_	I-Premise

299	While	_	_	O
300	a	_	_	B-Claim
301	higher	_	_	I-Claim
302	rate	_	_	I-Claim
303	of	_	_	I-Claim
304	side	_	_	I-Claim
305	effects	_	_	I-Claim
306	,	_	_	I-Claim
307	albeit	_	_	I-Claim
308	mild	_	_	I-Claim
309	to	_	_	I-Claim
310	moderate	_	_	I-Claim
311	,	_	_	I-Claim
312	was	_	_	I-Claim
313	detected	_	_	I-Claim
314	with	_	_	I-Claim
315	1/3	_	_	I-Claim
316	dose	_	_	I-Claim
317	bacillus	_	_	I-Claim
318	Calmette-GuÃ©rin	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	gemcitabine	_	_	I-Claim
322	,	_	_	I-Claim
323	our	_	_	B-Claim
324	study	_	_	I-Claim
325	failed	_	_	I-Claim
326	to	_	_	I-Claim
327	show	_	_	I-Claim
328	significant	_	_	I-Claim
329	differences	_	_	I-Claim
330	between	_	_	I-Claim
331	the	_	_	I-Claim
332	2	_	_	I-Claim
333	drugs	_	_	I-Claim
334	in	_	_	I-Claim
335	terms	_	_	I-Claim
336	of	_	_	I-Claim
337	quality	_	_	I-Claim
338	of	_	_	I-Claim
339	life	_	_	I-Claim
340	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	first-line	_	_	O
8	,	_	_	O
9	single-agent	_	_	O
10	trastuzumab	_	_	O
11	in	_	_	O
12	women	_	_	O
13	with	_	_	O
14	HER2-overexpressing	_	_	O
15	metastatic	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	One	_	_	O
20	hundred	_	_	O
21	fourteen	_	_	O
22	women	_	_	O
23	with	_	_	O
24	HER2-overexpressing	_	_	O
25	metastatic	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	were	_	_	O
29	randomized	_	_	O
30	to	_	_	O
31	receive	_	_	O
32	first-line	_	_	O
33	treatment	_	_	O
34	with	_	_	O
35	trastuzumab	_	_	O
36	4	_	_	O
37	mg/kg	_	_	O
38	loading	_	_	O
39	dose	_	_	O
40	,	_	_	O
41	followed	_	_	O
42	by	_	_	O
43	2	_	_	O
44	mg/kg	_	_	O
45	weekly	_	_	O
46	,	_	_	O
47	or	_	_	O
48	a	_	_	O
49	higher	_	_	O
50	8	_	_	O
51	mg/kg	_	_	O
52	loading	_	_	O
53	dose	_	_	O
54	,	_	_	O
55	followed	_	_	O
56	by	_	_	O
57	4	_	_	O
58	mg/kg	_	_	O
59	weekly	_	_	O
60	.	_	_	O

61	The	_	_	B-Premise
62	objective	_	_	I-Premise
63	response	_	_	I-Premise
64	rate	_	_	I-Premise
65	was	_	_	I-Premise
66	26	_	_	I-Premise
67	%	_	_	I-Premise
68	(	_	_	I-Premise
69	95	_	_	I-Premise
70	%	_	_	I-Premise
71	confidence	_	_	I-Premise
72	interval	_	_	I-Premise
73	[	_	_	I-Premise
74	CI	_	_	I-Premise
75	]	_	_	I-Premise
76	,	_	_	I-Premise
77	18.2	_	_	I-Premise
78	%	_	_	I-Premise
79	to	_	_	I-Premise
80	34.4	_	_	I-Premise
81	%	_	_	I-Premise
82	)	_	_	I-Premise
83	,	_	_	I-Premise
84	with	_	_	I-Premise
85	seven	_	_	I-Premise
86	complete	_	_	I-Premise
87	and	_	_	I-Premise
88	23	_	_	I-Premise
89	partial	_	_	I-Premise
90	responses	_	_	I-Premise
91	.	_	_	I-Premise

92	Response	_	_	B-Premise
93	rates	_	_	I-Premise
94	in	_	_	I-Premise
95	111	_	_	I-Premise
96	assessable	_	_	I-Premise
97	patients	_	_	I-Premise
98	with	_	_	I-Premise
99	3+	_	_	I-Premise
100	and	_	_	I-Premise
101	2+	_	_	I-Premise
102	HER2	_	_	I-Premise
103	overexpression	_	_	I-Premise
104	by	_	_	I-Premise
105	immunohistochemistry	_	_	I-Premise
106	(	_	_	I-Premise
107	IHC	_	_	I-Premise
108	)	_	_	I-Premise
109	were	_	_	I-Premise
110	35	_	_	I-Premise
111	%	_	_	I-Premise
112	(	_	_	I-Premise
113	95	_	_	I-Premise
114	%	_	_	I-Premise
115	CI	_	_	I-Premise
116	,	_	_	I-Premise
117	24.4	_	_	I-Premise
118	%	_	_	I-Premise
119	to	_	_	I-Premise
120	44.7	_	_	I-Premise
121	%	_	_	I-Premise
122	)	_	_	I-Premise
123	and	_	_	I-Premise
124	none	_	_	I-Premise
125	(	_	_	I-Premise
126	95	_	_	I-Premise
127	%	_	_	I-Premise
128	CI	_	_	I-Premise
129	,	_	_	I-Premise
130	0	_	_	I-Premise
131	%	_	_	I-Premise
132	to	_	_	I-Premise
133	15.5	_	_	I-Premise
134	%	_	_	I-Premise
135	)	_	_	I-Premise
136	,	_	_	I-Premise
137	respectively	_	_	I-Premise
138	.	_	_	I-Premise

139	The	_	_	B-Premise
140	clinical	_	_	I-Premise
141	benefit	_	_	I-Premise
142	rates	_	_	I-Premise
143	in	_	_	I-Premise
144	assessable	_	_	I-Premise
145	patients	_	_	I-Premise
146	with	_	_	I-Premise
147	3+	_	_	I-Premise
148	and	_	_	I-Premise
149	2+	_	_	I-Premise
150	HER2	_	_	I-Premise
151	overexpression	_	_	I-Premise
152	were	_	_	I-Premise
153	48	_	_	I-Premise
154	%	_	_	I-Premise
155	and	_	_	I-Premise
156	7	_	_	I-Premise
157	%	_	_	I-Premise
158	,	_	_	I-Premise
159	respectively	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	response	_	_	I-Premise
163	rates	_	_	I-Premise
164	in	_	_	I-Premise
165	108	_	_	I-Premise
166	assessable	_	_	I-Premise
167	patients	_	_	I-Premise
168	with	_	_	I-Premise
169	and	_	_	I-Premise
170	without	_	_	I-Premise
171	HER2	_	_	I-Premise
172	gene	_	_	I-Premise
173	amplification	_	_	I-Premise
174	by	_	_	I-Premise
175	fluorescence	_	_	I-Premise
176	in	_	_	I-Premise
177	situ	_	_	I-Premise
178	hybridization	_	_	I-Premise
179	(	_	_	I-Premise
180	FISH	_	_	I-Premise
181	)	_	_	I-Premise
182	analysis	_	_	I-Premise
183	were	_	_	I-Premise
184	34	_	_	I-Premise
185	%	_	_	I-Premise
186	(	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	,	_	_	I-Premise
191	23.9	_	_	I-Premise
192	%	_	_	I-Premise
193	to	_	_	I-Premise
194	45.7	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	7	_	_	I-Premise
199	%	_	_	I-Premise
200	(	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	,	_	_	I-Premise
205	0.8	_	_	I-Premise
206	%	_	_	I-Premise
207	to	_	_	I-Premise
208	22.8	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	.	_	_	I-Premise

214	Seventeen	_	_	B-Premise
215	(	_	_	I-Premise
216	57	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	of	_	_	I-Premise
220	30	_	_	I-Premise
221	patients	_	_	I-Premise
222	with	_	_	I-Premise
223	an	_	_	I-Premise
224	objective	_	_	I-Premise
225	response	_	_	I-Premise
226	and	_	_	I-Premise
227	22	_	_	I-Premise
228	(	_	_	I-Premise
229	51	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	of	_	_	I-Premise
233	43	_	_	I-Premise
234	patients	_	_	I-Premise
235	with	_	_	I-Premise
236	clinical	_	_	I-Premise
237	benefit	_	_	I-Premise
238	had	_	_	I-Premise
239	not	_	_	I-Premise
240	experienced	_	_	I-Premise
241	disease	_	_	I-Premise
242	progression	_	_	I-Premise
243	at	_	_	I-Premise
244	follow-up	_	_	I-Premise
245	at	_	_	I-Premise
246	12	_	_	I-Premise
247	months	_	_	I-Premise
248	or	_	_	I-Premise
249	later	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	most	_	_	I-Premise
253	common	_	_	I-Premise
254	treatment-related	_	_	I-Premise
255	adverse	_	_	I-Premise
256	events	_	_	I-Premise
257	were	_	_	I-Premise
258	chills	_	_	I-Premise
259	(	_	_	I-Premise
260	25	_	_	I-Premise
261	%	_	_	I-Premise
262	of	_	_	I-Premise
263	patients	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	asthenia	_	_	I-Premise
267	(	_	_	I-Premise
268	23	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	fever	_	_	I-Premise
273	(	_	_	I-Premise
274	22	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	pain	_	_	I-Premise
279	(	_	_	I-Premise
280	18	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	nausea	_	_	I-Premise
286	(	_	_	I-Premise
287	14	_	_	I-Premise
288	%	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Cardiac	_	_	B-Premise
292	dysfunction	_	_	I-Premise
293	occurred	_	_	I-Premise
294	in	_	_	I-Premise
295	two	_	_	I-Premise
296	patients	_	_	I-Premise
297	(	_	_	I-Premise
298	2	_	_	I-Premise
299	%	_	_	I-Premise
300	)	_	_	I-Premise
301	;	_	_	I-Premise
302	both	_	_	I-Premise
303	had	_	_	I-Premise
304	histories	_	_	I-Premise
305	of	_	_	I-Premise
306	cardiac	_	_	I-Premise
307	disease	_	_	I-Premise
308	and	_	_	I-Premise
309	did	_	_	I-Premise
310	not	_	_	I-Premise
311	require	_	_	I-Premise
312	additional	_	_	I-Premise
313	intervention	_	_	I-Premise
314	after	_	_	I-Premise
315	discontinuation	_	_	I-Premise
316	of	_	_	I-Premise
317	trastuzumab	_	_	I-Premise
318	.	_	_	I-Premise

319	There	_	_	B-Claim
320	was	_	_	I-Claim
321	no	_	_	I-Claim
322	clear	_	_	I-Claim
323	evidence	_	_	I-Claim
324	of	_	_	I-Claim
325	a	_	_	I-Claim
326	dose-response	_	_	I-Claim
327	relationship	_	_	I-Claim
328	for	_	_	I-Claim
329	response	_	_	I-Claim
330	,	_	_	I-Claim
331	survival	_	_	I-Claim
332	,	_	_	I-Claim
333	or	_	_	I-Claim
334	adverse	_	_	I-Claim
335	events	_	_	I-Claim
336	.	_	_	I-Claim

337	Single-agent	_	_	B-Claim
338	trastuzumab	_	_	I-Claim
339	is	_	_	I-Claim
340	active	_	_	I-Claim
341	and	_	_	I-Claim
342	well	_	_	I-Claim
343	tolerated	_	_	I-Claim
344	as	_	_	I-Claim
345	first-line	_	_	I-Claim
346	treatment	_	_	I-Claim
347	of	_	_	I-Claim
348	women	_	_	I-Claim
349	with	_	_	I-Claim
350	metastatic	_	_	I-Claim
351	breast	_	_	I-Claim
352	cancer	_	_	I-Claim
353	with	_	_	I-Claim
354	HER2	_	_	I-Claim
355	3+	_	_	I-Claim
356	overexpression	_	_	I-Claim
357	by	_	_	I-Claim
358	IHC	_	_	I-Claim
359	or	_	_	I-Claim
360	gene	_	_	I-Claim
361	amplification	_	_	I-Claim
362	by	_	_	I-Claim
363	FISH	_	_	I-Claim
364	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	influence	_	_	O
4	of	_	_	O
5	bladder	_	_	O
6	neck	_	_	O
7	preservation	_	_	O
8	on	_	_	O
9	urinary	_	_	O
10	continence	_	_	O
11	,	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	and	_	_	O
16	surgical	_	_	O
17	margins	_	_	O
18	after	_	_	O
19	radical	_	_	O
20	prostatectomy	_	_	O
21	.	_	_	O

22	A	_	_	O
23	total	_	_	O
24	of	_	_	O
25	208	_	_	O
26	men	_	_	O
27	who	_	_	O
28	presented	_	_	O
29	for	_	_	O
30	radical	_	_	O
31	prostatectomy	_	_	O
32	were	_	_	O
33	randomized	_	_	O
34	to	_	_	O
35	complete	_	_	O
36	bladder	_	_	O
37	neck	_	_	O
38	preservation	_	_	O
39	with	_	_	O
40	subsequent	_	_	O
41	urethro-urethral	_	_	O
42	anastomosis	_	_	O
43	or	_	_	O
44	to	_	_	O
45	no	_	_	O
46	preservation	_	_	O
47	as	_	_	O
48	controls	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	failed	_	_	O
53	bladder	_	_	O
54	neck	_	_	O
55	preservation	_	_	O
56	were	_	_	O
57	not	_	_	O
58	included	_	_	O
59	in	_	_	O
60	study	_	_	O
61	.	_	_	O

62	We	_	_	O
63	documented	_	_	O
64	objective	_	_	O
65	continence	_	_	O
66	by	_	_	O
67	the	_	_	O
68	24-hour	_	_	O
69	pad	_	_	O
70	test	_	_	O
71	,	_	_	O
72	social	_	_	O
73	continence	_	_	O
74	by	_	_	O
75	the	_	_	O
76	number	_	_	O
77	of	_	_	O
78	pads	_	_	O
79	per	_	_	O
80	day	_	_	O
81	and	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	outcomes	_	_	O
86	by	_	_	O
87	the	_	_	O
88	validated	_	_	O
89	Incontinence	_	_	O
90	Quality	_	_	O
91	of	_	_	O
92	Life	_	_	O
93	questionnaire	_	_	O
94	in	_	_	O
95	a	_	_	O
96	single	_	_	O
97	blind	_	_	O
98	setting	_	_	O
99	.	_	_	O

100	Cancer	_	_	O
101	resection	_	_	O
102	was	_	_	O
103	assessed	_	_	O
104	by	_	_	O
105	surgical	_	_	O
106	margin	_	_	O
107	status	_	_	O
108	.	_	_	O

109	At	_	_	B-Premise
110	0	_	_	I-Premise
111	,	_	_	I-Premise
112	3	_	_	I-Premise
113	,	_	_	I-Premise
114	6	_	_	I-Premise
115	and	_	_	I-Premise
116	12	_	_	I-Premise
117	months	_	_	I-Premise
118	mean	_	_	I-Premise
119	urine	_	_	I-Premise
120	loss	_	_	I-Premise
121	in	_	_	I-Premise
122	the	_	_	I-Premise
123	control	_	_	I-Premise
124	vs	_	_	I-Premise
125	the	_	_	I-Premise
126	bladder	_	_	I-Premise
127	neck	_	_	I-Premise
128	preservation	_	_	I-Premise
129	group	_	_	I-Premise
130	was	_	_	I-Premise
131	713.3	_	_	I-Premise
132	vs	_	_	I-Premise
133	237.0	_	_	I-Premise
134	,	_	_	I-Premise
135	49.6	_	_	I-Premise
136	vs	_	_	I-Premise
137	15.6	_	_	I-Premise
138	,	_	_	I-Premise
139	44.4	_	_	I-Premise
140	vs	_	_	I-Premise
141	5.5	_	_	I-Premise
142	and	_	_	I-Premise
143	25.4	_	_	I-Premise
144	vs	_	_	I-Premise
145	3.1	_	_	I-Premise
146	gm	_	_	I-Premise
147	,	_	_	I-Premise
148	respectively	_	_	I-Premise
149	(	_	_	I-Premise
150	each	_	_	I-Premise
151	p	_	_	I-Premise
152	<	_	_	I-Premise
153	0.001	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	At	_	_	B-Premise
157	3	_	_	I-Premise
158	,	_	_	I-Premise
159	6	_	_	I-Premise
160	and	_	_	I-Premise
161	12	_	_	I-Premise
162	months	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	control	_	_	I-Premise
166	vs	_	_	I-Premise
167	the	_	_	I-Premise
168	preservation	_	_	I-Premise
169	group	_	_	I-Premise
170	the	_	_	I-Premise
171	social	_	_	I-Premise
172	continence	_	_	I-Premise
173	rate	_	_	I-Premise
174	was	_	_	I-Premise
175	55.3	_	_	I-Premise
176	%	_	_	I-Premise
177	vs	_	_	I-Premise
178	84.2	_	_	I-Premise
179	%	_	_	I-Premise
180	(	_	_	I-Premise
181	p	_	_	I-Premise
182	<	_	_	I-Premise
183	0.001	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	74.8	_	_	I-Premise
187	%	_	_	I-Premise
188	vs	_	_	I-Premise
189	89.5	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	=	_	_	I-Premise
194	0.05	_	_	I-Premise
195	)	_	_	I-Premise
196	and	_	_	I-Premise
197	81.4	_	_	I-Premise
198	%	_	_	I-Premise
199	vs	_	_	I-Premise
200	94.7	_	_	I-Premise
201	%	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0.027	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	quality	_	_	I-Premise
211	of	_	_	I-Premise
212	life	_	_	I-Premise
213	score	_	_	I-Premise
214	was	_	_	I-Premise
215	80.4	_	_	I-Premise
216	vs	_	_	I-Premise
217	90.3	_	_	I-Premise
218	(	_	_	I-Premise
219	p	_	_	I-Premise
220	<	_	_	I-Premise
221	0.001	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	85.4	_	_	I-Premise
225	vs	_	_	I-Premise
226	91.7	_	_	I-Premise
227	(	_	_	I-Premise
228	p	_	_	I-Premise
229	=	_	_	I-Premise
230	0.016	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	86.0	_	_	I-Premise
234	vs	_	_	I-Premise
235	93.8	_	_	I-Premise
236	(	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.001	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	We	_	_	B-Premise
245	noted	_	_	I-Premise
246	significantly	_	_	I-Premise
247	less	_	_	I-Premise
248	urine	_	_	I-Premise
249	loss	_	_	I-Premise
250	,	_	_	I-Premise
251	higher	_	_	I-Premise
252	objective	_	_	I-Premise
253	and	_	_	I-Premise
254	social	_	_	I-Premise
255	continence	_	_	I-Premise
256	rates	_	_	I-Premise
257	,	_	_	I-Premise
258	and	_	_	I-Premise
259	higher	_	_	I-Premise
260	quality	_	_	I-Premise
261	of	_	_	I-Premise
262	life	_	_	I-Premise
263	scores	_	_	I-Premise
264	after	_	_	I-Premise
265	complete	_	_	I-Premise
266	bladder	_	_	I-Premise
267	neck	_	_	I-Premise
268	preservation	_	_	I-Premise
269	at	_	_	I-Premise
270	all	_	_	I-Premise
271	followup	_	_	I-Premise
272	points	_	_	I-Premise
273	.	_	_	I-Premise

274	On	_	_	O
275	multiple	_	_	O
276	logistic	_	_	O
277	regression	_	_	O
278	analysis	_	_	O
279	complete	_	_	O
280	bladder	_	_	O
281	neck	_	_	O
282	preservation	_	_	O
283	was	_	_	O
284	an	_	_	O
285	independent	_	_	O
286	positive	_	_	O
287	predictor	_	_	O
288	of	_	_	O
289	continence	_	_	O
290	.	_	_	O

291	No	_	_	B-Premise
292	significant	_	_	I-Premise
293	difference	_	_	I-Premise
294	was	_	_	I-Premise
295	found	_	_	I-Premise
296	in	_	_	I-Premise
297	surgical	_	_	I-Premise
298	margin	_	_	I-Premise
299	status	_	_	I-Premise
300	between	_	_	I-Premise
301	the	_	_	I-Premise
302	control	_	_	I-Premise
303	and	_	_	I-Premise
304	bladder	_	_	I-Premise
305	neck	_	_	I-Premise
306	preservation	_	_	I-Premise
307	groups	_	_	I-Premise
308	(	_	_	I-Premise
309	12.5	_	_	I-Premise
310	%	_	_	I-Premise
311	vs	_	_	I-Premise
312	14.7	_	_	I-Premise
313	%	_	_	I-Premise
314	,	_	_	I-Premise
315	p	_	_	I-Premise
316	=	_	_	I-Premise
317	0.65	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	In	_	_	B-Claim
321	what	_	_	I-Claim
322	is	_	_	I-Claim
323	to	_	_	I-Claim
324	our	_	_	I-Claim
325	knowledge	_	_	I-Claim
326	the	_	_	I-Claim
327	first	_	_	I-Claim
328	prospective	_	_	I-Claim
329	,	_	_	I-Claim
330	randomized	_	_	I-Claim
331	,	_	_	I-Claim
332	controlled	_	_	I-Claim
333	,	_	_	I-Claim
334	single	_	_	I-Claim
335	blind	_	_	I-Claim
336	trial	_	_	I-Claim
337	complete	_	_	I-Claim
338	bladder	_	_	I-Claim
339	neck	_	_	I-Claim
340	preservation	_	_	I-Claim
341	during	_	_	I-Claim
342	radical	_	_	I-Claim
343	prostatectomy	_	_	I-Claim
344	was	_	_	I-Claim
345	associated	_	_	I-Claim
346	with	_	_	I-Claim
347	a	_	_	I-Claim
348	significantly	_	_	I-Claim
349	higher	_	_	I-Claim
350	urinary	_	_	I-Claim
351	continence	_	_	I-Claim
352	rate	_	_	I-Claim
353	and	_	_	I-Claim
354	increased	_	_	I-Claim
355	patient	_	_	I-Claim
356	satisfaction	_	_	I-Claim
357	without	_	_	I-Claim
358	compromising	_	_	I-Claim
359	resection	_	_	I-Claim
360	margins	_	_	I-Claim
361	.	_	_	I-Claim


0	Docetaxel	_	_	O
1	administered	_	_	O
2	every	_	_	O
3	3	_	_	O
4	weeks	_	_	O
5	is	_	_	O
6	a	_	_	O
7	standard	_	_	O
8	treatment	_	_	O
9	for	_	_	O
10	castration-resistant	_	_	O
11	advanced	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	We	_	_	O
16	hypothesised	_	_	O
17	that	_	_	O
18	2-weekly	_	_	O
19	administration	_	_	O
20	of	_	_	O
21	docetaxel	_	_	O
22	would	_	_	O
23	be	_	_	O
24	better	_	_	O
25	tolerated	_	_	O
26	than	_	_	O
27	3-weekly	_	_	O
28	docetaxel	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	castration-resistant	_	_	O
33	advanced	_	_	O
34	prostate	_	_	O
35	cancer	_	_	O
36	,	_	_	O
37	and	_	_	O
38	did	_	_	O
39	a	_	_	O
40	prospective	_	_	O
41	,	_	_	O
42	multicentre	_	_	O
43	,	_	_	O
44	randomised	_	_	O
45	,	_	_	O
46	phase	_	_	O
47	3	_	_	O
48	study	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	efficacy	_	_	O
52	and	_	_	O
53	safety	_	_	O
54	.	_	_	O

55	Eligible	_	_	O
56	patients	_	_	O
57	had	_	_	O
58	advanced	_	_	O
59	prostate	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	metastasis	_	_	O
63	,	_	_	O
64	a	_	_	O
65	prostate-specific-antigen	_	_	O
66	test	_	_	O
67	result	_	_	O
68	of	_	_	O
69	more	_	_	O
70	than	_	_	O
71	10Â·0	_	_	O
72	ng/mL	_	_	O
73	,	_	_	O
74	and	_	_	O
75	WHO	_	_	O
76	performance	_	_	O
77	status	_	_	O
78	score	_	_	O
79	of	_	_	O
80	0-2	_	_	O
81	)	_	_	O
82	,	_	_	O
83	had	_	_	O
84	received	_	_	O
85	no	_	_	O
86	chemotherapy	_	_	O
87	(	_	_	O
88	except	_	_	O
89	with	_	_	O
90	estramustine	_	_	O
91	)	_	_	O
92	,	_	_	O
93	had	_	_	O
94	undergone	_	_	O
95	surgical	_	_	O
96	or	_	_	O
97	chemical	_	_	O
98	castration	_	_	O
99	,	_	_	O
100	and	_	_	O
101	had	_	_	O
102	been	_	_	O
103	referred	_	_	O
104	to	_	_	O
105	a	_	_	O
106	treatment	_	_	O
107	centre	_	_	O
108	in	_	_	O
109	Finland	_	_	O
110	,	_	_	O
111	Ireland	_	_	O
112	,	_	_	O
113	or	_	_	O
114	Sweden	_	_	O
115	.	_	_	O

116	Enrolment	_	_	O
117	and	_	_	O
118	treatment	_	_	O
119	were	_	_	O
120	done	_	_	O
121	between	_	_	O
122	March	_	_	O
123	1	_	_	O
124	,	_	_	O
125	2004	_	_	O
126	,	_	_	O
127	and	_	_	O
128	May	_	_	O
129	31	_	_	O
130	,	_	_	O
131	2009	_	_	O
132	.	_	_	O

133	Randomisation	_	_	O
134	was	_	_	O
135	done	_	_	O
136	centrally	_	_	O
137	and	_	_	O
138	stratified	_	_	O
139	by	_	_	O
140	centre	_	_	O
141	and	_	_	O
142	WHO	_	_	O
143	performance	_	_	O
144	status	_	_	O
145	score	_	_	O
146	of	_	_	O
147	0-1	_	_	O
148	vs	_	_	O
149	2	_	_	O
150	.	_	_	O

151	Patients	_	_	O
152	were	_	_	O
153	assigned	_	_	O
154	75	_	_	O
155	mg/m	_	_	O
156	(	_	_	O
157	2	_	_	O
158	)	_	_	O
159	docetaxel	_	_	O
160	intravenously	_	_	O
161	on	_	_	O
162	day	_	_	O
163	1	_	_	O
164	of	_	_	O
165	a	_	_	O
166	3-week	_	_	O
167	cycle	_	_	O
168	,	_	_	O
169	or	_	_	O
170	50	_	_	O
171	mg/m	_	_	O
172	(	_	_	O
173	2	_	_	O
174	)	_	_	O
175	docetaxel	_	_	O
176	intravenously	_	_	O
177	on	_	_	O
178	days	_	_	O
179	1	_	_	O
180	and	_	_	O
181	15	_	_	O
182	of	_	_	O
183	a	_	_	O
184	4-week	_	_	O
185	cycle	_	_	O
186	.	_	_	O

187	10	_	_	O
188	mg	_	_	O
189	oral	_	_	O
190	prednisolone	_	_	O
191	was	_	_	O
192	administered	_	_	O
193	daily	_	_	O
194	to	_	_	O
195	all	_	_	O
196	patients	_	_	O
197	.	_	_	O

198	The	_	_	O
199	primary	_	_	O
200	endpoint	_	_	O
201	was	_	_	O
202	time	_	_	O
203	to	_	_	O
204	treatment	_	_	O
205	failure	_	_	O
206	(	_	_	O
207	TTTF	_	_	O
208	)	_	_	O
209	.	_	_	O

210	We	_	_	O
211	assessed	_	_	O
212	data	_	_	O
213	in	_	_	O
214	the	_	_	O
215	per-protocol	_	_	O
216	population	_	_	O
217	.	_	_	O

218	177	_	_	O
219	patients	_	_	O
220	were	_	_	O
221	randomly	_	_	O
222	assigned	_	_	O
223	to	_	_	O
224	the	_	_	O
225	2-weekly	_	_	O
226	docetaxel	_	_	O
227	group	_	_	O
228	and	_	_	O
229	184	_	_	O
230	to	_	_	O
231	the	_	_	O
232	3-weekly	_	_	O
233	group	_	_	O
234	.	_	_	O

235	170	_	_	O
236	patients	_	_	O
237	in	_	_	O
238	the	_	_	O
239	2-weekly	_	_	O
240	group	_	_	O
241	and	_	_	O
242	176	_	_	O
243	in	_	_	O
244	the	_	_	O
245	3-weekly	_	_	O
246	group	_	_	O
247	were	_	_	O
248	included	_	_	O
249	in	_	_	O
250	the	_	_	O
251	analysis	_	_	O
252	.	_	_	O

253	The	_	_	B-Premise
254	2-weekly	_	_	I-Premise
255	administration	_	_	I-Premise
256	was	_	_	I-Premise
257	associated	_	_	I-Premise
258	with	_	_	I-Premise
259	significantly	_	_	I-Premise
260	longer	_	_	I-Premise
261	TTTF	_	_	I-Premise
262	than	_	_	I-Premise
263	was	_	_	I-Premise
264	3-weekly	_	_	I-Premise
265	administration	_	_	I-Premise
266	(	_	_	I-Premise
267	5Â·6	_	_	I-Premise
268	months	_	_	I-Premise
269	,	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	5Â·0-6Â·2	_	_	I-Premise
274	vs	_	_	I-Premise
275	4Â·9	_	_	I-Premise
276	months	_	_	I-Premise
277	,	_	_	I-Premise
278	4Â·5-5Â·4	_	_	I-Premise
279	;	_	_	I-Premise
280	hazard	_	_	I-Premise
281	ratio	_	_	I-Premise
282	1Â·3	_	_	I-Premise
283	,	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	1Â·1-1Â·6	_	_	I-Premise
288	,	_	_	I-Premise
289	p=0Â·014	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Grade	_	_	B-Premise
293	3-4	_	_	I-Premise
294	adverse	_	_	I-Premise
295	events	_	_	I-Premise
296	occurred	_	_	I-Premise
297	more	_	_	I-Premise
298	frequently	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	3-weekly	_	_	I-Premise
302	than	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	2-weekly	_	_	I-Premise
306	administration	_	_	I-Premise
307	group	_	_	I-Premise
308	,	_	_	I-Premise
309	including	_	_	I-Premise
310	neutropenia	_	_	I-Premise
311	(	_	_	I-Premise
312	93	_	_	I-Premise
313	[	_	_	I-Premise
314	53	_	_	I-Premise
315	%	_	_	I-Premise
316	]	_	_	I-Premise
317	vs	_	_	I-Premise
318	61	_	_	I-Premise
319	[	_	_	I-Premise
320	36	_	_	I-Premise
321	%	_	_	I-Premise
322	]	_	_	I-Premise
323	)	_	_	I-Premise
324	,	_	_	I-Premise
325	leucopenia	_	_	I-Premise
326	(	_	_	I-Premise
327	51	_	_	I-Premise
328	[	_	_	I-Premise
329	29	_	_	I-Premise
330	%	_	_	I-Premise
331	]	_	_	I-Premise
332	vs	_	_	I-Premise
333	22	_	_	I-Premise
334	[	_	_	I-Premise
335	13	_	_	I-Premise
336	%	_	_	I-Premise
337	]	_	_	I-Premise
338	)	_	_	I-Premise
339	,	_	_	I-Premise
340	and	_	_	I-Premise
341	febrile	_	_	I-Premise
342	neutropenia	_	_	I-Premise
343	(	_	_	I-Premise
344	25	_	_	I-Premise
345	[	_	_	I-Premise
346	14	_	_	I-Premise
347	%	_	_	I-Premise
348	]	_	_	I-Premise
349	vs	_	_	I-Premise
350	six	_	_	I-Premise
351	[	_	_	I-Premise
352	4	_	_	I-Premise
353	%	_	_	I-Premise
354	]	_	_	I-Premise
355	)	_	_	I-Premise
356	.	_	_	I-Premise

357	Neutropenic	_	_	B-Premise
358	infections	_	_	I-Premise
359	were	_	_	I-Premise
360	reported	_	_	I-Premise
361	more	_	_	I-Premise
362	frequently	_	_	I-Premise
363	in	_	_	I-Premise
364	patients	_	_	I-Premise
365	who	_	_	I-Premise
366	received	_	_	I-Premise
367	docetaxel	_	_	I-Premise
368	every	_	_	I-Premise
369	3	_	_	I-Premise
370	weeks	_	_	I-Premise
371	(	_	_	I-Premise
372	43	_	_	I-Premise
373	[	_	_	I-Premise
374	24	_	_	I-Premise
375	%	_	_	I-Premise
376	]	_	_	I-Premise
377	vs	_	_	I-Premise
378	11	_	_	I-Premise
379	[	_	_	I-Premise
380	6	_	_	I-Premise
381	%	_	_	I-Premise
382	]	_	_	I-Premise
383	,	_	_	I-Premise
384	p=0Â·002	_	_	I-Premise
385	)	_	_	I-Premise
386	.	_	_	I-Premise

387	Administration	_	_	B-Claim
388	of	_	_	I-Claim
389	docetaxel	_	_	I-Claim
390	every	_	_	I-Claim
391	2	_	_	I-Claim
392	weeks	_	_	I-Claim
393	seems	_	_	I-Claim
394	to	_	_	I-Claim
395	be	_	_	I-Claim
396	well	_	_	I-Claim
397	tolerated	_	_	I-Claim
398	in	_	_	I-Claim
399	patients	_	_	I-Claim
400	with	_	_	I-Claim
401	castration-resistant	_	_	I-Claim
402	advanced	_	_	I-Claim
403	prostate	_	_	I-Claim
404	cancer	_	_	I-Claim
405	and	_	_	I-Claim
406	could	_	_	I-Claim
407	be	_	_	I-Claim
408	a	_	_	I-Claim
409	useful	_	_	I-Claim
410	option	_	_	I-Claim
411	when	_	_	I-Claim
412	3-weekly	_	_	I-Claim
413	single-dose	_	_	I-Claim
414	administration	_	_	I-Claim
415	is	_	_	I-Claim
416	unlikely	_	_	I-Claim
417	to	_	_	I-Claim
418	be	_	_	I-Claim
419	tolerated	_	_	I-Claim
420	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	gastric	_	_	I-Claim
5	or	_	_	I-Claim
6	gastroesophageal	_	_	I-Claim
7	cancer	_	_	I-Claim
8	(	_	_	I-Claim
9	AGGEC	_	_	I-Claim
10	)	_	_	I-Claim
11	providing	_	_	I-Claim
12	clinical	_	_	I-Claim
13	benefit	_	_	I-Claim
14	with	_	_	I-Claim
15	improved	_	_	I-Claim
16	palliation	_	_	I-Claim
17	is	_	_	I-Claim
18	highly	_	_	I-Claim
19	desirable	_	_	I-Claim
20	.	_	_	I-Claim

21	However	_	_	O
22	,	_	_	O
23	a	_	_	O
24	prospective	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	clinical	_	_	O
28	benefit	_	_	O
29	in	_	_	O
30	AGGEC	_	_	O
31	patients	_	_	O
32	has	_	_	O
33	never	_	_	O
34	before	_	_	O
35	been	_	_	O
36	reported	_	_	O
37	in	_	_	O
38	a	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	setting	_	_	O
42	.	_	_	O

43	In	_	_	O
44	a	_	_	O
45	multinational	_	_	O
46	trial	_	_	O
47	(	_	_	O
48	V325	_	_	O
49	)	_	_	O
50	,	_	_	O
51	445	_	_	O
52	patients	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	and	_	_	O
57	treated	_	_	O
58	with	_	_	O
59	either	_	_	O
60	docetaxel	_	_	O
61	plus	_	_	O
62	cisplatin	_	_	O
63	and	_	_	O
64	fluorouracil	_	_	O
65	(	_	_	O
66	DCF	_	_	O
67	)	_	_	O
68	or	_	_	O
69	cisplatin	_	_	O
70	and	_	_	O
71	fluorouracil	_	_	O
72	(	_	_	O
73	CF	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Clinical	_	_	O
77	benefit	_	_	O
78	was	_	_	O
79	prospectively	_	_	O
80	evaluated	_	_	O
81	in	_	_	O
82	this	_	_	O
83	trial	_	_	O
84	as	_	_	O
85	a	_	_	O
86	secondary	_	_	O
87	end	_	_	O
88	point	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	measure	_	_	O
93	for	_	_	O
94	clinical	_	_	O
95	benefit	_	_	O
96	analysis	_	_	O
97	was	_	_	O
98	time	_	_	O
99	to	_	_	O
100	definitive	_	_	O
101	worsening	_	_	O
102	by	_	_	O
103	one	_	_	O
104	or	_	_	O
105	more	_	_	O
106	categories	_	_	O
107	of	_	_	O
108	Karnofsky	_	_	O
109	performance	_	_	O
110	status	_	_	O
111	(	_	_	O
112	KPS	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	clinical	_	_	O
117	benefit	_	_	O
118	end	_	_	O
119	points	_	_	O
120	included	_	_	O
121	time	_	_	O
122	to	_	_	O
123	5	_	_	O
124	%	_	_	O
125	definitive	_	_	O
126	weight	_	_	O
127	loss	_	_	O
128	,	_	_	O
129	time	_	_	O
130	to	_	_	O
131	definitive	_	_	O
132	worsening	_	_	O
133	of	_	_	O
134	appetite	_	_	O
135	by	_	_	O
136	one	_	_	O
137	grade	_	_	O
138	,	_	_	O
139	pain-free	_	_	O
140	survival	_	_	O
141	(	_	_	O
142	defined	_	_	O
143	as	_	_	O
144	time	_	_	O
145	to	_	_	O
146	first	_	_	O
147	appearance	_	_	O
148	of	_	_	O
149	pain	_	_	O
150	)	_	_	O
151	,	_	_	O
152	and	_	_	O
153	time	_	_	O
154	to	_	_	O
155	first	_	_	O
156	cancer	_	_	O
157	pain-related	_	_	O
158	opioid	_	_	O
159	intake	_	_	O
160	.	_	_	O

161	Clinical	_	_	O
162	benefit	_	_	O
163	assessments	_	_	O
164	were	_	_	O
165	recorded	_	_	O
166	at	_	_	O
167	each	_	_	O
168	clinic	_	_	O
169	visit	_	_	O
170	.	_	_	O

171	Clinical	_	_	O
172	benefit	_	_	O
173	assessments	_	_	O
174	were	_	_	O
175	performed	_	_	O
176	in	_	_	O
177	more	_	_	O
178	than	_	_	O
179	75	_	_	O
180	%	_	_	O
181	of	_	_	O
182	patients	_	_	O
183	throughout	_	_	O
184	V325	_	_	O
185	.	_	_	O

186	DCF	_	_	B-Premise
187	significantly	_	_	I-Premise
188	prolonged	_	_	I-Premise
189	time	_	_	I-Premise
190	to	_	_	I-Premise
191	definitive	_	_	I-Premise
192	worsening	_	_	I-Premise
193	of	_	_	I-Premise
194	KPS	_	_	I-Premise
195	compared	_	_	I-Premise
196	with	_	_	I-Premise
197	CF	_	_	I-Premise
198	(	_	_	I-Premise
199	median	_	_	I-Premise
200	,	_	_	I-Premise
201	6.1	_	_	I-Premise
202	v	_	_	I-Premise
203	4.8	_	_	I-Premise
204	months	_	_	I-Premise
205	;	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	,	_	_	I-Premise
209	1.38	_	_	I-Premise
210	;	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	CI	_	_	I-Premise
214	,	_	_	I-Premise
215	1.08	_	_	I-Premise
216	to	_	_	I-Premise
217	1.76	_	_	I-Premise
218	;	_	_	I-Premise
219	log-rank	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	.009	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Although	_	_	B-Premise
226	time	_	_	I-Premise
227	to	_	_	I-Premise
228	definitive	_	_	I-Premise
229	weight	_	_	I-Premise
230	loss	_	_	I-Premise
231	and	_	_	I-Premise
232	time	_	_	I-Premise
233	to	_	_	I-Premise
234	definitive	_	_	I-Premise
235	worsening	_	_	I-Premise
236	of	_	_	I-Premise
237	appetite	_	_	I-Premise
238	favored	_	_	I-Premise
239	DCF	_	_	I-Premise
240	,	_	_	I-Premise
241	the	_	_	B-Premise
242	results	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	statistically	_	_	I-Premise
246	significant	_	_	I-Premise
247	.	_	_	I-Premise

248	Pain-free	_	_	B-Premise
249	survival	_	_	I-Premise
250	and	_	_	I-Premise
251	time	_	_	I-Premise
252	to	_	_	I-Premise
253	first	_	_	I-Premise
254	cancer	_	_	I-Premise
255	pain-related	_	_	I-Premise
256	opioid	_	_	I-Premise
257	intake	_	_	I-Premise
258	were	_	_	I-Premise
259	comparable	_	_	I-Premise
260	.	_	_	I-Premise

261	To	_	_	O
262	our	_	_	O
263	knowledge	_	_	O
264	,	_	_	O
265	V325	_	_	O
266	is	_	_	O
267	the	_	_	O
268	first	_	_	O
269	phase	_	_	O
270	III	_	_	O
271	trial	_	_	O
272	to	_	_	O
273	report	_	_	O
274	clinical	_	_	O
275	benefit	_	_	O
276	in	_	_	O
277	AGGEC	_	_	O
278	patients	_	_	O
279	.	_	_	O

280	Clinical	_	_	O
281	benefit	_	_	O
282	was	_	_	O
283	assessed	_	_	O
284	beyond	_	_	O
285	protocol-specific	_	_	O
286	chemotherapy	_	_	O
287	.	_	_	O

288	The	_	_	B-Claim
289	addition	_	_	I-Claim
290	of	_	_	I-Claim
291	D	_	_	I-Claim
292	to	_	_	I-Claim
293	CF	_	_	I-Claim
294	not	_	_	I-Claim
295	only	_	_	I-Claim
296	significantly	_	_	I-Claim
297	improved	_	_	I-Claim
298	clinical	_	_	I-Claim
299	benefit	_	_	I-Claim
300	but	_	_	I-Claim
301	also	_	_	I-Claim
302	improved	_	_	I-Claim
303	quality	_	_	I-Claim
304	of	_	_	I-Claim
305	life	_	_	I-Claim
306	,	_	_	I-Claim
307	time	_	_	I-Claim
308	to	_	_	I-Claim
309	progression	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	overall	_	_	I-Claim
313	survival	_	_	I-Claim
314	compared	_	_	I-Claim
315	with	_	_	I-Claim
316	CF	_	_	I-Claim
317	.	_	_	I-Claim


0	The	_	_	O
1	addition	_	_	O
2	of	_	_	O
3	mTOR	_	_	O
4	inhibitor	_	_	O
5	everolimus	_	_	O
6	(	_	_	O
7	EVE	_	_	O
8	)	_	_	O
9	to	_	_	O
10	exemestane	_	_	O
11	(	_	_	O
12	EXE	_	_	O
13	)	_	_	O
14	was	_	_	O
15	evaluated	_	_	O
16	in	_	_	O
17	an	_	_	O
18	international	_	_	O
19	,	_	_	O
20	phase	_	_	O
21	3	_	_	O
22	study	_	_	O
23	(	_	_	O
24	BOLERO-2	_	_	O
25	)	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	hormone-receptor-positive	_	_	O
30	(	_	_	O
31	HR	_	_	O
32	(	_	_	O
33	+	_	_	O
34	)	_	_	O
35	)	_	_	O
36	breast	_	_	O
37	cancer	_	_	O
38	refractory	_	_	O
39	to	_	_	O
40	letrozole	_	_	O
41	or	_	_	O
42	anastrozole	_	_	O
43	.	_	_	O

44	The	_	_	O
45	safety	_	_	O
46	and	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	anticancer	_	_	O
50	treatments	_	_	O
51	may	_	_	O
52	be	_	_	O
53	influenced	_	_	O
54	by	_	_	O
55	ethnicity	_	_	O
56	(	_	_	O
57	Sekine	_	_	O
58	et	_	_	O
59	al	_	_	O
60	.	_	_	O

61	in	_	_	O
62	Br	_	_	O
63	J	_	_	O
64	Cancer	_	_	O
65	99:1757-62	_	_	O
66	,	_	_	O
67	2008	_	_	O
68	)	_	_	O
69	.	_	_	O

70	Safety	_	_	O
71	and	_	_	O
72	efficacy	_	_	O
73	results	_	_	O
74	from	_	_	O
75	Asian	_	_	O
76	versus	_	_	O
77	non-Asian	_	_	O
78	patients	_	_	O
79	in	_	_	O
80	BOLERO-2	_	_	O
81	are	_	_	O
82	reported	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	were	_	_	O
86	randomized	_	_	O
87	(	_	_	O
88	2:1	_	_	O
89	)	_	_	O
90	to	_	_	O
91	10	_	_	O
92	mg/day	_	_	O
93	EVE	_	_	O
94	+	_	_	O
95	EXE	_	_	O
96	or	_	_	O
97	placebo	_	_	O
98	(	_	_	O
99	PBO	_	_	O
100	)	_	_	O
101	+	_	_	O
102	EXE	_	_	O
103	.	_	_	O

104	Primary	_	_	O
105	endpoint	_	_	O
106	was	_	_	O
107	progression-free	_	_	O
108	survival	_	_	O
109	(	_	_	O
110	PFS	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Secondary	_	_	O
114	endpoints	_	_	O
115	included	_	_	O
116	overall	_	_	O
117	survival	_	_	O
118	,	_	_	O
119	response	_	_	O
120	rate	_	_	O
121	,	_	_	O
122	clinical	_	_	O
123	benefit	_	_	O
124	rate	_	_	O
125	,	_	_	O
126	and	_	_	O
127	safety	_	_	O
128	.	_	_	O

129	Of	_	_	O
130	143	_	_	O
131	Asian	_	_	O
132	patients	_	_	O
133	,	_	_	O
134	98	_	_	O
135	received	_	_	O
136	EVE	_	_	O
137	+	_	_	O
138	EXE	_	_	O
139	and	_	_	O
140	45	_	_	O
141	received	_	_	O
142	PBO	_	_	O
143	+	_	_	O
144	EXE	_	_	O
145	.	_	_	O

146	Treatment	_	_	B-Premise
147	with	_	_	I-Premise
148	EVE	_	_	I-Premise
149	+	_	_	I-Premise
150	EXE	_	_	I-Premise
151	significantly	_	_	I-Premise
152	improved	_	_	I-Premise
153	median	_	_	I-Premise
154	PFS	_	_	I-Premise
155	versus	_	_	I-Premise
156	PBO	_	_	I-Premise
157	+	_	_	I-Premise
158	EXE	_	_	I-Premise
159	among	_	_	I-Premise
160	Asian	_	_	I-Premise
161	patients	_	_	I-Premise
162	by	_	_	I-Premise
163	38	_	_	I-Premise
164	%	_	_	I-Premise
165	(	_	_	I-Premise
166	HR	_	_	I-Premise
167	=	_	_	I-Premise
168	0.62	_	_	I-Premise
169	;	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	,	_	_	I-Premise
174	0.41-0.94	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	Median	_	_	B-Premise
178	PFS	_	_	I-Premise
179	was	_	_	I-Premise
180	also	_	_	I-Premise
181	improved	_	_	I-Premise
182	among	_	_	I-Premise
183	non-Asian	_	_	I-Premise
184	patients	_	_	I-Premise
185	by	_	_	I-Premise
186	59	_	_	I-Premise
187	%	_	_	I-Premise
188	(	_	_	I-Premise
189	HR	_	_	I-Premise
190	=	_	_	I-Premise
191	0.41	_	_	I-Premise
192	;	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.33-0.50	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Median	_	_	B-Premise
201	PFS	_	_	I-Premise
202	duration	_	_	I-Premise
203	among	_	_	I-Premise
204	EVE-treated	_	_	I-Premise
205	Asian	_	_	I-Premise
206	patients	_	_	I-Premise
207	was	_	_	I-Premise
208	8.48	_	_	I-Premise
209	versus	_	_	I-Premise
210	4.14	_	_	I-Premise
211	months	_	_	I-Premise
212	for	_	_	I-Premise
213	PBO	_	_	I-Premise
214	+	_	_	I-Premise
215	EXE	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	7.33	_	_	I-Premise
219	versus	_	_	I-Premise
220	2.83	_	_	I-Premise
221	months	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	in	_	_	I-Premise
226	non-Asian	_	_	I-Premise
227	patients	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	most	_	_	I-Premise
231	common	_	_	I-Premise
232	grade	_	_	I-Premise
233	3/4	_	_	I-Premise
234	adverse	_	_	I-Premise
235	events	_	_	I-Premise
236	(	_	_	I-Premise
237	stomatitis	_	_	I-Premise
238	,	_	_	I-Premise
239	anemia	_	_	I-Premise
240	,	_	_	I-Premise
241	elevated	_	_	I-Premise
242	liver	_	_	I-Premise
243	enzymes	_	_	I-Premise
244	,	_	_	I-Premise
245	hyperglycemia	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	dyspnea	_	_	I-Premise
249	)	_	_	I-Premise
250	occurred	_	_	I-Premise
251	at	_	_	I-Premise
252	similar	_	_	I-Premise
253	frequencies	_	_	I-Premise
254	in	_	_	I-Premise
255	Asian	_	_	I-Premise
256	and	_	_	I-Premise
257	non-Asian	_	_	I-Premise
258	patients	_	_	I-Premise
259	.	_	_	I-Premise

260	Grade	_	_	B-Premise
261	1/2	_	_	I-Premise
262	interstitial	_	_	I-Premise
263	lung	_	_	I-Premise
264	disease	_	_	I-Premise
265	occurred	_	_	I-Premise
266	more	_	_	I-Premise
267	frequently	_	_	I-Premise
268	in	_	_	I-Premise
269	Asian	_	_	I-Premise
270	patients	_	_	I-Premise
271	.	_	_	I-Premise

272	Quality	_	_	B-Premise
273	of	_	_	I-Premise
274	life	_	_	I-Premise
275	was	_	_	I-Premise
276	similar	_	_	I-Premise
277	between	_	_	I-Premise
278	treatment	_	_	I-Premise
279	arms	_	_	I-Premise
280	in	_	_	I-Premise
281	Asian	_	_	I-Premise
282	patients	_	_	I-Premise
283	.	_	_	I-Premise

284	Adding	_	_	B-Claim
285	EVE	_	_	I-Claim
286	to	_	_	I-Claim
287	EXE	_	_	I-Claim
288	provided	_	_	I-Claim
289	substantial	_	_	I-Claim
290	clinical	_	_	I-Claim
291	benefit	_	_	I-Claim
292	in	_	_	I-Claim
293	both	_	_	I-Claim
294	Asian	_	_	I-Claim
295	and	_	_	I-Claim
296	non-Asian	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	similar	_	_	I-Claim
300	safety	_	_	I-Claim
301	profiles	_	_	I-Claim
302	.	_	_	I-Claim

303	This	_	_	B-Claim
304	combination	_	_	I-Claim
305	represents	_	_	I-Claim
306	an	_	_	I-Claim
307	improvement	_	_	I-Claim
308	in	_	_	I-Claim
309	the	_	_	I-Claim
310	management	_	_	I-Claim
311	of	_	_	I-Claim
312	postmenopausal	_	_	I-Claim
313	women	_	_	I-Claim
314	with	_	_	I-Claim
315	HR	_	_	I-Claim
316	(	_	_	I-Claim
317	+	_	_	I-Claim
318	)	_	_	I-Claim
319	/HER2	_	_	I-Claim
320	(	_	_	I-Claim
321	-	_	_	I-Claim
322	)	_	_	I-Claim
323	advanced	_	_	I-Claim
324	breast	_	_	I-Claim
325	cancer	_	_	I-Claim
326	progressing	_	_	I-Claim
327	on	_	_	I-Claim
328	nonsteroidal	_	_	I-Claim
329	aromatase	_	_	I-Claim
330	inhibitors	_	_	I-Claim
331	,	_	_	I-Claim
332	regardless	_	_	I-Claim
333	of	_	_	I-Claim
334	ethnicity	_	_	I-Claim
335	.	_	_	I-Claim


0	Older	_	_	B-Claim
1	patients	_	_	I-Claim
2	,	_	_	I-Claim
3	even	_	_	I-Claim
4	if	_	_	I-Claim
5	fit	_	_	I-Claim
6	,	_	_	I-Claim
7	are	_	_	I-Claim
8	often	_	_	I-Claim
9	considered	_	_	I-Claim
10	incapable	_	_	I-Claim
11	of	_	_	I-Claim
12	tolerating	_	_	I-Claim
13	platinum-based	_	_	I-Claim
14	systemic	_	_	I-Claim
15	therapy	_	_	I-Claim
16	.	_	_	I-Claim

17	We	_	_	O
18	performed	_	_	O
19	a	_	_	O
20	retrospective	_	_	O
21	analysis	_	_	O
22	of	_	_	O
23	Eastern	_	_	O
24	Cooperative	_	_	O
25	Oncology	_	_	O
26	Group	_	_	O
27	(	_	_	O
28	ECOG	_	_	O
29	)	_	_	O
30	5592	_	_	O
31	,	_	_	O
32	a	_	_	O
33	phase	_	_	O
34	III	_	_	O
35	randomized	_	_	O
36	trial	_	_	O
37	of	_	_	O
38	platinum-based	_	_	O
39	chemotherapy	_	_	O
40	regimens	_	_	O
41	for	_	_	O
42	non-small-cell	_	_	O
43	lung	_	_	O
44	cancer	_	_	O
45	(	_	_	O
46	NSCLC	_	_	O
47	)	_	_	O
48	,	_	_	O
49	and	_	_	O
50	compared	_	_	O
51	outcomes	_	_	O
52	in	_	_	O
53	enrollees	_	_	O
54	70	_	_	O
55	years	_	_	O
56	of	_	_	O
57	age	_	_	O
58	and	_	_	O
59	older	_	_	O
60	with	_	_	O
61	those	_	_	O
62	in	_	_	O
63	younger	_	_	O
64	patients	_	_	O
65	.	_	_	O

66	ECOG	_	_	O
67	carried	_	_	O
68	out	_	_	O
69	a	_	_	O
70	randomized	_	_	O
71	phase	_	_	O
72	III	_	_	O
73	trial	_	_	O
74	of	_	_	O
75	cisplatin	_	_	O
76	plus	_	_	O
77	either	_	_	O
78	etoposide	_	_	O
79	or	_	_	O
80	paclitaxel	_	_	O
81	in	_	_	O
82	chemotherapy-naÃ¯ve	_	_	O
83	NSCLC	_	_	O
84	patients	_	_	O
85	with	_	_	O
86	stages	_	_	O
87	III	_	_	O
88	(	_	_	O
89	B	_	_	O
90	)	_	_	O
91	or	_	_	O
92	IV	_	_	O
93	disease	_	_	O
94	.	_	_	O

95	Toxic	_	_	O
96	effects	_	_	O
97	,	_	_	O
98	response	_	_	O
99	rates	_	_	O
100	,	_	_	O
101	and	_	_	O
102	survival	_	_	O
103	rates	_	_	O
104	were	_	_	O
105	compared	_	_	O
106	between	_	_	O
107	age	_	_	O
108	groups	_	_	O
109	.	_	_	O

110	All	_	_	O
111	P	_	_	O
112	values	_	_	O
113	were	_	_	O
114	two-sided	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	574	_	_	O
120	patients	_	_	O
121	enrolled	_	_	O
122	from	_	_	O
123	August	_	_	O
124	1993	_	_	O
125	through	_	_	O
126	December	_	_	O
127	1994	_	_	O
128	were	_	_	O
129	evaluable	_	_	O
130	.	_	_	O

131	Eighty-six	_	_	O
132	(	_	_	O
133	15	_	_	O
134	%	_	_	O
135	)	_	_	O
136	were	_	_	O
137	70	_	_	O
138	years	_	_	O
139	old	_	_	O
140	or	_	_	O
141	older	_	_	O
142	.	_	_	O

143	Older	_	_	B-Premise
144	patients	_	_	I-Premise
145	had	_	_	I-Premise
146	a	_	_	I-Premise
147	higher	_	_	I-Premise
148	incidence	_	_	I-Premise
149	of	_	_	I-Premise
150	cardiovascular	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=.009	_	_	I-Premise
154	)	_	_	I-Premise
155	and	_	_	I-Premise
156	respiratory	_	_	I-Premise
157	(	_	_	I-Premise
158	P	_	_	I-Premise
159	=.04	_	_	I-Premise
160	)	_	_	I-Premise
161	comorbidities	_	_	I-Premise
162	and	_	_	I-Premise
163	nonanalgesic	_	_	I-Premise
164	medication	_	_	I-Premise
165	use	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	=.02	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Leukopenia	_	_	B-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.001	_	_	I-Premise
176	)	_	_	I-Premise
177	and	_	_	I-Premise
178	neuropsychiatric	_	_	I-Premise
179	toxicity	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	=.002	_	_	I-Premise
183	)	_	_	I-Premise
184	were	_	_	I-Premise
185	more	_	_	I-Premise
186	common	_	_	I-Premise
187	in	_	_	I-Premise
188	elderly	_	_	I-Premise
189	men	_	_	I-Premise
190	than	_	_	I-Premise
191	in	_	_	I-Premise
192	younger	_	_	I-Premise
193	men	_	_	I-Premise
194	.	_	_	I-Premise

195	Elderly	_	_	B-Premise
196	women	_	_	I-Premise
197	lost	_	_	I-Premise
198	more	_	_	I-Premise
199	weight	_	_	I-Premise
200	than	_	_	I-Premise
201	younger	_	_	I-Premise
202	women	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=.006	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Other	_	_	B-Premise
209	toxic	_	_	I-Premise
210	effects	_	_	I-Premise
211	were	_	_	I-Premise
212	similar	_	_	I-Premise
213	in	_	_	I-Premise
214	older	_	_	I-Premise
215	and	_	_	I-Premise
216	younger	_	_	I-Premise
217	patients	_	_	I-Premise
218	.	_	_	I-Premise

219	The	_	_	B-Premise
220	proportions	_	_	I-Premise
221	with	_	_	I-Premise
222	clinical	_	_	I-Premise
223	partial	_	_	I-Premise
224	or	_	_	I-Premise
225	complete	_	_	I-Premise
226	response	_	_	I-Premise
227	(	_	_	I-Premise
228	21.5	_	_	I-Premise
229	%	_	_	I-Premise
230	versus	_	_	I-Premise
231	23.3	_	_	I-Premise
232	%	_	_	I-Premise
233	;	_	_	I-Premise
234	Fisher	_	_	I-Premise
235	's	_	_	I-Premise
236	exact	_	_	I-Premise
237	test	_	_	I-Premise
238	,	_	_	I-Premise
239	P	_	_	I-Premise
240	=.66	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	median	_	_	I-Premise
244	time	_	_	I-Premise
245	to	_	_	I-Premise
246	progression	_	_	I-Premise
247	(	_	_	I-Premise
248	4.37	_	_	I-Premise
249	versus	_	_	I-Premise
250	4.30	_	_	I-Premise
251	months	_	_	I-Premise
252	;	_	_	I-Premise
253	log-rank	_	_	I-Premise
254	test	_	_	I-Premise
255	,	_	_	I-Premise
256	P	_	_	I-Premise
257	=.29	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	survival	_	_	I-Premise
262	distribution	_	_	I-Premise
263	(	_	_	I-Premise
264	log-rank	_	_	I-Premise
265	test	_	_	I-Premise
266	,	_	_	I-Premise
267	P	_	_	I-Premise
268	=.29	_	_	I-Premise
269	;	_	_	I-Premise
270	median	_	_	I-Premise
271	survival	_	_	I-Premise
272	,	_	_	I-Premise
273	9.05	_	_	I-Premise
274	versus	_	_	I-Premise
275	8.53	_	_	I-Premise
276	months	_	_	I-Premise
277	;	_	_	I-Premise
278	1-year	_	_	I-Premise
279	survival	_	_	I-Premise
280	,	_	_	I-Premise
281	38	_	_	I-Premise
282	%	_	_	I-Premise
283	versus	_	_	I-Premise
284	29	_	_	I-Premise
285	%	_	_	I-Premise
286	;	_	_	I-Premise
287	and	_	_	I-Premise
288	2-year	_	_	I-Premise
289	survival	_	_	I-Premise
290	,	_	_	I-Premise
291	14	_	_	I-Premise
292	%	_	_	I-Premise
293	versus	_	_	I-Premise
294	12	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	were	_	_	I-Premise
298	similar	_	_	I-Premise
299	in	_	_	I-Premise
300	patients	_	_	I-Premise
301	younger	_	_	I-Premise
302	than	_	_	I-Premise
303	70	_	_	I-Premise
304	years	_	_	I-Premise
305	and	_	_	I-Premise
306	70	_	_	I-Premise
307	years	_	_	I-Premise
308	old	_	_	I-Premise
309	or	_	_	I-Premise
310	older	_	_	I-Premise
311	.	_	_	I-Premise

312	Baseline	_	_	B-Premise
313	quality-of-life	_	_	I-Premise
314	and	_	_	I-Premise
315	treatment-outcome	_	_	I-Premise
316	indices	_	_	I-Premise
317	were	_	_	I-Premise
318	similar	_	_	I-Premise
319	.	_	_	I-Premise

320	Equivalent	_	_	B-Premise
321	declines	_	_	I-Premise
322	over	_	_	I-Premise
323	time	_	_	I-Premise
324	in	_	_	I-Premise
325	functional	_	_	I-Premise
326	well-being	_	_	I-Premise
327	occurred	_	_	I-Premise
328	in	_	_	I-Premise
329	both	_	_	I-Premise
330	groups	_	_	I-Premise
331	.	_	_	I-Premise

332	Response	_	_	B-Claim
333	rate	_	_	I-Claim
334	,	_	_	I-Claim
335	toxicity	_	_	I-Claim
336	,	_	_	I-Claim
337	and	_	_	I-Claim
338	survival	_	_	I-Claim
339	in	_	_	I-Claim
340	fit	_	_	I-Claim
341	,	_	_	I-Claim
342	elderly	_	_	I-Claim
343	NSCLC	_	_	I-Claim
344	patients	_	_	I-Claim
345	receiving	_	_	I-Claim
346	platinum-based	_	_	I-Claim
347	treatment	_	_	I-Claim
348	appear	_	_	I-Claim
349	to	_	_	I-Claim
350	be	_	_	I-Claim
351	similar	_	_	I-Claim
352	to	_	_	I-Claim
353	those	_	_	I-Claim
354	in	_	_	I-Claim
355	younger	_	_	I-Claim
356	patients	_	_	I-Claim
357	,	_	_	I-Claim
358	although	_	_	B-Claim
359	patients	_	_	I-Claim
360	70	_	_	I-Claim
361	years	_	_	I-Claim
362	old	_	_	I-Claim
363	or	_	_	I-Claim
364	older	_	_	I-Claim
365	have	_	_	I-Claim
366	more	_	_	I-Claim
367	comorbidities	_	_	I-Claim
368	and	_	_	I-Claim
369	can	_	_	I-Claim
370	expect	_	_	I-Claim
371	more	_	_	I-Claim
372	leukopenia	_	_	I-Claim
373	and	_	_	I-Claim
374	neuropsychiatric	_	_	I-Claim
375	toxicity	_	_	I-Claim
376	.	_	_	I-Claim

377	Advanced	_	_	B-Claim
378	age	_	_	I-Claim
379	alone	_	_	I-Claim
380	should	_	_	I-Claim
381	not	_	_	I-Claim
382	preclude	_	_	I-Claim
383	appropriate	_	_	I-Claim
384	NSCLC	_	_	I-Claim
385	treatment	_	_	I-Claim
386	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	two	_	_	O
6	doses	_	_	O
7	of	_	_	O
8	megestrol	_	_	O
9	acetate	_	_	O
10	(	_	_	O
11	MA	_	_	O
12	)	_	_	O
13	compared	_	_	O
14	with	_	_	O
15	placebo	_	_	O
16	on	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	(	_	_	O
21	QoL	_	_	O
22	)	_	_	O
23	and	_	_	O
24	nutritional	_	_	O
25	status	_	_	O
26	(	_	_	O
27	NS	_	_	O
28	)	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	advanced	_	_	O
33	endocrine-insensitive	_	_	O
34	cancer	_	_	O
35	.	_	_	O

36	Two	_	_	O
37	hundred	_	_	O
38	forty	_	_	O
39	patients	_	_	O
40	were	_	_	O
41	randomised	_	_	O
42	to	_	_	O
43	double-blind	_	_	O
44	MA	_	_	O
45	480	_	_	O
46	mg/day	_	_	O
47	,	_	_	O
48	MA	_	_	O
49	160	_	_	O
50	mg/day	_	_	O
51	,	_	_	O
52	or	_	_	O
53	matching	_	_	O
54	placebo	_	_	O
55	for	_	_	O
56	12	_	_	O
57	weeks	_	_	O
58	.	_	_	O

59	Nutritional	_	_	O
60	status	_	_	O
61	(	_	_	O
62	including	_	_	O
63	weight	_	_	O
64	,	_	_	O
65	skinfold	_	_	O
66	thickness	_	_	O
67	and	_	_	O
68	midarm	_	_	O
69	circumference	_	_	O
70	)	_	_	O
71	and	_	_	O
72	QoL	_	_	O
73	(	_	_	O
74	using	_	_	O
75	6	_	_	O
76	linear	_	_	O
77	analogue	_	_	O
78	self-assessment	_	_	O
79	(	_	_	O
80	LASA	_	_	O
81	)	_	_	O
82	scales	_	_	O
83	)	_	_	O
84	were	_	_	O
85	assessed	_	_	O
86	at	_	_	O
87	randomisation	_	_	O
88	and	_	_	O
89	after	_	_	O
90	four	_	_	O
91	,	_	_	O
92	eight	_	_	O
93	and	_	_	O
94	12	_	_	O
95	weeks	_	_	O
96	.	_	_	O

97	A	_	_	O
98	QoL	_	_	O
99	ranking	_	_	O
100	incorporating	_	_	O
101	QoL	_	_	O
102	and	_	_	O
103	death	_	_	O
104	was	_	_	O
105	also	_	_	O
106	used	_	_	O
107	ranging	_	_	O
108	from	_	_	O
109	1	_	_	O
110	=	_	_	O
111	dead	_	_	O
112	to	_	_	O
113	5	_	_	O
114	=	_	_	O
115	much	_	_	O
116	better	_	_	O
117	QoL	_	_	O
118	.	_	_	O

119	One	_	_	O
120	hundred	_	_	O
121	seventy-four	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	assessable	_	_	O
125	at	_	_	O
126	week	_	_	O
127	four	_	_	O
128	,	_	_	O
129	136	_	_	O
130	at	_	_	O
131	week	_	_	O
132	eight	_	_	O
133	and	_	_	O
134	103	_	_	O
135	patients	_	_	O
136	at	_	_	O
137	week	_	_	O
138	12	_	_	O
139	.	_	_	O

140	Patients	_	_	B-Premise
141	receiving	_	_	I-Premise
142	MA	_	_	I-Premise
143	reported	_	_	I-Premise
144	substantially	_	_	I-Premise
145	better	_	_	I-Premise
146	appetite	_	_	I-Premise
147	(	_	_	I-Premise
148	P	_	_	I-Premise
149	=	_	_	I-Premise
150	0.001	_	_	I-Premise
151	)	_	_	I-Premise
152	,	_	_	I-Premise
153	mood	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.001	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	overall	_	_	I-Premise
161	quality	_	_	I-Premise
162	of	_	_	I-Premise
163	life	_	_	I-Premise
164	(	_	_	I-Premise
165	P	_	_	I-Premise
166	<	_	_	I-Premise
167	0.001	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	possibly	_	_	I-Premise
172	less	_	_	I-Premise
173	nausea	_	_	I-Premise
174	and	_	_	I-Premise
175	vomiting	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	0.08	_	_	I-Premise
180	)	_	_	I-Premise
181	than	_	_	I-Premise
182	patients	_	_	I-Premise
183	receiving	_	_	I-Premise
184	placebo	_	_	I-Premise
185	,	_	_	I-Premise
186	based	_	_	I-Premise
187	on	_	_	I-Premise
188	a	_	_	I-Premise
189	test	_	_	I-Premise
190	for	_	_	I-Premise
191	trend	_	_	I-Premise
192	.	_	_	I-Premise

193	A	_	_	B-Premise
194	larger	_	_	I-Premise
195	benefit	_	_	I-Premise
196	was	_	_	I-Premise
197	seen	_	_	I-Premise
198	with	_	_	I-Premise
199	the	_	_	I-Premise
200	higher	_	_	I-Premise
201	dose	_	_	I-Premise
202	which	_	_	I-Premise
203	(	_	_	I-Premise
204	unlike	_	_	I-Premise
205	the	_	_	I-Premise
206	lower	_	_	I-Premise
207	dose	_	_	I-Premise
208	)	_	_	I-Premise
209	was	_	_	I-Premise
210	significantly	_	_	I-Premise
211	better	_	_	I-Premise
212	in	_	_	I-Premise
213	pairwise	_	_	I-Premise
214	comparisons	_	_	I-Premise
215	with	_	_	I-Premise
216	placebo	_	_	I-Premise
217	for	_	_	I-Premise
218	appetite	_	_	I-Premise
219	,	_	_	I-Premise
220	mood	_	_	I-Premise
221	and	_	_	I-Premise
222	overall	_	_	I-Premise
223	QoL	_	_	I-Premise
224	(	_	_	I-Premise
225	each	_	_	I-Premise
226	P	_	_	I-Premise
227	<	_	_	I-Premise
228	or	_	_	I-Premise
229	=	_	_	I-Premise
230	0.001	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Despite	_	_	B-Premise
234	some	_	_	I-Premise
235	missing	_	_	I-Premise
236	data	_	_	I-Premise
237	on	_	_	I-Premise
238	QoL	_	_	I-Premise
239	scores	_	_	I-Premise
240	,	_	_	I-Premise
241	QoL	_	_	I-Premise
242	ranking	_	_	I-Premise
243	was	_	_	I-Premise
244	available	_	_	I-Premise
245	on	_	_	I-Premise
246	227	_	_	I-Premise
247	(	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	of	_	_	I-Premise
252	patients	_	_	I-Premise
253	with	_	_	I-Premise
254	significantly	_	_	I-Premise
255	higher	_	_	I-Premise
256	QoL	_	_	I-Premise
257	ranking	_	_	I-Premise
258	associated	_	_	I-Premise
259	with	_	_	I-Premise
260	MA	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0.002	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Improvements	_	_	B-Premise
268	in	_	_	I-Premise
269	QoL	_	_	I-Premise
270	occurred	_	_	I-Premise
271	early	_	_	I-Premise
272	within	_	_	I-Premise
273	four	_	_	I-Premise
274	weeks	_	_	I-Premise
275	and	_	_	I-Premise
276	were	_	_	I-Premise
277	sustained	_	_	I-Premise
278	.	_	_	I-Premise

279	No	_	_	B-Premise
280	statistically	_	_	I-Premise
281	significant	_	_	I-Premise
282	differences	_	_	I-Premise
283	were	_	_	I-Premise
284	observed	_	_	I-Premise
285	in	_	_	I-Premise
286	NS	_	_	I-Premise
287	measurements	_	_	I-Premise
288	,	_	_	I-Premise
289	including	_	_	I-Premise
290	weight	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	=	_	_	I-Premise
294	0.29	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	Side	_	_	B-Premise
298	effects	_	_	I-Premise
299	of	_	_	I-Premise
300	therapy	_	_	I-Premise
301	were	_	_	I-Premise
302	minor	_	_	I-Premise
303	and	_	_	I-Premise
304	did	_	_	I-Premise
305	not	_	_	I-Premise
306	differ	_	_	I-Premise
307	significantly	_	_	I-Premise
308	across	_	_	I-Premise
309	treatments	_	_	I-Premise
310	.	_	_	I-Premise

311	Megestrol	_	_	B-Claim
312	acetate	_	_	I-Claim
313	given	_	_	I-Claim
314	at	_	_	I-Claim
315	480	_	_	I-Claim
316	mg/day	_	_	I-Claim
317	is	_	_	I-Claim
318	useful	_	_	I-Claim
319	palliation	_	_	I-Claim
320	in	_	_	I-Claim
321	patients	_	_	I-Claim
322	with	_	_	I-Claim
323	endocrine-insensitive	_	_	I-Claim
324	advanced	_	_	I-Claim
325	cancer	_	_	I-Claim
326	.	_	_	I-Claim

327	It	_	_	B-Claim
328	improves	_	_	I-Claim
329	appetite	_	_	I-Claim
330	,	_	_	I-Claim
331	mood	_	_	I-Claim
332	and	_	_	I-Claim
333	overall	_	_	I-Claim
334	quality	_	_	I-Claim
335	of	_	_	I-Claim
336	life	_	_	I-Claim
337	in	_	_	I-Claim
338	these	_	_	I-Claim
339	patients	_	_	I-Claim
340	,	_	_	I-Claim
341	although	_	_	B-Claim
342	not	_	_	I-Claim
343	through	_	_	I-Claim
344	a	_	_	I-Claim
345	direct	_	_	I-Claim
346	effect	_	_	I-Claim
347	on	_	_	I-Claim
348	nutritional	_	_	I-Claim
349	status	_	_	I-Claim
350	.	_	_	I-Claim


0	Suramin	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	novel	_	_	I-Claim
4	agent	_	_	I-Claim
5	that	_	_	I-Claim
6	has	_	_	I-Claim
7	demonstrated	_	_	I-Claim
8	preliminary	_	_	I-Claim
9	evidence	_	_	I-Claim
10	of	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	hormone-refractory	_	_	I-Claim
15	prostate	_	_	I-Claim
16	cancer	_	_	I-Claim
17	(	_	_	I-Claim
18	HRPC	_	_	I-Claim
19	)	_	_	I-Claim
20	.	_	_	I-Claim

21	A	_	_	O
22	prospective	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	was	_	_	O
27	designed	_	_	O
28	to	_	_	O
29	evaluate	_	_	O
30	pain	_	_	O
31	and	_	_	O
32	opioid	_	_	O
33	analgesic	_	_	O
34	intake	_	_	O
35	as	_	_	O
36	surrogates	_	_	O
37	for	_	_	O
38	antitumor	_	_	O
39	response	_	_	O
40	in	_	_	O
41	HRPC	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	significant	_	_	O
45	,	_	_	O
46	opioid	_	_	O
47	analgesic-dependent	_	_	O
48	pain	_	_	O
49	.	_	_	O

50	A	_	_	O
51	double-blind	_	_	O
52	,	_	_	O
53	placebo-controlled	_	_	O
54	trial	_	_	O
55	randomized	_	_	O
56	patients	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	a	_	_	O
60	78-day	_	_	O
61	,	_	_	O
62	outpatient	_	_	O
63	regimen	_	_	O
64	of	_	_	O
65	either	_	_	O
66	suramin	_	_	O
67	plus	_	_	O
68	hydrocortisone	_	_	O
69	(	_	_	O
70	HC	_	_	O
71	,	_	_	O
72	40	_	_	O
73	mg/d	_	_	O
74	)	_	_	O
75	or	_	_	O
76	placebo	_	_	O
77	plus	_	_	O
78	HC	_	_	O
79	.	_	_	O

80	Treatment	_	_	O
81	assignment	_	_	O
82	was	_	_	O
83	unblinded	_	_	O
84	when	_	_	O
85	either	_	_	O
86	disease	_	_	O
87	progression	_	_	O
88	or	_	_	O
89	dose-limiting	_	_	O
90	toxicity	_	_	O
91	occurred	_	_	O
92	;	_	_	O
93	placebo	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	allowed	_	_	O
97	to	_	_	O
98	cross-over	_	_	O
99	to	_	_	O
100	open-label	_	_	O
101	suramin	_	_	O
102	plus	_	_	O
103	HC	_	_	O
104	.	_	_	O

105	In	_	_	O
106	addition	_	_	O
107	to	_	_	O
108	pain	_	_	O
109	and	_	_	O
110	opioid	_	_	O
111	analgesic	_	_	O
112	intake	_	_	O
113	,	_	_	O
114	prostate-specific	_	_	O
115	antigen	_	_	O
116	(	_	_	O
117	PSA	_	_	O
118	)	_	_	O
119	response	_	_	O
120	,	_	_	O
121	time	_	_	O
122	to	_	_	O
123	disease	_	_	O
124	progression	_	_	O
125	,	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	,	_	_	O
130	performance	_	_	O
131	status	_	_	O
132	,	_	_	O
133	and	_	_	O
134	survival	_	_	O
135	were	_	_	O
136	compared	_	_	O
137	.	_	_	O

138	Overall	_	_	B-Premise
139	mean	_	_	I-Premise
140	reductions	_	_	I-Premise
141	in	_	_	I-Premise
142	combined	_	_	I-Premise
143	pain	_	_	I-Premise
144	and	_	_	I-Premise
145	opioid	_	_	I-Premise
146	analgesic	_	_	I-Premise
147	intake	_	_	I-Premise
148	were	_	_	I-Premise
149	greater	_	_	I-Premise
150	for	_	_	I-Premise
151	suramin	_	_	I-Premise
152	plus	_	_	I-Premise
153	HC	_	_	I-Premise
154	(	_	_	I-Premise
155	rank	_	_	I-Premise
156	sum	_	_	I-Premise
157	P	_	_	I-Premise
158	=.0001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	Pain	_	_	B-Premise
162	response	_	_	I-Premise
163	was	_	_	I-Premise
164	achieved	_	_	I-Premise
165	in	_	_	I-Premise
166	a	_	_	I-Premise
167	higher	_	_	I-Premise
168	proportion	_	_	I-Premise
169	of	_	_	I-Premise
170	patients	_	_	I-Premise
171	receiving	_	_	I-Premise
172	suramin	_	_	I-Premise
173	than	_	_	I-Premise
174	placebo	_	_	I-Premise
175	(	_	_	I-Premise
176	43	_	_	I-Premise
177	%	_	_	I-Premise
178	v	_	_	I-Premise
179	28	_	_	I-Premise
180	%	_	_	I-Premise
181	;	_	_	I-Premise
182	P	_	_	I-Premise
183	=.001	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	O
187	duration	_	_	B-Premise
188	of	_	_	I-Premise
189	response	_	_	I-Premise
190	was	_	_	I-Premise
191	longer	_	_	I-Premise
192	for	_	_	I-Premise
193	suramin	_	_	I-Premise
194	responders	_	_	I-Premise
195	(	_	_	I-Premise
196	median	_	_	I-Premise
197	,	_	_	I-Premise
198	240	_	_	I-Premise
199	v	_	_	I-Premise
200	69	_	_	I-Premise
201	days	_	_	I-Premise
202	;	_	_	I-Premise
203	P	_	_	I-Premise
204	=.0027	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Time	_	_	B-Premise
208	to	_	_	I-Premise
209	disease	_	_	I-Premise
210	progression	_	_	I-Premise
211	was	_	_	I-Premise
212	longer	_	_	I-Premise
213	(	_	_	I-Premise
214	relative	_	_	I-Premise
215	risk	_	_	I-Premise
216	=	_	_	I-Premise
217	1.5	_	_	I-Premise
218	;	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	confidence	_	_	I-Premise
222	interval	_	_	I-Premise
223	,	_	_	I-Premise
224	1.2	_	_	I-Premise
225	to	_	_	I-Premise
226	1.9	_	_	I-Premise
227	)	_	_	I-Premise
228	and	_	_	O
229	the	_	_	B-Premise
230	proportion	_	_	I-Premise
231	of	_	_	I-Premise
232	patients	_	_	I-Premise
233	with	_	_	I-Premise
234	a	_	_	I-Premise
235	greater	_	_	I-Premise
236	than	_	_	I-Premise
237	50	_	_	I-Premise
238	%	_	_	I-Premise
239	decline	_	_	I-Premise
240	in	_	_	I-Premise
241	PSA	_	_	I-Premise
242	was	_	_	I-Premise
243	higher	_	_	I-Premise
244	(	_	_	I-Premise
245	33	_	_	I-Premise
246	%	_	_	I-Premise
247	v	_	_	I-Premise
248	16	_	_	I-Premise
249	%	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	=.01	_	_	I-Premise
253	)	_	_	I-Premise
254	in	_	_	I-Premise
255	patients	_	_	I-Premise
256	who	_	_	I-Premise
257	received	_	_	I-Premise
258	suramin	_	_	I-Premise
259	.	_	_	I-Premise

260	Neither	_	_	B-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	nor	_	_	I-Premise
265	performance	_	_	I-Premise
266	status	_	_	I-Premise
267	was	_	_	I-Premise
268	decreased	_	_	I-Premise
269	by	_	_	I-Premise
270	suramin	_	_	I-Premise
271	treatment	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	O
274	overall	_	_	B-Premise
275	survival	_	_	I-Premise
276	was	_	_	I-Premise
277	similar	_	_	I-Premise
278	.	_	_	I-Premise

279	Most	_	_	B-Premise
280	adverse	_	_	I-Premise
281	events	_	_	I-Premise
282	were	_	_	I-Premise
283	of	_	_	I-Premise
284	mild	_	_	I-Premise
285	or	_	_	I-Premise
286	moderate	_	_	I-Premise
287	intensity	_	_	I-Premise
288	and	_	_	I-Premise
289	were	_	_	I-Premise
290	easily	_	_	I-Premise
291	managed	_	_	I-Premise
292	medically	_	_	I-Premise
293	.	_	_	I-Premise

294	Outpatient	_	_	B-Claim
295	treatment	_	_	I-Claim
296	with	_	_	I-Claim
297	suramin	_	_	I-Claim
298	plus	_	_	I-Claim
299	HC	_	_	I-Claim
300	is	_	_	I-Claim
301	well	_	_	I-Claim
302	tolerated	_	_	I-Claim
303	and	_	_	I-Claim
304	provides	_	_	I-Claim
305	moderate	_	_	I-Claim
306	palliative	_	_	I-Claim
307	benefit	_	_	I-Claim
308	and	_	_	I-Claim
309	delay	_	_	I-Claim
310	in	_	_	I-Claim
311	disease	_	_	I-Claim
312	progression	_	_	I-Claim
313	for	_	_	I-Claim
314	patients	_	_	I-Claim
315	with	_	_	I-Claim
316	symptomatic	_	_	I-Claim
317	HRPC	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	vinflunine	_	_	O
3	(	_	_	O
4	VFL	_	_	O
5	)	_	_	O
6	to	_	_	O
7	docetaxel	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	stage	_	_	O
12	IIIB/IV	_	_	O
13	non-small-cell	_	_	O
14	lung	_	_	O
15	cancer	_	_	O
16	(	_	_	O
17	NSCLC	_	_	O
18	)	_	_	O
19	who	_	_	O
20	have	_	_	O
21	experienced	_	_	O
22	treatment	_	_	O
23	failure	_	_	O
24	with	_	_	O
25	first-line	_	_	O
26	platinum-based	_	_	O
27	chemotherapy	_	_	O
28	.	_	_	O

29	Randomized	_	_	O
30	,	_	_	O
31	multicenter	_	_	O
32	,	_	_	O
33	phase	_	_	O
34	III	_	_	O
35	study	_	_	O
36	,	_	_	O
37	551	_	_	O
38	patients	_	_	O
39	received	_	_	O
40	either	_	_	O
41	vinflunine	_	_	O
42	320	_	_	O
43	mg/m	_	_	O
44	(	_	_	O
45	2	_	_	O
46	)	_	_	O
47	or	_	_	O
48	docetaxel	_	_	O
49	75	_	_	O
50	mg/m	_	_	O
51	(	_	_	O
52	2	_	_	O
53	)	_	_	O
54	every	_	_	O
55	21	_	_	O
56	days	_	_	O
57	until	_	_	O
58	disease	_	_	O
59	progression	_	_	O
60	or	_	_	O
61	serious	_	_	O
62	toxicity	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	end	_	_	O
67	point	_	_	O
68	was	_	_	O
69	progression-free	_	_	O
70	survival	_	_	O
71	(	_	_	O
72	PFS	_	_	O
73	)	_	_	O
74	.	_	_	O

75	The	_	_	O
76	noninferiority	_	_	O
77	analysis	_	_	O
78	was	_	_	O
79	based	_	_	O
80	on	_	_	O
81	a	_	_	O
82	10	_	_	O
83	%	_	_	O
84	difference	_	_	O
85	(	_	_	O
86	types	_	_	O
87	I/II	_	_	O
88	error	_	_	O
89	rates	_	_	O
90	:	_	_	O
91	5	_	_	O
92	%	_	_	O
93	/20	_	_	O
94	%	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Secondary	_	_	O
98	end	_	_	O
99	points	_	_	O
100	included	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	(	_	_	O
104	ORR	_	_	O
105	)	_	_	O
106	,	_	_	O
107	response	_	_	O
108	duration	_	_	O
109	,	_	_	O
110	overall	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	OS	_	_	O
114	)	_	_	O
115	,	_	_	O
116	clinical	_	_	O
117	benefit	_	_	O
118	,	_	_	O
119	quality	_	_	O
120	of	_	_	O
121	life	_	_	O
122	(	_	_	O
123	QOL	_	_	O
124	)	_	_	O
125	,	_	_	O
126	and	_	_	O
127	safety	_	_	O
128	.	_	_	O

129	Median	_	_	B-Premise
130	PFS	_	_	I-Premise
131	was	_	_	I-Premise
132	2.3	_	_	I-Premise
133	months	_	_	I-Premise
134	for	_	_	I-Premise
135	each	_	_	I-Premise
136	arm	_	_	I-Premise
137	(	_	_	I-Premise
138	HR	_	_	I-Premise
139	,	_	_	I-Premise
140	1.004	_	_	I-Premise
141	;	_	_	I-Premise
142	95	_	_	I-Premise
143	%	_	_	I-Premise
144	CI	_	_	I-Premise
145	,	_	_	I-Premise
146	0.841	_	_	I-Premise
147	to	_	_	I-Premise
148	1.199	_	_	I-Premise
149	)	_	_	I-Premise
150	.	_	_	I-Premise

151	ORR	_	_	B-Premise
152	,	_	_	I-Premise
153	stable	_	_	I-Premise
154	disease	_	_	I-Premise
155	,	_	_	I-Premise
156	median	_	_	I-Premise
157	OS	_	_	I-Premise
158	,	_	_	I-Premise
159	were	_	_	I-Premise
160	4.4	_	_	I-Premise
161	%	_	_	I-Premise
162	versus	_	_	I-Premise
163	5.5	_	_	I-Premise
164	%	_	_	I-Premise
165	,	_	_	I-Premise
166	36.0	_	_	I-Premise
167	%	_	_	I-Premise
168	versus	_	_	I-Premise
169	39.6	_	_	I-Premise
170	%	_	_	I-Premise
171	,	_	_	I-Premise
172	6.7	_	_	I-Premise
173	versus	_	_	I-Premise
174	7.2	_	_	I-Premise
175	months	_	_	I-Premise
176	(	_	_	I-Premise
177	HR	_	_	I-Premise
178	,	_	_	I-Premise
179	0.973	_	_	I-Premise
180	;	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.805	_	_	I-Premise
186	to	_	_	I-Premise
187	1.176	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	respectively	_	_	I-Premise
191	.	_	_	I-Premise

192	No	_	_	B-Premise
193	significant	_	_	I-Premise
194	difference	_	_	I-Premise
195	in	_	_	I-Premise
196	patient	_	_	I-Premise
197	benefit	_	_	I-Premise
198	and	_	_	I-Premise
199	QOL	_	_	I-Premise
200	(	_	_	I-Premise
201	Functional	_	_	I-Premise
202	Assessment	_	_	I-Premise
203	of	_	_	I-Premise
204	Cancer	_	_	I-Premise
205	Therapy-Lung	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	No	_	_	B-Premise
209	unexpected	_	_	I-Premise
210	adverse	_	_	I-Premise
211	events	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	.	_	_	I-Premise

215	Grade	_	_	B-Premise
216	higher	_	_	I-Premise
217	than	_	_	I-Premise
218	0	_	_	I-Premise
219	(	_	_	I-Premise
220	vinflunine	_	_	I-Premise
221	v	_	_	I-Premise
222	docetaxel	_	_	I-Premise
223	)	_	_	I-Premise
224	anemia	_	_	I-Premise
225	(	_	_	I-Premise
226	82.1	_	_	I-Premise
227	%	_	_	I-Premise
228	v	_	_	I-Premise
229	79.8	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	neutropenia	_	_	I-Premise
234	(	_	_	I-Premise
235	49.3	_	_	I-Premise
236	v	_	_	I-Premise
237	39.02	_	_	I-Premise
238	%	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	thrombocytopenia	_	_	I-Premise
242	(	_	_	I-Premise
243	30.6	_	_	I-Premise
244	%	_	_	I-Premise
245	v	_	_	I-Premise
246	14.3	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	febrile	_	_	I-Premise
251	neutropenia	_	_	I-Premise
252	(	_	_	I-Premise
253	3.3	_	_	I-Premise
254	%	_	_	I-Premise
255	v	_	_	I-Premise
256	4.7	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	constipation	_	_	I-Premise
261	(	_	_	I-Premise
262	39.2	_	_	I-Premise
263	%	_	_	I-Premise
264	v	_	_	I-Premise
265	11.7	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	fatigue	_	_	I-Premise
270	(	_	_	I-Premise
271	36.6	_	_	I-Premise
272	%	_	_	I-Premise
273	v	_	_	I-Premise
274	33.9	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	injection	_	_	I-Premise
279	site	_	_	I-Premise
280	reaction	_	_	I-Premise
281	(	_	_	I-Premise
282	31.9	_	_	I-Premise
283	%	_	_	I-Premise
284	v	_	_	I-Premise
285	0.7	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	nausea	_	_	I-Premise
290	(	_	_	I-Premise
291	26.7	_	_	I-Premise
292	%	_	_	I-Premise
293	v	_	_	I-Premise
294	23.7	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	vomiting	_	_	I-Premise
299	(	_	_	I-Premise
300	23.8	_	_	I-Premise
301	%	_	_	I-Premise
302	v	_	_	I-Premise
303	14.2	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	,	_	_	I-Premise
307	alopecia	_	_	I-Premise
308	(	_	_	I-Premise
309	19.8	_	_	I-Premise
310	%	_	_	I-Premise
311	v	_	_	I-Premise
312	35.4	_	_	I-Premise
313	%	_	_	I-Premise
314	)	_	_	I-Premise
315	,	_	_	I-Premise
316	stomatis	_	_	I-Premise
317	(	_	_	I-Premise
318	19.4	_	_	I-Premise
319	%	_	_	I-Premise
320	v	_	_	I-Premise
321	12.4	_	_	I-Premise
322	%	_	_	I-Premise
323	)	_	_	I-Premise
324	,	_	_	I-Premise
325	abdominal	_	_	I-Premise
326	pain	_	_	I-Premise
327	(	_	_	I-Premise
328	20.1	_	_	I-Premise
329	%	_	_	I-Premise
330	v	_	_	I-Premise
331	3.6	_	_	I-Premise
332	%	_	_	I-Premise
333	)	_	_	I-Premise
334	,	_	_	I-Premise
335	myalgia	_	_	I-Premise
336	(	_	_	I-Premise
337	14.7	_	_	I-Premise
338	%	_	_	I-Premise
339	v	_	_	I-Premise
340	6.6	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	,	_	_	I-Premise
344	peripheral	_	_	I-Premise
345	neuropathy	_	_	I-Premise
346	(	_	_	I-Premise
347	10.7	_	_	I-Premise
348	%	_	_	I-Premise
349	v	_	_	I-Premise
350	15.0	_	_	I-Premise
351	%	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	arthralgia	_	_	I-Premise
355	(	_	_	I-Premise
356	7.0	_	_	I-Premise
357	%	_	_	I-Premise
358	v	_	_	I-Premise
359	7.7	_	_	I-Premise
360	%	_	_	I-Premise
361	)	_	_	I-Premise
362	,	_	_	I-Premise
363	diarrhea	_	_	I-Premise
364	(	_	_	I-Premise
365	6.2	_	_	I-Premise
366	%	_	_	I-Premise
367	v	_	_	I-Premise
368	12.4	_	_	I-Premise
369	%	_	_	I-Premise
370	)	_	_	I-Premise
371	,	_	_	I-Premise
372	edema	_	_	I-Premise
373	(	_	_	I-Premise
374	1.5	_	_	I-Premise
375	%	_	_	I-Premise
376	v	_	_	I-Premise
377	5.4	_	_	I-Premise
378	%	_	_	I-Premise
379	)	_	_	I-Premise
380	,	_	_	I-Premise
381	and	_	_	I-Premise
382	nail	_	_	I-Premise
383	disorders	_	_	I-Premise
384	(	_	_	I-Premise
385	1.1	_	_	I-Premise
386	%	_	_	I-Premise
387	v	_	_	I-Premise
388	5	_	_	I-Premise
389	;	_	_	I-Premise
390	1	_	_	I-Premise
391	%	_	_	I-Premise
392	)	_	_	I-Premise
393	were	_	_	I-Premise
394	observed	_	_	I-Premise
395	.	_	_	I-Premise

396	This	_	_	B-Claim
397	noninferiority	_	_	I-Claim
398	phase	_	_	I-Claim
399	III	_	_	I-Claim
400	study	_	_	I-Claim
401	showed	_	_	I-Claim
402	similar	_	_	I-Claim
403	efficacy	_	_	I-Claim
404	end	_	_	I-Claim
405	points	_	_	I-Claim
406	for	_	_	I-Claim
407	vinflunine	_	_	I-Claim
408	and	_	_	I-Claim
409	docetaxel	_	_	I-Claim
410	.	_	_	I-Claim

411	Despite	_	_	B-Claim
412	higher	_	_	I-Claim
413	rates	_	_	I-Claim
414	of	_	_	I-Claim
415	some	_	_	I-Claim
416	adverse	_	_	I-Claim
417	effects	_	_	I-Claim
418	(	_	_	I-Claim
419	anemia	_	_	I-Claim
420	,	_	_	I-Claim
421	abdominal	_	_	I-Claim
422	pain	_	_	I-Claim
423	,	_	_	I-Claim
424	constipation	_	_	I-Claim
425	,	_	_	I-Claim
426	fatigue	_	_	I-Claim
427	)	_	_	I-Claim
428	the	_	_	B-Claim
429	overall	_	_	I-Claim
430	toxicity	_	_	I-Claim
431	profile	_	_	I-Claim
432	of	_	_	I-Claim
433	vinflunine	_	_	I-Claim
434	was	_	_	I-Claim
435	manageable	_	_	I-Claim
436	.	_	_	I-Claim

437	Therefore	_	_	O
438	,	_	_	O
439	VFL	_	_	B-Claim
440	may	_	_	I-Claim
441	be	_	_	I-Claim
442	another	_	_	I-Claim
443	option	_	_	I-Claim
444	in	_	_	I-Claim
445	the	_	_	I-Claim
446	second-line	_	_	I-Claim
447	treatment	_	_	I-Claim
448	of	_	_	I-Claim
449	patients	_	_	I-Claim
450	with	_	_	I-Claim
451	advanced	_	_	I-Claim
452	NSCLC	_	_	I-Claim
453	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	,	_	_	O
3	placebo-controlled	_	_	O
4	single-blind	_	_	O
5	trial	_	_	O
6	investigated	_	_	O
7	the	_	_	O
8	safety	_	_	O
9	and	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	SAMITALÂ®	_	_	O
13	,	_	_	O
14	a	_	_	O
15	formulation	_	_	O
16	of	_	_	O
17	highly	_	_	O
18	standardised	_	_	O
19	botanical	_	_	O
20	extracts	_	_	O
21	,	_	_	O
22	in	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	chemo/radiotherapy-induced	_	_	O
27	oral	_	_	O
28	mucositis	_	_	O
29	(	_	_	O
30	OM	_	_	O
31	)	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	head	_	_	O
36	and	_	_	O
37	neck	_	_	O
38	cancer	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	received	_	_	O
42	SAMITALÂ®	_	_	O
43	or	_	_	O
44	placebo	_	_	O
45	four	_	_	O
46	times	_	_	O
47	daily	_	_	O
48	for	_	_	O
49	up	_	_	O
50	to	_	_	O
51	50	_	_	O
52	days	_	_	O
53	during	_	_	O
54	scheduled	_	_	O
55	chemo/radiotherapy	_	_	O
56	.	_	_	O

57	Severity	_	_	O
58	of	_	_	O
59	OM	_	_	O
60	was	_	_	O
61	monitored	_	_	O
62	according	_	_	O
63	to	_	_	O
64	a	_	_	O
65	modified	_	_	O
66	WHO	_	_	O
67	severity	_	_	O
68	scale	_	_	O
69	,	_	_	O
70	and	_	_	O
71	pain	_	_	O
72	and	_	_	O
73	quality-of-life	_	_	O
74	assessments	_	_	O
75	were	_	_	O
76	based	_	_	O
77	on	_	_	O
78	the	_	_	O
79	effect	_	_	O
80	of	_	_	O
81	symptoms	_	_	O
82	of	_	_	O
83	OM	_	_	O
84	on	_	_	O
85	relevant	_	_	O
86	daily	_	_	O
87	activities	_	_	O
88	,	_	_	O
89	according	_	_	O
90	to	_	_	O
91	a	_	_	O
92	visual	_	_	O
93	analogue	_	_	O
94	scale	_	_	O
95	.	_	_	O

96	Mean	_	_	B-Premise
97	scores	_	_	I-Premise
98	for	_	_	I-Premise
99	the	_	_	I-Premise
100	severity	_	_	I-Premise
101	of	_	_	I-Premise
102	OM	_	_	I-Premise
103	were	_	_	I-Premise
104	significantly	_	_	I-Premise
105	(	_	_	I-Premise
106	p	_	_	I-Premise
107	<	_	_	I-Premise
108	0.05	_	_	I-Premise
109	versus	_	_	I-Premise
110	baseline	_	_	I-Premise
111	)	_	_	I-Premise
112	reduced	_	_	I-Premise
113	from	_	_	I-Premise
114	day	_	_	I-Premise
115	31	_	_	I-Premise
116	until	_	_	I-Premise
117	the	_	_	I-Premise
118	end	_	_	I-Premise
119	of	_	_	I-Premise
120	treatment	_	_	I-Premise
121	in	_	_	I-Premise
122	patients	_	_	I-Premise
123	treated	_	_	I-Premise
124	with	_	_	I-Premise
125	SAMITALÂ®	_	_	I-Premise
126	(	_	_	I-Premise
127	n	_	_	I-Premise
128	=	_	_	I-Premise
129	20	_	_	I-Premise
130	)	_	_	I-Premise
131	.	_	_	I-Premise

132	No	_	_	B-Premise
133	significant	_	_	I-Premise
134	improvement	_	_	I-Premise
135	was	_	_	I-Premise
136	observed	_	_	I-Premise
137	in	_	_	I-Premise
138	the	_	_	I-Premise
139	placebo	_	_	I-Premise
140	group	_	_	I-Premise
141	(	_	_	I-Premise
142	n	_	_	I-Premise
143	=	_	_	I-Premise
144	10	_	_	I-Premise
145	)	_	_	I-Premise
146	.	_	_	I-Premise

147	Pain	_	_	B-Premise
148	reduction	_	_	I-Premise
149	was	_	_	I-Premise
150	significant	_	_	I-Premise
151	from	_	_	I-Premise
152	day	_	_	I-Premise
153	4	_	_	I-Premise
154	till	_	_	I-Premise
155	end	_	_	I-Premise
156	of	_	_	I-Premise
157	treatment	_	_	I-Premise
158	with	_	_	I-Premise
159	SAMITALÂ®	_	_	I-Premise
160	and	_	_	I-Premise
161	from	_	_	I-Premise
162	days	_	_	I-Premise
163	7	_	_	I-Premise
164	to	_	_	I-Premise
165	21	_	_	I-Premise
166	in	_	_	I-Premise
167	placebo	_	_	I-Premise
168	patients	_	_	I-Premise
169	.	_	_	I-Premise

170	SAMITALÂ®	_	_	B-Premise
171	also	_	_	I-Premise
172	significantly	_	_	I-Premise
173	improved	_	_	I-Premise
174	quality	_	_	I-Premise
175	of	_	_	I-Premise
176	life	_	_	I-Premise
177	,	_	_	I-Premise
178	as	_	_	I-Premise
179	shown	_	_	I-Premise
180	by	_	_	I-Premise
181	improvements	_	_	I-Premise
182	in	_	_	I-Premise
183	scores	_	_	I-Premise
184	for	_	_	I-Premise
185	relevant	_	_	I-Premise
186	daily	_	_	I-Premise
187	activities	_	_	I-Premise
188	including	_	_	I-Premise
189	eating	_	_	I-Premise
190	,	_	_	I-Premise
191	drinking	_	_	I-Premise
192	and	_	_	I-Premise
193	sleeping	_	_	I-Premise
194	.	_	_	I-Premise

195	All	_	_	O
196	SAMITALÂ®	_	_	O
197	patients	_	_	O
198	completed	_	_	O
199	the	_	_	O
200	treatment	_	_	O
201	period	_	_	O
202	,	_	_	O
203	but	_	_	O
204	no	_	_	O
205	placebo	_	_	O
206	recipients	_	_	O
207	completed	_	_	O
208	treatment	_	_	O
209	.	_	_	O

210	No	_	_	B-Premise
211	severe	_	_	I-Premise
212	adverse	_	_	I-Premise
213	events	_	_	I-Premise
214	were	_	_	I-Premise
215	observed	_	_	I-Premise
216	with	_	_	I-Premise
217	SAMITALÂ®	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	systemic	_	_	I-Premise
221	absorption	_	_	I-Premise
222	of	_	_	I-Premise
223	relevant	_	_	I-Premise
224	active	_	_	I-Premise
225	ingredients	_	_	I-Premise
226	was	_	_	I-Premise
227	undetectable	_	_	I-Premise
228	.	_	_	I-Premise

229	SAMITALÂ®	_	_	B-Claim
230	significantly	_	_	I-Claim
231	decreased	_	_	I-Claim
232	the	_	_	I-Claim
233	severity	_	_	I-Claim
234	of	_	_	I-Claim
235	chemo/radiotherapy-induced	_	_	I-Claim
236	OM	_	_	I-Claim
237	in	_	_	I-Claim
238	patients	_	_	I-Claim
239	with	_	_	I-Claim
240	head	_	_	I-Claim
241	and	_	_	I-Claim
242	neck	_	_	I-Claim
243	cancer	_	_	I-Claim
244	,	_	_	I-Claim
245	with	_	_	I-Claim
246	no	_	_	I-Claim
247	treatment-related	_	_	I-Claim
248	adverse	_	_	I-Claim
249	events	_	_	I-Claim
250	.	_	_	I-Claim

251	Pain	_	_	B-Claim
252	relief	_	_	I-Claim
253	lasted	_	_	I-Claim
254	through	_	_	I-Claim
255	the	_	_	I-Claim
256	treatment	_	_	I-Claim
257	period	_	_	I-Claim
258	,	_	_	I-Claim
259	and	_	_	I-Claim
260	improvements	_	_	I-Claim
261	in	_	_	I-Claim
262	quality	_	_	I-Claim
263	of	_	_	I-Claim
264	life	_	_	I-Claim
265	were	_	_	I-Claim
266	reflected	_	_	I-Claim
267	by	_	_	I-Claim
268	the	_	_	I-Claim
269	significant	_	_	I-Claim
270	benefits	_	_	I-Claim
271	of	_	_	I-Claim
272	SAMITALÂ®	_	_	I-Claim
273	on	_	_	I-Claim
274	activities	_	_	I-Claim
275	like	_	_	I-Claim
276	drinking	_	_	I-Claim
277	,	_	_	I-Claim
278	eating	_	_	I-Claim
279	and	_	_	I-Claim
280	speaking	_	_	I-Claim
281	.	_	_	I-Claim


0	Patients	_	_	O
1	who	_	_	O
2	develop	_	_	O
3	castration-resistant	_	_	O
4	prostate	_	_	O
5	cancer	_	_	O
6	(	_	_	O
7	CRPCa	_	_	O
8	)	_	_	O
9	typically	_	_	O
10	continue	_	_	O
11	on	_	_	O
12	androgen	_	_	O
13	deprivation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	ADT	_	_	O
17	)	_	_	O
18	.	_	_	O

19	Whether	_	_	O
20	these	_	_	O
21	patients	_	_	O
22	need	_	_	O
23	to	_	_	O
24	remain	_	_	O
25	on	_	_	O
26	ADT	_	_	O
27	has	_	_	O
28	not	_	_	O
29	been	_	_	O
30	well	_	_	O
31	studied	_	_	O
32	.	_	_	O

33	We	_	_	O
34	conducted	_	_	O
35	a	_	_	O
36	multicenter	_	_	O
37	randomized	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	compare	_	_	O
41	an	_	_	O
42	intermittent	_	_	O
43	versus	_	_	O
44	continuous	_	_	O
45	approach	_	_	O
46	to	_	_	O
47	ADT	_	_	O
48	in	_	_	O
49	CRPCa	_	_	O
50	patients	_	_	O
51	.	_	_	O

52	Overall	_	_	O
53	survival	_	_	O
54	,	_	_	O
55	health-related	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	,	_	_	O
63	and	_	_	O
64	cost	_	_	O
65	were	_	_	O
66	the	_	_	O
67	main	_	_	O
68	endpoints	_	_	O
69	.	_	_	O

70	CRPCa	_	_	O
71	patients	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	2:1	_	_	O
75	to	_	_	O
76	intermittent	_	_	O
77	or	_	_	O
78	continuous	_	_	O
79	luteinizing	_	_	O
80	hormone-releasing	_	_	O
81	hormone	_	_	O
82	agonists	_	_	O
83	(	_	_	O
84	LHRHa	_	_	O
85	)	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	were	_	_	O
89	followed	_	_	O
90	with	_	_	O
91	clinical	_	_	O
92	assessments	_	_	O
93	,	_	_	O
94	laboratory	_	_	O
95	investigations	_	_	O
96	,	_	_	O
97	and	_	_	O
98	QOL	_	_	O
99	questionnaires	_	_	O
100	(	_	_	O
101	EORTC	_	_	O
102	QLQ-C30	_	_	O
103	or	_	_	O
104	PROSQOLI	_	_	O
105	)	_	_	O
106	every	_	_	O
107	2	_	_	O
108	months	_	_	O
109	.	_	_	O

110	If	_	_	O
111	the	_	_	O
112	serum	_	_	O
113	testosterone	_	_	O
114	rose	_	_	O
115	above	_	_	O
116	castrate	_	_	O
117	levels	_	_	O
118	(	_	_	O
119	1.75	_	_	O
120	nmol/L	_	_	O
121	)	_	_	O
122	,	_	_	O
123	LHRHa	_	_	O
124	were	_	_	O
125	reinitiated	_	_	O
126	.	_	_	O

127	The	_	_	O
128	study	_	_	O
129	was	_	_	O
130	designed	_	_	O
131	to	_	_	O
132	close	_	_	O
133	if	_	_	O
134	>	_	_	O
135	50	_	_	O
136	%	_	_	O
137	of	_	_	O
138	patients	_	_	O
139	needed	_	_	O
140	to	_	_	O
141	restart	_	_	O
142	ADT	_	_	O
143	in	_	_	O
144	the	_	_	O
145	intermittent	_	_	O
146	arm	_	_	O
147	.	_	_	O

148	Thirty-one	_	_	O
149	patients	_	_	O
150	were	_	_	O
151	followed	_	_	O
152	with	_	_	O
153	a	_	_	O
154	median	_	_	O
155	follow-up	_	_	O
156	of	_	_	O
157	26.8	_	_	O
158	months-18	_	_	O
159	in	_	_	O
160	the	_	_	O
161	intermittent	_	_	O
162	arm	_	_	O
163	and	_	_	O
164	13	_	_	O
165	in	_	_	O
166	the	_	_	O
167	continuous	_	_	O
168	.	_	_	O

169	Twelve	_	_	O
170	of	_	_	O
171	18	_	_	O
172	patients	_	_	O
173	on	_	_	O
174	the	_	_	O
175	intermittent	_	_	O
176	arm	_	_	O
177	were	_	_	O
178	reinitiated	_	_	O
179	on	_	_	O
180	LHRHa	_	_	O
181	at	_	_	O
182	a	_	_	O
183	median	_	_	O
184	time	_	_	O
185	of	_	_	O
186	17.9	_	_	O
187	months	_	_	O
188	.	_	_	O

189	There	_	_	B-Premise
190	was	_	_	I-Premise
191	no	_	_	I-Premise
192	difference	_	_	I-Premise
193	in	_	_	I-Premise
194	overall	_	_	I-Premise
195	or	_	_	I-Premise
196	cancer-specific	_	_	I-Premise
197	survival	_	_	I-Premise
198	between	_	_	I-Premise
199	the	_	_	I-Premise
200	2	_	_	I-Premise
201	arms	_	_	I-Premise
202	.	_	_	I-Premise

203	There	_	_	B-Premise
204	was	_	_	I-Premise
205	no	_	_	I-Premise
206	statistically	_	_	I-Premise
207	significant	_	_	I-Premise
208	difference	_	_	I-Premise
209	in	_	_	I-Premise
210	QOL	_	_	I-Premise
211	between	_	_	I-Premise
212	the	_	_	I-Premise
213	2	_	_	I-Premise
214	arms	_	_	I-Premise
215	at	_	_	I-Premise
216	0	_	_	I-Premise
217	and	_	_	I-Premise
218	12	_	_	I-Premise
219	months	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	total	_	_	I-Premise
223	mean	_	_	I-Premise
224	costs	_	_	I-Premise
225	at	_	_	I-Premise
226	24	_	_	I-Premise
227	months	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	lower	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	intermittent	_	_	I-Premise
234	arm	_	_	I-Premise
235	(	_	_	I-Premise
236	$	_	_	I-Premise
237	3135	_	_	I-Premise
238	vs.	_	_	I-Premise
239	$	_	_	I-Premise
240	8253	_	_	I-Premise
241	Canadian	_	_	I-Premise
242	dollars	_	_	I-Premise
243	,	_	_	I-Premise
244	P=0.0167	_	_	I-Premise
245	)	_	_	I-Premise
246	compared	_	_	I-Premise
247	with	_	_	I-Premise
248	the	_	_	I-Premise
249	continuous	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	main	_	_	I-Premise
253	limitation	_	_	I-Premise
254	of	_	_	I-Premise
255	this	_	_	I-Premise
256	study	_	_	I-Premise
257	is	_	_	I-Premise
258	the	_	_	I-Premise
259	small	_	_	I-Premise
260	sample	_	_	I-Premise
261	size	_	_	I-Premise
262	.	_	_	I-Premise

263	We	_	_	B-Claim
264	have	_	_	I-Claim
265	observed	_	_	I-Claim
266	that	_	_	I-Claim
267	intermittent	_	_	I-Claim
268	ADT	_	_	I-Claim
269	in	_	_	I-Claim
270	patients	_	_	I-Claim
271	with	_	_	I-Claim
272	CRPCa	_	_	I-Claim
273	,	_	_	I-Claim
274	using	_	_	I-Claim
275	a	_	_	I-Claim
276	testosterone	_	_	I-Claim
277	of	_	_	I-Claim
278	>	_	_	I-Claim
279	1.75	_	_	I-Claim
280	ngmol/L	_	_	I-Claim
281	as	_	_	I-Claim
282	a	_	_	I-Claim
283	trigger	_	_	I-Claim
284	to	_	_	I-Claim
285	reinitiate	_	_	I-Claim
286	LHRHa	_	_	I-Claim
287	,	_	_	I-Claim
288	results	_	_	I-Claim
289	in	_	_	I-Claim
290	a	_	_	I-Claim
291	substantial	_	_	I-Claim
292	cost	_	_	I-Claim
293	savings	_	_	I-Claim
294	with	_	_	I-Claim
295	no	_	_	I-Claim
296	negative	_	_	I-Claim
297	impact	_	_	I-Claim
298	on	_	_	I-Claim
299	oncologic	_	_	I-Claim
300	and	_	_	I-Claim
301	QOL	_	_	I-Claim
302	outcomes	_	_	I-Claim
303	.	_	_	I-Claim


0	Menopausal	_	_	O
1	hormone	_	_	O
2	therapy	_	_	O
3	continues	_	_	O
4	in	_	_	O
5	clinical	_	_	O
6	use	_	_	O
7	but	_	_	O
8	questions	_	_	O
9	remain	_	_	O
10	regarding	_	_	O
11	its	_	_	O
12	risks	_	_	O
13	and	_	_	O
14	benefits	_	_	O
15	for	_	_	O
16	chronic	_	_	O
17	disease	_	_	O
18	prevention	_	_	O
19	.	_	_	O

20	To	_	_	O
21	report	_	_	O
22	a	_	_	O
23	comprehensive	_	_	O
24	,	_	_	O
25	integrated	_	_	O
26	overview	_	_	O
27	of	_	_	O
28	findings	_	_	O
29	from	_	_	O
30	the	_	_	O
31	2	_	_	O
32	Women	_	_	O
33	's	_	_	O
34	Health	_	_	O
35	Initiative	_	_	O
36	(	_	_	O
37	WHI	_	_	O
38	)	_	_	O
39	hormone	_	_	O
40	therapy	_	_	O
41	trials	_	_	O
42	with	_	_	O
43	extended	_	_	O
44	postintervention	_	_	O
45	follow-up	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	27,347	_	_	O
51	postmenopausal	_	_	O
52	women	_	_	O
53	aged	_	_	O
54	50	_	_	O
55	to	_	_	O
56	79	_	_	O
57	years	_	_	O
58	were	_	_	O
59	enrolled	_	_	O
60	at	_	_	O
61	40	_	_	O
62	US	_	_	O
63	centers	_	_	O
64	.	_	_	O

65	Women	_	_	O
66	with	_	_	O
67	an	_	_	O
68	intact	_	_	O
69	uterus	_	_	O
70	received	_	_	O
71	conjugated	_	_	O
72	equine	_	_	O
73	estrogens	_	_	O
74	(	_	_	O
75	CEE	_	_	O
76	;	_	_	O
77	0.625	_	_	O
78	mg/d	_	_	O
79	)	_	_	O
80	plus	_	_	O
81	medroxyprogesterone	_	_	O
82	acetate	_	_	O
83	(	_	_	O
84	MPA	_	_	O
85	;	_	_	O
86	2.5	_	_	O
87	mg/d	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	8506	_	_	O
93	)	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	8102	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Women	_	_	O
103	with	_	_	O
104	prior	_	_	O
105	hysterectomy	_	_	O
106	received	_	_	O
107	CEE	_	_	O
108	alone	_	_	O
109	(	_	_	O
110	0.625	_	_	O
111	mg/d	_	_	O
112	)	_	_	O
113	(	_	_	O
114	n	_	_	O
115	=	_	_	O
116	5310	_	_	O
117	)	_	_	O
118	or	_	_	O
119	placebo	_	_	O
120	(	_	_	O
121	n	_	_	O
122	=	_	_	O
123	5429	_	_	O
124	)	_	_	O
125	.	_	_	O

126	The	_	_	O
127	intervention	_	_	O
128	lasted	_	_	O
129	a	_	_	O
130	median	_	_	O
131	of	_	_	O
132	5.6	_	_	O
133	years	_	_	O
134	in	_	_	O
135	CEE	_	_	O
136	plus	_	_	O
137	MPA	_	_	O
138	trial	_	_	O
139	and	_	_	O
140	7.2	_	_	O
141	years	_	_	O
142	in	_	_	O
143	CEE	_	_	O
144	alone	_	_	O
145	trial	_	_	O
146	with	_	_	O
147	13	_	_	O
148	years	_	_	O
149	of	_	_	O
150	cumulative	_	_	O
151	follow-up	_	_	O
152	until	_	_	O
153	September	_	_	O
154	30	_	_	O
155	,	_	_	O
156	2010	_	_	O
157	.	_	_	O

158	Primary	_	_	O
159	efficacy	_	_	O
160	and	_	_	O
161	safety	_	_	O
162	outcomes	_	_	O
163	were	_	_	O
164	coronary	_	_	O
165	heart	_	_	O
166	disease	_	_	O
167	(	_	_	O
168	CHD	_	_	O
169	)	_	_	O
170	and	_	_	O
171	invasive	_	_	O
172	breast	_	_	O
173	cancer	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	.	_	_	O

177	A	_	_	O
178	global	_	_	O
179	index	_	_	O
180	also	_	_	O
181	included	_	_	O
182	stroke	_	_	O
183	,	_	_	O
184	pulmonary	_	_	O
185	embolism	_	_	O
186	,	_	_	O
187	colorectal	_	_	O
188	cancer	_	_	O
189	,	_	_	O
190	endometrial	_	_	O
191	cancer	_	_	O
192	,	_	_	O
193	hip	_	_	O
194	fracture	_	_	O
195	,	_	_	O
196	and	_	_	O
197	death	_	_	O
198	.	_	_	O

199	During	_	_	B-Premise
200	the	_	_	I-Premise
201	CEE	_	_	I-Premise
202	plus	_	_	I-Premise
203	MPA	_	_	I-Premise
204	intervention	_	_	I-Premise
205	phase	_	_	I-Premise
206	,	_	_	I-Premise
207	the	_	_	I-Premise
208	numbers	_	_	I-Premise
209	of	_	_	I-Premise
210	CHD	_	_	I-Premise
211	cases	_	_	I-Premise
212	were	_	_	I-Premise
213	196	_	_	I-Premise
214	for	_	_	I-Premise
215	CEE	_	_	I-Premise
216	plus	_	_	I-Premise
217	MPA	_	_	I-Premise
218	vs	_	_	I-Premise
219	159	_	_	I-Premise
220	for	_	_	I-Premise
221	placebo	_	_	I-Premise
222	(	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	[	_	_	I-Premise
226	HR	_	_	I-Premise
227	]	_	_	I-Premise
228	,	_	_	I-Premise
229	1.18	_	_	I-Premise
230	;	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	,	_	_	I-Premise
235	0.95-1.45	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	206	_	_	I-Premise
239	vs	_	_	I-Premise
240	155	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	,	_	_	I-Premise
244	for	_	_	I-Premise
245	invasive	_	_	I-Premise
246	breast	_	_	I-Premise
247	cancer	_	_	I-Premise
248	(	_	_	I-Premise
249	HR	_	_	I-Premise
250	,	_	_	I-Premise
251	1.24	_	_	I-Premise
252	;	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	CI	_	_	I-Premise
256	,	_	_	I-Premise
257	1.01-1.53	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Other	_	_	B-Premise
261	risks	_	_	I-Premise
262	included	_	_	I-Premise
263	increased	_	_	I-Premise
264	stroke	_	_	I-Premise
265	,	_	_	I-Premise
266	pulmonary	_	_	I-Premise
267	embolism	_	_	I-Premise
268	,	_	_	I-Premise
269	dementia	_	_	I-Premise
270	(	_	_	I-Premise
271	in	_	_	I-Premise
272	women	_	_	I-Premise
273	aged	_	_	I-Premise
274	â‰¥65	_	_	I-Premise
275	years	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	gallbladder	_	_	I-Premise
279	disease	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	urinary	_	_	I-Premise
283	incontinence	_	_	I-Premise
284	;	_	_	I-Premise
285	benefits	_	_	I-Premise
286	included	_	_	I-Premise
287	decreased	_	_	I-Premise
288	hip	_	_	I-Premise
289	fractures	_	_	I-Premise
290	,	_	_	I-Premise
291	diabetes	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	vasomotor	_	_	I-Premise
295	symptoms	_	_	I-Premise
296	.	_	_	I-Premise

297	Most	_	_	B-Premise
298	risks	_	_	I-Premise
299	and	_	_	I-Premise
300	benefits	_	_	I-Premise
301	dissipated	_	_	I-Premise
302	postintervention	_	_	I-Premise
303	,	_	_	I-Premise
304	although	_	_	B-Premise
305	some	_	_	I-Premise
306	elevation	_	_	I-Premise
307	in	_	_	I-Premise
308	breast	_	_	I-Premise
309	cancer	_	_	I-Premise
310	risk	_	_	I-Premise
311	persisted	_	_	I-Premise
312	during	_	_	I-Premise
313	cumulative	_	_	I-Premise
314	follow-up	_	_	I-Premise
315	(	_	_	I-Premise
316	434	_	_	I-Premise
317	cases	_	_	I-Premise
318	for	_	_	I-Premise
319	CEE	_	_	I-Premise
320	plus	_	_	I-Premise
321	MPA	_	_	I-Premise
322	vs	_	_	I-Premise
323	323	_	_	I-Premise
324	for	_	_	I-Premise
325	placebo	_	_	I-Premise
326	;	_	_	I-Premise
327	HR	_	_	I-Premise
328	,	_	_	I-Premise
329	1.28	_	_	I-Premise
330	[	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	,	_	_	I-Premise
335	1.11-1.48	_	_	I-Premise
336	]	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	The	_	_	B-Premise
340	risks	_	_	I-Premise
341	and	_	_	I-Premise
342	benefits	_	_	I-Premise
343	were	_	_	I-Premise
344	more	_	_	I-Premise
345	balanced	_	_	I-Premise
346	during	_	_	I-Premise
347	the	_	_	I-Premise
348	CEE	_	_	I-Premise
349	alone	_	_	I-Premise
350	intervention	_	_	I-Premise
351	with	_	_	I-Premise
352	204	_	_	I-Premise
353	CHD	_	_	I-Premise
354	cases	_	_	I-Premise
355	for	_	_	I-Premise
356	CEE	_	_	I-Premise
357	alone	_	_	I-Premise
358	vs	_	_	I-Premise
359	222	_	_	I-Premise
360	cases	_	_	I-Premise
361	for	_	_	I-Premise
362	placebo	_	_	I-Premise
363	(	_	_	I-Premise
364	HR	_	_	I-Premise
365	,	_	_	I-Premise
366	0.94	_	_	I-Premise
367	;	_	_	I-Premise
368	95	_	_	I-Premise
369	%	_	_	I-Premise
370	CI	_	_	I-Premise
371	,	_	_	I-Premise
372	0.78-1.14	_	_	I-Premise
373	)	_	_	I-Premise
374	and	_	_	I-Premise
375	104	_	_	I-Premise
376	vs	_	_	I-Premise
377	135	_	_	I-Premise
378	,	_	_	I-Premise
379	respectively	_	_	I-Premise
380	,	_	_	I-Premise
381	for	_	_	I-Premise
382	invasive	_	_	I-Premise
383	breast	_	_	I-Premise
384	cancer	_	_	I-Premise
385	(	_	_	I-Premise
386	HR	_	_	I-Premise
387	,	_	_	I-Premise
388	0.79	_	_	I-Premise
389	;	_	_	I-Premise
390	95	_	_	I-Premise
391	%	_	_	I-Premise
392	CI	_	_	I-Premise
393	,	_	_	I-Premise
394	0.61-1.02	_	_	I-Premise
395	)	_	_	I-Premise
396	;	_	_	I-Premise
397	cumulatively	_	_	I-Premise
398	,	_	_	I-Premise
399	there	_	_	I-Premise
400	were	_	_	I-Premise
401	168	_	_	I-Premise
402	vs	_	_	I-Premise
403	216	_	_	I-Premise
404	,	_	_	I-Premise
405	respectively	_	_	I-Premise
406	,	_	_	I-Premise
407	cases	_	_	I-Premise
408	of	_	_	I-Premise
409	breast	_	_	I-Premise
410	cancer	_	_	I-Premise
411	diagnosed	_	_	I-Premise
412	(	_	_	I-Premise
413	HR	_	_	I-Premise
414	,	_	_	I-Premise
415	0.79	_	_	I-Premise
416	;	_	_	I-Premise
417	95	_	_	I-Premise
418	%	_	_	I-Premise
419	CI	_	_	I-Premise
420	,	_	_	I-Premise
421	0.65-0.97	_	_	I-Premise
422	)	_	_	I-Premise
423	.	_	_	I-Premise

424	Results	_	_	O
425	for	_	_	O
426	other	_	_	O
427	outcomes	_	_	O
428	were	_	_	O
429	similar	_	_	O
430	to	_	_	O
431	CEE	_	_	O
432	plus	_	_	O
433	MPA	_	_	O
434	.	_	_	O

435	Neither	_	_	O
436	regimen	_	_	O
437	affected	_	_	O
438	all-cause	_	_	O
439	mortality	_	_	O
440	.	_	_	O

441	For	_	_	B-Premise
442	CEE	_	_	I-Premise
443	alone	_	_	I-Premise
444	,	_	_	I-Premise
445	younger	_	_	I-Premise
446	women	_	_	I-Premise
447	(	_	_	I-Premise
448	aged	_	_	I-Premise
449	50-59	_	_	I-Premise
450	years	_	_	I-Premise
451	)	_	_	I-Premise
452	had	_	_	I-Premise
453	more	_	_	I-Premise
454	favorable	_	_	I-Premise
455	results	_	_	I-Premise
456	for	_	_	I-Premise
457	all-cause	_	_	I-Premise
458	mortality	_	_	I-Premise
459	,	_	_	I-Premise
460	myocardial	_	_	I-Premise
461	infarction	_	_	I-Premise
462	,	_	_	I-Premise
463	and	_	_	I-Premise
464	the	_	_	I-Premise
465	global	_	_	I-Premise
466	index	_	_	I-Premise
467	(	_	_	I-Premise
468	nominal	_	_	I-Premise
469	P	_	_	I-Premise
470	<	_	_	I-Premise
471	.05	_	_	I-Premise
472	for	_	_	I-Premise
473	trend	_	_	I-Premise
474	by	_	_	I-Premise
475	age	_	_	I-Premise
476	)	_	_	I-Premise
477	.	_	_	I-Premise

478	Absolute	_	_	B-Premise
479	risks	_	_	I-Premise
480	of	_	_	I-Premise
481	adverse	_	_	I-Premise
482	events	_	_	I-Premise
483	(	_	_	I-Premise
484	measured	_	_	I-Premise
485	by	_	_	I-Premise
486	the	_	_	I-Premise
487	global	_	_	I-Premise
488	index	_	_	I-Premise
489	)	_	_	I-Premise
490	per	_	_	I-Premise
491	10,000	_	_	I-Premise
492	women	_	_	I-Premise
493	annually	_	_	I-Premise
494	taking	_	_	I-Premise
495	CEE	_	_	I-Premise
496	plus	_	_	I-Premise
497	MPA	_	_	I-Premise
498	ranged	_	_	I-Premise
499	from	_	_	I-Premise
500	12	_	_	I-Premise
501	excess	_	_	I-Premise
502	cases	_	_	I-Premise
503	for	_	_	I-Premise
504	ages	_	_	I-Premise
505	of	_	_	I-Premise
506	50-59	_	_	I-Premise
507	years	_	_	I-Premise
508	to	_	_	I-Premise
509	38	_	_	I-Premise
510	for	_	_	I-Premise
511	ages	_	_	I-Premise
512	of	_	_	I-Premise
513	70-79	_	_	I-Premise
514	years	_	_	I-Premise
515	;	_	_	I-Premise
516	for	_	_	I-Premise
517	women	_	_	I-Premise
518	taking	_	_	I-Premise
519	CEE	_	_	I-Premise
520	alone	_	_	I-Premise
521	,	_	_	I-Premise
522	from	_	_	I-Premise
523	19	_	_	I-Premise
524	fewer	_	_	I-Premise
525	cases	_	_	I-Premise
526	for	_	_	I-Premise
527	ages	_	_	I-Premise
528	of	_	_	I-Premise
529	50-59	_	_	I-Premise
530	years	_	_	I-Premise
531	to	_	_	I-Premise
532	51	_	_	I-Premise
533	excess	_	_	I-Premise
534	cases	_	_	I-Premise
535	for	_	_	I-Premise
536	ages	_	_	I-Premise
537	of	_	_	I-Premise
538	70-79	_	_	I-Premise
539	years	_	_	I-Premise
540	.	_	_	I-Premise

541	Quality-of-life	_	_	O
542	outcomes	_	_	O
543	had	_	_	O
544	mixed	_	_	O
545	results	_	_	O
546	in	_	_	O
547	both	_	_	O
548	trials	_	_	O
549	.	_	_	O

550	Menopausal	_	_	B-Claim
551	hormone	_	_	I-Claim
552	therapy	_	_	I-Claim
553	has	_	_	I-Claim
554	a	_	_	I-Claim
555	complex	_	_	I-Claim
556	pattern	_	_	I-Claim
557	of	_	_	I-Claim
558	risks	_	_	I-Claim
559	and	_	_	I-Claim
560	benefits	_	_	I-Claim
561	.	_	_	I-Claim

562	Findings	_	_	B-Claim
563	from	_	_	I-Claim
564	the	_	_	I-Claim
565	intervention	_	_	I-Claim
566	and	_	_	I-Claim
567	extended	_	_	I-Claim
568	postintervention	_	_	I-Claim
569	follow-up	_	_	I-Claim
570	of	_	_	I-Claim
571	the	_	_	I-Claim
572	2	_	_	I-Claim
573	WHI	_	_	I-Claim
574	hormone	_	_	I-Claim
575	therapy	_	_	I-Claim
576	trials	_	_	I-Claim
577	do	_	_	I-Claim
578	not	_	_	I-Claim
579	support	_	_	I-Claim
580	use	_	_	I-Claim
581	of	_	_	I-Claim
582	this	_	_	I-Claim
583	therapy	_	_	I-Claim
584	for	_	_	I-Claim
585	chronic	_	_	I-Claim
586	disease	_	_	I-Claim
587	prevention	_	_	I-Claim
588	,	_	_	I-Claim
589	although	_	_	B-Claim
590	it	_	_	I-Claim
591	is	_	_	I-Claim
592	appropriate	_	_	I-Claim
593	for	_	_	I-Claim
594	symptom	_	_	I-Claim
595	management	_	_	I-Claim
596	in	_	_	I-Claim
597	some	_	_	I-Claim
598	women	_	_	I-Claim
599	.	_	_	I-Claim


0	Colorectal	_	_	O
1	cancer	_	_	O
2	survivors	_	_	O
3	are	_	_	O
4	at	_	_	O
5	risk	_	_	O
6	for	_	_	O
7	poor	_	_	O
8	health	_	_	O
9	outcomes	_	_	O
10	because	_	_	O
11	of	_	_	O
12	unhealthy	_	_	O
13	lifestyles	_	_	O
14	,	_	_	O
15	but	_	_	O
16	few	_	_	O
17	studies	_	_	O
18	have	_	_	O
19	developed	_	_	O
20	translatable	_	_	O
21	health	_	_	O
22	behavior	_	_	O
23	change	_	_	O
24	interventions	_	_	O
25	.	_	_	O

26	This	_	_	O
27	study	_	_	O
28	aimed	_	_	O
29	to	_	_	O
30	determine	_	_	O
31	the	_	_	O
32	effects	_	_	O
33	of	_	_	O
34	a	_	_	O
35	telephone-delivered	_	_	O
36	multiple	_	_	O
37	health	_	_	O
38	behavior	_	_	O
39	change	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	CanChange	_	_	O
43	)	_	_	O
44	on	_	_	O
45	health	_	_	O
46	and	_	_	O
47	behavioral	_	_	O
48	outcomes	_	_	O
49	among	_	_	O
50	colorectal	_	_	O
51	cancer	_	_	O
52	survivors	_	_	O
53	.	_	_	O

54	In	_	_	O
55	this	_	_	O
56	two-group	_	_	O
57	randomized	_	_	O
58	controlled	_	_	O
59	trial	_	_	O
60	,	_	_	O
61	410	_	_	O
62	colorectal	_	_	O
63	cancer	_	_	O
64	survivors	_	_	O
65	were	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	the	_	_	O
70	health	_	_	O
71	coaching	_	_	O
72	intervention	_	_	O
73	(	_	_	O
74	11	_	_	O
75	theory-based	_	_	O
76	telephone-delivered	_	_	O
77	health	_	_	O
78	coaching	_	_	O
79	sessions	_	_	O
80	delivered	_	_	O
81	over	_	_	O
82	6	_	_	O
83	months	_	_	O
84	focusing	_	_	O
85	on	_	_	O
86	physical	_	_	O
87	activity	_	_	O
88	,	_	_	O
89	weight	_	_	O
90	management	_	_	O
91	,	_	_	O
92	dietary	_	_	O
93	habits	_	_	O
94	,	_	_	O
95	alcohol	_	_	O
96	,	_	_	O
97	and	_	_	O
98	smoking	_	_	O
99	)	_	_	O
100	or	_	_	O
101	usual	_	_	O
102	care	_	_	O
103	.	_	_	O

104	Assessment	_	_	O
105	of	_	_	O
106	primary	_	_	O
107	(	_	_	O
108	ie	_	_	O
109	,	_	_	O
110	physical	_	_	O
111	activity	_	_	O
112	[	_	_	O
113	Godin	_	_	O
114	Leisure	_	_	O
115	Time	_	_	O
116	Index	_	_	O
117	]	_	_	O
118	,	_	_	O
119	health-related	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	[	_	_	O
124	HRQoL	_	_	O
125	;	_	_	O
126	Short	_	_	O
127	Form-36	_	_	O
128	]	_	_	O
129	,	_	_	O
130	and	_	_	O
131	cancer-related	_	_	O
132	fatigue	_	_	O
133	[	_	_	O
134	Functional	_	_	O
135	Assessment	_	_	O
136	of	_	_	O
137	Chronic	_	_	O
138	Illness	_	_	O
139	Therapy	_	_	O
140	Fatigue	_	_	O
141	Scale	_	_	O
142	]	_	_	O
143	)	_	_	O
144	and	_	_	O
145	secondary	_	_	O
146	outcomes	_	_	O
147	(	_	_	O
148	ie	_	_	O
149	,	_	_	O
150	body	_	_	O
151	mass	_	_	O
152	index	_	_	O
153	[	_	_	O
154	kg/m	_	_	O
155	(	_	_	O
156	2	_	_	O
157	)	_	_	O
158	]	_	_	O
159	,	_	_	O
160	diet	_	_	O
161	and	_	_	O
162	alcohol	_	_	O
163	intake	_	_	O
164	[	_	_	O
165	Food	_	_	O
166	Frequency	_	_	O
167	Questionnaire	_	_	O
168	]	_	_	O
169	,	_	_	O
170	and	_	_	O
171	smoking	_	_	O
172	)	_	_	O
173	were	_	_	O
174	conducted	_	_	O
175	at	_	_	O
176	baseline	_	_	O
177	and	_	_	O
178	6	_	_	O
179	and	_	_	O
180	12	_	_	O
181	months	_	_	O
182	.	_	_	O

183	At	_	_	B-Premise
184	12	_	_	I-Premise
185	months	_	_	I-Premise
186	,	_	_	I-Premise
187	significant	_	_	I-Premise
188	intervention	_	_	I-Premise
189	effects	_	_	I-Premise
190	were	_	_	I-Premise
191	observed	_	_	I-Premise
192	for	_	_	I-Premise
193	moderate	_	_	I-Premise
194	physical	_	_	I-Premise
195	activity	_	_	I-Premise
196	(	_	_	I-Premise
197	28.5	_	_	I-Premise
198	minutes	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=	_	_	I-Premise
202	.003	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	body	_	_	I-Premise
206	mass	_	_	I-Premise
207	index	_	_	I-Premise
208	(	_	_	I-Premise
209	-0.9	_	_	I-Premise
210	kg/m	_	_	I-Premise
211	(	_	_	I-Premise
212	2	_	_	I-Premise
213	)	_	_	I-Premise
214	;	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.001	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	energy	_	_	I-Premise
221	from	_	_	I-Premise
222	total	_	_	I-Premise
223	fat	_	_	I-Premise
224	(	_	_	I-Premise
225	-7.0	_	_	I-Premise
226	%	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.006	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	energy	_	_	I-Premise
235	from	_	_	I-Premise
236	saturated	_	_	I-Premise
237	fat	_	_	I-Premise
238	(	_	_	I-Premise
239	-2.8	_	_	I-Premise
240	%	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.016	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	A	_	_	B-Premise
248	significant	_	_	I-Premise
249	intervention	_	_	I-Premise
250	effect	_	_	I-Premise
251	was	_	_	I-Premise
252	reported	_	_	I-Premise
253	for	_	_	I-Premise
254	vegetable	_	_	I-Premise
255	intake	_	_	I-Premise
256	(	_	_	I-Premise
257	0.4	_	_	I-Premise
258	servings	_	_	I-Premise
259	per	_	_	I-Premise
260	day	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.001	_	_	I-Premise
265	)	_	_	I-Premise
266	at	_	_	I-Premise
267	6	_	_	I-Premise
268	months	_	_	I-Premise
269	.	_	_	I-Premise

270	No	_	_	B-Premise
271	significant	_	_	I-Premise
272	group	_	_	I-Premise
273	differences	_	_	I-Premise
274	were	_	_	I-Premise
275	found	_	_	I-Premise
276	at	_	_	I-Premise
277	6	_	_	I-Premise
278	or	_	_	I-Premise
279	12	_	_	I-Premise
280	months	_	_	I-Premise
281	for	_	_	I-Premise
282	HRQoL	_	_	I-Premise
283	,	_	_	I-Premise
284	cancer-related	_	_	I-Premise
285	fatigue	_	_	I-Premise
286	,	_	_	I-Premise
287	fruit	_	_	I-Premise
288	,	_	_	I-Premise
289	fiber	_	_	I-Premise
290	,	_	_	I-Premise
291	or	_	_	I-Premise
292	alcohol	_	_	I-Premise
293	intake	_	_	I-Premise
294	,	_	_	I-Premise
295	or	_	_	I-Premise
296	smoking	_	_	I-Premise
297	.	_	_	I-Premise

298	The	_	_	B-Claim
299	CanChange	_	_	I-Claim
300	intervention	_	_	I-Claim
301	was	_	_	I-Claim
302	effective	_	_	I-Claim
303	for	_	_	I-Claim
304	improving	_	_	I-Claim
305	physical	_	_	I-Claim
306	activity	_	_	I-Claim
307	,	_	_	I-Claim
308	dietary	_	_	I-Claim
309	habits	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	body	_	_	I-Claim
313	mass	_	_	I-Claim
314	index	_	_	I-Claim
315	in	_	_	I-Claim
316	colorectal	_	_	I-Claim
317	cancer	_	_	I-Claim
318	survivors	_	_	I-Claim
319	.	_	_	I-Claim

320	The	_	_	O
321	intervention	_	_	O
322	is	_	_	O
323	translatable	_	_	O
324	through	_	_	O
325	existing	_	_	O
326	telephone	_	_	O
327	cancer	_	_	O
328	support	_	_	O
329	and	_	_	O
330	information	_	_	O
331	services	_	_	O
332	in	_	_	O
333	Australia	_	_	O
334	and	_	_	O
335	other	_	_	O
336	countries	_	_	O
337	.	_	_	O


0	Evaluation	_	_	O
1	of	_	_	O
2	health-related	_	_	O
3	quality-of-life	_	_	O
4	(	_	_	O
5	HRQoL	_	_	O
6	)	_	_	O
7	and	_	_	O
8	symptom	_	_	O
9	improvement	_	_	O
10	were	_	_	O
11	preplanned	_	_	O
12	secondary	_	_	O
13	objectives	_	_	O
14	for	_	_	O
15	the	_	_	O
16	overall	_	_	O
17	population	_	_	O
18	and	_	_	O
19	posthoc	_	_	O
20	analyses	_	_	O
21	for	_	_	O
22	epidermal	_	_	O
23	growth	_	_	O
24	factor	_	_	O
25	receptor	_	_	O
26	(	_	_	O
27	EGFR	_	_	O
28	)	_	_	O
29	mutation-positive/negative	_	_	O
30	subgroups	_	_	O
31	in	_	_	O
32	IPASS	_	_	O
33	.	_	_	O

34	HRQoL	_	_	O
35	was	_	_	O
36	assessed	_	_	O
37	using	_	_	O
38	the	_	_	O
39	Functional	_	_	O
40	Assessment	_	_	O
41	of	_	_	O
42	Cancer	_	_	O
43	Therapy-Lung	_	_	O
44	(	_	_	O
45	FACT-L	_	_	O
46	)	_	_	O
47	and	_	_	O
48	Trial	_	_	O
49	Outcome	_	_	O
50	Index	_	_	O
51	(	_	_	O
52	TOI	_	_	O
53	)	_	_	O
54	;	_	_	O
55	symptom	_	_	O
56	improvement	_	_	O
57	by	_	_	O
58	the	_	_	O
59	Lung	_	_	O
60	Cancer	_	_	O
61	Subscale	_	_	O
62	(	_	_	O
63	LCS	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Improvements	_	_	O
67	defined	_	_	O
68	as	_	_	O
69	:	_	_	O
70	6	_	_	O
71	or	_	_	O
72	more	_	_	O
73	(	_	_	O
74	FACT-L	_	_	O
75	;	_	_	O
76	TOI	_	_	O
77	)	_	_	O
78	,	_	_	O
79	2	_	_	O
80	or	_	_	O
81	more	_	_	O
82	(	_	_	O
83	LCS	_	_	O
84	)	_	_	O
85	points	_	_	O
86	increase	_	_	O
87	maintained	_	_	O
88	for	_	_	O
89	21	_	_	O
90	or	_	_	O
91	more	_	_	O
92	days	_	_	O
93	.	_	_	O

94	Overall	_	_	O
95	(	_	_	O
96	n	_	_	O
97	=	_	_	O
98	1151/1217	_	_	O
99	evaluable	_	_	O
100	)	_	_	O
101	,	_	_	O
102	HRQoL	_	_	O
103	improvement	_	_	O
104	rates	_	_	O
105	were	_	_	O
106	significantly	_	_	O
107	greater	_	_	O
108	with	_	_	O
109	gefitinib	_	_	O
110	versus	_	_	O
111	carboplatin/paclitaxel	_	_	O
112	;	_	_	O
113	symptom	_	_	O
114	improvement	_	_	O
115	rates	_	_	O
116	were	_	_	O
117	similar	_	_	O
118	for	_	_	O
119	both	_	_	O
120	treatments	_	_	O
121	.	_	_	O

122	Significantly	_	_	B-Premise
123	more	_	_	I-Premise
124	patients	_	_	I-Premise
125	recorded	_	_	I-Premise
126	improvements	_	_	I-Premise
127	in	_	_	I-Premise
128	HRQoL	_	_	I-Premise
129	and	_	_	I-Premise
130	symptoms	_	_	I-Premise
131	with	_	_	I-Premise
132	gefitinib	_	_	I-Premise
133	in	_	_	I-Premise
134	the	_	_	I-Premise
135	EGFR	_	_	I-Premise
136	mutation-positive	_	_	I-Premise
137	subgroup	_	_	I-Premise
138	(	_	_	I-Premise
139	n	_	_	I-Premise
140	=	_	_	I-Premise
141	259	_	_	I-Premise
142	;	_	_	I-Premise
143	FACT-L	_	_	I-Premise
144	70.2	_	_	I-Premise
145	%	_	_	I-Premise
146	versus	_	_	I-Premise
147	44.5	_	_	I-Premise
148	%	_	_	I-Premise
149	;	_	_	I-Premise
150	odds	_	_	I-Premise
151	ratio	_	_	I-Premise
152	,	_	_	I-Premise
153	3.01	_	_	I-Premise
154	[	_	_	I-Premise
155	95	_	_	I-Premise
156	%	_	_	I-Premise
157	confidence	_	_	I-Premise
158	interval	_	_	I-Premise
159	,	_	_	I-Premise
160	1.79-5.07	_	_	I-Premise
161	]	_	_	I-Premise
162	;	_	_	I-Premise
163	p	_	_	I-Premise
164	<	_	_	I-Premise
165	0.001	_	_	I-Premise
166	;	_	_	I-Premise
167	TOI	_	_	I-Premise
168	70.2	_	_	I-Premise
169	%	_	_	I-Premise
170	versus	_	_	I-Premise
171	38.3	_	_	I-Premise
172	%	_	_	I-Premise
173	;	_	_	I-Premise
174	3.96	_	_	I-Premise
175	[	_	_	I-Premise
176	2.33-6.71	_	_	I-Premise
177	]	_	_	I-Premise
178	;	_	_	I-Premise
179	p	_	_	I-Premise
180	<	_	_	I-Premise
181	0.001	_	_	I-Premise
182	;	_	_	I-Premise
183	LCS	_	_	I-Premise
184	75.6	_	_	I-Premise
185	%	_	_	I-Premise
186	versus	_	_	I-Premise
187	53.9	_	_	I-Premise
188	%	_	_	I-Premise
189	;	_	_	I-Premise
190	2.70	_	_	I-Premise
191	[	_	_	I-Premise
192	1.58-4.62	_	_	I-Premise
193	]	_	_	I-Premise
194	;	_	_	I-Premise
195	p	_	_	I-Premise
196	<	_	_	I-Premise
197	0.001	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	with	_	_	I-Premise
202	carboplatin/paclitaxel	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	EGFR	_	_	I-Premise
206	mutation-negative	_	_	I-Premise
207	subgroup	_	_	I-Premise
208	(	_	_	I-Premise
209	n	_	_	I-Premise
210	=	_	_	I-Premise
211	169	_	_	I-Premise
212	;	_	_	I-Premise
213	FACT-L	_	_	I-Premise
214	14.6	_	_	I-Premise
215	%	_	_	I-Premise
216	versus	_	_	I-Premise
217	36.3	_	_	I-Premise
218	%	_	_	I-Premise
219	;	_	_	I-Premise
220	odds	_	_	I-Premise
221	ratio	_	_	I-Premise
222	,	_	_	I-Premise
223	0.31	_	_	I-Premise
224	[	_	_	I-Premise
225	0.15-0.65	_	_	I-Premise
226	]	_	_	I-Premise
227	;	_	_	I-Premise
228	p	_	_	I-Premise
229	=	_	_	I-Premise
230	0.002	_	_	I-Premise
231	;	_	_	I-Premise
232	TOI	_	_	I-Premise
233	12.4	_	_	I-Premise
234	%	_	_	I-Premise
235	versus	_	_	I-Premise
236	28.8	_	_	I-Premise
237	%	_	_	I-Premise
238	;	_	_	I-Premise
239	0.35	_	_	I-Premise
240	[	_	_	I-Premise
241	0.16-0.79	_	_	I-Premise
242	]	_	_	I-Premise
243	;	_	_	I-Premise
244	p	_	_	I-Premise
245	=	_	_	I-Premise
246	0.011	_	_	I-Premise
247	;	_	_	I-Premise
248	LCS	_	_	I-Premise
249	20.2	_	_	I-Premise
250	%	_	_	I-Premise
251	versus	_	_	I-Premise
252	47.5	_	_	I-Premise
253	%	_	_	I-Premise
254	;	_	_	I-Premise
255	0.28	_	_	I-Premise
256	[	_	_	I-Premise
257	0.14-0.55	_	_	I-Premise
258	]	_	_	I-Premise
259	;	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Median	_	_	B-Premise
266	time-to-worsening	_	_	I-Premise
267	(	_	_	I-Premise
268	months	_	_	I-Premise
269	)	_	_	I-Premise
270	FACT-L	_	_	I-Premise
271	score	_	_	I-Premise
272	was	_	_	I-Premise
273	longer	_	_	I-Premise
274	with	_	_	I-Premise
275	gefitinib	_	_	I-Premise
276	versus	_	_	I-Premise
277	carboplatin/paclitaxel	_	_	I-Premise
278	for	_	_	I-Premise
279	the	_	_	I-Premise
280	overall	_	_	I-Premise
281	population	_	_	I-Premise
282	(	_	_	I-Premise
283	8.3	_	_	I-Premise
284	versus	_	_	I-Premise
285	2.5	_	_	I-Premise
286	)	_	_	I-Premise
287	and	_	_	I-Premise
288	EGFR	_	_	I-Premise
289	mutation-positive	_	_	I-Premise
290	subgroup	_	_	I-Premise
291	(	_	_	I-Premise
292	15.6	_	_	I-Premise
293	versus	_	_	I-Premise
294	3.0	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	and	_	_	I-Premise
298	similar	_	_	I-Premise
299	for	_	_	I-Premise
300	both	_	_	I-Premise
301	treatments	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	EGFR	_	_	I-Premise
305	mutation-negative	_	_	I-Premise
306	subgroup	_	_	I-Premise
307	(	_	_	I-Premise
308	1.4	_	_	I-Premise
309	versus	_	_	I-Premise
310	1.4	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Median	_	_	B-Premise
314	time-to-improvement	_	_	I-Premise
315	with	_	_	I-Premise
316	gefitinib	_	_	I-Premise
317	was	_	_	I-Premise
318	8	_	_	I-Premise
319	days	_	_	I-Premise
320	in	_	_	I-Premise
321	patients	_	_	I-Premise
322	with	_	_	I-Premise
323	EGFR	_	_	I-Premise
324	mutation-positive	_	_	I-Premise
325	tumors	_	_	I-Premise
326	who	_	_	I-Premise
327	improved	_	_	I-Premise
328	.	_	_	I-Premise

329	HRQoL	_	_	B-Claim
330	and	_	_	I-Claim
331	symptom	_	_	I-Claim
332	endpoints	_	_	I-Claim
333	were	_	_	I-Claim
334	consistent	_	_	I-Claim
335	with	_	_	I-Claim
336	efficacy	_	_	I-Claim
337	outcomes	_	_	I-Claim
338	in	_	_	I-Claim
339	IPASS	_	_	I-Claim
340	and	_	_	I-Claim
341	favored	_	_	I-Claim
342	gefitinib	_	_	I-Claim
343	in	_	_	I-Claim
344	patients	_	_	I-Claim
345	with	_	_	I-Claim
346	EGFR	_	_	I-Claim
347	mutation-positive	_	_	I-Claim
348	tumors	_	_	I-Claim
349	and	_	_	I-Claim
350	carboplatin/paclitaxel	_	_	I-Claim
351	in	_	_	I-Claim
352	patients	_	_	I-Claim
353	with	_	_	I-Claim
354	EGFR	_	_	I-Claim
355	mutation-negative	_	_	I-Claim
356	tumors	_	_	I-Claim
357	.	_	_	I-Claim


0	In	_	_	B-Claim
1	a	_	_	I-Claim
2	randomized	_	_	I-Claim
3	clinical	_	_	I-Claim
4	trial	_	_	I-Claim
5	in	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non-small-cell	_	_	I-Claim
10	lung	_	_	I-Claim
11	cancer	_	_	I-Claim
12	(	_	_	I-Claim
13	NSCLC	_	_	I-Claim
14	)	_	_	I-Claim
15	,	_	_	I-Claim
16	infusion	_	_	I-Claim
17	with	_	_	I-Claim
18	adenosine	_	_	I-Claim
19	5'-triphosphate	_	_	I-Claim
20	(	_	_	I-Claim
21	ATP	_	_	I-Claim
22	)	_	_	I-Claim
23	inhibited	_	_	I-Claim
24	loss	_	_	I-Claim
25	of	_	_	I-Claim
26	body	_	_	I-Claim
27	weight	_	_	I-Claim
28	and	_	_	I-Claim
29	quality	_	_	I-Claim
30	of	_	_	I-Claim
31	life	_	_	I-Claim
32	.	_	_	I-Claim

33	In	_	_	O
34	the	_	_	O
35	present	_	_	O
36	article	_	_	O
37	,	_	_	O
38	the	_	_	O
39	effects	_	_	O
40	of	_	_	O
41	ATP	_	_	O
42	on	_	_	O
43	body	_	_	O
44	composition	_	_	O
45	,	_	_	O
46	energy	_	_	O
47	intake	_	_	O
48	,	_	_	O
49	and	_	_	O
50	energy	_	_	O
51	expenditure	_	_	O
52	as	_	_	O
53	secondary	_	_	O
54	outcome	_	_	O
55	measures	_	_	O
56	in	_	_	O
57	the	_	_	O
58	same	_	_	O
59	patients	_	_	O
60	are	_	_	O
61	reported	_	_	O
62	.	_	_	O

63	Patients	_	_	O
64	with	_	_	O
65	NSCLC	_	_	O
66	,	_	_	O
67	stage	_	_	O
68	IIIB	_	_	O
69	or	_	_	O
70	IV	_	_	O
71	,	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	receive	_	_	O
76	either	_	_	O
77	10	_	_	O
78	intravenous	_	_	O
79	,	_	_	O
80	30-hour	_	_	O
81	ATP	_	_	O
82	infusions	_	_	O
83	every	_	_	O
84	2	_	_	O
85	to	_	_	O
86	4	_	_	O
87	weeks	_	_	O
88	or	_	_	O
89	no	_	_	O
90	ATP	_	_	O
91	.	_	_	O

92	Fat	_	_	O
93	mass	_	_	O
94	(	_	_	O
95	FM	_	_	O
96	)	_	_	O
97	,	_	_	O
98	fat-free	_	_	O
99	mass	_	_	O
100	(	_	_	O
101	FFM	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	arm	_	_	O
106	muscle	_	_	O
107	area	_	_	O
108	were	_	_	O
109	assessed	_	_	O
110	at	_	_	O
111	4-week	_	_	O
112	intervals	_	_	O
113	for	_	_	O
114	28	_	_	O
115	weeks	_	_	O
116	.	_	_	O

117	Food	_	_	O
118	intake	_	_	O
119	,	_	_	O
120	body	_	_	O
121	cell	_	_	O
122	mass	_	_	O
123	(	_	_	O
124	BCM	_	_	O
125	)	_	_	O
126	,	_	_	O
127	and	_	_	O
128	resting	_	_	O
129	energy	_	_	O
130	expenditure	_	_	O
131	(	_	_	O
132	REE	_	_	O
133	)	_	_	O
134	were	_	_	O
135	assessed	_	_	O
136	at	_	_	O
137	8-week	_	_	O
138	intervals	_	_	O
139	for	_	_	O
140	16	_	_	O
141	weeks	_	_	O
142	.	_	_	O

143	Between-group	_	_	O
144	differences	_	_	O
145	were	_	_	O
146	tested	_	_	O
147	for	_	_	O
148	statistical	_	_	O
149	significance	_	_	O
150	by	_	_	O
151	repeated-measures	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	covariance	_	_	O
155	.	_	_	O

156	Fifty-eight	_	_	O
157	patients	_	_	O
158	were	_	_	O
159	randomized	_	_	O
160	(	_	_	O
161	28	_	_	O
162	ATP	_	_	O
163	,	_	_	O
164	30	_	_	O
165	control	_	_	O
166	)	_	_	O
167	.	_	_	O

168	No	_	_	B-Premise
169	change	_	_	I-Premise
170	in	_	_	I-Premise
171	body	_	_	I-Premise
172	composition	_	_	I-Premise
173	over	_	_	I-Premise
174	the	_	_	I-Premise
175	28-week	_	_	I-Premise
176	follow-up	_	_	I-Premise
177	period	_	_	I-Premise
178	was	_	_	I-Premise
179	found	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	ATP	_	_	I-Premise
183	group	_	_	I-Premise
184	,	_	_	I-Premise
185	whereas	_	_	I-Premise
186	,	_	_	I-Premise
187	per	_	_	I-Premise
188	4	_	_	I-Premise
189	weeks	_	_	I-Premise
190	,	_	_	I-Premise
191	the	_	_	I-Premise
192	control	_	_	I-Premise
193	group	_	_	I-Premise
194	lost	_	_	I-Premise
195	0.6	_	_	I-Premise
196	kg	_	_	I-Premise
197	of	_	_	I-Premise
198	FM	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	=.004	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	0.5	_	_	I-Premise
205	kg	_	_	I-Premise
206	of	_	_	I-Premise
207	FFM	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=.02	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	1.8	_	_	I-Premise
214	%	_	_	I-Premise
215	of	_	_	I-Premise
216	arm	_	_	I-Premise
217	muscle	_	_	I-Premise
218	area	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=.02	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	and	_	_	I-Premise
225	0.6	_	_	I-Premise
226	%	_	_	I-Premise
227	of	_	_	I-Premise
228	BCM/kg	_	_	I-Premise
229	body	_	_	I-Premise
230	weight	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	=.054	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	decreased	_	_	I-Premise
237	568	_	_	I-Premise
238	KJ/d	_	_	I-Premise
239	in	_	_	I-Premise
240	energy	_	_	I-Premise
241	intake	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=.0001	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Appetite	_	_	B-Premise
248	also	_	_	I-Premise
249	remained	_	_	I-Premise
250	stable	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	ATP	_	_	I-Premise
254	group	_	_	I-Premise
255	but	_	_	I-Premise
256	decreased	_	_	I-Premise
257	significantly	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	control	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=.0004	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	No	_	_	B-Premise
268	significant	_	_	I-Premise
269	differences	_	_	I-Premise
270	in	_	_	I-Premise
271	REE	_	_	I-Premise
272	between	_	_	I-Premise
273	the	_	_	I-Premise
274	ATP	_	_	I-Premise
275	and	_	_	I-Premise
276	control	_	_	I-Premise
277	groups	_	_	I-Premise
278	were	_	_	I-Premise
279	observed	_	_	I-Premise
280	.	_	_	I-Premise

281	The	_	_	B-Claim
282	inhibition	_	_	I-Claim
283	of	_	_	I-Claim
284	weight	_	_	I-Claim
285	loss	_	_	I-Claim
286	by	_	_	I-Claim
287	ATP	_	_	I-Claim
288	infusions	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	advanced	_	_	I-Claim
293	NSCLC	_	_	I-Claim
294	is	_	_	I-Claim
295	attributed	_	_	I-Claim
296	to	_	_	I-Claim
297	counteracting	_	_	I-Claim
298	the	_	_	I-Claim
299	loss	_	_	I-Claim
300	of	_	_	I-Claim
301	both	_	_	I-Claim
302	metabolically	_	_	I-Claim
303	active	_	_	I-Claim
304	and	_	_	I-Claim
305	inactive	_	_	I-Claim
306	tissues	_	_	I-Claim
307	.	_	_	I-Claim

308	These	_	_	B-Premise
309	effects	_	_	I-Premise
310	are	_	_	I-Premise
311	partly	_	_	I-Premise
312	ascribed	_	_	I-Premise
313	to	_	_	I-Premise
314	maintenance	_	_	I-Premise
315	of	_	_	I-Premise
316	energy	_	_	I-Premise
317	intake	_	_	I-Premise
318	.	_	_	I-Premise


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	treatment	_	_	O
4	with	_	_	O
5	single-agent	_	_	O
6	docetaxel	_	_	O
7	would	_	_	O
8	result	_	_	O
9	in	_	_	O
10	longer	_	_	O
11	survival	_	_	O
12	than	_	_	O
13	would	_	_	O
14	best	_	_	O
15	supportive	_	_	O
16	care	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	non-small-cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	who	_	_	O
24	had	_	_	O
25	previously	_	_	O
26	been	_	_	O
27	treated	_	_	O
28	with	_	_	O
29	platinum-based	_	_	O
30	chemotherapy	_	_	O
31	.	_	_	O

32	Secondary	_	_	O
33	end	_	_	O
34	points	_	_	O
35	included	_	_	O
36	assessment	_	_	O
37	of	_	_	O
38	response	_	_	O
39	(	_	_	O
40	docetaxel	_	_	O
41	arm	_	_	O
42	only	_	_	O
43	)	_	_	O
44	,	_	_	O
45	toxicity	_	_	O
46	,	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	.	_	_	O

52	Patients	_	_	O
53	with	_	_	O
54	performance	_	_	O
55	statuses	_	_	O
56	of	_	_	O
57	0	_	_	O
58	to	_	_	O
59	2	_	_	O
60	and	_	_	O
61	stage	_	_	O
62	IIIB/IV	_	_	O
63	non-small-cell	_	_	O
64	lung	_	_	O
65	cancer	_	_	O
66	with	_	_	O
67	either	_	_	O
68	measurable	_	_	O
69	or	_	_	O
70	evaluable	_	_	O
71	lesions	_	_	O
72	were	_	_	O
73	eligible	_	_	O
74	for	_	_	O
75	entry	_	_	O
76	onto	_	_	O
77	the	_	_	O
78	study	_	_	O
79	if	_	_	O
80	they	_	_	O
81	had	_	_	O
82	undergone	_	_	O
83	one	_	_	O
84	or	_	_	O
85	more	_	_	O
86	platinum-based	_	_	O
87	chemotherapy	_	_	O
88	regimens	_	_	O
89	and	_	_	O
90	if	_	_	O
91	they	_	_	O
92	had	_	_	O
93	adequate	_	_	O
94	hematology	_	_	O
95	and	_	_	O
96	biochemistry	_	_	O
97	parameters	_	_	O
98	.	_	_	O

99	They	_	_	O
100	were	_	_	O
101	excluded	_	_	O
102	if	_	_	O
103	they	_	_	O
104	had	_	_	O
105	symptomatic	_	_	O
106	brain	_	_	O
107	metastases	_	_	O
108	or	_	_	O
109	if	_	_	O
110	they	_	_	O
111	had	_	_	O
112	previously	_	_	O
113	been	_	_	O
114	treated	_	_	O
115	with	_	_	O
116	paclitaxel	_	_	O
117	.	_	_	O

118	Patients	_	_	O
119	were	_	_	O
120	stratified	_	_	O
121	by	_	_	O
122	performance	_	_	O
123	status	_	_	O
124	and	_	_	O
125	best	_	_	O
126	response	_	_	O
127	to	_	_	O
128	cisplatin	_	_	O
129	chemotherapy	_	_	O
130	and	_	_	O
131	were	_	_	O
132	then	_	_	O
133	randomized	_	_	O
134	to	_	_	O
135	treatment	_	_	O
136	with	_	_	O
137	docetaxel	_	_	O
138	100	_	_	O
139	mg/m	_	_	O
140	(	_	_	O
141	2	_	_	O
142	)	_	_	O
143	(	_	_	O
144	49	_	_	O
145	patients	_	_	O
146	)	_	_	O
147	or	_	_	O
148	75	_	_	O
149	mg/m	_	_	O
150	(	_	_	O
151	2	_	_	O
152	)	_	_	O
153	(	_	_	O
154	55	_	_	O
155	patients	_	_	O
156	)	_	_	O
157	or	_	_	O
158	best	_	_	O
159	supportive	_	_	O
160	care	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	in	_	_	O
164	both	_	_	O
165	arms	_	_	O
166	were	_	_	O
167	assessed	_	_	O
168	every	_	_	O
169	3	_	_	O
170	weeks	_	_	O
171	.	_	_	O

172	One	_	_	O
173	hundred	_	_	O
174	four	_	_	O
175	patients	_	_	O
176	(	_	_	O
177	103	_	_	O
178	of	_	_	O
179	whom	_	_	O
180	were	_	_	O
181	eligible	_	_	O
182	for	_	_	O
183	entry	_	_	O
184	onto	_	_	O
185	the	_	_	O
186	study	_	_	O
187	)	_	_	O
188	were	_	_	O
189	well	_	_	O
190	balanced	_	_	O
191	for	_	_	O
192	prognostic	_	_	O
193	factors	_	_	O
194	.	_	_	O

195	Of	_	_	O
196	84	_	_	O
197	patients	_	_	O
198	with	_	_	O
199	measurable	_	_	O
200	lesions	_	_	O
201	,	_	_	O
202	six	_	_	O
203	(	_	_	O
204	7	_	_	O
205	.	_	_	O

206	1	_	_	O
207	%	_	_	O
208	)	_	_	O
209	achieved	_	_	O
210	partial	_	_	O
211	responses	_	_	O
212	(	_	_	O
213	three	_	_	O
214	patients	_	_	O
215	at	_	_	O
216	each	_	_	O
217	dose	_	_	O
218	level	_	_	O
219	)	_	_	O
220	.	_	_	O

221	Time	_	_	B-Premise
222	to	_	_	I-Premise
223	progression	_	_	I-Premise
224	was	_	_	I-Premise
225	longer	_	_	I-Premise
226	for	_	_	I-Premise
227	docetaxel	_	_	I-Premise
228	patients	_	_	I-Premise
229	than	_	_	I-Premise
230	for	_	_	I-Premise
231	best	_	_	I-Premise
232	supportive	_	_	I-Premise
233	care	_	_	I-Premise
234	patients	_	_	I-Premise
235	(	_	_	I-Premise
236	10.6	_	_	I-Premise
237	v	_	_	I-Premise
238	6.7	_	_	I-Premise
239	weeks	_	_	I-Premise
240	,	_	_	I-Premise
241	respectively	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	.001	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	as	_	_	I-Premise
249	was	_	_	I-Premise
250	median	_	_	I-Premise
251	survival	_	_	I-Premise
252	(	_	_	I-Premise
253	7.0	_	_	I-Premise
254	v	_	_	I-Premise
255	4.6	_	_	I-Premise
256	months	_	_	I-Premise
257	;	_	_	I-Premise
258	log-rank	_	_	I-Premise
259	test	_	_	I-Premise
260	,	_	_	I-Premise
261	P	_	_	I-Premise
262	=.047	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	difference	_	_	I-Premise
267	was	_	_	I-Premise
268	more	_	_	I-Premise
269	significant	_	_	I-Premise
270	for	_	_	I-Premise
271	docetaxel	_	_	I-Premise
272	75	_	_	I-Premise
273	mg/m	_	_	I-Premise
274	(	_	_	I-Premise
275	2	_	_	I-Premise
276	)	_	_	I-Premise
277	patients	_	_	I-Premise
278	,	_	_	I-Premise
279	compared	_	_	I-Premise
280	with	_	_	I-Premise
281	corresponding	_	_	I-Premise
282	best	_	_	I-Premise
283	supportive	_	_	I-Premise
284	care	_	_	I-Premise
285	patients	_	_	I-Premise
286	(	_	_	I-Premise
287	7.5	_	_	I-Premise
288	v	_	_	I-Premise
289	4.6	_	_	I-Premise
290	months	_	_	I-Premise
291	;	_	_	I-Premise
292	log-rank	_	_	I-Premise
293	test	_	_	I-Premise
294	,	_	_	I-Premise
295	P	_	_	I-Premise
296	=.010	_	_	I-Premise
297	;	_	_	I-Premise
298	1-year	_	_	I-Premise
299	survival	_	_	I-Premise
300	,	_	_	I-Premise
301	37	_	_	I-Premise
302	%	_	_	I-Premise
303	v	_	_	I-Premise
304	11	_	_	I-Premise
305	%	_	_	I-Premise
306	;	_	_	I-Premise
307	chi	_	_	I-Premise
308	(	_	_	I-Premise
309	2	_	_	I-Premise
310	)	_	_	I-Premise
311	test	_	_	I-Premise
312	,	_	_	I-Premise
313	P	_	_	I-Premise
314	=.003	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	Febrile	_	_	B-Premise
318	neutropenia	_	_	I-Premise
319	occurred	_	_	I-Premise
320	in	_	_	I-Premise
321	11	_	_	I-Premise
322	patients	_	_	I-Premise
323	treated	_	_	I-Premise
324	with	_	_	I-Premise
325	docetaxel	_	_	I-Premise
326	100	_	_	I-Premise
327	mg/m	_	_	I-Premise
328	(	_	_	I-Premise
329	2	_	_	I-Premise
330	)	_	_	I-Premise
331	,	_	_	I-Premise
332	three	_	_	I-Premise
333	of	_	_	I-Premise
334	whom	_	_	I-Premise
335	died	_	_	I-Premise
336	,	_	_	I-Premise
337	and	_	_	I-Premise
338	in	_	_	I-Premise
339	one	_	_	I-Premise
340	patient	_	_	I-Premise
341	treated	_	_	I-Premise
342	with	_	_	I-Premise
343	docetaxel	_	_	I-Premise
344	75	_	_	I-Premise
345	mg/m	_	_	I-Premise
346	(	_	_	I-Premise
347	2	_	_	I-Premise
348	)	_	_	I-Premise
349	.	_	_	I-Premise

350	Grade	_	_	B-Premise
351	3	_	_	I-Premise
352	or	_	_	I-Premise
353	4	_	_	I-Premise
354	nonhematologic	_	_	I-Premise
355	toxicity	_	_	I-Premise
356	,	_	_	I-Premise
357	with	_	_	I-Premise
358	the	_	_	I-Premise
359	exception	_	_	I-Premise
360	of	_	_	I-Premise
361	diarrhea	_	_	I-Premise
362	,	_	_	I-Premise
363	occurred	_	_	I-Premise
364	at	_	_	I-Premise
365	a	_	_	I-Premise
366	similar	_	_	I-Premise
367	rate	_	_	I-Premise
368	in	_	_	I-Premise
369	both	_	_	I-Premise
370	the	_	_	I-Premise
371	docetaxel	_	_	I-Premise
372	and	_	_	I-Premise
373	best	_	_	I-Premise
374	supportive	_	_	I-Premise
375	care	_	_	I-Premise
376	groups	_	_	I-Premise
377	.	_	_	I-Premise

378	Treatment	_	_	B-Claim
379	with	_	_	I-Claim
380	docetaxel	_	_	I-Claim
381	is	_	_	I-Claim
382	associated	_	_	I-Claim
383	with	_	_	I-Claim
384	significant	_	_	I-Claim
385	prolongation	_	_	I-Claim
386	of	_	_	I-Claim
387	survival	_	_	I-Claim
388	,	_	_	I-Claim
389	and	_	_	O
390	at	_	_	B-Claim
391	a	_	_	I-Claim
392	dose	_	_	I-Claim
393	of	_	_	I-Claim
394	75	_	_	I-Claim
395	mg/m	_	_	I-Claim
396	(	_	_	I-Claim
397	2	_	_	I-Claim
398	)	_	_	I-Claim
399	,	_	_	I-Claim
400	the	_	_	I-Claim
401	benefits	_	_	I-Claim
402	of	_	_	I-Claim
403	docetaxel	_	_	I-Claim
404	therapy	_	_	I-Claim
405	outweigh	_	_	I-Claim
406	the	_	_	I-Claim
407	risks	_	_	I-Claim
408	.	_	_	I-Claim


0	Enhanced	_	_	O
1	recovery	_	_	O
2	programmes	_	_	O
3	(	_	_	O
4	ERPs	_	_	O
5	)	_	_	O
6	have	_	_	O
7	been	_	_	O
8	shown	_	_	O
9	to	_	_	O
10	reduce	_	_	O
11	length	_	_	O
12	of	_	_	O
13	hospital	_	_	O
14	stay	_	_	O
15	(	_	_	O
16	LOS	_	_	O
17	)	_	_	O
18	and	_	_	O
19	complications	_	_	O
20	in	_	_	O
21	colorectal	_	_	O
22	surgery	_	_	O
23	.	_	_	O

24	Whether	_	_	O
25	ERPs	_	_	O
26	have	_	_	O
27	the	_	_	O
28	same	_	_	O
29	benefits	_	_	O
30	in	_	_	O
31	open	_	_	O
32	liver	_	_	O
33	resection	_	_	O
34	surgery	_	_	O
35	is	_	_	O
36	unclear	_	_	O
37	,	_	_	O
38	and	_	_	O
39	randomized	_	_	O
40	clinical	_	_	O
41	trials	_	_	O
42	are	_	_	O
43	lacking	_	_	O
44	.	_	_	O

45	Consecutive	_	_	O
46	patients	_	_	O
47	scheduled	_	_	O
48	for	_	_	O
49	open	_	_	O
50	liver	_	_	O
51	resection	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	an	_	_	O
56	ERP	_	_	O
57	group	_	_	O
58	or	_	_	O
59	standard	_	_	O
60	care	_	_	O
61	.	_	_	O

62	Primary	_	_	O
63	endpoints	_	_	O
64	were	_	_	O
65	time	_	_	O
66	until	_	_	O
67	medically	_	_	O
68	fit	_	_	O
69	for	_	_	O
70	discharge	_	_	O
71	(	_	_	O
72	MFD	_	_	O
73	)	_	_	O
74	and	_	_	O
75	LOS	_	_	O
76	.	_	_	O

77	Secondary	_	_	O
78	endpoints	_	_	O
79	were	_	_	O
80	postoperative	_	_	O
81	morbidity	_	_	O
82	,	_	_	O
83	pain	_	_	O
84	scores	_	_	O
85	,	_	_	O
86	readmission	_	_	O
87	rate	_	_	O
88	,	_	_	O
89	mortality	_	_	O
90	,	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	(	_	_	O
95	QoL	_	_	O
96	)	_	_	O
97	and	_	_	O
98	patient	_	_	O
99	satisfaction	_	_	O
100	.	_	_	O

101	ERP	_	_	O
102	elements	_	_	O
103	included	_	_	O
104	greater	_	_	O
105	preoperative	_	_	O
106	education	_	_	O
107	,	_	_	O
108	preoperative	_	_	O
109	oral	_	_	O
110	carbohydrate	_	_	O
111	loading	_	_	O
112	,	_	_	O
113	postoperative	_	_	O
114	goal-directed	_	_	O
115	fluid	_	_	O
116	therapy	_	_	O
117	,	_	_	O
118	early	_	_	O
119	mobilization	_	_	O
120	and	_	_	O
121	physiotherapy	_	_	O
122	.	_	_	O

123	Both	_	_	O
124	groups	_	_	O
125	received	_	_	O
126	standardized	_	_	O
127	anaesthesia	_	_	O
128	with	_	_	O
129	epidural	_	_	O
130	analgesia	_	_	O
131	.	_	_	O

132	The	_	_	O
133	analysis	_	_	O
134	included	_	_	O
135	46	_	_	O
136	patients	_	_	O
137	in	_	_	O
138	the	_	_	O
139	ERP	_	_	O
140	group	_	_	O
141	and	_	_	O
142	45	_	_	O
143	in	_	_	O
144	the	_	_	O
145	standard	_	_	O
146	care	_	_	O
147	group	_	_	O
148	.	_	_	O

149	Median	_	_	B-Premise
150	MFD	_	_	I-Premise
151	time	_	_	I-Premise
152	was	_	_	I-Premise
153	reduced	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	ERP	_	_	I-Premise
157	group	_	_	I-Premise
158	(	_	_	I-Premise
159	3	_	_	I-Premise
160	days	_	_	I-Premise
161	versus	_	_	I-Premise
162	6	_	_	I-Premise
163	days	_	_	I-Premise
164	with	_	_	I-Premise
165	standard	_	_	I-Premise
166	care	_	_	I-Premise
167	;	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	0Â·001	_	_	I-Premise
171	)	_	_	I-Premise
172	,	_	_	I-Premise
173	as	_	_	I-Premise
174	was	_	_	I-Premise
175	LOS	_	_	I-Premise
176	(	_	_	I-Premise
177	4	_	_	I-Premise
178	days	_	_	I-Premise
179	versus	_	_	I-Premise
180	7	_	_	I-Premise
181	days	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	0Â·001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	ERP	_	_	I-Premise
190	significantly	_	_	I-Premise
191	reduced	_	_	I-Premise
192	the	_	_	I-Premise
193	rate	_	_	I-Premise
194	of	_	_	I-Premise
195	medical	_	_	I-Premise
196	complications	_	_	I-Premise
197	(	_	_	I-Premise
198	7	_	_	I-Premise
199	versus	_	_	I-Premise
200	27	_	_	I-Premise
201	per	_	_	I-Premise
202	cent	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0Â·020	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	but	_	_	B-Premise
210	not	_	_	I-Premise
211	surgical	_	_	I-Premise
212	complications	_	_	I-Premise
213	(	_	_	I-Premise
214	15	_	_	I-Premise
215	versus	_	_	I-Premise
216	11	_	_	I-Premise
217	per	_	_	I-Premise
218	cent	_	_	I-Premise
219	;	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0Â·612	_	_	I-Premise
223	)	_	_	I-Premise
224	,	_	_	I-Premise
225	readmissions	_	_	I-Premise
226	(	_	_	I-Premise
227	4	_	_	I-Premise
228	versus	_	_	I-Premise
229	0	_	_	I-Premise
230	per	_	_	I-Premise
231	cent	_	_	I-Premise
232	;	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	0Â·153	_	_	I-Premise
236	)	_	_	I-Premise
237	or	_	_	I-Premise
238	mortality	_	_	I-Premise
239	(	_	_	I-Premise
240	both	_	_	I-Premise
241	2	_	_	I-Premise
242	per	_	_	I-Premise
243	cent	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	=	_	_	I-Premise
247	0Â·987	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	QoL	_	_	B-Premise
251	over	_	_	I-Premise
252	28	_	_	I-Premise
253	days	_	_	I-Premise
254	was	_	_	I-Premise
255	significantly	_	_	I-Premise
256	better	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	ERP	_	_	I-Premise
260	group	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0Â·002	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	was	_	_	I-Premise
269	no	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	patient	_	_	I-Premise
273	satisfaction	_	_	I-Premise
274	.	_	_	I-Premise

275	ERPs	_	_	B-Claim
276	for	_	_	I-Claim
277	open	_	_	I-Claim
278	liver	_	_	I-Claim
279	resection	_	_	I-Claim
280	surgery	_	_	I-Claim
281	are	_	_	I-Claim
282	safe	_	_	I-Claim
283	and	_	_	I-Claim
284	effective	_	_	I-Claim
285	.	_	_	I-Claim

286	Patients	_	_	B-Claim
287	treated	_	_	I-Claim
288	in	_	_	I-Claim
289	the	_	_	I-Claim
290	ERP	_	_	I-Claim
291	recovered	_	_	I-Claim
292	faster	_	_	I-Claim
293	,	_	_	I-Claim
294	were	_	_	I-Claim
295	discharged	_	_	I-Claim
296	sooner	_	_	I-Claim
297	,	_	_	I-Claim
298	and	_	_	I-Claim
299	had	_	_	I-Claim
300	fewer	_	_	I-Claim
301	medical-related	_	_	I-Claim
302	complications	_	_	I-Claim
303	and	_	_	I-Claim
304	improved	_	_	I-Claim
305	QoL	_	_	I-Claim
306	.	_	_	I-Claim


0	Although	_	_	O
1	chemotherapy-induced	_	_	O
2	cognitive	_	_	O
3	impairment	_	_	O
4	is	_	_	O
5	common	_	_	O
6	among	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	,	_	_	O
11	evidence	_	_	O
12	for	_	_	O
13	effective	_	_	O
14	interventions	_	_	O
15	addressing	_	_	O
16	cognitive	_	_	O
17	deficits	_	_	O
18	is	_	_	O
19	limited	_	_	O
20	.	_	_	O

21	This	_	_	O
22	randomized	_	_	O
23	controlled	_	_	O
24	trial	_	_	O
25	examined	_	_	O
26	the	_	_	O
27	feasibility	_	_	O
28	and	_	_	O
29	preliminary	_	_	O
30	efficacy	_	_	O
31	of	_	_	O
32	a	_	_	O
33	Tibetan	_	_	O
34	Sound	_	_	O
35	Meditation	_	_	O
36	(	_	_	O
37	TSM	_	_	O
38	)	_	_	O
39	program	_	_	O
40	to	_	_	O
41	improve	_	_	O
42	cognitive	_	_	O
43	function	_	_	O
44	and	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	in	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	patients	_	_	O
52	.	_	_	O

53	Forty-seven	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	patients	_	_	O
57	(	_	_	O
58	mean	_	_	O
59	age	_	_	O
60	56.3	_	_	O
61	years	_	_	O
62	)	_	_	O
63	,	_	_	O
64	who	_	_	O
65	were	_	_	O
66	staged	_	_	O
67	I-III	_	_	O
68	at	_	_	O
69	diagnosis	_	_	O
70	,	_	_	O
71	6-60	_	_	O
72	months	_	_	O
73	post-chemotherapy	_	_	O
74	,	_	_	O
75	and	_	_	O
76	reported	_	_	O
77	cognitive	_	_	O
78	impairment	_	_	O
79	at	_	_	O
80	study	_	_	O
81	entry	_	_	O
82	were	_	_	O
83	recruited	_	_	O
84	.	_	_	O

85	Participants	_	_	O
86	were	_	_	O
87	randomized	_	_	O
88	to	_	_	O
89	either	_	_	O
90	two	_	_	O
91	weekly	_	_	O
92	TSM	_	_	O
93	sessions	_	_	O
94	for	_	_	O
95	6	_	_	O
96	weeks	_	_	O
97	or	_	_	O
98	a	_	_	O
99	wait	_	_	O
100	list	_	_	O
101	control	_	_	O
102	group	_	_	O
103	.	_	_	O

104	Neuropsychological	_	_	O
105	assessments	_	_	O
106	were	_	_	O
107	completed	_	_	O
108	at	_	_	O
109	baseline	_	_	O
110	and	_	_	O
111	1	_	_	O
112	month	_	_	O
113	post-treatment	_	_	O
114	.	_	_	O

115	Self-report	_	_	O
116	measures	_	_	O
117	of	_	_	O
118	cognitive	_	_	O
119	function	_	_	O
120	(	_	_	O
121	Functional	_	_	O
122	Assessment	_	_	O
123	of	_	_	O
124	Cancer	_	_	O
125	Therapy	_	_	O
126	(	_	_	O
127	FACT	_	_	O
128	)	_	_	O
129	-Cog	_	_	O
130	)	_	_	O
131	,	_	_	O
132	quality	_	_	O
133	of	_	_	O
134	life	_	_	O
135	(	_	_	O
136	SF-36	_	_	O
137	)	_	_	O
138	,	_	_	O
139	depressive	_	_	O
140	symptoms	_	_	O
141	(	_	_	O
142	Center	_	_	O
143	for	_	_	O
144	Epidemiologic	_	_	O
145	Studies	_	_	O
146	Depression	_	_	O
147	Scale	_	_	O
148	)	_	_	O
149	,	_	_	O
150	sleep	_	_	O
151	disturbance	_	_	O
152	(	_	_	O
153	Pittsburgh	_	_	O
154	Sleep	_	_	O
155	Quality	_	_	O
156	Index	_	_	O
157	)	_	_	O
158	,	_	_	O
159	fatigue	_	_	O
160	(	_	_	O
161	Brief	_	_	O
162	Fatigue	_	_	O
163	Inventory	_	_	O
164	)	_	_	O
165	,	_	_	O
166	and	_	_	O
167	spirituality	_	_	O
168	(	_	_	O
169	FACT-Sp	_	_	O
170	)	_	_	O
171	were	_	_	O
172	completed	_	_	O
173	at	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	the	_	_	O
177	end	_	_	O
178	of	_	_	O
179	treatment	_	_	O
180	,	_	_	O
181	and	_	_	O
182	1	_	_	O
183	month	_	_	O
184	later	_	_	O
185	.	_	_	O

186	Relative	_	_	B-Premise
187	to	_	_	I-Premise
188	the	_	_	I-Premise
189	control	_	_	I-Premise
190	group	_	_	I-Premise
191	,	_	_	I-Premise
192	women	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	TSM	_	_	I-Premise
196	group	_	_	I-Premise
197	performed	_	_	I-Premise
198	better	_	_	I-Premise
199	on	_	_	I-Premise
200	the	_	_	I-Premise
201	verbal	_	_	I-Premise
202	memory	_	_	I-Premise
203	test	_	_	I-Premise
204	(	_	_	I-Premise
205	Rey	_	_	I-Premise
206	Auditory	_	_	I-Premise
207	Verbal	_	_	I-Premise
208	Learning	_	_	I-Premise
209	Test	_	_	I-Premise
210	trial	_	_	I-Premise
211	1	_	_	I-Premise
212	)	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	=	_	_	I-Premise
216	0.06	_	_	I-Premise
217	)	_	_	I-Premise
218	and	_	_	I-Premise
219	the	_	_	I-Premise
220	short-term	_	_	I-Premise
221	memory	_	_	I-Premise
222	and	_	_	I-Premise
223	processing	_	_	I-Premise
224	speed	_	_	I-Premise
225	task	_	_	I-Premise
226	(	_	_	I-Premise
227	Digit	_	_	I-Premise
228	Symbol	_	_	I-Premise
229	)	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.09	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	reported	_	_	I-Premise
237	improved	_	_	I-Premise
238	cognitive	_	_	I-Premise
239	function	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0.06	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	cognitive	_	_	I-Premise
247	abilities	_	_	I-Premise
248	(	_	_	I-Premise
249	p	_	_	I-Premise
250	=	_	_	I-Premise
251	0.08	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	mental	_	_	I-Premise
255	health	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.04	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	spirituality	_	_	I-Premise
264	(	_	_	I-Premise
265	p	_	_	I-Premise
266	=	_	_	I-Premise
267	0.05	_	_	I-Premise
268	)	_	_	I-Premise
269	at	_	_	I-Premise
270	the	_	_	I-Premise
271	end	_	_	I-Premise
272	of	_	_	I-Premise
273	treatment	_	_	I-Premise
274	but	_	_	I-Premise
275	not	_	_	I-Premise
276	1	_	_	I-Premise
277	month	_	_	I-Premise
278	later	_	_	I-Premise
279	.	_	_	I-Premise

280	This	_	_	B-Claim
281	randomized	_	_	I-Claim
282	controlled	_	_	I-Claim
283	trial	_	_	I-Claim
284	revealed	_	_	I-Claim
285	that	_	_	I-Claim
286	TSM	_	_	I-Claim
287	program	_	_	I-Claim
288	appears	_	_	I-Claim
289	to	_	_	I-Claim
290	be	_	_	I-Claim
291	a	_	_	I-Claim
292	feasible	_	_	I-Claim
293	and	_	_	I-Claim
294	acceptable	_	_	I-Claim
295	intervention	_	_	I-Claim
296	and	_	_	I-Claim
297	may	_	_	I-Claim
298	be	_	_	I-Claim
299	associated	_	_	I-Claim
300	with	_	_	I-Claim
301	short-term	_	_	I-Claim
302	improvements	_	_	I-Claim
303	in	_	_	I-Claim
304	objective	_	_	I-Claim
305	and	_	_	I-Claim
306	subjective	_	_	I-Claim
307	cognitive	_	_	I-Claim
308	function	_	_	I-Claim
309	as	_	_	I-Claim
310	well	_	_	I-Claim
311	as	_	_	I-Claim
312	mental	_	_	I-Claim
313	health	_	_	I-Claim
314	and	_	_	I-Claim
315	spirituality	_	_	I-Claim
316	in	_	_	I-Claim
317	breast	_	_	I-Claim
318	cancer	_	_	I-Claim
319	patients	_	_	I-Claim
320	.	_	_	I-Claim


0	The	_	_	B-Claim
1	choice	_	_	I-Claim
2	of	_	_	I-Claim
3	reconstruction	_	_	I-Claim
4	after	_	_	I-Claim
5	gastrectomy	_	_	I-Claim
6	and	_	_	I-Claim
7	the	_	_	I-Claim
8	significance	_	_	I-Claim
9	of	_	_	I-Claim
10	remaining	_	_	I-Claim
11	reservoir	_	_	I-Claim
12	function	_	_	I-Claim
13	is	_	_	I-Claim
14	a	_	_	I-Claim
15	matter	_	_	I-Claim
16	of	_	_	I-Claim
17	controversy	_	_	I-Claim
18	.	_	_	I-Claim

19	To	_	_	O
20	broaden	_	_	O
21	the	_	_	O
22	criteria	_	_	O
23	for	_	_	O
24	choice	_	_	O
25	of	_	_	O
26	treatment	_	_	O
27	,	_	_	O
28	we	_	_	O
29	conducted	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	randomized	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	to	_	_	O
36	determine	_	_	O
37	the	_	_	O
38	impact	_	_	O
39	of	_	_	O
40	various	_	_	O
41	gastrectomy	_	_	O
42	procedures	_	_	O
43	on	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	.	_	_	O

48	Consecutive	_	_	O
49	patients	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	64	_	_	O
54	)	_	_	O
55	eligible	_	_	O
56	for	_	_	O
57	curative	_	_	O
58	gastric	_	_	O
59	cancer	_	_	O
60	surgery	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	to	_	_	O
64	have	_	_	O
65	either	_	_	O
66	a	_	_	O
67	total	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	31	_	_	O
72	)	_	_	O
73	or	_	_	O
74	subtotal	_	_	O
75	(	_	_	O
76	n	_	_	O
77	=	_	_	O
78	13	_	_	O
79	)	_	_	O
80	gastrectomy	_	_	O
81	or	_	_	O
82	a	_	_	O
83	jejunal	_	_	O
84	S-shaped	_	_	O
85	pouch	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	20	_	_	O
90	)	_	_	O
91	implanted	_	_	O
92	as	_	_	O
93	a	_	_	O
94	gastric	_	_	O
95	substitute	_	_	O
96	.	_	_	O

97	The	_	_	O
98	quality-of-life	_	_	O
99	evaluation	_	_	O
100	was	_	_	O
101	based	_	_	O
102	on	_	_	O
103	a	_	_	O
104	battery	_	_	O
105	of	_	_	O
106	questionnaires	_	_	O
107	covering	_	_	O
108	both	_	_	O
109	general	_	_	O
110	and	_	_	O
111	specific	_	_	O
112	aspects	_	_	O
113	of	_	_	O
114	life	_	_	O
115	.	_	_	O

116	The	_	_	O
117	patients	_	_	O
118	were	_	_	O
119	rated	_	_	O
120	by	_	_	O
121	one	_	_	O
122	of	_	_	O
123	two	_	_	O
124	psychiatrists	_	_	O
125	who	_	_	O
126	were	_	_	O
127	blinded	_	_	O
128	to	_	_	O
129	the	_	_	O
130	patients	_	_	O
131	'	_	_	O
132	group	_	_	O
133	affiliation	_	_	O
134	.	_	_	O

135	Assessments	_	_	O
136	were	_	_	O
137	made	_	_	O
138	on	_	_	O
139	three	_	_	O
140	occasions	_	_	O
141	:	_	_	O
142	during	_	_	O
143	the	_	_	O
144	week	_	_	O
145	prior	_	_	O
146	to	_	_	O
147	surgery	_	_	O
148	and	_	_	O
149	3	_	_	O
150	and	_	_	O
151	12	_	_	O
152	months	_	_	O
153	after	_	_	O
154	the	_	_	O
155	surgical	_	_	O
156	intervention	_	_	O
157	.	_	_	O

158	The	_	_	B-Premise
159	postoperative	_	_	I-Premise
160	complication	_	_	I-Premise
161	and	_	_	I-Premise
162	mortality	_	_	I-Premise
163	rates	_	_	I-Premise
164	were	_	_	I-Premise
165	similar	_	_	I-Premise
166	in	_	_	I-Premise
167	all	_	_	I-Premise
168	treatment	_	_	I-Premise
169	groups	_	_	I-Premise
170	,	_	_	I-Premise
171	with	_	_	I-Premise
172	few	_	_	I-Premise
173	serious	_	_	I-Premise
174	complications	_	_	I-Premise
175	recorded	_	_	I-Premise
176	.	_	_	I-Premise

177	Irrespective	_	_	B-Premise
178	of	_	_	I-Premise
179	type	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	,	_	_	I-Premise
183	the	_	_	I-Premise
184	patients	_	_	I-Premise
185	suffered	_	_	I-Premise
186	from	_	_	I-Premise
187	alimentary	_	_	I-Premise
188	symptoms	_	_	I-Premise
189	and	_	_	I-Premise
190	functional	_	_	I-Premise
191	limitations	_	_	I-Premise
192	in	_	_	I-Premise
193	everyday	_	_	I-Premise
194	life	_	_	I-Premise
195	,	_	_	I-Premise
196	whereas	_	_	B-Premise
197	their	_	_	I-Premise
198	mental	_	_	I-Premise
199	well-being	_	_	I-Premise
200	improved	_	_	I-Premise
201	after	_	_	I-Premise
202	surgery	_	_	I-Premise
203	.	_	_	I-Premise

204	Patients	_	_	B-Premise
205	who	_	_	I-Premise
206	underwent	_	_	I-Premise
207	subtotal	_	_	I-Premise
208	gastrectomy	_	_	I-Premise
209	had	_	_	I-Premise
210	the	_	_	I-Premise
211	best	_	_	I-Premise
212	outcome	_	_	I-Premise
213	,	_	_	I-Premise
214	especially	_	_	I-Premise
215	with	_	_	I-Premise
216	respect	_	_	I-Premise
217	to	_	_	I-Premise
218	complaints	_	_	I-Premise
219	of	_	_	I-Premise
220	diarrhea	_	_	I-Premise
221	.	_	_	I-Premise

222	Patients	_	_	B-Premise
223	given	_	_	I-Premise
224	a	_	_	I-Premise
225	gastric	_	_	I-Premise
226	substitute	_	_	I-Premise
227	after	_	_	I-Premise
228	gastrectomy	_	_	I-Premise
229	showed	_	_	I-Premise
230	no	_	_	I-Premise
231	difference	_	_	I-Premise
232	from	_	_	I-Premise
233	those	_	_	I-Premise
234	who	_	_	I-Premise
235	had	_	_	I-Premise
236	only	_	_	I-Premise
237	a	_	_	I-Premise
238	total	_	_	I-Premise
239	gastrectomy	_	_	I-Premise
240	.	_	_	I-Premise

241	We	_	_	B-Claim
242	conclude	_	_	I-Claim
243	that	_	_	I-Claim
244	despite	_	_	I-Claim
245	significant	_	_	I-Claim
246	unfavorable	_	_	I-Claim
247	consequences	_	_	I-Claim
248	that	_	_	I-Claim
249	follow	_	_	I-Claim
250	gastrectomy	_	_	I-Claim
251	,	_	_	I-Claim
252	patients	_	_	I-Claim
253	recover	_	_	I-Claim
254	with	_	_	I-Claim
255	an	_	_	I-Claim
256	improved	_	_	I-Claim
257	mental	_	_	I-Claim
258	status	_	_	I-Claim
259	.	_	_	I-Claim

260	A	_	_	B-Claim
261	pouch	_	_	I-Claim
262	reconstruction	_	_	I-Claim
263	after	_	_	I-Claim
264	total	_	_	I-Claim
265	gastrectomy	_	_	I-Claim
266	does	_	_	I-Claim
267	not	_	_	I-Claim
268	improve	_	_	I-Claim
269	quality	_	_	I-Claim
270	of	_	_	I-Claim
271	life	_	_	I-Claim
272	,	_	_	I-Claim
273	but	_	_	O
274	a	_	_	B-Claim
275	subtotal	_	_	I-Claim
276	gastrectomy	_	_	I-Claim
277	has	_	_	I-Claim
278	advantages	_	_	I-Claim
279	that	_	_	I-Claim
280	must	_	_	I-Claim
281	be	_	_	I-Claim
282	considered	_	_	I-Claim
283	when	_	_	I-Claim
284	the	_	_	I-Claim
285	procedure	_	_	I-Claim
286	is	_	_	I-Claim
287	clinically	_	_	I-Claim
288	feasible	_	_	I-Claim
289	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	epoetin	_	_	O
6	alfa	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	solid	_	_	O
18	tumors	_	_	O
19	and	_	_	O
20	mild-to-moderate	_	_	O
21	anemia	_	_	O
22	receiving	_	_	O
23	platinum-based	_	_	O
24	chemotherapy	_	_	O
25	relative	_	_	O
26	to	_	_	O
27	population	_	_	O
28	norms	_	_	O
29	.	_	_	O

30	In	_	_	O
31	the	_	_	O
32	original	_	_	O
33	study	_	_	O
34	,	_	_	O
35	patients	_	_	O
36	(	_	_	O
37	n	_	_	O
38	=	_	_	O
39	316	_	_	O
40	)	_	_	O
41	with	_	_	O
42	hemoglobin	_	_	O
43	(	_	_	O
44	Hb	_	_	O
45	)	_	_	O
46	levels	_	_	O
47	<	_	_	O
48	or	_	_	O
49	=12.1	_	_	O
50	g/dl	_	_	O
51	were	_	_	O
52	randomized	_	_	O
53	2:1	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	either	_	_	O
57	epoetin	_	_	O
58	alfa	_	_	O
59	at	_	_	O
60	a	_	_	O
61	dose	_	_	O
62	of	_	_	O
63	10,000	_	_	O
64	U	_	_	O
65	thrice	_	_	O
66	weekly	_	_	O
67	s.c.	_	_	O
68	or	_	_	O
69	best	_	_	O
70	supportive	_	_	O
71	care	_	_	O
72	(	_	_	O
73	BSC	_	_	O
74	)	_	_	O
75	to	_	_	O
76	compare	_	_	O
77	the	_	_	O
78	effects	_	_	O
79	on	_	_	O
80	transfusion	_	_	O
81	use	_	_	O
82	,	_	_	O
83	hematologic	_	_	O
84	response	_	_	O
85	,	_	_	O
86	and	_	_	O
87	QOL	_	_	O
88	(	_	_	O
89	measured	_	_	O
90	by	_	_	O
91	the	_	_	O
92	Functional	_	_	O
93	Assessment	_	_	O
94	of	_	_	O
95	Cancer	_	_	O
96	Therapy-Anemia	_	_	O
97	[	_	_	O
98	FACT-An	_	_	O
99	]	_	_	O
100	and	_	_	O
101	Cancer	_	_	O
102	Linear	_	_	O
103	Analogue	_	_	O
104	Scale	_	_	O
105	[	_	_	O
106	CLAS	_	_	O
107	]	_	_	O
108	)	_	_	O
109	.	_	_	O

110	The	_	_	O
111	QOL	_	_	O
112	data	_	_	O
113	from	_	_	O
114	this	_	_	O
115	previously	_	_	O
116	reported	_	_	O
117	trial	_	_	O
118	were	_	_	O
119	reanalyzed	_	_	O
120	here	_	_	O
121	relative	_	_	O
122	to	_	_	O
123	population	_	_	O
124	norms	_	_	O
125	.	_	_	O

126	Mean	_	_	O
127	baseline	_	_	O
128	QOL	_	_	O
129	scores	_	_	O
130	were	_	_	O
131	similar	_	_	O
132	between	_	_	O
133	groups	_	_	O
134	.	_	_	O

135	At	_	_	O
136	study	_	_	O
137	completion	_	_	O
138	,	_	_	O
139	mean	_	_	O
140	CLAS	_	_	O
141	,	_	_	O
142	FACT-An	_	_	O
143	,	_	_	O
144	FACT-An	_	_	O
145	Anemia	_	_	O
146	subscale	_	_	O
147	,	_	_	O
148	and	_	_	O
149	FACT-An	_	_	O
150	Fatigue	_	_	O
151	subscale	_	_	O
152	scores	_	_	O
153	were	_	_	O
154	significantly	_	_	O
155	higher	_	_	O
156	for	_	_	O
157	patients	_	_	O
158	given	_	_	O
159	epoetin	_	_	O
160	alfa	_	_	O
161	than	_	_	O
162	for	_	_	O
163	those	_	_	O
164	treated	_	_	O
165	with	_	_	O
166	BSC	_	_	O
167	.	_	_	O

168	Compared	_	_	O
169	with	_	_	O
170	population	_	_	O
171	norms	_	_	O
172	,	_	_	O
173	both	_	_	O
174	groups	_	_	O
175	had	_	_	O
176	impaired	_	_	O
177	QOL	_	_	O
178	at	_	_	O
179	baseline	_	_	O
180	.	_	_	O

181	Differences	_	_	B-Premise
182	in	_	_	I-Premise
183	mean	_	_	I-Premise
184	QOL	_	_	I-Premise
185	change	_	_	I-Premise
186	scores	_	_	I-Premise
187	from	_	_	I-Premise
188	baseline	_	_	I-Premise
189	to	_	_	I-Premise
190	study	_	_	I-Premise
191	end	_	_	I-Premise
192	for	_	_	I-Premise
193	epoetin	_	_	I-Premise
194	alfa	_	_	I-Premise
195	versus	_	_	I-Premise
196	BSC	_	_	I-Premise
197	were	_	_	I-Premise
198	3.17	_	_	I-Premise
199	points	_	_	I-Premise
200	for	_	_	I-Premise
201	the	_	_	I-Premise
202	FACT-General	_	_	I-Premise
203	Total	_	_	I-Premise
204	,	_	_	I-Premise
205	9.90	_	_	I-Premise
206	for	_	_	I-Premise
207	the	_	_	I-Premise
208	FACT-An	_	_	I-Premise
209	Fatigue	_	_	I-Premise
210	subscale	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	7.30	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	FACT-An	_	_	I-Premise
217	Anemia	_	_	I-Premise
218	subscale	_	_	I-Premise
219	.	_	_	I-Premise

220	This	_	_	B-Premise
221	was	_	_	I-Premise
222	equivalent	_	_	I-Premise
223	to	_	_	I-Premise
224	corrections	_	_	I-Premise
225	in	_	_	I-Premise
226	QOL	_	_	I-Premise
227	deficits	_	_	I-Premise
228	attributable	_	_	I-Premise
229	to	_	_	I-Premise
230	epoetin	_	_	I-Premise
231	alfa	_	_	I-Premise
232	of	_	_	I-Premise
233	97.3	_	_	I-Premise
234	%	_	_	I-Premise
235	,	_	_	I-Premise
236	40.7	_	_	I-Premise
237	%	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	38.0	_	_	I-Premise
241	%	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	FACT-General	_	_	I-Premise
245	Total	_	_	I-Premise
246	,	_	_	I-Premise
247	FACT-An	_	_	I-Premise
248	Fatigue	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	FACT-An	_	_	I-Premise
252	Anemia	_	_	I-Premise
253	subscale	_	_	I-Premise
254	scores	_	_	I-Premise
255	,	_	_	I-Premise
256	respectively	_	_	I-Premise
257	,	_	_	I-Premise
258	versus	_	_	I-Premise
259	BSC	_	_	I-Premise
260	.	_	_	I-Premise

261	A	_	_	B-Premise
262	somewhat	_	_	I-Premise
263	greater	_	_	I-Premise
264	QOL	_	_	I-Premise
265	benefit	_	_	I-Premise
266	was	_	_	I-Premise
267	observed	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	FACT-An	_	_	I-Premise
271	Fatigue	_	_	I-Premise
272	and	_	_	I-Premise
273	FACT-An	_	_	I-Premise
274	Anemia	_	_	I-Premise
275	subscales	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	subset	_	_	I-Premise
279	of	_	_	I-Premise
280	patients	_	_	I-Premise
281	with	_	_	I-Premise
282	baseline	_	_	I-Premise
283	Hb	_	_	I-Premise
284	levels	_	_	I-Premise
285	>	_	_	I-Premise
286	10.5	_	_	I-Premise
287	g/dl	_	_	I-Premise
288	.	_	_	I-Premise

289	Patients	_	_	B-Premise
290	in	_	_	I-Premise
291	this	_	_	I-Premise
292	study	_	_	I-Premise
293	had	_	_	I-Premise
294	impaired	_	_	I-Premise
295	QOL	_	_	I-Premise
296	compared	_	_	I-Premise
297	with	_	_	I-Premise
298	population	_	_	I-Premise
299	norms	_	_	I-Premise
300	.	_	_	I-Premise

301	Early	_	_	B-Claim
302	treatment	_	_	I-Claim
303	with	_	_	I-Claim
304	epoetin	_	_	I-Claim
305	alfa	_	_	I-Claim
306	to	_	_	I-Claim
307	correct	_	_	I-Claim
308	anemia	_	_	I-Claim
309	improved	_	_	I-Claim
310	QOL	_	_	I-Claim
311	in	_	_	I-Claim
312	a	_	_	I-Claim
313	statistically	_	_	I-Claim
314	significant	_	_	I-Claim
315	and	_	_	I-Claim
316	clinically	_	_	I-Claim
317	meaningful	_	_	I-Claim
318	way	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	improvements	_	_	I-Claim
322	were	_	_	I-Claim
323	greater	_	_	I-Claim
324	in	_	_	I-Claim
325	patients	_	_	I-Claim
326	with	_	_	I-Claim
327	baseline	_	_	I-Claim
328	Hb	_	_	I-Claim
329	levels	_	_	I-Claim
330	>	_	_	I-Claim
331	10.5	_	_	I-Claim
332	g/dl	_	_	I-Claim
333	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	Chinese	_	_	O
6	medicine	_	_	O
7	(	_	_	O
8	CM	_	_	O
9	)	_	_	O
10	comprehensive	_	_	O
11	regimen	_	_	O
12	as	_	_	O
13	the	_	_	O
14	maintenance	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	MT	_	_	O
18	)	_	_	O
19	on	_	_	O
20	time	_	_	O
21	to	_	_	O
22	progression	_	_	O
23	(	_	_	O
24	TTP	_	_	O
25	)	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	of	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	advanced	_	_	O
37	non-small-cell	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	(	_	_	O
41	NSCLC	_	_	O
42	)	_	_	O
43	.	_	_	O

44	The	_	_	O
45	study	_	_	O
46	was	_	_	O
47	a	_	_	O
48	prospective	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	and	_	_	O
52	controlled	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	.	_	_	O

56	Fifty	_	_	O
57	non-progressive	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	advanced	_	_	O
61	NSCLC	_	_	O
62	who	_	_	O
63	responded	_	_	O
64	to	_	_	O
65	first-line	_	_	O
66	therapy	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	into	_	_	O
70	the	_	_	O
71	test	_	_	O
72	group	_	_	O
73	(	_	_	O
74	25	_	_	O
75	cases	_	_	O
76	,	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	CM	_	_	O
80	comprehensive	_	_	O
81	regimen	_	_	O
82	:	_	_	O
83	intravenous	_	_	O
84	dripping	_	_	O
85	of	_	_	O
86	Chinese	_	_	O
87	herbal	_	_	O
88	preparation	_	_	O
89	,	_	_	O
90	oral	_	_	O
91	administration	_	_	O
92	of	_	_	O
93	Chinese	_	_	O
94	herbal	_	_	O
95	decoction	_	_	O
96	,	_	_	O
97	and	_	_	O
98	point	_	_	O
99	application	_	_	O
100	)	_	_	O
101	and	_	_	O
102	the	_	_	O
103	control	_	_	O
104	group	_	_	O
105	[	_	_	O
106	25	_	_	O
107	cases	_	_	O
108	,	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	one	_	_	O
112	of	_	_	O
113	three	_	_	O
114	single-agent	_	_	O
115	maintenance	_	_	O
116	chemotherapy	_	_	O
117	regimens	_	_	O
118	:	_	_	O
119	pemetrexed	_	_	O
120	(	_	_	O
121	500	_	_	O
122	mg/m2	_	_	O
123	,	_	_	O
124	day	_	_	O
125	1	_	_	O
126	)	_	_	O
127	,	_	_	O
128	docetaxel	_	_	O
129	(	_	_	O
130	75	_	_	O
131	mg/m2	_	_	O
132	,	_	_	O
133	day	_	_	O
134	1	_	_	O
135	)	_	_	O
136	,	_	_	O
137	and	_	_	O
138	gemcitabine	_	_	O
139	(	_	_	O
140	1000	_	_	O
141	mg/mi	_	_	O
142	,	_	_	O
143	day	_	_	O
144	1	_	_	O
145	and	_	_	O
146	day	_	_	O
147	8	_	_	O
148	)	_	_	O
149	in	_	_	O
150	the	_	_	O
151	ratio	_	_	O
152	of	_	_	O
153	1:1	_	_	O
154	]	_	_	O
155	.	_	_	O

156	Each	_	_	O
157	cycle	_	_	O
158	consisted	_	_	O
159	of	_	_	O
160	21	_	_	O
161	days	_	_	O
162	.	_	_	O

163	Cycles	_	_	O
164	were	_	_	O
165	repeated	_	_	O
166	until	_	_	O
167	the	_	_	O
168	disease	_	_	O
169	progressed	_	_	O
170	,	_	_	O
171	or	_	_	O
172	intolerable	_	_	O
173	toxic	_	_	O
174	or	_	_	O
175	adverse	_	_	O
176	reaction	_	_	O
177	occurred	_	_	O
178	,	_	_	O
179	or	_	_	O
180	patients	_	_	O
181	refused	_	_	O
182	to	_	_	O
183	continue	_	_	O
184	the	_	_	O
185	treatment	_	_	O
186	.	_	_	O

187	The	_	_	O
188	primary	_	_	O
189	end	_	_	O
190	point	_	_	O
191	was	_	_	O
192	TTP	_	_	O
193	and	_	_	O
194	the	_	_	O
195	secondary	_	_	O
196	end	_	_	O
197	point	_	_	O
198	was	_	_	O
199	QOL	_	_	O
200	.	_	_	O

201	QOL	_	_	O
202	was	_	_	O
203	evaluated	_	_	O
204	using	_	_	O
205	the	_	_	O
206	European	_	_	O
207	Organization	_	_	O
208	for	_	_	O
209	Research	_	_	O
210	and	_	_	O
211	Treatment	_	_	O
212	of	_	_	O
213	Cancer	_	_	O
214	quality-of-life	_	_	O
215	questionnaire	_	_	O
216	QLQ-LC43	_	_	O
217	(	_	_	O
218	EORTC	_	_	O
219	QLQ-LC43	_	_	O
220	)	_	_	O
221	.	_	_	O

222	TTP	_	_	O
223	of	_	_	O
224	fifty	_	_	O
225	patients	_	_	O
226	and	_	_	O
227	QOL	_	_	O
228	of	_	_	O
229	43	_	_	O
230	patients	_	_	O
231	had	_	_	O
232	been	_	_	O
233	statistically	_	_	O
234	analyzed	_	_	O
235	.	_	_	O

236	(	_	_	O
237	1	_	_	O
238	)	_	_	O
239	The	_	_	B-Premise
240	TTP	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	test	_	_	I-Premise
244	group	_	_	I-Premise
245	was	_	_	I-Premise
246	prolonged	_	_	I-Premise
247	for	_	_	I-Premise
248	23	_	_	I-Premise
249	days	_	_	I-Premise
250	when	_	_	I-Premise
251	compared	_	_	I-Premise
252	with	_	_	I-Premise
253	that	_	_	I-Premise
254	of	_	_	I-Premise
255	the	_	_	I-Premise
256	control	_	_	I-Premise
257	group	_	_	I-Premise
258	,	_	_	I-Premise
259	with	_	_	I-Premise
260	insignificant	_	_	I-Premise
261	difference	_	_	I-Premise
262	(	_	_	I-Premise
263	87	_	_	I-Premise
264	days	_	_	I-Premise
265	vs	_	_	I-Premise
266	64	_	_	I-Premise
267	days	_	_	I-Premise
268	,	_	_	I-Premise
269	P=0.063	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	(	_	_	O
273	2	_	_	O
274	)	_	_	O
275	The	_	_	B-Premise
276	scores	_	_	I-Premise
277	of	_	_	I-Premise
278	domains	_	_	I-Premise
279	in	_	_	I-Premise
280	EORTC	_	_	I-Premise
281	QLQ-LC43	_	_	I-Premise
282	were	_	_	I-Premise
283	statistically	_	_	I-Premise
284	significantly	_	_	I-Premise
285	better	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	test	_	_	I-Premise
289	group	_	_	I-Premise
290	than	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	control	_	_	I-Premise
294	group	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	<	_	_	I-Premise
298	0.05	_	_	I-Premise
299	)	_	_	I-Premise
300	except	_	_	B-Premise
301	cognitive	_	_	I-Premise
302	and	_	_	I-Premise
303	social	_	_	I-Premise
304	functions	_	_	I-Premise
305	,	_	_	I-Premise
306	the	_	_	I-Premise
307	symptoms	_	_	I-Premise
308	of	_	_	I-Premise
309	dysphagia	_	_	I-Premise
310	and	_	_	I-Premise
311	pain	_	_	I-Premise
312	in	_	_	I-Premise
313	other	_	_	I-Premise
314	parts	_	_	I-Premise
315	.	_	_	I-Premise

316	(	_	_	O
317	1	_	_	O
318	)	_	_	O
319	The	_	_	B-Claim
320	CM	_	_	I-Claim
321	comprehensive	_	_	I-Claim
322	regimen	_	_	I-Claim
323	as	_	_	I-Claim
324	MT	_	_	I-Claim
325	had	_	_	I-Claim
326	equivalent	_	_	I-Claim
327	efficacy	_	_	I-Claim
328	on	_	_	I-Claim
329	TTP	_	_	I-Claim
330	when	_	_	I-Claim
331	compared	_	_	I-Claim
332	with	_	_	I-Claim
333	single-agent	_	_	I-Claim
334	maintenance	_	_	I-Claim
335	chemotherapy	_	_	I-Claim
336	regimen	_	_	I-Claim
337	.	_	_	I-Claim

338	It	_	_	B-Claim
339	was	_	_	I-Claim
340	advantageous	_	_	I-Claim
341	over	_	_	I-Claim
342	improving	_	_	I-Claim
343	the	_	_	I-Claim
344	QOL	_	_	I-Claim
345	.	_	_	I-Claim

346	(	_	_	O
347	2	_	_	O
348	)	_	_	O
349	It	_	_	B-Claim
350	is	_	_	I-Claim
351	necessary	_	_	I-Claim
352	to	_	_	I-Claim
353	enlarge	_	_	I-Claim
354	the	_	_	I-Claim
355	sample	_	_	I-Claim
356	size	_	_	I-Claim
357	to	_	_	I-Claim
358	further	_	_	I-Claim
359	confirm	_	_	I-Claim
360	the	_	_	I-Claim
361	therapeutic	_	_	I-Claim
362	efficacy	_	_	I-Claim
363	of	_	_	I-Claim
364	CM	_	_	I-Claim
365	comprehensive	_	_	I-Claim
366	regimen	_	_	I-Claim
367	as	_	_	I-Claim
368	MT	_	_	I-Claim
369	in	_	_	I-Claim
370	treatment	_	_	I-Claim
371	of	_	_	I-Claim
372	patients	_	_	I-Claim
373	with	_	_	I-Claim
374	advanced	_	_	I-Claim
375	NSCLC	_	_	I-Claim
376	.	_	_	I-Claim


0	Restorative	_	_	O
1	proctocolectomy	_	_	O
2	with	_	_	O
3	ileal	_	_	O
4	pouch-anal	_	_	O
5	anastomosis	_	_	O
6	(	_	_	O
7	IPAA	_	_	O
8	)	_	_	O
9	is	_	_	O
10	the	_	_	O
11	standard	_	_	O
12	surgical	_	_	O
13	procedure	_	_	O
14	for	_	_	O
15	ulcerative	_	_	O
16	colitis	_	_	O
17	(	_	_	O
18	UC	_	_	O
19	)	_	_	O
20	and	_	_	O
21	familial	_	_	O
22	adenomatous	_	_	O
23	polyposis	_	_	O
24	(	_	_	O
25	FAP	_	_	O
26	)	_	_	O
27	.	_	_	O

28	While	_	_	O
29	minimal	_	_	O
30	invasive	_	_	O
31	techniques	_	_	O
32	have	_	_	O
33	been	_	_	O
34	applied	_	_	O
35	increasingly	_	_	O
36	,	_	_	O
37	clear	_	_	O
38	evidence	_	_	O
39	of	_	_	O
40	superiority	_	_	O
41	for	_	_	O
42	laparoscopic	_	_	O
43	pouch	_	_	O
44	procedures	_	_	O
45	is	_	_	O
46	not	_	_	O
47	yet	_	_	O
48	available	_	_	O
49	.	_	_	O

50	The	_	_	O
51	aim	_	_	O
52	of	_	_	O
53	the	_	_	O
54	LapConPouch	_	_	O
55	Trial	_	_	O
56	was	_	_	O
57	to	_	_	O
58	compare	_	_	O
59	the	_	_	O
60	effectiveness	_	_	O
61	of	_	_	O
62	laparoscopic	_	_	O
63	(	_	_	O
64	LAP	_	_	O
65	)	_	_	O
66	versus	_	_	O
67	conventional	_	_	O
68	(	_	_	O
69	CON	_	_	O
70	)	_	_	O
71	ileoanal	_	_	O
72	pouch	_	_	O
73	procedure	_	_	O
74	in	_	_	O
75	patients	_	_	O
76	undergoing	_	_	O
77	elective	_	_	O
78	restorative	_	_	O
79	proctocolectomy	_	_	O
80	.	_	_	O

81	The	_	_	O
82	trial	_	_	O
83	was	_	_	O
84	designed	_	_	O
85	as	_	_	O
86	a	_	_	O
87	single-centre	_	_	O
88	,	_	_	O
89	pre-operatively	_	_	O
90	randomized	_	_	O
91	,	_	_	O
92	controlled	_	_	O
93	trial	_	_	O
94	using	_	_	O
95	a	_	_	O
96	two-group	_	_	O
97	parallel	_	_	O
98	superiority	_	_	O
99	design	_	_	O
100	.	_	_	O

101	Eligible	_	_	O
102	for	_	_	O
103	participation	_	_	O
104	were	_	_	O
105	patients	_	_	O
106	scheduled	_	_	O
107	for	_	_	O
108	restorative	_	_	O
109	proctocolectomy	_	_	O
110	either	_	_	O
111	for	_	_	O
112	FAP	_	_	O
113	or	_	_	O
114	for	_	_	O
115	UC	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	and	_	_	O
119	outcome	_	_	O
120	assessors	_	_	O
121	were	_	_	O
122	blinded	_	_	O
123	to	_	_	O
124	group	_	_	O
125	assignment	_	_	O
126	.	_	_	O

127	The	_	_	O
128	primary	_	_	O
129	endpoint	_	_	O
130	was	_	_	O
131	defined	_	_	O
132	as	_	_	O
133	the	_	_	O
134	amount	_	_	O
135	of	_	_	O
136	blood	_	_	O
137	loss	_	_	O
138	.	_	_	O

139	Statistical	_	_	O
140	analyses	_	_	O
141	were	_	_	O
142	explorative	_	_	O
143	since	_	_	O
144	the	_	_	O
145	trial	_	_	O
146	had	_	_	O
147	to	_	_	O
148	be	_	_	O
149	stopped	_	_	O
150	prematurely	_	_	O
151	.	_	_	O

152	A	_	_	O
153	total	_	_	O
154	of	_	_	O
155	42	_	_	O
156	patients	_	_	O
157	(	_	_	O
158	21	_	_	O
159	LAP	_	_	O
160	(	_	_	O
161	50.0	_	_	O
162	%	_	_	O
163	)	_	_	O
164	;	_	_	O
165	21	_	_	O
166	CON	_	_	O
167	(	_	_	O
168	50.0	_	_	O
169	%	_	_	O
170	)	_	_	O
171	)	_	_	O
172	were	_	_	O
173	randomized	_	_	O
174	.	_	_	O

175	The	_	_	B-Premise
176	trial	_	_	I-Premise
177	had	_	_	I-Premise
178	to	_	_	I-Premise
179	be	_	_	I-Premise
180	stopped	_	_	I-Premise
181	prematurely	_	_	I-Premise
182	due	_	_	I-Premise
183	to	_	_	I-Premise
184	insufficient	_	_	I-Premise
185	patient	_	_	I-Premise
186	recruitment	_	_	I-Premise
187	.	_	_	I-Premise

188	There	_	_	B-Premise
189	was	_	_	I-Premise
190	no	_	_	I-Premise
191	difference	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	amount	_	_	I-Premise
195	of	_	_	I-Premise
196	blood	_	_	I-Premise
197	loss	_	_	I-Premise
198	between	_	_	I-Premise
199	both	_	_	I-Premise
200	groups	_	_	I-Premise
201	:	_	_	I-Premise
202	LAP	_	_	I-Premise
203	261.5	_	_	I-Premise
204	Â±	_	_	I-Premise
205	195.4	_	_	I-Premise
206	ml	_	_	I-Premise
207	,	_	_	I-Premise
208	CON	_	_	I-Premise
209	228.1	_	_	I-Premise
210	Â±	_	_	I-Premise
211	119.5	_	_	I-Premise
212	ml	_	_	I-Premise
213	.	_	_	I-Premise

214	Secondary	_	_	O
215	endpoints	_	_	O
216	differ	_	_	O
217	in	_	_	O
218	both	_	_	O
219	groups	_	_	O
220	.	_	_	O

221	Laparoscopic	_	_	B-Claim
222	surgery	_	_	I-Claim
223	was	_	_	I-Claim
224	superior	_	_	I-Claim
225	regarding	_	_	I-Claim
226	the	_	_	I-Claim
227	length	_	_	I-Claim
228	of	_	_	I-Claim
229	skin	_	_	I-Claim
230	incision	_	_	I-Claim
231	;	_	_	I-Claim
232	in	_	_	O
233	contrast	_	_	O
234	,	_	_	O
235	the	_	_	B-Claim
236	conventional	_	_	I-Claim
237	approach	_	_	I-Claim
238	was	_	_	I-Claim
239	superior	_	_	I-Claim
240	in	_	_	I-Claim
241	duration	_	_	I-Claim
242	of	_	_	I-Claim
243	operation	_	_	I-Claim
244	.	_	_	I-Claim

245	There	_	_	B-Premise
246	were	_	_	I-Premise
247	no	_	_	I-Premise
248	discrepancies	_	_	I-Premise
249	in	_	_	I-Premise
250	length	_	_	I-Premise
251	of	_	_	I-Premise
252	hospital	_	_	I-Premise
253	stay	_	_	I-Premise
254	,	_	_	I-Premise
255	postoperative	_	_	I-Premise
256	pain	_	_	I-Premise
257	,	_	_	I-Premise
258	bowel	_	_	I-Premise
259	function	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	quality	_	_	I-Premise
263	of	_	_	I-Premise
264	life	_	_	I-Premise
265	between	_	_	I-Premise
266	both	_	_	I-Premise
267	approaches	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	O
270	conversion	_	_	O
271	rate	_	_	O
272	from	_	_	O
273	LAP	_	_	O
274	to	_	_	O
275	CON	_	_	O
276	approach	_	_	O
277	was	_	_	O
278	23.8	_	_	O
279	%	_	_	O
280	.	_	_	O

281	There	_	_	B-Claim
282	was	_	_	I-Claim
283	no	_	_	I-Claim
284	difference	_	_	I-Claim
285	with	_	_	I-Claim
286	respect	_	_	I-Claim
287	to	_	_	I-Claim
288	blood	_	_	I-Claim
289	loss	_	_	I-Claim
290	between	_	_	I-Claim
291	the	_	_	I-Claim
292	LAP	_	_	I-Claim
293	and	_	_	I-Claim
294	the	_	_	I-Claim
295	CON	_	_	I-Claim
296	group	_	_	I-Claim
297	.	_	_	I-Claim

298	The	_	_	B-Claim
299	LAP	_	_	I-Claim
300	approach	_	_	I-Claim
301	is	_	_	I-Claim
302	feasible	_	_	I-Claim
303	for	_	_	I-Claim
304	restorative	_	_	I-Claim
305	proctocolectomy	_	_	I-Claim
306	,	_	_	I-Claim
307	and	_	_	I-Claim
308	IPAA	_	_	I-Claim
309	seems	_	_	I-Claim
310	at	_	_	I-Claim
311	least	_	_	I-Claim
312	as	_	_	I-Claim
313	safe	_	_	I-Claim
314	as	_	_	I-Claim
315	CON	_	_	I-Claim
316	surgery	_	_	I-Claim
317	.	_	_	I-Claim

318	The	_	_	O
319	most	_	_	O
320	obvious	_	_	O
321	advantage	_	_	O
322	of	_	_	O
323	the	_	_	O
324	minimal	_	_	O
325	invasive	_	_	O
326	technique	_	_	O
327	is	_	_	O
328	the	_	_	O
329	improved	_	_	O
330	cosmesis	_	_	O
331	.	_	_	O


0	This	_	_	O
1	analysis	_	_	O
2	of	_	_	O
3	the	_	_	O
4	results	_	_	O
5	of	_	_	O
6	a	_	_	O
7	randomized	_	_	O
8	,	_	_	O
9	controlled	_	_	O
10	trial	_	_	O
11	evaluating	_	_	O
12	the	_	_	O
13	effects	_	_	O
14	of	_	_	O
15	epoetin	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	EPO	_	_	O
19	)	_	_	O
20	therapy	_	_	O
21	on	_	_	O
22	transfusion	_	_	O
23	requirements	_	_	O
24	,	_	_	O
25	hemoglobin	_	_	O
26	(	_	_	O
27	Hb	_	_	O
28	)	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	(	_	_	O
35	QOL	_	_	O
36	)	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	cancer	_	_	O
41	receiving	_	_	O
42	platinum-based	_	_	O
43	chemotherapy	_	_	O
44	was	_	_	O
45	conducted	_	_	O
46	to	_	_	O
47	evaluate	_	_	O
48	the	_	_	O
49	effect	_	_	O
50	of	_	_	O
51	initial	_	_	O
52	Hb	_	_	O
53	level	_	_	O
54	on	_	_	O
55	study	_	_	O
56	outcomes	_	_	O
57	.	_	_	O

58	Patients	_	_	O
59	with	_	_	O
60	Hb	_	_	O
61	levels	_	_	O
62	<	_	_	O
63	or	_	_	O
64	=12.1	_	_	O
65	g/dl	_	_	O
66	were	_	_	O
67	randomized	_	_	O
68	2:1	_	_	O
69	to	_	_	O
70	receive	_	_	O
71	EPO	_	_	O
72	,	_	_	O
73	10,000	_	_	O
74	U	_	_	O
75	three	_	_	O
76	times	_	_	O
77	weekly	_	_	O
78	s.c.	_	_	O
79	or	_	_	O
80	best	_	_	O
81	supportive	_	_	O
82	care	_	_	O
83	(	_	_	O
84	BSC	_	_	O
85	)	_	_	O
86	until	_	_	O
87	4	_	_	O
88	weeks	_	_	O
89	after	_	_	O
90	their	_	_	O
91	last	_	_	O
92	chemotherapy	_	_	O
93	cycle	_	_	O
94	.	_	_	O

95	For	_	_	O
96	this	_	_	O
97	analysis	_	_	O
98	,	_	_	O
99	patients	_	_	O
100	were	_	_	O
101	stratified	_	_	O
102	by	_	_	O
103	baseline	_	_	O
104	Hb	_	_	O
105	level	_	_	O
106	(	_	_	O
107	<	_	_	O
108	or	_	_	O
109	=9.7	_	_	O
110	g/dl	_	_	O
111	,	_	_	O
112	>	_	_	O
113	9.7	_	_	O
114	g/dl	_	_	O
115	to	_	_	O
116	<	_	_	O
117	or	_	_	O
118	=10.5	_	_	O
119	g/dl	_	_	O
120	,	_	_	O
121	>	_	_	O
122	10.5	_	_	O
123	g/dl	_	_	O
124	to	_	_	O
125	<	_	_	O
126	or	_	_	O
127	=11.3	_	_	O
128	g/dl	_	_	O
129	,	_	_	O
130	and	_	_	O
131	>	_	_	O
132	11.3	_	_	O
133	g/dl	_	_	O
134	to	_	_	O
135	<	_	_	O
136	or	_	_	O
137	=12.1	_	_	O
138	g/dl	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	study	_	_	O
143	results	_	_	O
144	were	_	_	O
145	reanalyzed	_	_	O
146	.	_	_	O

147	Significantly	_	_	B-Premise
148	fewer	_	_	I-Premise
149	EPO	_	_	I-Premise
150	patients	_	_	I-Premise
151	than	_	_	I-Premise
152	BSC	_	_	I-Premise
153	patients	_	_	I-Premise
154	with	_	_	I-Premise
155	initial	_	_	I-Premise
156	Hb	_	_	I-Premise
157	levels	_	_	I-Premise
158	>	_	_	I-Premise
159	9.7	_	_	I-Premise
160	g/dl	_	_	I-Premise
161	to	_	_	I-Premise
162	<	_	_	I-Premise
163	or	_	_	I-Premise
164	=12.1	_	_	I-Premise
165	g/dl	_	_	I-Premise
166	required	_	_	I-Premise
167	transfusions	_	_	I-Premise
168	.	_	_	I-Premise

169	EPO	_	_	B-Premise
170	maintained	_	_	I-Premise
171	Hb	_	_	I-Premise
172	levels	_	_	I-Premise
173	throughout	_	_	I-Premise
174	the	_	_	I-Premise
175	study	_	_	I-Premise
176	for	_	_	I-Premise
177	patients	_	_	I-Premise
178	with	_	_	I-Premise
179	Hb	_	_	I-Premise
180	levels	_	_	I-Premise
181	>	_	_	I-Premise
182	11.3	_	_	I-Premise
183	g/dl	_	_	I-Premise
184	to	_	_	I-Premise
185	<	_	_	I-Premise
186	or	_	_	I-Premise
187	=12.1	_	_	I-Premise
188	g/dl	_	_	I-Premise
189	,	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	a	_	_	I-Premise
193	decrease	_	_	I-Premise
194	with	_	_	I-Premise
195	BSC	_	_	I-Premise
196	.	_	_	I-Premise

197	For	_	_	B-Premise
198	patients	_	_	I-Premise
199	with	_	_	I-Premise
200	baseline	_	_	I-Premise
201	Hb	_	_	I-Premise
202	levels	_	_	I-Premise
203	>	_	_	I-Premise
204	10.5	_	_	I-Premise
205	g/dl	_	_	I-Premise
206	,	_	_	I-Premise
207	for	_	_	I-Premise
208	whom	_	_	I-Premise
209	the	_	_	I-Premise
210	mean	_	_	I-Premise
211	changes	_	_	I-Premise
212	from	_	_	I-Premise
213	baseline	_	_	I-Premise
214	to	_	_	I-Premise
215	last	_	_	I-Premise
216	assessment	_	_	I-Premise
217	were	_	_	I-Premise
218	measured	_	_	I-Premise
219	by	_	_	I-Premise
220	the	_	_	I-Premise
221	Cancer	_	_	I-Premise
222	Linear	_	_	I-Premise
223	Analogue	_	_	I-Premise
224	Scale	_	_	I-Premise
225	assessments	_	_	I-Premise
226	of	_	_	I-Premise
227	energy	_	_	I-Premise
228	and	_	_	I-Premise
229	overall	_	_	I-Premise
230	QOL	_	_	I-Premise
231	as	_	_	I-Premise
232	well	_	_	I-Premise
233	as	_	_	I-Premise
234	by	_	_	I-Premise
235	the	_	_	I-Premise
236	Functional	_	_	I-Premise
237	Assessment	_	_	I-Premise
238	of	_	_	I-Premise
239	Cancer	_	_	I-Premise
240	Therapy	_	_	I-Premise
241	(	_	_	I-Premise
242	FACT	_	_	I-Premise
243	)	_	_	I-Premise
244	-Fatigue	_	_	I-Premise
245	and	_	_	I-Premise
246	FACT-An	_	_	I-Premise
247	Anemia	_	_	I-Premise
248	subscale	_	_	I-Premise
249	,	_	_	I-Premise
250	QOL	_	_	I-Premise
251	scores	_	_	I-Premise
252	were	_	_	I-Premise
253	significantly	_	_	I-Premise
254	greater	_	_	I-Premise
255	with	_	_	I-Premise
256	EPO	_	_	I-Premise
257	than	_	_	I-Premise
258	with	_	_	I-Premise
259	BSC	_	_	I-Premise
260	.	_	_	I-Premise

261	QOL	_	_	B-Premise
262	declined	_	_	I-Premise
263	in	_	_	I-Premise
264	patients	_	_	I-Premise
265	receiving	_	_	I-Premise
266	BSC	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	O
269	the	_	_	B-Premise
270	mean	_	_	I-Premise
271	decreases	_	_	I-Premise
272	in	_	_	I-Premise
273	QOL	_	_	I-Premise
274	scores	_	_	I-Premise
275	were	_	_	I-Premise
276	greater	_	_	I-Premise
277	for	_	_	I-Premise
278	BSC	_	_	I-Premise
279	patients	_	_	I-Premise
280	with	_	_	I-Premise
281	baseline	_	_	I-Premise
282	Hb	_	_	I-Premise
283	levels	_	_	I-Premise
284	>	_	_	I-Premise
285	10.5	_	_	I-Premise
286	g/dl	_	_	I-Premise
287	,	_	_	I-Premise
288	compared	_	_	I-Premise
289	with	_	_	I-Premise
290	the	_	_	I-Premise
291	overall	_	_	I-Premise
292	BSC	_	_	I-Premise
293	group	_	_	I-Premise
294	.	_	_	I-Premise

295	In	_	_	B-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	cancer	_	_	I-Claim
299	receiving	_	_	I-Claim
300	platinum-based	_	_	I-Claim
301	chemotherapy	_	_	I-Claim
302	and	_	_	I-Claim
303	with	_	_	I-Claim
304	baseline	_	_	I-Claim
305	Hb	_	_	I-Claim
306	levels	_	_	I-Claim
307	>	_	_	I-Claim
308	10.5	_	_	I-Claim
309	g/dl	_	_	I-Claim
310	,	_	_	I-Claim
311	early	_	_	I-Claim
312	intervention	_	_	I-Claim
313	with	_	_	I-Claim
314	EPO	_	_	I-Claim
315	reduces	_	_	I-Claim
316	transfusions	_	_	I-Claim
317	,	_	_	I-Claim
318	maintains	_	_	I-Claim
319	Hb	_	_	I-Claim
320	level	_	_	I-Claim
321	,	_	_	I-Claim
322	and	_	_	I-Claim
323	maintains	_	_	I-Claim
324	or	_	_	I-Claim
325	improves	_	_	I-Claim
326	QOL	_	_	I-Claim
327	.	_	_	I-Claim

328	This	_	_	B-Claim
329	study	_	_	I-Claim
330	supports	_	_	I-Claim
331	the	_	_	I-Claim
332	positive	_	_	I-Claim
333	effects	_	_	I-Claim
334	of	_	_	I-Claim
335	early	_	_	I-Claim
336	intervention	_	_	I-Claim
337	when	_	_	I-Claim
338	analyzed	_	_	I-Claim
339	according	_	_	I-Claim
340	to	_	_	I-Claim
341	initial	_	_	I-Claim
342	Hb	_	_	I-Claim
343	value	_	_	I-Claim
344	.	_	_	I-Claim


0	The	_	_	B-Claim
1	extent	_	_	I-Claim
2	to	_	_	I-Claim
3	which	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	may	_	_	I-Claim
6	relieve	_	_	I-Claim
7	tumour-related	_	_	I-Claim
8	symptoms	_	_	I-Claim
9	,	_	_	I-Claim
10	improve	_	_	I-Claim
11	quality	_	_	I-Claim
12	of	_	_	I-Claim
13	life	_	_	I-Claim
14	and	_	_	I-Claim
15	prolong	_	_	I-Claim
16	survival	_	_	I-Claim
17	in	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	gastric	_	_	I-Claim
21	cancer	_	_	I-Claim
22	is	_	_	I-Claim
23	not	_	_	I-Claim
24	known	_	_	I-Claim
25	in	_	_	I-Claim
26	spite	_	_	I-Claim
27	of	_	_	I-Claim
28	the	_	_	I-Claim
29	extensive	_	_	I-Claim
30	use	_	_	I-Claim
31	of	_	_	I-Claim
32	this	_	_	I-Claim
33	treatment	_	_	I-Claim
34	modality	_	_	I-Claim
35	.	_	_	I-Claim

36	The	_	_	O
37	aim	_	_	O
38	of	_	_	O
39	this	_	_	O
40	study	_	_	O
41	was	_	_	O
42	to	_	_	O
43	estimate	_	_	O
44	any	_	_	O
45	gain	_	_	O
46	in	_	_	O
47	the	_	_	O
48	quantity	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	produced	_	_	O
54	by	_	_	O
55	chemotherapy	_	_	O
56	in	_	_	O
57	these	_	_	O
58	patients	_	_	O
59	.	_	_	O

60	Between	_	_	O
61	January	_	_	O
62	1991	_	_	O
63	and	_	_	O
64	February	_	_	O
65	1995	_	_	O
66	,	_	_	O
67	61	_	_	O
68	patients	_	_	O
69	with	_	_	O
70	gastric	_	_	O
71	cancer	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	either	_	_	O
76	chemotherapy	_	_	O
77	in	_	_	O
78	addition	_	_	O
79	to	_	_	O
80	best	_	_	O
81	supportive	_	_	O
82	care	_	_	O
83	or	_	_	O
84	to	_	_	O
85	best	_	_	O
86	supportive	_	_	O
87	care	_	_	O
88	.	_	_	O

89	Chemotherapy	_	_	O
90	was	_	_	O
91	allowed	_	_	O
92	in	_	_	O
93	the	_	_	O
94	latter	_	_	O
95	group	_	_	O
96	if	_	_	O
97	the	_	_	O
98	supportive	_	_	O
99	measures	_	_	O
100	did	_	_	O
101	not	_	_	O
102	lead	_	_	O
103	to	_	_	O
104	palliation	_	_	O
105	.	_	_	O

106	Chemotherapy	_	_	O
107	was	_	_	O
108	the	_	_	O
109	ELF-regimen	_	_	O
110	consisting	_	_	O
111	of	_	_	O
112	5-fluorouracil	_	_	O
113	,	_	_	O
114	leucovorin	_	_	O
115	and	_	_	O
116	etoposide	_	_	O
117	,	_	_	O
118	or	_	_	O
119	,	_	_	O
120	in	_	_	O
121	elderly	_	_	O
122	patients	_	_	O
123	with	_	_	O
124	poor	_	_	O
125	performance	_	_	O
126	,	_	_	O
127	a	_	_	O
128	5-fluorouracil/leucovorin	_	_	O
129	regimen	_	_	O
130	(	_	_	O
131	FLv	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	was	_	_	O
138	evaluated	_	_	O
139	with	_	_	O
140	the	_	_	O
141	EORTC-QLQ-C30	_	_	O
142	instrument	_	_	O
143	.	_	_	O

144	More	_	_	B-Premise
145	patients	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	chemotherapy	_	_	I-Premise
149	group	_	_	I-Premise
150	(	_	_	I-Premise
151	45	_	_	I-Premise
152	%	_	_	I-Premise
153	,	_	_	I-Premise
154	14/31	_	_	I-Premise
155	)	_	_	I-Premise
156	had	_	_	I-Premise
157	an	_	_	I-Premise
158	improved	_	_	I-Premise
159	or	_	_	I-Premise
160	prolonged	_	_	I-Premise
161	high	_	_	I-Premise
162	quality	_	_	I-Premise
163	of	_	_	I-Premise
164	life	_	_	I-Premise
165	for	_	_	I-Premise
166	a	_	_	I-Premise
167	minimum	_	_	I-Premise
168	period	_	_	I-Premise
169	of	_	_	I-Premise
170	4	_	_	I-Premise
171	months	_	_	I-Premise
172	compared	_	_	I-Premise
173	to	_	_	I-Premise
174	those	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	best	_	_	I-Premise
178	supportive	_	_	I-Premise
179	care	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	20	_	_	I-Premise
183	%	_	_	I-Premise
184	,	_	_	I-Premise
185	6/30	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	A	_	_	B-Premise
193	similar	_	_	I-Premise
194	difference	_	_	I-Premise
195	was	_	_	I-Premise
196	seen	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	treating	_	_	I-Premise
200	physician	_	_	I-Premise
201	's	_	_	I-Premise
202	evaluation	_	_	I-Premise
203	of	_	_	I-Premise
204	whether	_	_	I-Premise
205	the	_	_	I-Premise
206	patient	_	_	I-Premise
207	was	_	_	I-Premise
208	subjectively	_	_	I-Premise
209	improved	_	_	I-Premise
210	or	_	_	I-Premise
211	continued	_	_	I-Premise
212	to	_	_	I-Premise
213	do	_	_	I-Premise
214	well	_	_	I-Premise
215	for	_	_	I-Premise
216	at	_	_	I-Premise
217	least	_	_	I-Premise
218	4	_	_	I-Premise
219	months	_	_	I-Premise
220	(	_	_	I-Premise
221	17/31	_	_	I-Premise
222	,	_	_	I-Premise
223	55	_	_	I-Premise
224	%	_	_	I-Premise
225	versus	_	_	I-Premise
226	6/30	_	_	I-Premise
227	,	_	_	I-Premise
228	20	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.01	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Overall	_	_	B-Premise
237	survival	_	_	I-Premise
238	was	_	_	I-Premise
239	longer	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	chemotherapy	_	_	I-Premise
243	group	_	_	I-Premise
244	(	_	_	I-Premise
245	median	_	_	I-Premise
246	8	_	_	I-Premise
247	vs.	_	_	I-Premise
248	5	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	although	_	_	B-Premise
252	the	_	_	I-Premise
253	difference	_	_	I-Premise
254	was	_	_	I-Premise
255	not	_	_	I-Premise
256	statistically	_	_	I-Premise
257	significant	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.12	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	After	_	_	B-Premise
265	corrections	_	_	I-Premise
266	for	_	_	I-Premise
267	imbalances	_	_	I-Premise
268	in	_	_	I-Premise
269	pretreatment	_	_	I-Premise
270	characteristics	_	_	I-Premise
271	,	_	_	I-Premise
272	chemotherapy	_	_	I-Premise
273	treatment	_	_	I-Premise
274	was	_	_	I-Premise
275	,	_	_	I-Premise
276	however	_	_	I-Premise
277	,	_	_	I-Premise
278	associated	_	_	I-Premise
279	with	_	_	I-Premise
280	a	_	_	I-Premise
281	survival	_	_	I-Premise
282	benefit	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0.003	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	Also	_	_	B-Premise
290	,	_	_	I-Premise
291	the	_	_	I-Premise
292	quality-adjusted	_	_	I-Premise
293	survival	_	_	I-Premise
294	time	_	_	I-Premise
295	and	_	_	I-Premise
296	time	_	_	I-Premise
297	to	_	_	I-Premise
298	disease	_	_	I-Premise
299	progression	_	_	I-Premise
300	were	_	_	I-Premise
301	longer	_	_	I-Premise
302	for	_	_	I-Premise
303	patients	_	_	I-Premise
304	randomized	_	_	I-Premise
305	to	_	_	I-Premise
306	chemotherapy	_	_	I-Premise
307	(	_	_	I-Premise
308	median	_	_	I-Premise
309	5	_	_	I-Premise
310	vs.	_	_	I-Premise
311	2	_	_	I-Premise
312	months	_	_	I-Premise
313	,	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	0.03	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Claim
320	results	_	_	I-Claim
321	show	_	_	I-Claim
322	that	_	_	I-Claim
323	chemotherapy	_	_	I-Claim
324	can	_	_	I-Claim
325	add	_	_	I-Claim
326	to	_	_	I-Claim
327	both	_	_	I-Claim
328	quantity	_	_	I-Claim
329	and	_	_	I-Claim
330	quality	_	_	I-Claim
331	of	_	_	I-Claim
332	life	_	_	I-Claim
333	in	_	_	I-Claim
334	advanced	_	_	I-Claim
335	gastric	_	_	I-Claim
336	cancer	_	_	I-Claim
337	.	_	_	I-Claim

338	The	_	_	B-Claim
339	number	_	_	I-Claim
340	of	_	_	I-Claim
341	patients	_	_	I-Claim
342	who	_	_	I-Claim
343	benefit	_	_	I-Claim
344	from	_	_	I-Claim
345	treatment	_	_	I-Claim
346	is	_	_	I-Claim
347	,	_	_	I-Claim
348	however	_	_	I-Claim
349	,	_	_	I-Claim
350	still	_	_	I-Claim
351	rather	_	_	I-Claim
352	limited	_	_	I-Claim
353	.	_	_	I-Claim


0	Laparoscopic-assisted	_	_	B-Claim
1	colectomy	_	_	I-Claim
2	(	_	_	I-Claim
3	LAC	_	_	I-Claim
4	)	_	_	I-Claim
5	has	_	_	I-Claim
6	emerged	_	_	I-Claim
7	as	_	_	I-Claim
8	the	_	_	I-Claim
9	preferred	_	_	I-Claim
10	minimally	_	_	I-Claim
11	invasive	_	_	I-Claim
12	surgical	_	_	I-Claim
13	strategy	_	_	I-Claim
14	for	_	_	I-Claim
15	diseases	_	_	I-Claim
16	of	_	_	I-Claim
17	the	_	_	I-Claim
18	colon	_	_	I-Claim
19	.	_	_	I-Claim

20	The	_	_	B-Claim
21	safety	_	_	I-Claim
22	and	_	_	I-Claim
23	efficacy	_	_	I-Claim
24	of	_	_	I-Claim
25	LAC	_	_	I-Claim
26	for	_	_	I-Claim
27	colon	_	_	I-Claim
28	cancer	_	_	I-Claim
29	are	_	_	I-Claim
30	unknown	_	_	I-Claim
31	,	_	_	I-Claim
32	and	_	_	O
33	the	_	_	B-Claim
34	nature	_	_	I-Claim
35	and	_	_	I-Claim
36	magnitude	_	_	I-Claim
37	of	_	_	I-Claim
38	any	_	_	I-Claim
39	quality-of-life	_	_	I-Claim
40	(	_	_	I-Claim
41	QOL	_	_	I-Claim
42	)	_	_	I-Claim
43	benefit	_	_	I-Claim
44	resulting	_	_	I-Claim
45	from	_	_	I-Claim
46	LAC	_	_	I-Claim
47	for	_	_	I-Claim
48	colon	_	_	I-Claim
49	cancer	_	_	I-Claim
50	is	_	_	I-Claim
51	also	_	_	I-Claim
52	unknown	_	_	I-Claim
53	.	_	_	I-Claim

54	To	_	_	O
55	compare	_	_	O
56	short-term	_	_	O
57	QOL	_	_	O
58	outcomes	_	_	O
59	after	_	_	O
60	LAC	_	_	O
61	vs	_	_	O
62	open	_	_	O
63	colectomy	_	_	O
64	for	_	_	O
65	colon	_	_	O
66	cancer	_	_	O
67	.	_	_	O

68	Multicenter	_	_	O
69	,	_	_	O
70	randomized	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	(	_	_	O
74	Clinical	_	_	O
75	Outcomes	_	_	O
76	of	_	_	O
77	Surgical	_	_	O
78	Therapy	_	_	O
79	[	_	_	O
80	COST	_	_	O
81	]	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Between	_	_	O
85	September	_	_	O
86	1994	_	_	O
87	and	_	_	O
88	February	_	_	O
89	1999	_	_	O
90	,	_	_	O
91	37	_	_	O
92	of	_	_	O
93	48	_	_	O
94	centers	_	_	O
95	provided	_	_	O
96	data	_	_	O
97	for	_	_	O
98	the	_	_	O
99	QOL	_	_	O
100	component	_	_	O
101	of	_	_	O
102	the	_	_	O
103	trial	_	_	O
104	for	_	_	O
105	449	_	_	O
106	consecutive	_	_	O
107	patients	_	_	O
108	with	_	_	O
109	clinically	_	_	O
110	resectable	_	_	O
111	colon	_	_	O
112	cancer	_	_	O
113	.	_	_	O

114	Scores	_	_	O
115	on	_	_	O
116	the	_	_	O
117	Symptoms	_	_	O
118	Distress	_	_	O
119	Scale	_	_	O
120	(	_	_	O
121	SDS	_	_	O
122	)	_	_	O
123	,	_	_	O
124	Quality	_	_	O
125	of	_	_	O
126	Life	_	_	O
127	Index	_	_	O
128	,	_	_	O
129	and	_	_	O
130	a	_	_	O
131	single-item	_	_	O
132	global	_	_	O
133	rating	_	_	O
134	scale	_	_	O
135	at	_	_	O
136	2	_	_	O
137	days	_	_	O
138	,	_	_	O
139	2	_	_	O
140	weeks	_	_	O
141	,	_	_	O
142	and	_	_	O
143	2	_	_	O
144	months	_	_	O
145	postoperative	_	_	O
146	;	_	_	O
147	duration	_	_	O
148	of	_	_	O
149	postoperative	_	_	O
150	in-hospital	_	_	O
151	analgesic	_	_	O
152	use	_	_	O
153	;	_	_	O
154	and	_	_	O
155	length	_	_	O
156	of	_	_	O
157	stay	_	_	O
158	.	_	_	O

159	Of	_	_	O
160	449	_	_	O
161	patients	_	_	O
162	,	_	_	O
163	428	_	_	O
164	provided	_	_	O
165	QOL	_	_	O
166	data	_	_	O
167	.	_	_	O

168	In	_	_	B-Premise
169	an	_	_	I-Premise
170	intention-to-treat	_	_	I-Premise
171	analysis	_	_	I-Premise
172	comparing	_	_	I-Premise
173	SDS	_	_	I-Premise
174	pain	_	_	I-Premise
175	intensity	_	_	I-Premise
176	,	_	_	I-Premise
177	SDS	_	_	I-Premise
178	summary	_	_	I-Premise
179	,	_	_	I-Premise
180	QOL	_	_	I-Premise
181	Index	_	_	I-Premise
182	summary	_	_	I-Premise
183	,	_	_	I-Premise
184	and	_	_	I-Premise
185	global	_	_	I-Premise
186	rating	_	_	I-Premise
187	scale	_	_	I-Premise
188	scores	_	_	I-Premise
189	at	_	_	I-Premise
190	each	_	_	I-Premise
191	time	_	_	I-Premise
192	point	_	_	I-Premise
193	,	_	_	I-Premise
194	the	_	_	I-Premise
195	only	_	_	I-Premise
196	statistically	_	_	I-Premise
197	significant	_	_	I-Premise
198	difference	_	_	I-Premise
199	observed	_	_	I-Premise
200	between	_	_	I-Premise
201	groups	_	_	I-Premise
202	was	_	_	I-Premise
203	the	_	_	I-Premise
204	global	_	_	I-Premise
205	rating	_	_	I-Premise
206	scale	_	_	I-Premise
207	score	_	_	I-Premise
208	for	_	_	I-Premise
209	2	_	_	I-Premise
210	weeks	_	_	I-Premise
211	postsurgery	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	mean	_	_	I-Premise
215	(	_	_	I-Premise
216	median	_	_	I-Premise
217	)	_	_	I-Premise
218	global	_	_	I-Premise
219	rating	_	_	I-Premise
220	scale	_	_	I-Premise
221	scores	_	_	I-Premise
222	for	_	_	I-Premise
223	2	_	_	I-Premise
224	weeks	_	_	I-Premise
225	postsurgery	_	_	I-Premise
226	were	_	_	I-Premise
227	76.9	_	_	I-Premise
228	(	_	_	I-Premise
229	80	_	_	I-Premise
230	)	_	_	I-Premise
231	for	_	_	I-Premise
232	LAC	_	_	I-Premise
233	vs	_	_	I-Premise
234	74.4	_	_	I-Premise
235	(	_	_	I-Premise
236	75	_	_	I-Premise
237	)	_	_	I-Premise
238	for	_	_	I-Premise
239	open	_	_	I-Premise
240	colectomy	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=.009	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	While	_	_	B-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	hospital	_	_	I-Premise
250	,	_	_	I-Premise
251	patients	_	_	I-Premise
252	assigned	_	_	I-Premise
253	to	_	_	I-Premise
254	LAC	_	_	I-Premise
255	required	_	_	I-Premise
256	fewer	_	_	I-Premise
257	days	_	_	I-Premise
258	of	_	_	I-Premise
259	both	_	_	I-Premise
260	parenteral	_	_	I-Premise
261	analgesics	_	_	I-Premise
262	compared	_	_	I-Premise
263	with	_	_	I-Premise
264	patients	_	_	I-Premise
265	assigned	_	_	I-Premise
266	to	_	_	I-Premise
267	open	_	_	I-Premise
268	colectomy	_	_	I-Premise
269	(	_	_	I-Premise
270	mean	_	_	I-Premise
271	[	_	_	I-Premise
272	median	_	_	I-Premise
273	]	_	_	I-Premise
274	,	_	_	I-Premise
275	3.2	_	_	I-Premise
276	[	_	_	I-Premise
277	3	_	_	I-Premise
278	]	_	_	I-Premise
279	vs	_	_	I-Premise
280	4.0	_	_	I-Premise
281	[	_	_	I-Premise
282	4	_	_	I-Premise
283	]	_	_	I-Premise
284	days	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.001	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	oral	_	_	I-Premise
292	analgesics	_	_	I-Premise
293	(	_	_	I-Premise
294	mean	_	_	I-Premise
295	[	_	_	I-Premise
296	median	_	_	I-Premise
297	]	_	_	I-Premise
298	,	_	_	I-Premise
299	1.9	_	_	I-Premise
300	[	_	_	I-Premise
301	1	_	_	I-Premise
302	]	_	_	I-Premise
303	vs	_	_	I-Premise
304	2.2	_	_	I-Premise
305	[	_	_	I-Premise
306	2	_	_	I-Premise
307	]	_	_	I-Premise
308	days	_	_	I-Premise
309	;	_	_	I-Premise
310	P	_	_	I-Premise
311	=.03	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	Only	_	_	B-Claim
315	minimal	_	_	I-Claim
316	short-term	_	_	I-Claim
317	QOL	_	_	I-Claim
318	benefits	_	_	I-Claim
319	were	_	_	I-Claim
320	found	_	_	I-Claim
321	with	_	_	I-Claim
322	LAC	_	_	I-Claim
323	for	_	_	I-Claim
324	colon	_	_	I-Claim
325	cancer	_	_	I-Claim
326	compared	_	_	I-Claim
327	with	_	_	I-Claim
328	standard	_	_	I-Claim
329	open	_	_	I-Claim
330	colectomy	_	_	I-Claim
331	.	_	_	I-Claim

332	Until	_	_	B-Claim
333	ongoing	_	_	I-Claim
334	trials	_	_	I-Claim
335	establish	_	_	I-Claim
336	that	_	_	I-Claim
337	LAC	_	_	I-Claim
338	is	_	_	I-Claim
339	as	_	_	I-Claim
340	effective	_	_	I-Claim
341	as	_	_	I-Claim
342	open	_	_	I-Claim
343	colectomy	_	_	I-Claim
344	in	_	_	I-Claim
345	preventing	_	_	I-Claim
346	recurrence	_	_	I-Claim
347	and	_	_	I-Claim
348	death	_	_	I-Claim
349	from	_	_	I-Claim
350	colon	_	_	I-Claim
351	cancer	_	_	I-Claim
352	,	_	_	I-Claim
353	this	_	_	I-Claim
354	procedure	_	_	I-Claim
355	should	_	_	I-Claim
356	not	_	_	I-Claim
357	be	_	_	I-Claim
358	offered	_	_	I-Claim
359	to	_	_	I-Claim
360	patients	_	_	I-Claim
361	with	_	_	I-Claim
362	colon	_	_	I-Claim
363	cancer	_	_	I-Claim
364	.	_	_	I-Claim


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	prolonged	_	_	I-Claim
4	subclinical	_	_	I-Claim
5	hyperthyroidism	_	_	I-Claim
6	on	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	is	_	_	I-Claim
11	unclear	_	_	I-Claim
12	.	_	_	I-Claim

13	Therefore	_	_	O
14	,	_	_	O
15	we	_	_	O
16	evaluated	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	differentiated	_	_	O
24	thyroid	_	_	O
25	carcinoma	_	_	O
26	(	_	_	O
27	DTC	_	_	O
28	)	_	_	O
29	on	_	_	O
30	TSH-suppressive	_	_	O
31	thyroxine	_	_	O
32	therapy	_	_	O
33	as	_	_	O
34	a	_	_	O
35	model	_	_	O
36	for	_	_	O
37	subclinical	_	_	O
38	hyperthyroidism	_	_	O
39	and	_	_	O
40	we	_	_	O
41	investigated	_	_	O
42	whether	_	_	O
43	restoration	_	_	O
44	to	_	_	O
45	euthyroidism	_	_	O
46	affects	_	_	O
47	quality	_	_	O
48	of	_	_	O
49	life	_	_	O
50	.	_	_	O

51	We	_	_	O
52	performed	_	_	O
53	a	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	single-blinded	_	_	O
57	,	_	_	O
58	placebo-controlled	_	_	O
59	,	_	_	O
60	randomized	_	_	O
61	trial	_	_	O
62	of	_	_	O
63	6	_	_	O
64	months	_	_	O
65	'	_	_	O
66	duration	_	_	O
67	with	_	_	O
68	two	_	_	O
69	parallel	_	_	O
70	groups	_	_	O
71	.	_	_	O

72	Twenty-four	_	_	O
73	subjects	_	_	O
74	with	_	_	O
75	a	_	_	O
76	history	_	_	O
77	of	_	_	O
78	differentiated	_	_	O
79	thyroid	_	_	O
80	carcinoma	_	_	O
81	with	_	_	O
82	>	_	_	O
83	10	_	_	O
84	years	_	_	O
85	TSH-suppressive	_	_	O
86	therapy	_	_	O
87	with	_	_	O
88	L-thyroxine	_	_	O
89	completed	_	_	O
90	the	_	_	O
91	study	_	_	O
92	.	_	_	O

93	L-thyroxine	_	_	O
94	dose	_	_	O
95	was	_	_	O
96	replaced	_	_	O
97	by	_	_	O
98	study	_	_	O
99	medication	_	_	O
100	containing	_	_	O
101	L-thyroxine	_	_	O
102	or	_	_	O
103	L-thyroxine	_	_	O
104	plus	_	_	O
105	placebo	_	_	O
106	.	_	_	O

107	Medication	_	_	O
108	was	_	_	O
109	titrated	_	_	O
110	to	_	_	O
111	establish	_	_	O
112	continuation	_	_	O
113	of	_	_	O
114	TSH	_	_	O
115	suppression	_	_	O
116	(	_	_	O
117	low-TSH	_	_	O
118	group	_	_	O
119	)	_	_	O
120	and	_	_	O
121	euthyroidism	_	_	O
122	(	_	_	O
123	euthyroid	_	_	O
124	group	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Both	_	_	O
128	groups	_	_	O
129	consisted	_	_	O
130	of	_	_	O
131	12	_	_	O
132	patients	_	_	O
133	.	_	_	O

134	We	_	_	O
135	evaluated	_	_	O
136	quality	_	_	O
137	of	_	_	O
138	life	_	_	O
139	using	_	_	O
140	five	_	_	O
141	validated	_	_	O
142	questionnaires	_	_	O
143	.	_	_	O

144	At	_	_	O
145	baseline	_	_	O
146	,	_	_	O
147	the	_	_	O
148	somatic	_	_	O
149	disorder	_	_	O
150	questionnaire	_	_	O
151	(	_	_	O
152	SDQ	_	_	O
153	)	_	_	O
154	indicated	_	_	O
155	more	_	_	O
156	somatic	_	_	O
157	dysfunction	_	_	O
158	in	_	_	O
159	patients	_	_	O
160	as	_	_	O
161	compared	_	_	O
162	with	_	_	O
163	reference	_	_	O
164	values	_	_	O
165	,	_	_	O
166	whereas	_	_	O
167	the	_	_	O
168	depression	_	_	O
169	score	_	_	O
170	(	_	_	O
171	HADS	_	_	O
172	)	_	_	O
173	revealed	_	_	O
174	a	_	_	O
175	better	_	_	O
176	score	_	_	O
177	than	_	_	O
178	the	_	_	O
179	reference	_	_	O
180	group	_	_	O
181	.	_	_	O

182	All	_	_	O
183	other	_	_	O
184	quality	_	_	O
185	of	_	_	O
186	life	_	_	O
187	parameters	_	_	O
188	were	_	_	O
189	normal	_	_	O
190	.	_	_	O

191	At	_	_	O
192	baseline	_	_	O
193	,	_	_	O
194	no	_	_	O
195	significant	_	_	O
196	differences	_	_	O
197	between	_	_	O
198	the	_	_	O
199	low-TSH	_	_	O
200	and	_	_	O
201	the	_	_	O
202	euthyroidism	_	_	O
203	groups	_	_	O
204	were	_	_	O
205	observed	_	_	O
206	.	_	_	O

207	After	_	_	B-Premise
208	6	_	_	I-Premise
209	months	_	_	I-Premise
210	,	_	_	I-Premise
211	none	_	_	I-Premise
212	of	_	_	I-Premise
213	the	_	_	I-Premise
214	quality	_	_	I-Premise
215	of	_	_	I-Premise
216	life	_	_	I-Premise
217	parameters	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	low-TSH	_	_	I-Premise
221	group	_	_	I-Premise
222	was	_	_	I-Premise
223	different	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	values	_	_	I-Premise
227	.	_	_	I-Premise

228	In	_	_	B-Premise
229	the	_	_	I-Premise
230	euthyroid	_	_	I-Premise
231	group	_	_	I-Premise
232	,	_	_	I-Premise
233	motivation	_	_	I-Premise
234	was	_	_	I-Premise
235	significantly	_	_	I-Premise
236	improved	_	_	I-Premise
237	(	_	_	I-Premise
238	Multidimensional	_	_	I-Premise
239	Fatigue	_	_	I-Premise
240	Index-20	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.003	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	although	_	_	B-Premise
248	this	_	_	I-Premise
249	parameter	_	_	I-Premise
250	did	_	_	I-Premise
251	not	_	_	I-Premise
252	differ	_	_	I-Premise
253	from	_	_	I-Premise
254	the	_	_	I-Premise
255	reference	_	_	I-Premise
256	group	_	_	I-Premise
257	at	_	_	I-Premise
258	baseline	_	_	I-Premise
259	.	_	_	I-Premise

260	A	_	_	B-Premise
261	probable	_	_	I-Premise
262	worsening	_	_	I-Premise
263	in	_	_	I-Premise
264	role	_	_	I-Premise
265	limitations	_	_	I-Premise
266	as	_	_	I-Premise
267	a	_	_	I-Premise
268	result	_	_	I-Premise
269	of	_	_	I-Premise
270	physical	_	_	I-Premise
271	problems	_	_	I-Premise
272	(	_	_	I-Premise
273	Short	_	_	I-Premise
274	Form-36	_	_	I-Premise
275	;	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	0.050	_	_	I-Premise
279	)	_	_	I-Premise
280	was	_	_	I-Premise
281	observed	_	_	I-Premise
282	.	_	_	I-Premise

283	No	_	_	B-Premise
284	improvement	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	SDQ	_	_	I-Premise
288	score	_	_	I-Premise
289	was	_	_	I-Premise
290	observed	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	summary	_	_	I-Claim
294	,	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	in	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	DTC	_	_	I-Claim
302	and	_	_	I-Claim
303	long-term	_	_	I-Claim
304	subclinical	_	_	I-Claim
305	hyperthyroidism	_	_	I-Claim
306	in	_	_	I-Claim
307	general	_	_	I-Claim
308	is	_	_	I-Claim
309	preserved	_	_	I-Claim
310	.	_	_	I-Claim

311	Restoration	_	_	B-Claim
312	of	_	_	I-Claim
313	euthyroidism	_	_	I-Claim
314	in	_	_	I-Claim
315	general	_	_	I-Claim
316	does	_	_	I-Claim
317	not	_	_	I-Claim
318	affect	_	_	I-Claim
319	quality	_	_	I-Claim
320	of	_	_	I-Claim
321	life	_	_	I-Claim
322	.	_	_	I-Claim


0	Most	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	glioblastoma	_	_	O
4	are	_	_	O
5	older	_	_	O
6	than	_	_	O
7	60	_	_	O
8	years	_	_	O
9	,	_	_	O
10	but	_	_	O
11	treatment	_	_	O
12	guidelines	_	_	O
13	are	_	_	O
14	based	_	_	O
15	on	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	aged	_	_	O
20	only	_	_	O
21	up	_	_	O
22	to	_	_	O
23	70	_	_	O
24	years	_	_	O
25	.	_	_	O

26	We	_	_	O
27	did	_	_	O
28	a	_	_	O
29	randomised	_	_	O
30	trial	_	_	O
31	to	_	_	O
32	assess	_	_	O
33	the	_	_	O
34	optimum	_	_	O
35	palliative	_	_	O
36	treatment	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	aged	_	_	O
40	60	_	_	O
41	years	_	_	O
42	and	_	_	O
43	older	_	_	O
44	with	_	_	O
45	glioblastoma	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	with	_	_	O
49	newly	_	_	O
50	diagnosed	_	_	O
51	glioblastoma	_	_	O
52	were	_	_	O
53	recruited	_	_	O
54	from	_	_	O
55	Austria	_	_	O
56	,	_	_	O
57	Denmark	_	_	O
58	,	_	_	O
59	France	_	_	O
60	,	_	_	O
61	Norway	_	_	O
62	,	_	_	O
63	Sweden	_	_	O
64	,	_	_	O
65	Switzerland	_	_	O
66	,	_	_	O
67	and	_	_	O
68	Turkey	_	_	O
69	.	_	_	O

70	They	_	_	O
71	were	_	_	O
72	assigned	_	_	O
73	by	_	_	O
74	a	_	_	O
75	computer-generated	_	_	O
76	randomisation	_	_	O
77	schedule	_	_	O
78	,	_	_	O
79	stratified	_	_	O
80	by	_	_	O
81	centre	_	_	O
82	,	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	temozolomide	_	_	O
86	(	_	_	O
87	200	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	days	_	_	O
94	1-5	_	_	O
95	of	_	_	O
96	every	_	_	O
97	28	_	_	O
98	days	_	_	O
99	for	_	_	O
100	up	_	_	O
101	to	_	_	O
102	six	_	_	O
103	cycles	_	_	O
104	)	_	_	O
105	,	_	_	O
106	hypofractionated	_	_	O
107	radiotherapy	_	_	O
108	(	_	_	O
109	34Â·0	_	_	O
110	Gy	_	_	O
111	administered	_	_	O
112	in	_	_	O
113	3Â·4	_	_	O
114	Gy	_	_	O
115	fractions	_	_	O
116	over	_	_	O
117	2	_	_	O
118	weeks	_	_	O
119	)	_	_	O
120	,	_	_	O
121	or	_	_	O
122	standard	_	_	O
123	radiotherapy	_	_	O
124	(	_	_	O
125	60Â·0	_	_	O
126	Gy	_	_	O
127	administered	_	_	O
128	in	_	_	O
129	2Â·0	_	_	O
130	Gy	_	_	O
131	fractions	_	_	O
132	over	_	_	O
133	6	_	_	O
134	weeks	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Patients	_	_	O
138	and	_	_	O
139	study	_	_	O
140	staff	_	_	O
141	were	_	_	O
142	aware	_	_	O
143	of	_	_	O
144	treatment	_	_	O
145	assignment	_	_	O
146	.	_	_	O

147	The	_	_	O
148	primary	_	_	O
149	endpoint	_	_	O
150	was	_	_	O
151	overall	_	_	O
152	survival	_	_	O
153	.	_	_	O

154	Analyses	_	_	O
155	were	_	_	O
156	done	_	_	O
157	by	_	_	O
158	intention	_	_	O
159	to	_	_	O
160	treat	_	_	O
161	.	_	_	O

162	This	_	_	O
163	trial	_	_	O
164	is	_	_	O
165	registered	_	_	O
166	,	_	_	O
167	number	_	_	O
168	ISRCTN81470623	_	_	O
169	.	_	_	O

170	342	_	_	O
171	patients	_	_	O
172	were	_	_	O
173	enrolled	_	_	O
174	,	_	_	O
175	of	_	_	O
176	whom	_	_	O
177	291	_	_	O
178	were	_	_	O
179	randomised	_	_	O
180	across	_	_	O
181	three	_	_	O
182	treatment	_	_	O
183	groups	_	_	O
184	(	_	_	O
185	temozolomide	_	_	O
186	n=93	_	_	O
187	,	_	_	O
188	hypofractionated	_	_	O
189	radiotherapy	_	_	O
190	n=98	_	_	O
191	,	_	_	O
192	standard	_	_	O
193	radiotherapy	_	_	O
194	n=100	_	_	O
195	)	_	_	O
196	and	_	_	O
197	51	_	_	O
198	of	_	_	O
199	whom	_	_	O
200	were	_	_	O
201	randomised	_	_	O
202	across	_	_	O
203	only	_	_	O
204	two	_	_	O
205	groups	_	_	O
206	(	_	_	O
207	temozolomide	_	_	O
208	n=26	_	_	O
209	,	_	_	O
210	hypofractionated	_	_	O
211	radiotherapy	_	_	O
212	n=25	_	_	O
213	)	_	_	O
214	.	_	_	O

215	In	_	_	B-Premise
216	the	_	_	I-Premise
217	three-group	_	_	I-Premise
218	randomisation	_	_	I-Premise
219	,	_	_	I-Premise
220	in	_	_	I-Premise
221	comparison	_	_	I-Premise
222	with	_	_	I-Premise
223	standard	_	_	I-Premise
224	radiotherapy	_	_	I-Premise
225	,	_	_	I-Premise
226	median	_	_	I-Premise
227	overall	_	_	I-Premise
228	survival	_	_	I-Premise
229	was	_	_	I-Premise
230	significantly	_	_	I-Premise
231	longer	_	_	I-Premise
232	with	_	_	I-Premise
233	temozolomide	_	_	I-Premise
234	(	_	_	I-Premise
235	8Â·3	_	_	I-Premise
236	months	_	_	I-Premise
237	[	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	7Â·1-9Â·5	_	_	I-Premise
242	;	_	_	I-Premise
243	n=93	_	_	I-Premise
244	]	_	_	I-Premise
245	vs	_	_	I-Premise
246	6Â·0	_	_	I-Premise
247	months	_	_	I-Premise
248	[	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	5Â·1-6Â·8	_	_	I-Premise
253	;	_	_	I-Premise
254	n=100	_	_	I-Premise
255	]	_	_	I-Premise
256	,	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	[	_	_	I-Premise
260	HR	_	_	I-Premise
261	]	_	_	I-Premise
262	0Â·70	_	_	I-Premise
263	;	_	_	I-Premise
264	95	_	_	I-Premise
265	%	_	_	I-Premise
266	CI	_	_	I-Premise
267	0Â·52-0Â·93	_	_	I-Premise
268	,	_	_	I-Premise
269	p=0Â·01	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	but	_	_	I-Premise
273	not	_	_	I-Premise
274	with	_	_	I-Premise
275	hypofractionated	_	_	I-Premise
276	radiotherapy	_	_	I-Premise
277	(	_	_	I-Premise
278	7Â·5	_	_	I-Premise
279	months	_	_	I-Premise
280	[	_	_	I-Premise
281	6Â·5-8Â·6	_	_	I-Premise
282	;	_	_	I-Premise
283	n=98	_	_	I-Premise
284	]	_	_	I-Premise
285	,	_	_	I-Premise
286	HR	_	_	I-Premise
287	0Â·85	_	_	I-Premise
288	[	_	_	I-Premise
289	0Â·64-1Â·12	_	_	I-Premise
290	]	_	_	I-Premise
291	,	_	_	I-Premise
292	p=0Â·24	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	For	_	_	B-Premise
296	all	_	_	I-Premise
297	patients	_	_	I-Premise
298	who	_	_	I-Premise
299	received	_	_	I-Premise
300	temozolomide	_	_	I-Premise
301	or	_	_	I-Premise
302	hypofractionated	_	_	I-Premise
303	radiotherapy	_	_	I-Premise
304	(	_	_	I-Premise
305	n=242	_	_	I-Premise
306	)	_	_	I-Premise
307	overall	_	_	I-Premise
308	survival	_	_	I-Premise
309	was	_	_	I-Premise
310	similar	_	_	I-Premise
311	(	_	_	I-Premise
312	8Â·4	_	_	I-Premise
313	months	_	_	I-Premise
314	[	_	_	I-Premise
315	7Â·3-9Â·4	_	_	I-Premise
316	;	_	_	I-Premise
317	n=119	_	_	I-Premise
318	]	_	_	I-Premise
319	vs	_	_	I-Premise
320	7Â·4	_	_	I-Premise
321	months	_	_	I-Premise
322	[	_	_	I-Premise
323	6Â·4-8Â·4	_	_	I-Premise
324	;	_	_	I-Premise
325	n=123	_	_	I-Premise
326	]	_	_	I-Premise
327	;	_	_	I-Premise
328	HR	_	_	I-Premise
329	0Â·82	_	_	I-Premise
330	,	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	0Â·63-1Â·06	_	_	I-Premise
335	;	_	_	I-Premise
336	p=0Â·12	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	For	_	_	B-Premise
340	age	_	_	I-Premise
341	older	_	_	I-Premise
342	than	_	_	I-Premise
343	70	_	_	I-Premise
344	years	_	_	I-Premise
345	,	_	_	I-Premise
346	survival	_	_	I-Premise
347	was	_	_	I-Premise
348	better	_	_	I-Premise
349	with	_	_	I-Premise
350	temozolomide	_	_	I-Premise
351	and	_	_	I-Premise
352	with	_	_	I-Premise
353	hypofractionated	_	_	I-Premise
354	radiotherapy	_	_	I-Premise
355	than	_	_	I-Premise
356	with	_	_	I-Premise
357	standard	_	_	I-Premise
358	radiotherapy	_	_	I-Premise
359	(	_	_	I-Premise
360	HR	_	_	I-Premise
361	for	_	_	I-Premise
362	temozolomide	_	_	I-Premise
363	vs	_	_	I-Premise
364	standard	_	_	I-Premise
365	radiotherapy	_	_	I-Premise
366	0Â·35	_	_	I-Premise
367	[	_	_	I-Premise
368	0Â·21-0Â·56	_	_	I-Premise
369	]	_	_	I-Premise
370	,	_	_	I-Premise
371	p	_	_	I-Premise
372	<	_	_	I-Premise
373	0Â·0001	_	_	I-Premise
374	;	_	_	I-Premise
375	HR	_	_	I-Premise
376	for	_	_	I-Premise
377	hypofractionated	_	_	I-Premise
378	vs	_	_	I-Premise
379	standard	_	_	I-Premise
380	radiotherapy	_	_	I-Premise
381	0Â·59	_	_	I-Premise
382	[	_	_	I-Premise
383	95	_	_	I-Premise
384	%	_	_	I-Premise
385	CI	_	_	I-Premise
386	0Â·37-0Â·93	_	_	I-Premise
387	]	_	_	I-Premise
388	,	_	_	I-Premise
389	p=0Â·02	_	_	I-Premise
390	)	_	_	I-Premise
391	.	_	_	I-Premise

392	Patients	_	_	B-Premise
393	treated	_	_	I-Premise
394	with	_	_	I-Premise
395	temozolomide	_	_	I-Premise
396	who	_	_	I-Premise
397	had	_	_	I-Premise
398	tumour	_	_	I-Premise
399	MGMT	_	_	I-Premise
400	promoter	_	_	I-Premise
401	methylation	_	_	I-Premise
402	had	_	_	I-Premise
403	significantly	_	_	I-Premise
404	longer	_	_	I-Premise
405	survival	_	_	I-Premise
406	than	_	_	I-Premise
407	those	_	_	I-Premise
408	without	_	_	I-Premise
409	MGMT	_	_	I-Premise
410	promoter	_	_	I-Premise
411	methylation	_	_	I-Premise
412	(	_	_	I-Premise
413	9Â·7	_	_	I-Premise
414	months	_	_	I-Premise
415	[	_	_	I-Premise
416	95	_	_	I-Premise
417	%	_	_	I-Premise
418	CI	_	_	I-Premise
419	8Â·0-11Â·4	_	_	I-Premise
420	]	_	_	I-Premise
421	vs	_	_	I-Premise
422	6Â·8	_	_	I-Premise
423	months	_	_	I-Premise
424	[	_	_	I-Premise
425	5Â·9-7Â·7	_	_	I-Premise
426	]	_	_	I-Premise
427	;	_	_	I-Premise
428	HR	_	_	I-Premise
429	0Â·56	_	_	I-Premise
430	[	_	_	I-Premise
431	95	_	_	I-Premise
432	%	_	_	I-Premise
433	CI	_	_	I-Premise
434	0Â·34-0Â·93	_	_	I-Premise
435	]	_	_	I-Premise
436	,	_	_	I-Premise
437	p=0Â·02	_	_	I-Premise
438	)	_	_	I-Premise
439	,	_	_	I-Premise
440	but	_	_	I-Premise
441	no	_	_	I-Premise
442	difference	_	_	I-Premise
443	was	_	_	I-Premise
444	noted	_	_	I-Premise
445	between	_	_	I-Premise
446	those	_	_	I-Premise
447	with	_	_	I-Premise
448	methylated	_	_	I-Premise
449	and	_	_	I-Premise
450	unmethylated	_	_	I-Premise
451	MGMT	_	_	I-Premise
452	promoter	_	_	I-Premise
453	treated	_	_	I-Premise
454	with	_	_	I-Premise
455	radiotherapy	_	_	I-Premise
456	(	_	_	I-Premise
457	HR	_	_	I-Premise
458	0Â·97	_	_	I-Premise
459	[	_	_	I-Premise
460	95	_	_	I-Premise
461	%	_	_	I-Premise
462	CI	_	_	I-Premise
463	0Â·69-1Â·38	_	_	I-Premise
464	]	_	_	I-Premise
465	;	_	_	I-Premise
466	p=0Â·81	_	_	I-Premise
467	)	_	_	I-Premise
468	.	_	_	I-Premise

469	As	_	_	O
470	expected	_	_	O
471	,	_	_	O
472	the	_	_	B-Premise
473	most	_	_	I-Premise
474	common	_	_	I-Premise
475	grade	_	_	I-Premise
476	3-4	_	_	I-Premise
477	adverse	_	_	I-Premise
478	events	_	_	I-Premise
479	in	_	_	I-Premise
480	the	_	_	I-Premise
481	temozolomide	_	_	I-Premise
482	group	_	_	I-Premise
483	were	_	_	I-Premise
484	neutropenia	_	_	I-Premise
485	(	_	_	I-Premise
486	n=12	_	_	I-Premise
487	)	_	_	I-Premise
488	and	_	_	I-Premise
489	thrombocytopenia	_	_	I-Premise
490	(	_	_	I-Premise
491	n=18	_	_	I-Premise
492	)	_	_	I-Premise
493	.	_	_	I-Premise

494	Grade	_	_	B-Premise
495	3-5	_	_	I-Premise
496	infections	_	_	I-Premise
497	in	_	_	I-Premise
498	all	_	_	I-Premise
499	randomisation	_	_	I-Premise
500	groups	_	_	I-Premise
501	were	_	_	I-Premise
502	reported	_	_	I-Premise
503	in	_	_	I-Premise
504	18	_	_	I-Premise
505	patients	_	_	I-Premise
506	.	_	_	I-Premise

507	Two	_	_	B-Premise
508	patients	_	_	I-Premise
509	had	_	_	I-Premise
510	fatal	_	_	I-Premise
511	infections	_	_	I-Premise
512	(	_	_	I-Premise
513	one	_	_	I-Premise
514	in	_	_	I-Premise
515	the	_	_	I-Premise
516	temozolomide	_	_	I-Premise
517	group	_	_	I-Premise
518	and	_	_	I-Premise
519	one	_	_	I-Premise
520	in	_	_	I-Premise
521	the	_	_	I-Premise
522	standard	_	_	I-Premise
523	radiotherapy	_	_	I-Premise
524	group	_	_	I-Premise
525	)	_	_	I-Premise
526	and	_	_	I-Premise
527	one	_	_	I-Premise
528	in	_	_	I-Premise
529	the	_	_	I-Premise
530	temozolomide	_	_	I-Premise
531	group	_	_	I-Premise
532	with	_	_	I-Premise
533	grade	_	_	I-Premise
534	2	_	_	I-Premise
535	thrombocytopenia	_	_	I-Premise
536	died	_	_	I-Premise
537	from	_	_	I-Premise
538	complications	_	_	I-Premise
539	after	_	_	I-Premise
540	surgery	_	_	I-Premise
541	for	_	_	I-Premise
542	a	_	_	I-Premise
543	gastrointestinal	_	_	I-Premise
544	bleed	_	_	I-Premise
545	.	_	_	I-Premise

546	Standard	_	_	B-Claim
547	radiotherapy	_	_	I-Claim
548	was	_	_	I-Claim
549	associated	_	_	I-Claim
550	with	_	_	I-Claim
551	poor	_	_	I-Claim
552	outcomes	_	_	I-Claim
553	,	_	_	I-Claim
554	especially	_	_	I-Claim
555	in	_	_	I-Claim
556	patients	_	_	I-Claim
557	older	_	_	I-Claim
558	than	_	_	I-Claim
559	70	_	_	I-Claim
560	years	_	_	I-Claim
561	.	_	_	I-Claim

562	Both	_	_	B-Claim
563	temozolomide	_	_	I-Claim
564	and	_	_	I-Claim
565	hypofractionated	_	_	I-Claim
566	radiotherapy	_	_	I-Claim
567	should	_	_	I-Claim
568	be	_	_	I-Claim
569	considered	_	_	I-Claim
570	as	_	_	I-Claim
571	standard	_	_	I-Claim
572	treatment	_	_	I-Claim
573	options	_	_	I-Claim
574	in	_	_	I-Claim
575	elderly	_	_	I-Claim
576	patients	_	_	I-Claim
577	with	_	_	I-Claim
578	glioblastoma	_	_	I-Claim
579	.	_	_	I-Claim

580	MGMT	_	_	B-Claim
581	promoter	_	_	I-Claim
582	methylation	_	_	I-Claim
583	status	_	_	I-Claim
584	might	_	_	I-Claim
585	be	_	_	I-Claim
586	a	_	_	I-Claim
587	useful	_	_	I-Claim
588	predictive	_	_	I-Claim
589	marker	_	_	I-Claim
590	for	_	_	I-Claim
591	benefit	_	_	I-Claim
592	from	_	_	I-Claim
593	temozolomide	_	_	I-Claim
594	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	difference	_	_	O
4	of	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	side-effects	_	_	O
8	and	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	in	_	_	O
13	advanced	_	_	O
14	non-small-cell	_	_	O
15	lung	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NSCLC	_	_	O
19	)	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	oxaliplatin	_	_	O
24	plus	_	_	O
25	vinorelbine	_	_	O
26	or	_	_	O
27	cisplatin	_	_	O
28	plus	_	_	O
29	vinorelbine	_	_	O
30	.	_	_	O

31	Eligible	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	NL	_	_	O
38	(	_	_	O
39	oxaliplatin	_	_	O
40	+	_	_	O
41	vinorelbine	_	_	O
42	)	_	_	O
43	group	_	_	O
44	and	_	_	O
45	NP	_	_	O
46	(	_	_	O
47	cisplatin	_	_	O
48	+	_	_	O
49	vinorelbine	_	_	O
50	)	_	_	O
51	group	_	_	O
52	in	_	_	O
53	a	_	_	O
54	2:1	_	_	O
55	ratio	_	_	O
56	.	_	_	O

57	In	_	_	O
58	the	_	_	O
59	NL	_	_	O
60	group	_	_	O
61	,	_	_	O
62	70	_	_	O
63	evaluable	_	_	O
64	cases	_	_	O
65	were	_	_	O
66	treated	_	_	O
67	with	_	_	O
68	oxaliplatin	_	_	O
69	130	_	_	O
70	mg/m	_	_	O
71	(	_	_	O
72	2	_	_	O
73	)	_	_	O
74	i.v	_	_	O
75	.	_	_	O

76	on	_	_	O
77	day	_	_	O
78	2	_	_	O
79	,	_	_	O
80	and	_	_	O
81	vinorelbine	_	_	O
82	25	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	i.v	_	_	O
88	.	_	_	O

89	on	_	_	O
90	days	_	_	O
91	1	_	_	O
92	and	_	_	O
93	8	_	_	O
94	in	_	_	O
95	21	_	_	O
96	days	_	_	O
97	per	_	_	O
98	cycle	_	_	O
99	.	_	_	O

100	In	_	_	O
101	the	_	_	O
102	NP	_	_	O
103	group	_	_	O
104	,	_	_	O
105	32	_	_	O
106	evaluable	_	_	O
107	cases	_	_	O
108	were	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	cisplatin	_	_	O
112	80	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	i.v	_	_	O
118	.	_	_	O

119	divided	_	_	O
120	to	_	_	O
121	2	_	_	O
122	-	_	_	O
123	3	_	_	O
124	days	_	_	O
125	dosing	_	_	O
126	,	_	_	O
127	21	_	_	O
128	days	_	_	O
129	per	_	_	O
130	cycle	_	_	O
131	,	_	_	O
132	and	_	_	O
133	vinorelbine	_	_	O
134	administered	_	_	O
135	by	_	_	O
136	the	_	_	O
137	same	_	_	O
138	way	_	_	O
139	as	_	_	O
140	in	_	_	O
141	the	_	_	O
142	NL	_	_	O
143	group	_	_	O
144	.	_	_	O

145	The	_	_	O
146	response	_	_	O
147	rate	_	_	O
148	,	_	_	O
149	time	_	_	O
150	to	_	_	O
151	progression	_	_	O
152	(	_	_	O
153	TTP	_	_	O
154	)	_	_	O
155	,	_	_	O
156	one-year	_	_	O
157	survival	_	_	O
158	,	_	_	O
159	side-effects	_	_	O
160	and	_	_	O
161	the	_	_	O
162	quality	_	_	O
163	of	_	_	O
164	life	_	_	O
165	were	_	_	O
166	observed	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	response	_	_	I-Premise
170	rate	_	_	I-Premise
171	was	_	_	I-Premise
172	35.7	_	_	I-Premise
173	%	_	_	I-Premise
174	vs.	_	_	I-Premise
175	43.8	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.4	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	median	_	_	I-Premise
184	TTP	_	_	I-Premise
185	was	_	_	I-Premise
186	4.7	_	_	I-Premise
187	months	_	_	I-Premise
188	vs.	_	_	I-Premise
189	5.5	_	_	I-Premise
190	months	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.6	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	one-year	_	_	I-Premise
198	survival	_	_	I-Premise
199	rate	_	_	I-Premise
200	was	_	_	I-Premise
201	38.5	_	_	I-Premise
202	%	_	_	I-Premise
203	vs.	_	_	I-Premise
204	58.6	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.07	_	_	I-Premise
210	)	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	NL	_	_	I-Premise
214	and	_	_	I-Premise
215	NP	_	_	I-Premise
216	groups	_	_	I-Premise
217	,	_	_	I-Premise
218	respectively	_	_	I-Premise
219	.	_	_	I-Premise

220	Grade	_	_	B-Premise
221	I-II	_	_	I-Premise
222	neuro-sensory	_	_	I-Premise
223	toxicity	_	_	I-Premise
224	occurred	_	_	I-Premise
225	significantly	_	_	I-Premise
226	more	_	_	I-Premise
227	frequent	_	_	I-Premise
228	in	_	_	I-Premise
229	NL	_	_	I-Premise
230	group	_	_	I-Premise
231	than	_	_	I-Premise
232	in	_	_	I-Premise
233	NP	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	68.4	_	_	I-Premise
237	%	_	_	I-Premise
238	vs.	_	_	I-Premise
239	36.4	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.0017	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	However	_	_	B-Premise
248	,	_	_	I-Premise
249	Grade	_	_	I-Premise
250	I-II	_	_	I-Premise
251	granulocytopenia	_	_	I-Premise
252	was	_	_	I-Premise
253	significantly	_	_	I-Premise
254	less	_	_	I-Premise
255	occurred	_	_	I-Premise
256	in	_	_	I-Premise
257	NL	_	_	I-Premise
258	group	_	_	I-Premise
259	than	_	_	I-Premise
260	in	_	_	I-Premise
261	NP	_	_	I-Premise
262	group	_	_	I-Premise
263	(	_	_	I-Premise
264	49.4	_	_	I-Premise
265	%	_	_	I-Premise
266	vs.	_	_	I-Premise
267	70.6	_	_	I-Premise
268	%	_	_	I-Premise
269	,	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	0.037	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	There	_	_	B-Premise
276	was	_	_	I-Premise
277	no	_	_	I-Premise
278	statistically	_	_	I-Premise
279	difference	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	two	_	_	I-Premise
283	groups	_	_	I-Premise
284	regarding	_	_	I-Premise
285	quality	_	_	I-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	.	_	_	I-Premise

289	Due	_	_	B-Claim
290	to	_	_	I-Claim
291	good	_	_	I-Claim
292	efficacy	_	_	I-Claim
293	and	_	_	I-Claim
294	tolerability	_	_	I-Claim
295	,	_	_	I-Claim
296	the	_	_	I-Claim
297	NL	_	_	I-Claim
298	regimen	_	_	I-Claim
299	offered	_	_	I-Claim
300	a	_	_	I-Claim
301	new	_	_	I-Claim
302	candidate	_	_	I-Claim
303	for	_	_	I-Claim
304	treating	_	_	I-Claim
305	advanced	_	_	I-Claim
306	NSCLC	_	_	I-Claim
307	.	_	_	I-Claim


0	Restoring	_	_	O
1	sensory	_	_	O
2	innervation	_	_	O
3	may	_	_	O
4	be	_	_	O
5	a	_	_	O
6	useful	_	_	O
7	adjunct	_	_	O
8	in	_	_	O
9	free	_	_	O
10	flap	_	_	O
11	head	_	_	O
12	and	_	_	O
13	neck	_	_	O
14	reconstruction	_	_	O
15	but	_	_	O
16	,	_	_	O
17	as	_	_	O
18	yet	_	_	O
19	,	_	_	O
20	has	_	_	O
21	not	_	_	O
22	been	_	_	O
23	shown	_	_	O
24	to	_	_	O
25	improve	_	_	O
26	outcomes	_	_	O
27	of	_	_	O
28	breast	_	_	O
29	reconstruction	_	_	O
30	.	_	_	O

31	The	_	_	O
32	authors	_	_	O
33	'	_	_	O
34	previous	_	_	O
35	study	_	_	O
36	demonstrated	_	_	O
37	objectively	_	_	O
38	improved	_	_	O
39	sensation	_	_	O
40	in	_	_	O
41	a	_	_	O
42	group	_	_	O
43	of	_	_	O
44	innervated	_	_	O
45	transverse	_	_	O
46	rectus	_	_	O
47	abdominis	_	_	O
48	musculocutaneous	_	_	O
49	(	_	_	O
50	TRAM	_	_	O
51	)	_	_	O
52	flap	_	_	O
53	breast	_	_	O
54	reconstruction	_	_	O
55	patients	_	_	O
56	relative	_	_	O
57	to	_	_	O
58	noninnervated	_	_	O
59	flaps	_	_	O
60	.	_	_	O

61	This	_	_	O
62	study	_	_	O
63	compared	_	_	O
64	patient-rated	_	_	O
65	outcomes	_	_	O
66	of	_	_	O
67	free	_	_	O
68	TRAM	_	_	O
69	breast	_	_	O
70	reconstruction	_	_	O
71	in	_	_	O
72	innervated	_	_	O
73	versus	_	_	O
74	noninnervated	_	_	O
75	flaps	_	_	O
76	.	_	_	O

77	Twenty-seven	_	_	O
78	women	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	prospectively	_	_	O
82	to	_	_	O
83	undergo	_	_	O
84	either	_	_	O
85	innervated	_	_	O
86	or	_	_	O
87	noninnervated	_	_	O
88	free	_	_	O
89	TRAM	_	_	O
90	flap	_	_	O
91	breast	_	_	O
92	reconstruction	_	_	O
93	.	_	_	O

94	For	_	_	O
95	innervated	_	_	O
96	flaps	_	_	O
97	,	_	_	O
98	the	_	_	O
99	T10	_	_	O
100	intercostal	_	_	O
101	nerve	_	_	O
102	was	_	_	O
103	harvested	_	_	O
104	with	_	_	O
105	the	_	_	O
106	TRAM	_	_	O
107	flap	_	_	O
108	and	_	_	O
109	neurotized	_	_	O
110	to	_	_	O
111	the	_	_	O
112	T4	_	_	O
113	sensory	_	_	O
114	nerve	_	_	O
115	at	_	_	O
116	the	_	_	O
117	recipient	_	_	O
118	site	_	_	O
119	.	_	_	O

120	Three	_	_	O
121	validated	_	_	O
122	outcome	_	_	O
123	tools	_	_	O
124	were	_	_	O
125	administered	_	_	O
126	after	_	_	O
127	surgery	_	_	O
128	:	_	_	O
129	the	_	_	O
130	Medical	_	_	O
131	Outcomes	_	_	O
132	Study	_	_	O
133	36-Item	_	_	O
134	Short	_	_	O
135	Form	_	_	O
136	Health	_	_	O
137	Survey	_	_	O
138	,	_	_	O
139	the	_	_	O
140	Body	_	_	O
141	Image	_	_	O
142	after	_	_	O
143	Breast	_	_	O
144	Cancer	_	_	O
145	Questionnaire	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	Functional	_	_	O
150	Assessment	_	_	O
151	of	_	_	O
152	Cancer	_	_	O
153	Therapy-Breast	_	_	O
154	.	_	_	O

155	Results	_	_	B-Premise
156	were	_	_	I-Premise
157	correlated	_	_	I-Premise
158	with	_	_	I-Premise
159	previously	_	_	I-Premise
160	reported	_	_	I-Premise
161	objective	_	_	I-Premise
162	sensibility	_	_	I-Premise
163	outcomes	_	_	I-Premise
164	.	_	_	I-Premise

165	Eighteen	_	_	O
166	of	_	_	O
167	27	_	_	O
168	women	_	_	O
169	returned	_	_	O
170	their	_	_	O
171	questionnaires	_	_	O
172	a	_	_	O
173	mean	_	_	O
174	48	_	_	O
175	months	_	_	O
176	after	_	_	O
177	free	_	_	O
178	TRAM	_	_	O
179	flap	_	_	O
180	reconstruction	_	_	O
181	.	_	_	O

182	Demographic	_	_	O
183	analysis	_	_	O
184	revealed	_	_	O
185	no	_	_	O
186	significant	_	_	O
187	differences	_	_	O
188	in	_	_	O
189	patient	_	_	O
190	age	_	_	O
191	,	_	_	O
192	height	_	_	O
193	,	_	_	O
194	smoking	_	_	O
195	,	_	_	O
196	radiation	_	_	O
197	therapy	_	_	O
198	,	_	_	O
199	and	_	_	O
200	nipple-areola	_	_	O
201	complex	_	_	O
202	reconstruction	_	_	O
203	between	_	_	O
204	randomized	_	_	O
205	patient	_	_	O
206	groups	_	_	O
207	.	_	_	O

208	There	_	_	B-Premise
209	was	_	_	I-Premise
210	a	_	_	I-Premise
211	statistically	_	_	I-Premise
212	significant	_	_	I-Premise
213	improvement	_	_	I-Premise
214	in	_	_	I-Premise
215	all	_	_	I-Premise
216	three	_	_	I-Premise
217	measures	_	_	I-Premise
218	in	_	_	I-Premise
219	patients	_	_	I-Premise
220	who	_	_	I-Premise
221	were	_	_	I-Premise
222	randomized	_	_	I-Premise
223	to	_	_	I-Premise
224	receive	_	_	I-Premise
225	innervated	_	_	I-Premise
226	free	_	_	I-Premise
227	TRAM	_	_	I-Premise
228	flaps	_	_	I-Premise
229	compared	_	_	I-Premise
230	with	_	_	I-Premise
231	those	_	_	I-Premise
232	receiving	_	_	I-Premise
233	noninnervated	_	_	I-Premise
234	flaps	_	_	I-Premise
235	.	_	_	I-Premise

236	This	_	_	B-Claim
237	study	_	_	I-Claim
238	demonstrates	_	_	I-Claim
239	that	_	_	I-Claim
240	innervation	_	_	I-Claim
241	of	_	_	I-Claim
242	free	_	_	I-Claim
243	TRAM	_	_	I-Claim
244	flaps	_	_	I-Claim
245	used	_	_	I-Claim
246	for	_	_	I-Claim
247	breast	_	_	I-Claim
248	reconstruction	_	_	I-Claim
249	not	_	_	I-Claim
250	only	_	_	I-Claim
251	improves	_	_	I-Claim
252	sensibility	_	_	I-Claim
253	but	_	_	I-Claim
254	also	_	_	I-Claim
255	has	_	_	I-Claim
256	a	_	_	I-Claim
257	positive	_	_	I-Claim
258	effect	_	_	I-Claim
259	on	_	_	I-Claim
260	patient-rated	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	.	_	_	I-Claim


0	Despite	_	_	O
1	improvements	_	_	O
2	in	_	_	O
3	surgical	_	_	O
4	techniques	_	_	O
5	,	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	(	_	_	O
9	UI	_	_	O
10	)	_	_	O
11	is	_	_	O
12	not	_	_	O
13	uncommon	_	_	O
14	after	_	_	O
15	radical	_	_	O
16	prostatectomy	_	_	O
17	(	_	_	O
18	RP	_	_	O
19	)	_	_	O
20	,	_	_	O
21	and	_	_	O
22	it	_	_	O
23	may	_	_	O
24	dramatically	_	_	O
25	worsen	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	QoL	_	_	O
31	)	_	_	O
32	.	_	_	O

33	To	_	_	O
34	determine	_	_	O
35	the	_	_	O
36	benefit	_	_	O
37	of	_	_	O
38	starting	_	_	O
39	pelvic	_	_	O
40	floor	_	_	O
41	muscle	_	_	O
42	exercise	_	_	O
43	(	_	_	O
44	PFME	_	_	O
45	)	_	_	O
46	30d	_	_	O
47	before	_	_	O
48	RP	_	_	O
49	and	_	_	O
50	of	_	_	O
51	continuing	_	_	O
52	PFME	_	_	O
53	postoperatively	_	_	O
54	for	_	_	O
55	early	_	_	O
56	recovery	_	_	O
57	of	_	_	O
58	continence	_	_	O
59	.	_	_	O

60	A	_	_	O
61	randomised	_	_	O
62	,	_	_	O
63	prospective	_	_	O
64	study	_	_	O
65	was	_	_	O
66	designed	_	_	O
67	.	_	_	O

68	Men	_	_	O
69	with	_	_	O
70	localised	_	_	O
71	prostate	_	_	O
72	cancer	_	_	O
73	(	_	_	O
74	PCa	_	_	O
75	)	_	_	O
76	who	_	_	O
77	underwent	_	_	O
78	an	_	_	O
79	open	_	_	O
80	radical	_	_	O
81	retropubic	_	_	O
82	prostatectomy	_	_	O
83	(	_	_	O
84	RRP	_	_	O
85	)	_	_	O
86	at	_	_	O
87	our	_	_	O
88	department	_	_	O
89	of	_	_	O
90	urology	_	_	O
91	were	_	_	O
92	included	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	randomised	_	_	O
97	to	_	_	O
98	start	_	_	O
99	PFME	_	_	O
100	preoperatively	_	_	O
101	and	_	_	O
102	continue	_	_	O
103	postoperatively	_	_	O
104	(	_	_	O
105	active	_	_	O
106	group	_	_	O
107	:	_	_	O
108	A	_	_	O
109	)	_	_	O
110	or	_	_	O
111	to	_	_	O
112	start	_	_	O
113	PFME	_	_	O
114	postoperatively	_	_	O
115	alone	_	_	O
116	(	_	_	O
117	control	_	_	O
118	group	_	_	O
119	:	_	_	O
120	B	_	_	O
121	)	_	_	O
122	.	_	_	O

123	The	_	_	O
124	primary	_	_	O
125	outcome	_	_	O
126	measure	_	_	O
127	was	_	_	O
128	self-reported	_	_	O
129	continence	_	_	O
130	after	_	_	O
131	surgery	_	_	O
132	.	_	_	O

133	Secondary	_	_	O
134	outcome	_	_	O
135	measures	_	_	O
136	were	_	_	O
137	assessed	_	_	O
138	by	_	_	O
139	degree	_	_	O
140	of	_	_	O
141	UI	_	_	O
142	based	_	_	O
143	on	_	_	O
144	a	_	_	O
145	24-h	_	_	O
146	pad	_	_	O
147	test	_	_	O
148	and	_	_	O
149	QoL	_	_	O
150	instruments	_	_	O
151	(	_	_	O
152	International	_	_	O
153	Continence	_	_	O
154	Society	_	_	O
155	[	_	_	O
156	ICS	_	_	O
157	]	_	_	O
158	male	_	_	O
159	short	_	_	O
160	form	_	_	O
161	[	_	_	O
162	SF	_	_	O
163	]	_	_	O
164	)	_	_	O
165	.	_	_	O

166	Of	_	_	O
167	143	_	_	O
168	men	_	_	O
169	evaluated	_	_	O
170	for	_	_	O
171	the	_	_	O
172	study	_	_	O
173	,	_	_	O
174	118	_	_	O
175	were	_	_	O
176	randomised	_	_	O
177	either	_	_	O
178	to	_	_	O
179	start	_	_	O
180	PFME	_	_	O
181	preoperatively	_	_	O
182	and	_	_	O
183	continue	_	_	O
184	postoperatively	_	_	O
185	(	_	_	O
186	group	_	_	O
187	A	_	_	O
188	;	_	_	O
189	n=59	_	_	O
190	)	_	_	O
191	or	_	_	O
192	to	_	_	O
193	start	_	_	O
194	postoperative	_	_	O
195	PFME	_	_	O
196	(	_	_	O
197	group	_	_	O
198	B	_	_	O
199	;	_	_	O
200	n=59	_	_	O
201	)	_	_	O
202	.	_	_	O

203	After	_	_	B-Premise
204	1	_	_	I-Premise
205	mo	_	_	I-Premise
206	,	_	_	I-Premise
207	44.1	_	_	I-Premise
208	%	_	_	I-Premise
209	(	_	_	I-Premise
210	26	_	_	I-Premise
211	of	_	_	I-Premise
212	59	_	_	I-Premise
213	)	_	_	I-Premise
214	of	_	_	I-Premise
215	patients	_	_	I-Premise
216	were	_	_	I-Premise
217	continent	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	A	_	_	I-Premise
221	,	_	_	I-Premise
222	while	_	_	I-Premise
223	20.3	_	_	I-Premise
224	%	_	_	I-Premise
225	(	_	_	I-Premise
226	12	_	_	I-Premise
227	of	_	_	I-Premise
228	59	_	_	I-Premise
229	)	_	_	I-Premise
230	were	_	_	I-Premise
231	continent	_	_	I-Premise
232	in	_	_	I-Premise
233	group	_	_	I-Premise
234	B	_	_	I-Premise
235	(	_	_	I-Premise
236	p=0.018	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	At	_	_	B-Premise
240	3	_	_	I-Premise
241	mo	_	_	I-Premise
242	,	_	_	I-Premise
243	59.3	_	_	I-Premise
244	%	_	_	I-Premise
245	(	_	_	I-Premise
246	35	_	_	I-Premise
247	of	_	_	I-Premise
248	59	_	_	I-Premise
249	)	_	_	I-Premise
250	and	_	_	I-Premise
251	37.3	_	_	I-Premise
252	%	_	_	I-Premise
253	(	_	_	I-Premise
254	22	_	_	I-Premise
255	of	_	_	I-Premise
256	59	_	_	I-Premise
257	)	_	_	I-Premise
258	patients	_	_	I-Premise
259	were	_	_	I-Premise
260	continent	_	_	I-Premise
261	in	_	_	I-Premise
262	group	_	_	I-Premise
263	A	_	_	I-Premise
264	and	_	_	I-Premise
265	group	_	_	I-Premise
266	B	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	(	_	_	I-Premise
270	p=0.028	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	ICS	_	_	I-Premise
275	male	_	_	I-Premise
276	SF	_	_	I-Premise
277	mean	_	_	I-Premise
278	score	_	_	I-Premise
279	showed	_	_	I-Premise
280	better	_	_	I-Premise
281	results	_	_	I-Premise
282	in	_	_	I-Premise
283	group	_	_	I-Premise
284	A	_	_	I-Premise
285	than	_	_	I-Premise
286	in	_	_	I-Premise
287	group	_	_	I-Premise
288	B	_	_	I-Premise
289	patients	_	_	I-Premise
290	at	_	_	I-Premise
291	both	_	_	I-Premise
292	1	_	_	I-Premise
293	mo	_	_	I-Premise
294	(	_	_	I-Premise
295	14.6	_	_	I-Premise
296	vs	_	_	I-Premise
297	18.3	_	_	I-Premise
298	)	_	_	I-Premise
299	and	_	_	I-Premise
300	3	_	_	I-Premise
301	mo	_	_	I-Premise
302	(	_	_	I-Premise
303	8.1	_	_	I-Premise
304	vs	_	_	I-Premise
305	12.2	_	_	I-Premise
306	)	_	_	I-Premise
307	after	_	_	I-Premise
308	RP	_	_	I-Premise
309	(	_	_	I-Premise
310	p=0.002	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	In	_	_	B-Premise
314	age-adjusted	_	_	I-Premise
315	logistic	_	_	I-Premise
316	regression	_	_	I-Premise
317	analyses	_	_	I-Premise
318	,	_	_	I-Premise
319	patients	_	_	I-Premise
320	who	_	_	I-Premise
321	performed	_	_	I-Premise
322	preoperative	_	_	I-Premise
323	PFME	_	_	I-Premise
324	had	_	_	I-Premise
325	a	_	_	I-Premise
326	0.41-fold	_	_	I-Premise
327	lower	_	_	I-Premise
328	risk	_	_	I-Premise
329	of	_	_	I-Premise
330	being	_	_	I-Premise
331	incontinent	_	_	I-Premise
332	1	_	_	I-Premise
333	mo	_	_	I-Premise
334	after	_	_	I-Premise
335	RP	_	_	I-Premise
336	and	_	_	I-Premise
337	a	_	_	I-Premise
338	0.38-fold	_	_	I-Premise
339	lower	_	_	I-Premise
340	risk	_	_	I-Premise
341	of	_	_	I-Premise
342	being	_	_	I-Premise
343	incontinent	_	_	I-Premise
344	3	_	_	I-Premise
345	mo	_	_	I-Premise
346	after	_	_	I-Premise
347	RP	_	_	I-Premise
348	(	_	_	I-Premise
349	pâ‰¤0.001	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	Preoperative	_	_	B-Claim
353	PFME	_	_	I-Claim
354	may	_	_	I-Claim
355	improve	_	_	I-Claim
356	early	_	_	I-Claim
357	continence	_	_	I-Claim
358	and	_	_	I-Claim
359	QoL	_	_	I-Claim
360	outcomes	_	_	I-Claim
361	after	_	_	I-Claim
362	RP	_	_	I-Claim
363	.	_	_	I-Claim

364	Further	_	_	B-Claim
365	studies	_	_	I-Claim
366	are	_	_	I-Claim
367	needed	_	_	I-Claim
368	to	_	_	I-Claim
369	corroborate	_	_	I-Claim
370	our	_	_	I-Claim
371	results	_	_	I-Claim
372	.	_	_	I-Claim


0	The	_	_	O
1	role	_	_	O
2	of	_	_	O
3	chemotherapy	_	_	O
4	for	_	_	O
5	advanced	_	_	O
6	NSCLC	_	_	O
7	patients	_	_	O
8	and	_	_	O
9	ECOG	_	_	O
10	PS2	_	_	O
11	remains	_	_	O
12	controversial	_	_	O
13	.	_	_	O

14	We	_	_	O
15	evaluated	_	_	O
16	4	_	_	O
17	doses	_	_	O
18	of	_	_	O
19	3-weekly	_	_	O
20	docetaxel	_	_	O
21	to	_	_	O
22	identify	_	_	O
23	a	_	_	O
24	less	_	_	O
25	toxic	_	_	O
26	,	_	_	O
27	clinically	_	_	O
28	effective	_	_	O
29	dose	_	_	O
30	.	_	_	O

31	Seventy-three	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	stage	_	_	O
35	III	_	_	O
36	(	_	_	O
37	22	_	_	O
38	%	_	_	O
39	)	_	_	O
40	(	_	_	O
41	unsuitable	_	_	O
42	for	_	_	O
43	radical	_	_	O
44	surgery/radiotherapy	_	_	O
45	)	_	_	O
46	and	_	_	O
47	IV	_	_	O
48	(	_	_	O
49	78	_	_	O
50	%	_	_	O
51	)	_	_	O
52	NSCLC	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	4	_	_	O
58	doses	_	_	O
59	of	_	_	O
60	3-weekly	_	_	O
61	docetaxel	_	_	O
62	,	_	_	O
63	for	_	_	O
64	4	_	_	O
65	cycles	_	_	O
66	:	_	_	O
67	arm	_	_	O
68	(	_	_	O
69	A	_	_	O
70	)	_	_	O
71	40	_	_	O
72	mg/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	(	_	_	O
77	n=17	_	_	O
78	)	_	_	O
79	,	_	_	O
80	arm	_	_	O
81	(	_	_	O
82	B	_	_	O
83	)	_	_	O
84	50	_	_	O
85	mg/m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n=17	_	_	O
91	)	_	_	O
92	,	_	_	O
93	arm	_	_	O
94	(	_	_	O
95	C	_	_	O
96	)	_	_	O
97	60	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	(	_	_	O
103	n=19	_	_	O
104	)	_	_	O
105	,	_	_	O
106	arm	_	_	O
107	(	_	_	O
108	D	_	_	O
109	)	_	_	O
110	50	_	_	O
111	mg/m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	escalated	_	_	O
116	by	_	_	O
117	10	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	to	_	_	O
123	a	_	_	O
124	maximum	_	_	O
125	of	_	_	O
126	70	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	(	_	_	O
132	n=19	_	_	O
133	)	_	_	O
134	.	_	_	O

135	Primary	_	_	O
136	endpoints	_	_	O
137	:	_	_	O
138	maximum	_	_	O
139	tolerated	_	_	O
140	dose	_	_	O
141	,	_	_	O
142	RR	_	_	O
143	,	_	_	O
144	duration	_	_	O
145	of	_	_	O
146	response	_	_	O
147	,	_	_	O
148	symptom	_	_	O
149	improvement	_	_	O
150	,	_	_	O
151	toxicity	_	_	O
152	and	_	_	O
153	QoL	_	_	O
154	.	_	_	O

155	Secondary	_	_	O
156	endpoint	_	_	O
157	:	_	_	O
158	overall	_	_	O
159	survival	_	_	O
160	(	_	_	O
161	OS	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Patients	_	_	O
165	and	_	_	O
166	disease	_	_	O
167	characteristics	_	_	O
168	were	_	_	O
169	well	_	_	O
170	balanced	_	_	O
171	.	_	_	O

172	Median	_	_	O
173	age	_	_	O
174	was	_	_	O
175	67	_	_	O
176	(	_	_	O
177	range	_	_	O
178	45-81	_	_	O
179	)	_	_	O
180	,	_	_	O
181	there	_	_	O
182	were	_	_	O
183	32	_	_	O
184	male	_	_	O
185	and	_	_	O
186	41	_	_	O
187	female	_	_	O
188	,	_	_	O
189	histology	_	_	O
190	subtype	_	_	O
191	:	_	_	O
192	squamous/adenocarcinoma/mixed/NOS=42	_	_	O
193	%	_	_	O
194	/49	_	_	O
195	%	_	_	O
196	/4	_	_	O
197	%	_	_	O
198	/5	_	_	O
199	%	_	_	O
200	.	_	_	O

201	Seven	_	_	O
202	patients	_	_	O
203	did	_	_	O
204	not	_	_	O
205	receive	_	_	O
206	any	_	_	O
207	treatment	_	_	O
208	because	_	_	O
209	of	_	_	O
210	deterioration	_	_	O
211	in	_	_	O
212	PS	_	_	O
213	or	_	_	O
214	death	_	_	O
215	.	_	_	O

216	50	_	_	O
217	%	_	_	O
218	of	_	_	O
219	patients	_	_	O
220	in	_	_	O
221	arm	_	_	O
222	D	_	_	O
223	,	_	_	O
224	who	_	_	O
225	received	_	_	O
226	more	_	_	O
227	than	_	_	O
228	one	_	_	O
229	cycle	_	_	O
230	,	_	_	O
231	received	_	_	O
232	dose	_	_	O
233	escalation	_	_	O
234	.	_	_	O

235	There	_	_	B-Premise
236	was	_	_	I-Premise
237	no	_	_	I-Premise
238	statistical	_	_	I-Premise
239	difference	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	number	_	_	I-Premise
243	of	_	_	I-Premise
244	cycles	_	_	I-Premise
245	administered	_	_	I-Premise
246	(	_	_	I-Premise
247	arms	_	_	I-Premise
248	A	_	_	I-Premise
249	,	_	_	I-Premise
250	B	_	_	I-Premise
251	and	_	_	I-Premise
252	D	_	_	I-Premise
253	:	_	_	I-Premise
254	median	_	_	I-Premise
255	2	_	_	I-Premise
256	cycles	_	_	I-Premise
257	and	_	_	I-Premise
258	arm	_	_	I-Premise
259	C	_	_	I-Premise
260	:	_	_	I-Premise
261	median	_	_	I-Premise
262	3	_	_	I-Premise
263	cycles	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	no	_	_	I-Premise
267	difference	_	_	I-Premise
268	in	_	_	I-Premise
269	RR	_	_	I-Premise
270	:	_	_	I-Premise
271	arm	_	_	I-Premise
272	A=6	_	_	I-Premise
273	%	_	_	I-Premise
274	,	_	_	I-Premise
275	arm	_	_	I-Premise
276	B=6	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	arm	_	_	I-Premise
280	C=10	_	_	I-Premise
281	%	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	arm	_	_	I-Premise
285	D=0	_	_	I-Premise
286	%	_	_	I-Premise
287	.	_	_	I-Premise

288	There	_	_	B-Premise
289	was	_	_	I-Premise
290	no	_	_	I-Premise
291	statistically	_	_	I-Premise
292	significant	_	_	I-Premise
293	difference	_	_	I-Premise
294	in	_	_	I-Premise
295	grade	_	_	I-Premise
296	3/4	_	_	I-Premise
297	neutropenia	_	_	I-Premise
298	and	_	_	I-Premise
299	thrombocytopenia	_	_	I-Premise
300	between	_	_	I-Premise
301	the	_	_	I-Premise
302	four	_	_	I-Premise
303	arms	_	_	I-Premise
304	.	_	_	I-Premise

305	No	_	_	B-Premise
306	difference	_	_	I-Premise
307	was	_	_	I-Premise
308	observed	_	_	I-Premise
309	in	_	_	I-Premise
310	hospitalization	_	_	I-Premise
311	rate	_	_	I-Premise
312	,	_	_	I-Premise
313	blood	_	_	I-Premise
314	transfusions	_	_	I-Premise
315	,	_	_	I-Premise
316	antibiotics	_	_	I-Premise
317	administration	_	_	I-Premise
318	and	_	_	I-Premise
319	non-haematological	_	_	I-Premise
320	toxicity	_	_	I-Premise
321	.	_	_	I-Premise

322	QoL	_	_	O
323	:	_	_	O
324	no	_	_	O
325	difference	_	_	O
326	in	_	_	O
327	total	_	_	O
328	scores	_	_	O
329	between	_	_	O
330	baseline	_	_	O
331	and	_	_	O
332	cycles	_	_	O
333	1-4	_	_	O
334	.	_	_	O

335	There	_	_	B-Premise
336	was	_	_	I-Premise
337	a	_	_	I-Premise
338	significant	_	_	I-Premise
339	decrease	_	_	I-Premise
340	in	_	_	I-Premise
341	pain	_	_	I-Premise
342	scores	_	_	I-Premise
343	from	_	_	I-Premise
344	baseline	_	_	I-Premise
345	to	_	_	I-Premise
346	post	_	_	I-Premise
347	cycles	_	_	I-Premise
348	2	_	_	I-Premise
349	and	_	_	I-Premise
350	3	_	_	I-Premise
351	(	_	_	I-Premise
352	p=0.025	_	_	I-Premise
353	and	_	_	I-Premise
354	p=0.002	_	_	I-Premise
355	,	_	_	I-Premise
356	respectively	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	There	_	_	B-Premise
360	was	_	_	I-Premise
361	no	_	_	I-Premise
362	difference	_	_	I-Premise
363	in	_	_	I-Premise
364	OS	_	_	I-Premise
365	(	_	_	I-Premise
366	p=0.992	_	_	I-Premise
367	)	_	_	I-Premise
368	.	_	_	I-Premise

369	Median	_	_	B-Premise
370	survival	_	_	I-Premise
371	and	_	_	I-Premise
372	6-month	_	_	I-Premise
373	survival	_	_	I-Premise
374	were	_	_	I-Premise
375	61	_	_	I-Premise
376	,	_	_	I-Premise
377	86	_	_	I-Premise
378	,	_	_	I-Premise
379	88	_	_	I-Premise
380	and	_	_	I-Premise
381	97	_	_	I-Premise
382	days	_	_	I-Premise
383	and	_	_	I-Premise
384	29	_	_	I-Premise
385	%	_	_	I-Premise
386	,	_	_	I-Premise
387	33	_	_	I-Premise
388	%	_	_	I-Premise
389	,	_	_	I-Premise
390	21	_	_	I-Premise
391	%	_	_	I-Premise
392	and	_	_	I-Premise
393	26	_	_	I-Premise
394	%	_	_	I-Premise
395	for	_	_	I-Premise
396	arms	_	_	I-Premise
397	A	_	_	I-Premise
398	,	_	_	I-Premise
399	B	_	_	I-Premise
400	,	_	_	I-Premise
401	C	_	_	I-Premise
402	,	_	_	I-Premise
403	and	_	_	I-Premise
404	D	_	_	I-Premise
405	,	_	_	I-Premise
406	respectively	_	_	I-Premise
407	.	_	_	I-Premise

408	Clinical	_	_	B-Claim
409	efficacy	_	_	I-Claim
410	of	_	_	I-Claim
411	docetaxel	_	_	I-Claim
412	was	_	_	I-Claim
413	observed	_	_	I-Claim
414	at	_	_	I-Claim
415	all	_	_	I-Claim
416	dose	_	_	I-Claim
417	levels	_	_	I-Claim
418	.	_	_	I-Claim

419	Higher	_	_	B-Claim
420	dose	_	_	I-Claim
421	levels	_	_	I-Claim
422	were	_	_	I-Claim
423	not	_	_	I-Claim
424	associated	_	_	I-Claim
425	with	_	_	I-Claim
426	increased	_	_	I-Claim
427	toxicities	_	_	I-Claim
428	,	_	_	I-Claim
429	use	_	_	I-Claim
430	of	_	_	I-Claim
431	IV	_	_	I-Claim
432	antibiotics	_	_	I-Claim
433	or	_	_	I-Claim
434	hospitalization	_	_	I-Claim
435	rates	_	_	I-Claim
436	.	_	_	I-Claim

437	However	_	_	O
438	,	_	_	O
439	the	_	_	B-Premise
440	median	_	_	I-Premise
441	survival	_	_	I-Premise
442	observed	_	_	I-Premise
443	is	_	_	I-Premise
444	shorter	_	_	I-Premise
445	than	_	_	I-Premise
446	historical	_	_	I-Premise
447	data	_	_	I-Premise
448	and	_	_	I-Premise
449	do	_	_	I-Premise
450	not	_	_	I-Premise
451	support	_	_	I-Premise
452	further	_	_	I-Premise
453	evaluation	_	_	I-Premise
454	of	_	_	I-Premise
455	these	_	_	I-Premise
456	doses	_	_	I-Premise
457	of	_	_	I-Premise
458	single	_	_	I-Premise
459	agent	_	_	I-Premise
460	docetaxel	_	_	I-Premise
461	in	_	_	I-Premise
462	this	_	_	I-Premise
463	population	_	_	I-Premise
464	.	_	_	I-Premise


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	are	_	_	O
3	indicated	_	_	O
4	for	_	_	O
5	symptom	_	_	O
6	control	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastroenteropancreatic	_	_	O
11	neuroendocrine	_	_	O
12	tumors	_	_	O
13	(	_	_	O
14	NETs	_	_	O
15	)	_	_	O
16	.	_	_	O

17	The	_	_	O
18	ability	_	_	O
19	of	_	_	O
20	somatostatin	_	_	O
21	analogs	_	_	O
22	to	_	_	O
23	control	_	_	O
24	the	_	_	O
25	growth	_	_	O
26	of	_	_	O
27	well-differentiated	_	_	O
28	metastatic	_	_	O
29	NETs	_	_	O
30	is	_	_	O
31	a	_	_	O
32	matter	_	_	O
33	of	_	_	O
34	debate	_	_	O
35	.	_	_	O

36	We	_	_	O
37	performed	_	_	O
38	a	_	_	O
39	placebo-controlled	_	_	O
40	,	_	_	O
41	double-blind	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	IIIB	_	_	O
45	study	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	well-differentiated	_	_	O
50	metastatic	_	_	O
51	midgut	_	_	O
52	NETs	_	_	O
53	.	_	_	O

54	The	_	_	O
55	hypothesis	_	_	O
56	was	_	_	O
57	that	_	_	O
58	octreotide	_	_	O
59	LAR	_	_	O
60	prolongs	_	_	O
61	time	_	_	O
62	to	_	_	O
63	tumor	_	_	O
64	progression	_	_	O
65	and	_	_	O
66	survival	_	_	O
67	.	_	_	O

68	Treatment-naive	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	either	_	_	O
75	placebo	_	_	O
76	or	_	_	O
77	octreotide	_	_	O
78	LAR	_	_	O
79	30	_	_	O
80	mg	_	_	O
81	intramuscularly	_	_	O
82	in	_	_	O
83	monthly	_	_	O
84	intervals	_	_	O
85	until	_	_	O
86	tumor	_	_	O
87	progression	_	_	O
88	or	_	_	O
89	death	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	efficacy	_	_	O
94	end	_	_	O
95	point	_	_	O
96	was	_	_	O
97	time	_	_	O
98	to	_	_	O
99	tumor	_	_	O
100	progression	_	_	O
101	.	_	_	O

102	Secondary	_	_	O
103	end	_	_	O
104	points	_	_	O
105	were	_	_	O
106	survival	_	_	O
107	time	_	_	O
108	and	_	_	O
109	tumor	_	_	O
110	response	_	_	O
111	.	_	_	O

112	This	_	_	O
113	report	_	_	O
114	is	_	_	O
115	based	_	_	O
116	on	_	_	O
117	67	_	_	O
118	tumor	_	_	O
119	progressions	_	_	O
120	and	_	_	O
121	16	_	_	O
122	observed	_	_	O
123	deaths	_	_	O
124	in	_	_	O
125	85	_	_	O
126	patients	_	_	O
127	at	_	_	O
128	the	_	_	O
129	time	_	_	O
130	of	_	_	O
131	the	_	_	O
132	planned	_	_	O
133	interim	_	_	O
134	analysis	_	_	O
135	.	_	_	O

136	Median	_	_	B-Premise
137	time	_	_	I-Premise
138	to	_	_	I-Premise
139	tumor	_	_	I-Premise
140	progression	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	octreotide	_	_	I-Premise
144	LAR	_	_	I-Premise
145	and	_	_	I-Premise
146	placebo	_	_	I-Premise
147	groups	_	_	I-Premise
148	was	_	_	I-Premise
149	14.3	_	_	I-Premise
150	and	_	_	I-Premise
151	6	_	_	I-Premise
152	months	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	(	_	_	I-Premise
156	hazard	_	_	I-Premise
157	ratio	_	_	I-Premise
158	[	_	_	I-Premise
159	HR	_	_	I-Premise
160	]	_	_	I-Premise
161	=	_	_	I-Premise
162	0.34	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	CI	_	_	I-Premise
167	,	_	_	I-Premise
168	0.20	_	_	I-Premise
169	to	_	_	I-Premise
170	0.59	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.000072	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	After	_	_	B-Premise
178	6	_	_	I-Premise
179	months	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	,	_	_	I-Premise
183	stable	_	_	I-Premise
184	disease	_	_	I-Premise
185	was	_	_	I-Premise
186	observed	_	_	I-Premise
187	in	_	_	I-Premise
188	66.7	_	_	I-Premise
189	%	_	_	I-Premise
190	of	_	_	I-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	octreotide	_	_	I-Premise
195	LAR	_	_	I-Premise
196	group	_	_	I-Premise
197	and	_	_	I-Premise
198	37.2	_	_	I-Premise
199	%	_	_	I-Premise
200	of	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	placebo	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	Functionally	_	_	O
208	active	_	_	O
209	and	_	_	O
210	inactive	_	_	O
211	tumors	_	_	O
212	responded	_	_	O
213	similarly	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	most	_	_	I-Premise
217	favorable	_	_	I-Premise
218	effect	_	_	I-Premise
219	was	_	_	I-Premise
220	observed	_	_	I-Premise
221	in	_	_	I-Premise
222	patients	_	_	I-Premise
223	with	_	_	I-Premise
224	low	_	_	I-Premise
225	hepatic	_	_	I-Premise
226	tumor	_	_	I-Premise
227	load	_	_	I-Premise
228	and	_	_	I-Premise
229	resected	_	_	I-Premise
230	primary	_	_	I-Premise
231	tumor	_	_	I-Premise
232	.	_	_	I-Premise

233	Seven	_	_	B-Premise
234	and	_	_	I-Premise
235	nine	_	_	I-Premise
236	deaths	_	_	I-Premise
237	were	_	_	I-Premise
238	observed	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	octreotide	_	_	I-Premise
242	LAR	_	_	I-Premise
243	and	_	_	I-Premise
244	placebo	_	_	I-Premise
245	groups	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	HR	_	_	I-Premise
251	for	_	_	I-Premise
252	overall	_	_	I-Premise
253	survival	_	_	I-Premise
254	was	_	_	I-Premise
255	0.81	_	_	I-Premise
256	(	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	,	_	_	I-Premise
261	0.30	_	_	I-Premise
262	to	_	_	I-Premise
263	2.18	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Octreotide	_	_	B-Claim
267	LAR	_	_	I-Claim
268	significantly	_	_	I-Claim
269	lengthens	_	_	I-Claim
270	time	_	_	I-Claim
271	to	_	_	I-Claim
272	tumor	_	_	I-Claim
273	progression	_	_	I-Claim
274	compared	_	_	I-Claim
275	with	_	_	I-Claim
276	placebo	_	_	I-Claim
277	in	_	_	I-Claim
278	patients	_	_	I-Claim
279	with	_	_	I-Claim
280	functionally	_	_	I-Claim
281	active	_	_	I-Claim
282	and	_	_	I-Claim
283	inactive	_	_	I-Claim
284	metastatic	_	_	I-Claim
285	midgut	_	_	I-Claim
286	NETs	_	_	I-Claim
287	.	_	_	I-Claim

288	Because	_	_	B-Premise
289	of	_	_	I-Premise
290	the	_	_	I-Premise
291	low	_	_	I-Premise
292	number	_	_	I-Premise
293	of	_	_	I-Premise
294	observed	_	_	I-Premise
295	deaths	_	_	I-Premise
296	,	_	_	I-Premise
297	survival	_	_	I-Premise
298	analysis	_	_	I-Premise
299	was	_	_	I-Premise
300	not	_	_	I-Premise
301	confirmatory	_	_	I-Premise
302	.	_	_	I-Premise


0	In	_	_	B-Claim
1	the	_	_	I-Claim
2	context	_	_	I-Claim
3	of	_	_	I-Claim
4	chronic	_	_	I-Claim
5	physical	_	_	I-Claim
6	illness	_	_	I-Claim
7	,	_	_	I-Claim
8	such	_	_	I-Claim
9	as	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	depression	_	_	I-Claim
14	is	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	increased	_	_	I-Claim
18	morbidity	_	_	I-Claim
19	,	_	_	I-Claim
20	longer	_	_	I-Claim
21	periods	_	_	I-Claim
22	of	_	_	I-Claim
23	hospitalization	_	_	I-Claim
24	,	_	_	I-Claim
25	and	_	_	I-Claim
26	greater	_	_	I-Claim
27	overall	_	_	I-Claim
28	disability	_	_	I-Claim
29	.	_	_	I-Claim

30	Prompt	_	_	B-Claim
31	diagnosis	_	_	I-Claim
32	and	_	_	I-Claim
33	effective	_	_	I-Claim
34	treatment	_	_	I-Claim
35	is	_	_	I-Claim
36	,	_	_	I-Claim
37	therefore	_	_	I-Claim
38	,	_	_	I-Claim
39	essential	_	_	I-Claim
40	.	_	_	I-Claim

41	Several	_	_	O
42	small	_	_	O
43	studies	_	_	O
44	have	_	_	O
45	established	_	_	O
46	the	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	tricyclic	_	_	O
50	antidepressants	_	_	O
51	(	_	_	O
52	TCAs	_	_	O
53	)	_	_	O
54	in	_	_	O
55	this	_	_	O
56	setting	_	_	O
57	,	_	_	O
58	and	_	_	O
59	the	_	_	O
60	selective	_	_	O
61	serotonin	_	_	O
62	reuptake	_	_	O
63	inhibitors	_	_	O
64	(	_	_	O
65	SSRIs	_	_	O
66	)	_	_	O
67	would	_	_	O
68	appear	_	_	O
69	to	_	_	O
70	be	_	_	O
71	an	_	_	O
72	alternative	_	_	O
73	therapeutic	_	_	O
74	option	_	_	O
75	because	_	_	O
76	of	_	_	O
77	their	_	_	O
78	established	_	_	O
79	efficacy	_	_	O
80	and	_	_	O
81	better	_	_	O
82	tolerability	_	_	O
83	profile	_	_	O
84	.	_	_	O

85	This	_	_	O
86	was	_	_	O
87	a	_	_	O
88	multicenter	_	_	O
89	.	_	_	O

90	double-blind	_	_	O
91	,	_	_	O
92	parallel-group	_	_	O
93	study	_	_	O
94	in	_	_	O
95	which	_	_	O
96	179	_	_	O
97	women	_	_	O
98	with	_	_	O
99	breast	_	_	O
100	cancer	_	_	O
101	were	_	_	O
102	randomized	_	_	O
103	to	_	_	O
104	treatment	_	_	O
105	with	_	_	O
106	either	_	_	O
107	the	_	_	O
108	SSRI	_	_	O
109	paroxetine	_	_	O
110	(	_	_	O
111	20-40	_	_	O
112	mg/day	_	_	O
113	)	_	_	O
114	,	_	_	O
115	or	_	_	O
116	the	_	_	O
117	TCA	_	_	O
118	,	_	_	O
119	amitriptyline	_	_	O
120	(	_	_	O
121	75-150	_	_	O
122	mg/day	_	_	O
123	)	_	_	O
124	.	_	_	O

125	After	_	_	B-Premise
126	8-weeks	_	_	I-Premise
127	treatment	_	_	I-Premise
128	,	_	_	I-Premise
129	depressive	_	_	I-Premise
130	symptomatology	_	_	I-Premise
131	had	_	_	I-Premise
132	improved	_	_	I-Premise
133	markedly	_	_	I-Premise
134	and	_	_	I-Premise
135	to	_	_	I-Premise
136	a	_	_	I-Premise
137	similar	_	_	I-Premise
138	extent	_	_	I-Premise
139	in	_	_	I-Premise
140	both	_	_	I-Premise
141	groups	_	_	I-Premise
142	on	_	_	I-Premise
143	the	_	_	I-Premise
144	Montgomery	_	_	I-Premise
145	Asberg	_	_	I-Premise
146	Depression	_	_	I-Premise
147	Rating	_	_	I-Premise
148	Scale	_	_	I-Premise
149	.	_	_	I-Premise

150	Clinical	_	_	B-Premise
151	global	_	_	I-Premise
152	impression	_	_	I-Premise
153	(	_	_	I-Premise
154	CGI	_	_	I-Premise
155	)	_	_	I-Premise
156	Global	_	_	I-Premise
157	improvement	_	_	I-Premise
158	and	_	_	I-Premise
159	Patient	_	_	I-Premise
160	global	_	_	I-Premise
161	evaluation	_	_	I-Premise
162	scales	_	_	I-Premise
163	indicated	_	_	I-Premise
164	that	_	_	I-Premise
165	patients	_	_	I-Premise
166	were	_	_	I-Premise
167	minimally	_	_	I-Premise
168	to	_	_	I-Premise
169	much	_	_	I-Premise
170	improved	_	_	I-Premise
171	at	_	_	I-Premise
172	study	_	_	I-Premise
173	endpoint	_	_	I-Premise
174	:	_	_	I-Premise
175	a	_	_	I-Premise
176	change	_	_	I-Premise
177	from	_	_	I-Premise
178	moderately/mildly	_	_	I-Premise
179	ill	_	_	I-Premise
180	to	_	_	I-Premise
181	borderline	_	_	I-Premise
182	ill	_	_	I-Premise
183	on	_	_	I-Premise
184	the	_	_	I-Premise
185	CGI	_	_	I-Premise
186	severity	_	_	I-Premise
187	of	_	_	I-Premise
188	Illness	_	_	I-Premise
189	scale	_	_	I-Premise
190	.	_	_	I-Premise

191	A	_	_	B-Claim
192	steady	_	_	I-Claim
193	improvement	_	_	I-Claim
194	in	_	_	I-Claim
195	quality	_	_	I-Claim
196	of	_	_	I-Claim
197	life	_	_	I-Claim
198	was	_	_	I-Claim
199	also	_	_	I-Claim
200	observed	_	_	I-Claim
201	in	_	_	I-Claim
202	both	_	_	I-Claim
203	groups	_	_	I-Claim
204	.	_	_	I-Claim

205	There	_	_	B-Premise
206	were	_	_	I-Premise
207	no	_	_	I-Premise
208	clinically	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	between	_	_	I-Premise
212	the	_	_	I-Premise
213	groups	_	_	I-Premise
214	.	_	_	I-Premise

215	In	_	_	B-Premise
216	total	_	_	I-Premise
217	,	_	_	I-Premise
218	47	_	_	I-Premise
219	(	_	_	I-Premise
220	53.4	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	patients	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	paroxetine	_	_	I-Premise
227	group	_	_	I-Premise
228	and	_	_	I-Premise
229	53	_	_	I-Premise
230	(	_	_	I-Premise
231	59.6	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	patients	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	amitriptyline	_	_	I-Premise
238	group	_	_	I-Premise
239	had	_	_	I-Premise
240	adverse	_	_	I-Premise
241	experiences	_	_	I-Premise
242	,	_	_	I-Premise
243	the	_	_	I-Premise
244	most	_	_	I-Premise
245	common	_	_	I-Premise
246	of	_	_	I-Premise
247	which	_	_	I-Premise
248	were	_	_	I-Premise
249	the	_	_	I-Premise
250	well-recognized	_	_	I-Premise
251	side-effects	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	antidepressant	_	_	I-Premise
255	medications	_	_	I-Premise
256	or	_	_	I-Premise
257	chemotherapy	_	_	I-Premise
258	.	_	_	I-Premise

259	Anticholinergic	_	_	B-Premise
260	effects	_	_	I-Premise
261	were	_	_	I-Premise
262	almost	_	_	I-Premise
263	twice	_	_	I-Premise
264	as	_	_	I-Premise
265	frequent	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	amitriptyline	_	_	I-Premise
269	group	_	_	I-Premise
270	(	_	_	I-Premise
271	19.1	_	_	I-Premise
272	%	_	_	I-Premise
273	)	_	_	I-Premise
274	compared	_	_	I-Premise
275	with	_	_	I-Premise
276	paroxetine	_	_	I-Premise
277	(	_	_	I-Premise
278	11.4	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	This	_	_	O
283	study	_	_	O
284	has	_	_	O
285	demonstrated	_	_	O
286	that	_	_	O
287	paroxetine	_	_	B-Claim
288	is	_	_	I-Claim
289	a	_	_	I-Claim
290	suitable	_	_	I-Claim
291	alternative	_	_	I-Claim
292	to	_	_	I-Claim
293	amitriptyline	_	_	I-Claim
294	for	_	_	I-Claim
295	the	_	_	I-Claim
296	treatment	_	_	I-Claim
297	of	_	_	I-Claim
298	depression	_	_	I-Claim
299	in	_	_	I-Claim
300	patients	_	_	I-Claim
301	with	_	_	I-Claim
302	breast	_	_	I-Claim
303	cancer	_	_	I-Claim
304	.	_	_	I-Claim


0	In	_	_	O
1	anorectal	_	_	O
2	cancer	_	_	O
3	patients	_	_	O
4	,	_	_	O
5	an	_	_	O
6	acute	_	_	O
7	side	_	_	O
8	effect	_	_	O
9	of	_	_	O
10	chemoradiotherapy	_	_	O
11	is	_	_	O
12	gastrointestinal	_	_	O
13	toxicity	_	_	O
14	,	_	_	O
15	which	_	_	O
16	often	_	_	O
17	impedes	_	_	O
18	treatment	_	_	O
19	delivery	_	_	O
20	.	_	_	O

21	Based	_	_	O
22	on	_	_	O
23	previous	_	_	O
24	trials	_	_	O
25	,	_	_	O
26	octreotide	_	_	O
27	acetate	_	_	O
28	is	_	_	O
29	widely	_	_	O
30	recommended	_	_	O
31	for	_	_	O
32	the	_	_	O
33	control	_	_	O
34	of	_	_	O
35	chemotherapy-induced	_	_	O
36	diarrhea	_	_	O
37	.	_	_	O

38	However	_	_	O
39	,	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	of	_	_	O
43	octreotide	_	_	O
44	in	_	_	O
45	preventing	_	_	O
46	or	_	_	O
47	controlling	_	_	O
48	radiation-	_	_	O
49	and	_	_	O
50	chemoradiation-induced	_	_	O
51	diarrhea	_	_	O
52	is	_	_	O
53	not	_	_	O
54	known	_	_	O
55	.	_	_	O

56	A	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	double-blinded	_	_	O
60	,	_	_	O
61	placebo-controlled	_	_	O
62	trial	_	_	O
63	was	_	_	O
64	designed	_	_	O
65	to	_	_	O
66	determine	_	_	O
67	the	_	_	O
68	efficacy	_	_	O
69	of	_	_	O
70	long-acting	_	_	O
71	octreotide	_	_	O
72	acetate	_	_	O
73	(	_	_	O
74	LAO	_	_	O
75	)	_	_	O
76	in	_	_	O
77	preventing	_	_	O
78	the	_	_	O
79	onset	_	_	O
80	of	_	_	O
81	acute	_	_	O
82	diarrhea	_	_	O
83	in	_	_	O
84	patients	_	_	O
85	undergoing	_	_	O
86	chemoradiation	_	_	O
87	therapy	_	_	O
88	for	_	_	O
89	rectal	_	_	O
90	or	_	_	O
91	anal	_	_	O
92	cancer	_	_	O
93	.	_	_	O

94	Between	_	_	O
95	4	_	_	O
96	and	_	_	O
97	7	_	_	O
98	days	_	_	O
99	before	_	_	O
100	the	_	_	O
101	start	_	_	O
102	of	_	_	O
103	radiation	_	_	O
104	therapy	_	_	O
105	,	_	_	O
106	patients	_	_	O
107	received	_	_	O
108	a	_	_	O
109	30-mg	_	_	O
110	dose	_	_	O
111	of	_	_	O
112	LAO	_	_	O
113	(	_	_	O
114	109	_	_	O
115	patients	_	_	O
116	)	_	_	O
117	or	_	_	O
118	placebo	_	_	O
119	(	_	_	O
120	106	_	_	O
121	patients	_	_	O
122	)	_	_	O
123	via	_	_	O
124	intramuscular	_	_	O
125	injection	_	_	O
126	.	_	_	O

127	A	_	_	O
128	second	_	_	O
129	dose	_	_	O
130	was	_	_	O
131	given	_	_	O
132	on	_	_	O
133	day	_	_	O
134	22	_	_	O
135	(	_	_	O
136	+/-3	_	_	O
137	days	_	_	O
138	)	_	_	O
139	of	_	_	O
140	radiation	_	_	O
141	treatment	_	_	O
142	.	_	_	O

143	A	_	_	O
144	total	_	_	O
145	of	_	_	O
146	215	_	_	O
147	patients	_	_	O
148	were	_	_	O
149	included	_	_	O
150	in	_	_	O
151	the	_	_	O
152	final	_	_	O
153	analysis	_	_	O
154	.	_	_	O

155	The	_	_	O
156	primary	_	_	O
157	endpoint	_	_	O
158	was	_	_	O
159	the	_	_	O
160	incidence	_	_	O
161	of	_	_	O
162	grade	_	_	O
163	2-4	_	_	O
164	acute	_	_	O
165	diarrhea	_	_	O
166	;	_	_	O
167	secondary	_	_	O
168	endpoints	_	_	O
169	included	_	_	O
170	treatment	_	_	O
171	compliance	_	_	O
172	,	_	_	O
173	medical	_	_	O
174	resource	_	_	O
175	utilization	_	_	O
176	,	_	_	O
177	patient-reported	_	_	O
178	bowel	_	_	O
179	function	_	_	O
180	,	_	_	O
181	and	_	_	O
182	quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	(	_	_	O
186	QoL	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Statistical	_	_	O
190	tests	_	_	O
191	were	_	_	O
192	one-	_	_	O
193	or	_	_	O
194	two-sided	_	_	O
195	,	_	_	O
196	as	_	_	O
197	specified	_	_	O
198	.	_	_	O

199	After	_	_	B-Premise
200	a	_	_	I-Premise
201	median	_	_	I-Premise
202	follow-up	_	_	I-Premise
203	time	_	_	I-Premise
204	of	_	_	I-Premise
205	9.64	_	_	I-Premise
206	months	_	_	I-Premise
207	,	_	_	I-Premise
208	incidence	_	_	I-Premise
209	rates	_	_	I-Premise
210	of	_	_	I-Premise
211	grades	_	_	I-Premise
212	2-4	_	_	I-Premise
213	acute	_	_	I-Premise
214	diarrhea	_	_	I-Premise
215	were	_	_	I-Premise
216	similar	_	_	I-Premise
217	in	_	_	I-Premise
218	both	_	_	I-Premise
219	groups	_	_	I-Premise
220	(	_	_	I-Premise
221	49	_	_	I-Premise
222	%	_	_	I-Premise
223	placebo	_	_	I-Premise
224	vs	_	_	I-Premise
225	44	_	_	I-Premise
226	%	_	_	I-Premise
227	LAO	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.21	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	statistically	_	_	I-Premise
236	significant	_	_	I-Premise
237	treatment	_	_	I-Premise
238	differences	_	_	I-Premise
239	in	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	or	_	_	I-Premise
242	radiation	_	_	I-Premise
243	delivery	_	_	I-Premise
244	,	_	_	I-Premise
245	medical	_	_	I-Premise
246	resource	_	_	I-Premise
247	utilization	_	_	I-Premise
248	,	_	_	I-Premise
249	patient-reported	_	_	I-Premise
250	bowel	_	_	I-Premise
251	function	_	_	I-Premise
252	,	_	_	I-Premise
253	or	_	_	I-Premise
254	QoL	_	_	I-Premise
255	were	_	_	I-Premise
256	observed	_	_	I-Premise
257	.	_	_	I-Premise

258	In	_	_	B-Claim
259	this	_	_	I-Claim
260	study	_	_	I-Claim
261	,	_	_	I-Claim
262	the	_	_	I-Claim
263	prophylactic	_	_	I-Claim
264	use	_	_	I-Claim
265	of	_	_	I-Claim
266	LAO	_	_	I-Claim
267	did	_	_	I-Claim
268	not	_	_	I-Claim
269	prevent	_	_	I-Claim
270	the	_	_	I-Claim
271	incidence	_	_	I-Claim
272	or	_	_	I-Claim
273	reduce	_	_	I-Claim
274	the	_	_	I-Claim
275	severity	_	_	I-Claim
276	of	_	_	I-Claim
277	diarrhea	_	_	I-Claim
278	and	_	_	I-Claim
279	had	_	_	I-Claim
280	no	_	_	I-Claim
281	notable	_	_	I-Claim
282	impact	_	_	I-Claim
283	on	_	_	I-Claim
284	patient-reported	_	_	I-Claim
285	bowel	_	_	I-Claim
286	function	_	_	I-Claim
287	or	_	_	I-Claim
288	QoL	_	_	I-Claim
289	.	_	_	I-Claim


0	A	_	_	O
1	significant	_	_	O
2	proportion	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	develop	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	early	_	_	O
9	after	_	_	O
10	radical	_	_	O
11	prostatectomy	_	_	O
12	.	_	_	O

13	Posterior	_	_	O
14	reconstruction	_	_	O
15	of	_	_	O
16	supporting	_	_	O
17	tissues	_	_	O
18	has	_	_	O
19	been	_	_	O
20	found	_	_	O
21	to	_	_	O
22	reduce	_	_	O
23	incontinence	_	_	O
24	in	_	_	O
25	open	_	_	O
26	and	_	_	O
27	conventional	_	_	O
28	laparoscopic	_	_	O
29	prostatectomy	_	_	O
30	series	_	_	O
31	.	_	_	O

32	To	_	_	O
33	investigate	_	_	O
34	whether	_	_	O
35	our	_	_	O
36	version	_	_	O
37	of	_	_	O
38	a	_	_	O
39	posterior	_	_	O
40	musculofascial	_	_	O
41	reconstruction	_	_	O
42	will	_	_	O
43	reduce	_	_	O
44	early	_	_	O
45	incontinence	_	_	O
46	and	_	_	O
47	have	_	_	O
48	a	_	_	O
49	beneficial	_	_	O
50	effect	_	_	O
51	on	_	_	O
52	patients	_	_	O
53	'	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	(	_	_	O
58	QoL	_	_	O
59	)	_	_	O
60	.	_	_	O

61	One	_	_	O
62	hundred	_	_	O
63	seven	_	_	O
64	consecutive	_	_	O
65	patients	_	_	O
66	undergoing	_	_	O
67	primary	_	_	O
68	robot-assisted	_	_	O
69	radical	_	_	O
70	laparoscopic	_	_	O
71	prostatectomy	_	_	O
72	(	_	_	O
73	RALP	_	_	O
74	)	_	_	O
75	performed	_	_	O
76	by	_	_	O
77	a	_	_	O
78	single	_	_	O
79	surgeon	_	_	O
80	at	_	_	O
81	one	_	_	O
82	tertiary	_	_	O
83	referral	_	_	O
84	oncology	_	_	O
85	institution	_	_	O
86	were	_	_	O
87	alternately	_	_	O
88	assigned	_	_	O
89	(	_	_	O
90	not	_	_	O
91	randomised	_	_	O
92	)	_	_	O
93	to	_	_	O
94	intervention	_	_	O
95	(	_	_	O
96	n=53	_	_	O
97	)	_	_	O
98	or	_	_	O
99	control	_	_	O
100	groups	_	_	O
101	(	_	_	O
102	n=54	_	_	O
103	)	_	_	O
104	.	_	_	O

105	RALP	_	_	O
106	with	_	_	O
107	median	_	_	O
108	fibrous	_	_	O
109	raphe	_	_	O
110	reconstruction	_	_	O
111	(	_	_	O
112	MFRR	_	_	O
113	)	_	_	O
114	followed	_	_	O
115	by	_	_	O
116	formation	_	_	O
117	of	_	_	O
118	the	_	_	O
119	urethrovesical	_	_	O
120	anastomosis	_	_	O
121	(	_	_	O
122	intervention	_	_	O
123	group	_	_	O
124	)	_	_	O
125	versus	_	_	O
126	standard	_	_	O
127	anastomosis	_	_	O
128	without	_	_	O
129	posterior	_	_	O
130	reconstruction	_	_	O
131	(	_	_	O
132	control	_	_	O
133	group	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Measurements	_	_	O
137	included	_	_	O
138	incontinence	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	and	_	_	O
142	3-mo	_	_	O
143	intervals	_	_	O
144	;	_	_	O
145	QoL	_	_	O
146	as	_	_	O
147	measured	_	_	O
148	by	_	_	O
149	a	_	_	O
150	simple	_	_	O
151	questionnaire	_	_	O
152	,	_	_	O
153	the	_	_	O
154	European	_	_	O
155	Organisation	_	_	O
156	for	_	_	O
157	Research	_	_	O
158	and	_	_	O
159	Treatment	_	_	O
160	of	_	_	O
161	Cancer	_	_	O
162	(	_	_	O
163	EORTC	_	_	O
164	)	_	_	O
165	Quality	_	_	O
166	of	_	_	O
167	Life-Core	_	_	O
168	30	_	_	O
169	(	_	_	O
170	QLQ-C30	_	_	O
171	)	_	_	O
172	,	_	_	O
173	and	_	_	O
174	Prostate	_	_	O
175	Cancer	_	_	O
176	Module	_	_	O
177	(	_	_	O
178	PR25	_	_	O
179	)	_	_	O
180	questionnaires	_	_	O
181	preoperatively	_	_	O
182	and	_	_	O
183	at	_	_	O
184	6	_	_	O
185	mo	_	_	O
186	postprocedure	_	_	O
187	;	_	_	O
188	tumour	_	_	O
189	characteristics	_	_	O
190	;	_	_	O
191	operative	_	_	O
192	time	_	_	O
193	;	_	_	O
194	fascial	_	_	O
195	preservation	_	_	O
196	score	_	_	O
197	;	_	_	O
198	duration	_	_	O
199	of	_	_	O
200	catheterisation	_	_	O
201	;	_	_	O
202	and	_	_	O
203	anastomotic	_	_	O
204	leakage	_	_	O
205	on	_	_	O
206	cystogram	_	_	O
207	.	_	_	O

208	For	_	_	B-Premise
209	intervention	_	_	I-Premise
210	and	_	_	I-Premise
211	control	_	_	I-Premise
212	groups	_	_	I-Premise
213	respectively	_	_	I-Premise
214	,	_	_	I-Premise
215	mean	_	_	I-Premise
216	catheter	_	_	I-Premise
217	duration	_	_	I-Premise
218	was	_	_	I-Premise
219	11.74	_	_	I-Premise
220	d	_	_	I-Premise
221	and	_	_	I-Premise
222	12.74	_	_	I-Premise
223	d	_	_	I-Premise
224	(	_	_	I-Premise
225	p=0.451	_	_	I-Premise
226	)	_	_	I-Premise
227	;	_	_	I-Premise
228	leakage	_	_	I-Premise
229	on	_	_	I-Premise
230	cystogram	_	_	I-Premise
231	was	_	_	I-Premise
232	present	_	_	I-Premise
233	in	_	_	I-Premise
234	six	_	_	I-Premise
235	and	_	_	I-Premise
236	eight	_	_	I-Premise
237	cases	_	_	I-Premise
238	(	_	_	I-Premise
239	p=0.28	_	_	I-Premise
240	)	_	_	I-Premise
241	;	_	_	I-Premise
242	and	_	_	I-Premise
243	incontinence	_	_	I-Premise
244	(	_	_	I-Premise
245	any	_	_	I-Premise
246	involuntary	_	_	I-Premise
247	urine	_	_	I-Premise
248	loss	_	_	I-Premise
249	)	_	_	I-Premise
250	at	_	_	I-Premise
251	3	_	_	I-Premise
252	mo	_	_	I-Premise
253	was	_	_	I-Premise
254	75	_	_	I-Premise
255	%	_	_	I-Premise
256	and	_	_	I-Premise
257	69	_	_	I-Premise
258	%	_	_	I-Premise
259	(	_	_	I-Premise
260	p=0.391	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	at	_	_	I-Premise
264	6	_	_	I-Premise
265	mo	_	_	I-Premise
266	was	_	_	I-Premise
267	51	_	_	I-Premise
268	%	_	_	I-Premise
269	and	_	_	I-Premise
270	43	_	_	I-Premise
271	%	_	_	I-Premise
272	(	_	_	I-Premise
273	p=0.686	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Urinary	_	_	B-Premise
277	retention	_	_	I-Premise
278	occurred	_	_	I-Premise
279	only	_	_	I-Premise
280	in	_	_	I-Premise
281	one	_	_	I-Premise
282	case	_	_	I-Premise
283	(	_	_	I-Premise
284	control	_	_	I-Premise
285	group	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	The	_	_	B-Premise
289	percentage	_	_	I-Premise
290	of	_	_	I-Premise
291	cases	_	_	I-Premise
292	returning	_	_	I-Premise
293	to	_	_	I-Premise
294	baseline	_	_	I-Premise
295	in	_	_	I-Premise
296	all	_	_	I-Premise
297	QoL	_	_	I-Premise
298	domains	_	_	I-Premise
299	(	_	_	I-Premise
300	except	_	_	I-Premise
301	insomnia	_	_	I-Premise
302	)	_	_	I-Premise
303	was	_	_	I-Premise
304	similar	_	_	I-Premise
305	at	_	_	I-Premise
306	6	_	_	I-Premise
307	mo	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	two	_	_	I-Premise
311	groups	_	_	I-Premise
312	.	_	_	I-Premise

313	Short	_	_	B-Premise
314	follow-up	_	_	I-Premise
315	,	_	_	I-Premise
316	lack	_	_	I-Premise
317	of	_	_	I-Premise
318	blinding	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	probable	_	_	I-Premise
322	small	_	_	I-Premise
323	differences	_	_	I-Premise
324	in	_	_	I-Premise
325	our	_	_	I-Premise
326	method	_	_	I-Premise
327	of	_	_	I-Premise
328	MFRR	_	_	I-Premise
329	performed	_	_	I-Premise
330	compared	_	_	I-Premise
331	with	_	_	I-Premise
332	other	_	_	I-Premise
333	studies	_	_	I-Premise
334	were	_	_	I-Premise
335	identified	_	_	I-Premise
336	as	_	_	I-Premise
337	significant	_	_	I-Premise
338	limitations	_	_	I-Premise
339	.	_	_	I-Premise

340	No	_	_	B-Premise
341	significant	_	_	I-Premise
342	difference	_	_	I-Premise
343	in	_	_	I-Premise
344	any	_	_	I-Premise
345	of	_	_	I-Premise
346	the	_	_	I-Premise
347	analysed	_	_	I-Premise
348	outcome	_	_	I-Premise
349	measures	_	_	I-Premise
350	was	_	_	I-Premise
351	observed	_	_	I-Premise
352	.	_	_	I-Premise

353	Posterior	_	_	B-Claim
354	reconstruction	_	_	I-Claim
355	of	_	_	I-Claim
356	the	_	_	I-Claim
357	musculofascial	_	_	I-Claim
358	complex	_	_	I-Claim
359	does	_	_	I-Claim
360	not	_	_	I-Claim
361	appear	_	_	I-Claim
362	to	_	_	I-Claim
363	improve	_	_	I-Claim
364	early	_	_	I-Claim
365	urinary	_	_	I-Claim
366	incontinence	_	_	I-Claim
367	after	_	_	I-Claim
368	RALP	_	_	I-Claim
369	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	Gynecologic	_	_	O
3	Cancer	_	_	O
4	Intergroup	_	_	O
5	International	_	_	O
6	Collaboration	_	_	O
7	on	_	_	O
8	Ovarian	_	_	O
9	Neoplasms	_	_	O
10	7	_	_	O
11	(	_	_	O
12	ICON7	_	_	O
13	)	_	_	O
14	trial	_	_	O
15	,	_	_	O
16	bevacizumab	_	_	O
17	improved	_	_	O
18	progression-free	_	_	O
19	survival	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	ovarian	_	_	O
24	cancer	_	_	O
25	when	_	_	O
26	used	_	_	O
27	in	_	_	O
28	combination	_	_	O
29	with	_	_	O
30	first-line	_	_	O
31	chemotherapy	_	_	O
32	and	_	_	O
33	as	_	_	O
34	a	_	_	O
35	single-drug	_	_	O
36	continuation	_	_	O
37	treatment	_	_	O
38	for	_	_	O
39	18	_	_	O
40	cycles	_	_	O
41	.	_	_	O

42	In	_	_	O
43	a	_	_	O
44	preliminary	_	_	O
45	analysis	_	_	O
46	of	_	_	O
47	a	_	_	O
48	high-risk	_	_	O
49	subset	_	_	O
50	of	_	_	O
51	patients	_	_	O
52	,	_	_	O
53	there	_	_	O
54	was	_	_	O
55	also	_	_	O
56	an	_	_	O
57	improvement	_	_	O
58	in	_	_	O
59	overall	_	_	O
60	survival	_	_	O
61	.	_	_	O

62	This	_	_	O
63	study	_	_	O
64	aims	_	_	O
65	to	_	_	O
66	describe	_	_	O
67	the	_	_	O
68	health-related	_	_	O
69	quality-of-life	_	_	O
70	(	_	_	O
71	QoL	_	_	O
72	)	_	_	O
73	outcomes	_	_	O
74	from	_	_	O
75	ICON7	_	_	O
76	.	_	_	O

77	ICON7	_	_	O
78	is	_	_	O
79	a	_	_	O
80	randomised	_	_	O
81	,	_	_	O
82	multicentre	_	_	O
83	,	_	_	O
84	open-label	_	_	O
85	phase	_	_	O
86	3	_	_	O
87	trial	_	_	O
88	.	_	_	O

89	Between	_	_	O
90	Dec	_	_	O
91	18	_	_	O
92	,	_	_	O
93	2006	_	_	O
94	,	_	_	O
95	and	_	_	O
96	Feb	_	_	O
97	16	_	_	O
98	,	_	_	O
99	2009	_	_	O
100	,	_	_	O
101	after	_	_	O
102	a	_	_	O
103	surgical	_	_	O
104	procedure	_	_	O
105	aiming	_	_	O
106	to	_	_	O
107	debulk	_	_	O
108	the	_	_	O
109	disease	_	_	O
110	,	_	_	O
111	women	_	_	O
112	with	_	_	O
113	International	_	_	O
114	Federation	_	_	O
115	of	_	_	O
116	Gynecology	_	_	O
117	and	_	_	O
118	Obstetrics	_	_	O
119	(	_	_	O
120	FIGO	_	_	O
121	)	_	_	O
122	high-risk	_	_	O
123	stage	_	_	O
124	I-IV	_	_	O
125	epithelial	_	_	O
126	ovarian	_	_	O
127	cancer	_	_	O
128	were	_	_	O
129	randomly	_	_	O
130	allocated	_	_	O
131	(	_	_	O
132	1:1	_	_	O
133	)	_	_	O
134	by	_	_	O
135	computer	_	_	O
136	program	_	_	O
137	and	_	_	O
138	block	_	_	O
139	randomisation	_	_	O
140	to	_	_	O
141	receive	_	_	O
142	either	_	_	O
143	six	_	_	O
144	cycles	_	_	O
145	of	_	_	O
146	standard	_	_	O
147	chemotherapy	_	_	O
148	(	_	_	O
149	total	_	_	O
150	18	_	_	O
151	weeks	_	_	O
152	)	_	_	O
153	with	_	_	O
154	carboplatin	_	_	O
155	(	_	_	O
156	area	_	_	O
157	under	_	_	O
158	the	_	_	O
159	curve	_	_	O
160	5	_	_	O
161	or	_	_	O
162	6	_	_	O
163	)	_	_	O
164	and	_	_	O
165	paclitaxel	_	_	O
166	(	_	_	O
167	175	_	_	O
168	mg/m	_	_	O
169	(	_	_	O
170	2	_	_	O
171	)	_	_	O
172	)	_	_	O
173	alone	_	_	O
174	or	_	_	O
175	with	_	_	O
176	bevacizumab	_	_	O
177	(	_	_	O
178	7Â·5	_	_	O
179	mg/kg	_	_	O
180	)	_	_	O
181	given	_	_	O
182	intravenously	_	_	O
183	with	_	_	O
184	chemotherapy	_	_	O
185	and	_	_	O
186	continued	_	_	O
187	as	_	_	O
188	a	_	_	O
189	single	_	_	O
190	drug	_	_	O
191	thereafter	_	_	O
192	(	_	_	O
193	total	_	_	O
194	54	_	_	O
195	weeks	_	_	O
196	)	_	_	O
197	.	_	_	O

198	The	_	_	O
199	primary	_	_	O
200	QoL	_	_	O
201	endpoint	_	_	O
202	was	_	_	O
203	global	_	_	O
204	QoL	_	_	O
205	from	_	_	O
206	the	_	_	O
207	European	_	_	O
208	Organisation	_	_	O
209	for	_	_	O
210	Research	_	_	O
211	and	_	_	O
212	Treatment	_	_	O
213	of	_	_	O
214	Cancer	_	_	O
215	quality-of-life	_	_	O
216	questionnaire-core	_	_	O
217	30	_	_	O
218	at	_	_	O
219	week	_	_	O
220	54	_	_	O
221	,	_	_	O
222	analysed	_	_	O
223	by	_	_	O
224	ANOVA	_	_	O
225	and	_	_	O
226	adjusted	_	_	O
227	for	_	_	O
228	baseline	_	_	O
229	score	_	_	O
230	.	_	_	O

231	Analyses	_	_	O
232	were	_	_	O
233	by	_	_	O
234	intention	_	_	O
235	to	_	_	O
236	treat	_	_	O
237	.	_	_	O

238	The	_	_	O
239	ICON7	_	_	O
240	trial	_	_	O
241	has	_	_	O
242	completed	_	_	O
243	recruitment	_	_	O
244	and	_	_	O
245	remains	_	_	O
246	in	_	_	O
247	follow-up	_	_	O
248	.	_	_	O

249	This	_	_	O
250	study	_	_	O
251	is	_	_	O
252	registered	_	_	O
253	,	_	_	O
254	number	_	_	O
255	ISRCTN91273375	_	_	O
256	.	_	_	O

257	764	_	_	O
258	women	_	_	O
259	were	_	_	O
260	randomly	_	_	O
261	assigned	_	_	O
262	to	_	_	O
263	the	_	_	O
264	standard	_	_	O
265	chemotherapy	_	_	O
266	group	_	_	O
267	and	_	_	O
268	764	_	_	O
269	to	_	_	O
270	the	_	_	O
271	bevacizumab	_	_	O
272	group	_	_	O
273	.	_	_	O

274	At	_	_	O
275	baseline	_	_	O
276	,	_	_	O
277	684	_	_	O
278	(	_	_	O
279	90	_	_	O
280	%	_	_	O
281	)	_	_	O
282	of	_	_	O
283	women	_	_	O
284	in	_	_	O
285	the	_	_	O
286	standard	_	_	O
287	chemotherapy	_	_	O
288	group	_	_	O
289	and	_	_	O
290	691	_	_	O
291	(	_	_	O
292	90	_	_	O
293	%	_	_	O
294	)	_	_	O
295	of	_	_	O
296	those	_	_	O
297	in	_	_	O
298	the	_	_	O
299	bevacizumab	_	_	O
300	group	_	_	O
301	had	_	_	O
302	completed	_	_	O
303	QoL	_	_	O
304	questionnaires	_	_	O
305	.	_	_	O

306	At	_	_	O
307	week	_	_	O
308	54	_	_	O
309	,	_	_	O
310	502	_	_	O
311	(	_	_	O
312	66	_	_	O
313	%	_	_	O
314	)	_	_	O
315	women	_	_	O
316	in	_	_	O
317	the	_	_	O
318	bevacizumab	_	_	O
319	group	_	_	O
320	and	_	_	O
321	388	_	_	O
322	(	_	_	O
323	51	_	_	O
324	%	_	_	O
325	)	_	_	O
326	women	_	_	O
327	in	_	_	O
328	the	_	_	O
329	standard	_	_	O
330	chemotherapy	_	_	O
331	group	_	_	O
332	provided	_	_	O
333	QoL	_	_	O
334	data	_	_	O
335	.	_	_	O

336	Overall	_	_	B-Premise
337	,	_	_	I-Premise
338	the	_	_	I-Premise
339	mean	_	_	I-Premise
340	global	_	_	I-Premise
341	QoL	_	_	I-Premise
342	score	_	_	I-Premise
343	improved	_	_	I-Premise
344	during	_	_	I-Premise
345	chemotherapy	_	_	I-Premise
346	by	_	_	I-Premise
347	7Â·2	_	_	I-Premise
348	points	_	_	I-Premise
349	(	_	_	I-Premise
350	SD	_	_	I-Premise
351	24Â·4	_	_	I-Premise
352	)	_	_	I-Premise
353	when	_	_	I-Premise
354	analysed	_	_	I-Premise
355	for	_	_	I-Premise
356	all	_	_	I-Premise
357	women	_	_	I-Premise
358	with	_	_	I-Premise
359	data	_	_	I-Premise
360	at	_	_	I-Premise
361	baseline	_	_	I-Premise
362	and	_	_	I-Premise
363	week	_	_	I-Premise
364	18	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Premise
367	mean	_	_	I-Premise
368	global	_	_	I-Premise
369	QoL	_	_	I-Premise
370	score	_	_	I-Premise
371	at	_	_	I-Premise
372	54	_	_	I-Premise
373	weeks	_	_	I-Premise
374	was	_	_	I-Premise
375	higher	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	standard	_	_	I-Premise
379	chemotherapy	_	_	I-Premise
380	group	_	_	I-Premise
381	than	_	_	I-Premise
382	in	_	_	I-Premise
383	the	_	_	I-Premise
384	bevacizumab	_	_	I-Premise
385	group	_	_	I-Premise
386	(	_	_	I-Premise
387	76Â·1	_	_	I-Premise
388	[	_	_	I-Premise
389	SD	_	_	I-Premise
390	18Â·2	_	_	I-Premise
391	]	_	_	I-Premise
392	vs	_	_	I-Premise
393	69Â·7	_	_	I-Premise
394	[	_	_	I-Premise
395	19Â·1	_	_	I-Premise
396	]	_	_	I-Premise
397	points	_	_	I-Premise
398	;	_	_	I-Premise
399	difference	_	_	I-Premise
400	6Â·4	_	_	I-Premise
401	points	_	_	I-Premise
402	,	_	_	I-Premise
403	95	_	_	I-Premise
404	%	_	_	I-Premise
405	CI	_	_	I-Premise
406	3Â·7-9Â·0	_	_	I-Premise
407	,	_	_	I-Premise
408	p	_	_	I-Premise
409	<	_	_	I-Premise
410	0Â·0001	_	_	I-Premise
411	)	_	_	I-Premise
412	.	_	_	I-Premise

413	Bevacizumab	_	_	B-Claim
414	continuation	_	_	I-Claim
415	treatment	_	_	I-Claim
416	seems	_	_	I-Claim
417	to	_	_	I-Claim
418	be	_	_	I-Claim
419	associated	_	_	I-Claim
420	with	_	_	I-Claim
421	a	_	_	I-Claim
422	small	_	_	I-Claim
423	but	_	_	I-Claim
424	clinically	_	_	I-Claim
425	significant	_	_	I-Claim
426	decrement	_	_	I-Claim
427	in	_	_	I-Claim
428	QoL	_	_	I-Claim
429	compared	_	_	I-Claim
430	with	_	_	I-Claim
431	standard	_	_	I-Claim
432	treatment	_	_	I-Claim
433	for	_	_	I-Claim
434	women	_	_	I-Claim
435	with	_	_	I-Claim
436	ovarian	_	_	I-Claim
437	cancer	_	_	I-Claim
438	.	_	_	I-Claim

439	The	_	_	O
440	trade-off	_	_	O
441	between	_	_	O
442	the	_	_	O
443	prolongation	_	_	O
444	of	_	_	O
445	progression-free	_	_	O
446	survival	_	_	O
447	and	_	_	O
448	the	_	_	O
449	quality	_	_	O
450	of	_	_	O
451	that	_	_	O
452	period	_	_	O
453	of	_	_	O
454	time	_	_	O
455	needs	_	_	O
456	to	_	_	O
457	be	_	_	O
458	considered	_	_	O
459	in	_	_	O
460	clinical	_	_	O
461	practice	_	_	O
462	when	_	_	O
463	making	_	_	O
464	treatment	_	_	O
465	decisions	_	_	O
466	.	_	_	O


0	Mediating	_	_	O
1	mechanisms	_	_	O
2	of	_	_	O
3	a	_	_	O
4	12-week	_	_	O
5	group-based	_	_	O
6	exercise	_	_	O
7	intervention	_	_	O
8	on	_	_	O
9	cancer	_	_	O
10	survivors	_	_	O
11	'	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	QoL	_	_	O
17	)	_	_	O
18	were	_	_	O
19	examined	_	_	O
20	to	_	_	O
21	inform	_	_	O
22	future	_	_	O
23	exercise	_	_	O
24	intervention	_	_	O
25	development	_	_	O
26	.	_	_	O

27	Two	_	_	O
28	hundred	_	_	O
29	nine	_	_	O
30	cancer	_	_	O
31	survivors	_	_	O
32	â‰¥	_	_	O
33	3	_	_	O
34	months	_	_	O
35	posttreatment	_	_	O
36	(	_	_	O
37	57	_	_	O
38	%	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	)	_	_	O
42	aged	_	_	O
43	49.5	_	_	O
44	(	_	_	O
45	Â±	_	_	O
46	10.4	_	_	O
47	)	_	_	O
48	years	_	_	O
49	were	_	_	O
50	assigned	_	_	O
51	to	_	_	O
52	physical	_	_	O
53	exercise	_	_	O
54	(	_	_	O
55	n	_	_	O
56	=	_	_	O
57	147	_	_	O
58	)	_	_	O
59	or	_	_	O
60	wait-list	_	_	O
61	control	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	62	_	_	O
66	)	_	_	O
67	.	_	_	O

68	QoL	_	_	O
69	,	_	_	O
70	fatigue	_	_	O
71	,	_	_	O
72	emotional	_	_	O
73	distress	_	_	O
74	,	_	_	O
75	physical	_	_	O
76	activity	_	_	O
77	,	_	_	O
78	general	_	_	O
79	self-efficacy	_	_	O
80	and	_	_	O
81	mastery	_	_	O
82	were	_	_	O
83	assessed	_	_	O
84	at	_	_	O
85	baseline	_	_	O
86	and	_	_	O
87	post-intervention	_	_	O
88	using	_	_	O
89	questionnaires	_	_	O
90	.	_	_	O

91	Path	_	_	O
92	analysis	_	_	O
93	was	_	_	O
94	conducted	_	_	O
95	using	_	_	O
96	Mplus	_	_	O
97	to	_	_	O
98	explore	_	_	O
99	whether	_	_	O
100	improved	_	_	O
101	physical	_	_	O
102	activity	_	_	O
103	,	_	_	O
104	general	_	_	O
105	self-efficacy	_	_	O
106	and	_	_	O
107	mastery	_	_	O
108	mediated	_	_	O
109	the	_	_	O
110	effects	_	_	O
111	of	_	_	O
112	exercise	_	_	O
113	on	_	_	O
114	fatigue	_	_	O
115	and	_	_	O
116	distress	_	_	O
117	and	_	_	O
118	consequently	_	_	O
119	QoL	_	_	O
120	.	_	_	O

121	The	_	_	B-Premise
122	intervention	_	_	I-Premise
123	was	_	_	I-Premise
124	associated	_	_	I-Premise
125	with	_	_	I-Premise
126	increased	_	_	I-Premise
127	physical	_	_	I-Premise
128	activity	_	_	I-Premise
129	(	_	_	I-Premise
130	Î²	_	_	I-Premise
131	=	_	_	I-Premise
132	0.46	_	_	I-Premise
133	,	_	_	I-Premise
134	95	_	_	I-Premise
135	%	_	_	I-Premise
136	confidence	_	_	I-Premise
137	interval	_	_	I-Premise
138	(	_	_	I-Premise
139	CI	_	_	I-Premise
140	)	_	_	I-Premise
141	=	_	_	I-Premise
142	0.14	_	_	I-Premise
143	;	_	_	I-Premise
144	0.59	_	_	I-Premise
145	)	_	_	I-Premise
146	,	_	_	I-Premise
147	general	_	_	I-Premise
148	self-efficacy	_	_	I-Premise
149	(	_	_	I-Premise
150	Î²	_	_	I-Premise
151	=	_	_	I-Premise
152	2.41	_	_	I-Premise
153	,	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	=	_	_	I-Premise
158	0.35	_	_	I-Premise
159	;	_	_	I-Premise
160	4.73	_	_	I-Premise
161	)	_	_	I-Premise
162	,	_	_	I-Premise
163	and	_	_	I-Premise
164	mastery	_	_	I-Premise
165	(	_	_	I-Premise
166	Î²	_	_	I-Premise
167	=	_	_	I-Premise
168	1.75	_	_	I-Premise
169	,	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	=	_	_	I-Premise
174	0.36	_	_	I-Premise
175	;	_	_	I-Premise
176	2.78	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Further	_	_	O
180	,	_	_	O
181	the	_	_	B-Premise
182	intervention	_	_	I-Premise
183	had	_	_	I-Premise
184	both	_	_	I-Premise
185	a	_	_	I-Premise
186	direct	_	_	I-Premise
187	effect	_	_	I-Premise
188	on	_	_	I-Premise
189	fatigue	_	_	I-Premise
190	(	_	_	I-Premise
191	Î²	_	_	I-Premise
192	=	_	_	I-Premise
193	-1.09	_	_	I-Premise
194	,	_	_	I-Premise
195	95	_	_	I-Premise
196	%	_	_	I-Premise
197	CI	_	_	I-Premise
198	=	_	_	I-Premise
199	-2.12	_	_	I-Premise
200	;	_	_	I-Premise
201	0.01	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	and	_	_	I-Premise
205	an	_	_	I-Premise
206	indirect	_	_	I-Premise
207	effect	_	_	I-Premise
208	(	_	_	I-Premise
209	Î²	_	_	I-Premise
210	=	_	_	I-Premise
211	-0.54	_	_	I-Premise
212	,	_	_	I-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	CI	_	_	I-Premise
216	=	_	_	I-Premise
217	-1.00	_	_	I-Premise
218	;	_	_	I-Premise
219	-0.21	_	_	I-Premise
220	)	_	_	I-Premise
221	via	_	_	I-Premise
222	physical	_	_	I-Premise
223	activity	_	_	I-Premise
224	(	_	_	I-Premise
225	Î²	_	_	I-Premise
226	=	_	_	I-Premise
227	-0.29	_	_	I-Premise
228	,	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	=	_	_	I-Premise
233	-0.64	_	_	I-Premise
234	;	_	_	I-Premise
235	-0.07	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	general	_	_	I-Premise
239	self-efficacy	_	_	I-Premise
240	(	_	_	I-Premise
241	Î²	_	_	I-Premise
242	=	_	_	I-Premise
243	-0.25	_	_	I-Premise
244	,	_	_	I-Premise
245	95	_	_	I-Premise
246	%	_	_	I-Premise
247	CI	_	_	I-Premise
248	=	_	_	I-Premise
249	-0.61	_	_	I-Premise
250	;	_	_	I-Premise
251	-0.05	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	intervention	_	_	I-Premise
256	had	_	_	I-Premise
257	a	_	_	I-Premise
258	borderline	_	_	I-Premise
259	significant	_	_	I-Premise
260	direct	_	_	I-Premise
261	effect	_	_	I-Premise
262	on	_	_	I-Premise
263	reduced	_	_	I-Premise
264	distress	_	_	I-Premise
265	(	_	_	I-Premise
266	Î²	_	_	I-Premise
267	=	_	_	I-Premise
268	-1.32	_	_	I-Premise
269	,	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	=	_	_	I-Premise
274	-2.68	_	_	I-Premise
275	;	_	_	I-Premise
276	0.11	_	_	I-Premise
277	)	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	a	_	_	I-Premise
281	significant	_	_	I-Premise
282	indirect	_	_	I-Premise
283	effect	_	_	I-Premise
284	via	_	_	I-Premise
285	increased	_	_	I-Premise
286	general	_	_	I-Premise
287	self-efficacy	_	_	I-Premise
288	and	_	_	I-Premise
289	mastery	_	_	I-Premise
290	(	_	_	I-Premise
291	Î²	_	_	I-Premise
292	=	_	_	I-Premise
293	-1.06	_	_	I-Premise
294	,	_	_	I-Premise
295	95	_	_	I-Premise
296	%	_	_	I-Premise
297	CI	_	_	I-Premise
298	=	_	_	I-Premise
299	-1.89	_	_	I-Premise
300	;	_	_	I-Premise
301	-0.38	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Reductions	_	_	B-Premise
305	in	_	_	I-Premise
306	fatigue	_	_	I-Premise
307	(	_	_	I-Premise
308	Î²	_	_	I-Premise
309	=	_	_	I-Premise
310	-1.33	_	_	I-Premise
311	,	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	=-1.85	_	_	I-Premise
316	;	_	_	I-Premise
317	-0.83	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	distress	_	_	I-Premise
321	(	_	_	I-Premise
322	Î²	_	_	I-Premise
323	=	_	_	I-Premise
324	-0.86	_	_	I-Premise
325	,	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	=	_	_	I-Premise
330	-1.25	_	_	I-Premise
331	;	_	_	I-Premise
332	-0.52	_	_	I-Premise
333	)	_	_	I-Premise
334	were	_	_	I-Premise
335	associated	_	_	I-Premise
336	with	_	_	I-Premise
337	improved	_	_	I-Premise
338	QoL	_	_	I-Premise
339	.	_	_	I-Premise

340	Further	_	_	O
341	,	_	_	O
342	increased	_	_	B-Premise
343	physical	_	_	I-Premise
344	activity	_	_	I-Premise
345	was	_	_	I-Premise
346	directly	_	_	I-Premise
347	associated	_	_	I-Premise
348	with	_	_	I-Premise
349	improved	_	_	I-Premise
350	QoL	_	_	I-Premise
351	(	_	_	I-Premise
352	Î²	_	_	I-Premise
353	=	_	_	I-Premise
354	3.37	_	_	I-Premise
355	,	_	_	I-Premise
356	95	_	_	I-Premise
357	%	_	_	I-Premise
358	CI	_	_	I-Premise
359	=	_	_	I-Premise
360	1.01	_	_	I-Premise
361	;	_	_	I-Premise
362	5.54	_	_	I-Premise
363	)	_	_	I-Premise
364	.	_	_	I-Premise

365	The	_	_	B-Claim
366	beneficial	_	_	I-Claim
367	effect	_	_	I-Claim
368	of	_	_	I-Claim
369	group-based	_	_	I-Claim
370	physical	_	_	I-Claim
371	exercise	_	_	I-Claim
372	on	_	_	I-Claim
373	QoL	_	_	I-Claim
374	was	_	_	I-Claim
375	mediated	_	_	I-Claim
376	by	_	_	I-Claim
377	increased	_	_	I-Claim
378	physical	_	_	I-Claim
379	activity	_	_	I-Claim
380	,	_	_	I-Claim
381	general	_	_	I-Claim
382	self-efficacy	_	_	I-Claim
383	and	_	_	I-Claim
384	mastery	_	_	I-Claim
385	,	_	_	I-Claim
386	and	_	_	I-Claim
387	subsequent	_	_	I-Claim
388	reductions	_	_	I-Claim
389	in	_	_	I-Claim
390	fatigue	_	_	I-Claim
391	and	_	_	I-Claim
392	distress	_	_	I-Claim
393	.	_	_	I-Claim

394	In	_	_	B-Claim
395	addition	_	_	I-Claim
396	to	_	_	I-Claim
397	physical	_	_	I-Claim
398	activity	_	_	I-Claim
399	,	_	_	I-Claim
400	future	_	_	I-Claim
401	interventions	_	_	I-Claim
402	should	_	_	I-Claim
403	target	_	_	I-Claim
404	self-efficacy	_	_	I-Claim
405	and	_	_	I-Claim
406	mastery	_	_	I-Claim
407	.	_	_	I-Claim

408	This	_	_	B-Claim
409	may	_	_	I-Claim
410	lead	_	_	I-Claim
411	to	_	_	I-Claim
412	reduced	_	_	I-Claim
413	distress	_	_	I-Claim
414	and	_	_	I-Claim
415	fatigue	_	_	I-Claim
416	,	_	_	I-Claim
417	and	_	_	I-Claim
418	consequently	_	_	I-Claim
419	improved	_	_	I-Claim
420	QoL	_	_	I-Claim
421	of	_	_	I-Claim
422	cancer	_	_	I-Claim
423	survivors	_	_	I-Claim
424	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	post-operative	_	_	O
6	radiotherapy	_	_	O
7	(	_	_	O
8	RT	_	_	O
9	)	_	_	O
10	in	_	_	O
11	women	_	_	O
12	with	_	_	O
13	'low-risk	_	_	O
14	'	_	_	O
15	axillary	_	_	O
16	node-negative	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	[	_	_	O
20	tumour	_	_	O
21	size	_	_	O
22	of	_	_	O
23	less	_	_	O
24	than	_	_	O
25	5	_	_	O
26	cm	_	_	O
27	(	_	_	O
28	T0-2	_	_	O
29	)	_	_	O
30	although	_	_	O
31	the	_	_	O
32	eligibility	_	_	O
33	criteria	_	_	O
34	further	_	_	O
35	reduce	_	_	O
36	the	_	_	O
37	eligible	_	_	O
38	size	_	_	O
39	to	_	_	O
40	a	_	_	O
41	maximum	_	_	O
42	of	_	_	O
43	3	_	_	O
44	cm	_	_	O
45	]	_	_	O
46	treated	_	_	O
47	by	_	_	O
48	breast-conserving	_	_	O
49	surgery	_	_	O
50	and	_	_	O
51	endocrine	_	_	O
52	therapy	_	_	O
53	improves	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	and	_	_	O
58	is	_	_	O
59	more	_	_	O
60	cost-effective	_	_	O
61	.	_	_	O

62	A	_	_	O
63	randomised	_	_	O
64	controlled	_	_	O
65	clinical	_	_	O
66	trial	_	_	O
67	,	_	_	O
68	using	_	_	O
69	a	_	_	O
70	method	_	_	O
71	of	_	_	O
72	minimisation	_	_	O
73	balanced	_	_	O
74	by	_	_	O
75	centre	_	_	O
76	,	_	_	O
77	grade	_	_	O
78	of	_	_	O
79	cancer	_	_	O
80	,	_	_	O
81	age	_	_	O
82	,	_	_	O
83	lymphovascular	_	_	O
84	invasion	_	_	O
85	and	_	_	O
86	preoperative	_	_	O
87	endocrine	_	_	O
88	therapy	_	_	O
89	was	_	_	O
90	performed	_	_	O
91	.	_	_	O

92	Breast	_	_	O
93	cancer	_	_	O
94	clinics	_	_	O
95	in	_	_	O
96	cancer	_	_	O
97	centres	_	_	O
98	in	_	_	O
99	the	_	_	O
100	UK	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	aged	_	_	O
104	â‰¥	_	_	O
105	65	_	_	O
106	years	_	_	O
107	were	_	_	O
108	eligible	_	_	O
109	provided	_	_	O
110	that	_	_	O
111	their	_	_	O
112	breast	_	_	O
113	cancers	_	_	O
114	were	_	_	O
115	considered	_	_	O
116	to	_	_	O
117	be	_	_	O
118	at	_	_	O
119	low	_	_	O
120	risk	_	_	O
121	of	_	_	O
122	local	_	_	O
123	recurrence	_	_	O
124	,	_	_	O
125	they	_	_	O
126	were	_	_	O
127	suitable	_	_	O
128	for	_	_	O
129	breast	_	_	O
130	conservation	_	_	O
131	surgery	_	_	O
132	,	_	_	O
133	they	_	_	O
134	were	_	_	O
135	receiving	_	_	O
136	endocrine	_	_	O
137	therapy	_	_	O
138	and	_	_	O
139	they	_	_	O
140	were	_	_	O
141	willing	_	_	O
142	and	_	_	O
143	able	_	_	O
144	to	_	_	O
145	give	_	_	O
146	informed	_	_	O
147	consent	_	_	O
148	.	_	_	O

149	The	_	_	O
150	standard	_	_	O
151	treatment	_	_	O
152	of	_	_	O
153	post-operative	_	_	O
154	whole	_	_	O
155	breast	_	_	O
156	irradiation	_	_	O
157	or	_	_	O
158	the	_	_	O
159	omission	_	_	O
160	of	_	_	O
161	RT	_	_	O
162	.	_	_	O

163	Quality	_	_	O
164	of	_	_	O
165	life	_	_	O
166	was	_	_	O
167	the	_	_	O
168	primary	_	_	O
169	outcome	_	_	O
170	measure	_	_	O
171	,	_	_	O
172	together	_	_	O
173	with	_	_	O
174	anxiety	_	_	O
175	and	_	_	O
176	depression	_	_	O
177	and	_	_	O
178	cost-effectiveness	_	_	O
179	.	_	_	O

180	Secondary	_	_	O
181	outcome	_	_	O
182	measures	_	_	O
183	were	_	_	O
184	recurrence	_	_	O
185	rates	_	_	O
186	and	_	_	O
187	survival	_	_	O
188	,	_	_	O
189	and	_	_	O
190	treatment-related	_	_	O
191	morbidity	_	_	O
192	.	_	_	O

193	The	_	_	O
194	principal	_	_	O
195	method	_	_	O
196	of	_	_	O
197	data	_	_	O
198	collection	_	_	O
199	was	_	_	O
200	by	_	_	O
201	questionnaire	_	_	O
202	,	_	_	O
203	completed	_	_	O
204	at	_	_	O
205	home	_	_	O
206	with	_	_	O
207	a	_	_	O
208	research	_	_	O
209	nurse	_	_	O
210	on	_	_	O
211	four	_	_	O
212	occasions	_	_	O
213	over	_	_	O
214	15	_	_	O
215	months	_	_	O
216	,	_	_	O
217	then	_	_	O
218	by	_	_	O
219	postal	_	_	O
220	questionnaire	_	_	O
221	at	_	_	O
222	3	_	_	O
223	and	_	_	O
224	5	_	_	O
225	years	_	_	O
226	after	_	_	O
227	surgery	_	_	O
228	.	_	_	O

229	The	_	_	O
230	hypothesised	_	_	O
231	improvement	_	_	O
232	in	_	_	O
233	overall	_	_	O
234	quality	_	_	O
235	of	_	_	O
236	life	_	_	O
237	with	_	_	O
238	the	_	_	O
239	omission	_	_	O
240	of	_	_	O
241	RT	_	_	O
242	was	_	_	O
243	not	_	_	O
244	seen	_	_	O
245	in	_	_	O
246	the	_	_	O
247	summary	_	_	O
248	domains	_	_	O
249	of	_	_	O
250	the	_	_	O
251	European	_	_	O
252	Organisation	_	_	O
253	for	_	_	O
254	Research	_	_	O
255	in	_	_	O
256	the	_	_	O
257	Treatment	_	_	O
258	of	_	_	O
259	Cancer	_	_	O
260	(	_	_	O
261	EORTC	_	_	O
262	)	_	_	O
263	scales	_	_	O
264	.	_	_	O

265	Some	_	_	O
266	differences	_	_	O
267	were	_	_	O
268	apparent	_	_	O
269	within	_	_	O
270	subscales	_	_	O
271	of	_	_	O
272	the	_	_	O
273	EORTC	_	_	O
274	questionnaires	_	_	O
275	,	_	_	O
276	and	_	_	O
277	insights	_	_	O
278	into	_	_	O
279	the	_	_	O
280	impact	_	_	O
281	of	_	_	O
282	treatment	_	_	O
283	were	_	_	O
284	also	_	_	O
285	provided	_	_	O
286	by	_	_	O
287	the	_	_	O
288	qualitative	_	_	O
289	data	_	_	O
290	obtained	_	_	O
291	by	_	_	O
292	open-ended	_	_	O
293	questions	_	_	O
294	added	_	_	O
295	by	_	_	O
296	the	_	_	O
297	trial	_	_	O
298	team	_	_	O
299	.	_	_	O

300	Differences	_	_	O
301	were	_	_	O
302	most	_	_	O
303	apparent	_	_	O
304	shortly	_	_	O
305	after	_	_	O
306	the	_	_	O
307	time	_	_	O
308	of	_	_	O
309	completion	_	_	O
310	of	_	_	O
311	RT	_	_	O
312	.	_	_	O

313	RT	_	_	B-Premise
314	was	_	_	I-Premise
315	then	_	_	I-Premise
316	associated	_	_	I-Premise
317	with	_	_	I-Premise
318	increased	_	_	I-Premise
319	breast	_	_	I-Premise
320	symptoms	_	_	I-Premise
321	and	_	_	I-Premise
322	with	_	_	I-Premise
323	greater	_	_	I-Premise
324	(	_	_	I-Premise
325	self-reported	_	_	I-Premise
326	)	_	_	I-Premise
327	fatigue	_	_	I-Premise
328	,	_	_	I-Premise
329	but	_	_	I-Premise
330	with	_	_	I-Premise
331	lower	_	_	I-Premise
332	levels	_	_	I-Premise
333	of	_	_	I-Premise
334	insomnia	_	_	I-Premise
335	and	_	_	I-Premise
336	endocrine	_	_	I-Premise
337	side	_	_	I-Premise
338	effects	_	_	I-Premise
339	.	_	_	I-Premise

340	These	_	_	B-Premise
341	statistically	_	_	I-Premise
342	significant	_	_	I-Premise
343	differences	_	_	I-Premise
344	in	_	_	I-Premise
345	breast	_	_	I-Premise
346	symptoms	_	_	I-Premise
347	persisted	_	_	I-Premise
348	for	_	_	I-Premise
349	up	_	_	I-Premise
350	to	_	_	I-Premise
351	5	_	_	I-Premise
352	years	_	_	I-Premise
353	after	_	_	I-Premise
354	RT	_	_	I-Premise
355	[	_	_	I-Premise
356	mean	_	_	I-Premise
357	difference	_	_	I-Premise
358	,	_	_	I-Premise
359	RT	_	_	I-Premise
360	was	_	_	I-Premise
361	5.27	_	_	I-Premise
362	units	_	_	I-Premise
363	greater	_	_	I-Premise
364	than	_	_	I-Premise
365	no	_	_	I-Premise
366	RT	_	_	I-Premise
367	,	_	_	I-Premise
368	95	_	_	I-Premise
369	%	_	_	I-Premise
370	confidence	_	_	I-Premise
371	interval	_	_	I-Premise
372	(	_	_	I-Premise
373	CI	_	_	I-Premise
374	)	_	_	I-Premise
375	of	_	_	I-Premise
376	1.46	_	_	I-Premise
377	to	_	_	I-Premise
378	9.07	_	_	I-Premise
379	]	_	_	I-Premise
380	,	_	_	I-Premise
381	with	_	_	I-Premise
382	similar	_	_	I-Premise
383	,	_	_	I-Premise
384	though	_	_	I-Premise
385	non-significant	_	_	I-Premise
386	,	_	_	I-Premise
387	trends	_	_	I-Premise
388	in	_	_	I-Premise
389	insomnia	_	_	I-Premise
390	.	_	_	I-Premise

391	No	_	_	B-Premise
392	significant	_	_	I-Premise
393	difference	_	_	I-Premise
394	was	_	_	I-Premise
395	found	_	_	I-Premise
396	in	_	_	I-Premise
397	the	_	_	I-Premise
398	overall	_	_	I-Premise
399	quality	_	_	I-Premise
400	of	_	_	I-Premise
401	life	_	_	I-Premise
402	measure	_	_	I-Premise
403	,	_	_	I-Premise
404	with	_	_	I-Premise
405	the	_	_	I-Premise
406	no	_	_	I-Premise
407	RT	_	_	I-Premise
408	group	_	_	I-Premise
409	having	_	_	I-Premise
410	0.36	_	_	I-Premise
411	units	_	_	I-Premise
412	greater	_	_	I-Premise
413	quality	_	_	I-Premise
414	of	_	_	I-Premise
415	life	_	_	I-Premise
416	than	_	_	I-Premise
417	the	_	_	I-Premise
418	RT	_	_	I-Premise
419	group	_	_	I-Premise
420	(	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	-5.09	_	_	I-Premise
425	to	_	_	I-Premise
426	5.81	_	_	I-Premise
427	)	_	_	I-Premise
428	.	_	_	I-Premise

429	Breast	_	_	B-Claim
430	RT	_	_	I-Claim
431	is	_	_	I-Claim
432	tolerated	_	_	I-Claim
433	well	_	_	I-Claim
434	by	_	_	I-Claim
435	most	_	_	I-Claim
436	older	_	_	I-Claim
437	breast	_	_	I-Claim
438	cancer	_	_	I-Claim
439	patients	_	_	I-Claim
440	without	_	_	I-Claim
441	impairing	_	_	I-Claim
442	their	_	_	I-Claim
443	overall	_	_	I-Claim
444	health-related	_	_	I-Claim
445	quality	_	_	I-Claim
446	of	_	_	I-Claim
447	life	_	_	I-Claim
448	(	_	_	I-Claim
449	HRQoL	_	_	I-Claim
450	)	_	_	I-Claim
451	.	_	_	I-Claim

452	Although	_	_	O
453	HRQoL	_	_	O
454	should	_	_	O
455	always	_	_	O
456	be	_	_	O
457	taken	_	_	O
458	into	_	_	O
459	account	_	_	O
460	when	_	_	O
461	determining	_	_	O
462	treatment	_	_	O
463	,	_	_	O
464	our	_	_	B-Claim
465	results	_	_	I-Claim
466	show	_	_	I-Claim
467	that	_	_	I-Claim
468	the	_	_	I-Claim
469	addition	_	_	I-Claim
470	of	_	_	I-Claim
471	RT	_	_	I-Claim
472	does	_	_	I-Claim
473	not	_	_	I-Claim
474	impair	_	_	I-Claim
475	overall	_	_	I-Claim
476	quality	_	_	I-Claim
477	of	_	_	I-Claim
478	life	_	_	I-Claim
479	.	_	_	I-Claim

480	Further	_	_	B-Claim
481	economic	_	_	I-Claim
482	modelling	_	_	I-Claim
483	on	_	_	I-Claim
484	the	_	_	I-Claim
485	longer-term	_	_	I-Claim
486	costs	_	_	I-Claim
487	and	_	_	I-Claim
488	consequences	_	_	I-Claim
489	of	_	_	I-Claim
490	omitting	_	_	I-Claim
491	RT	_	_	I-Claim
492	is	_	_	I-Claim
493	required	_	_	I-Claim
494	.	_	_	I-Claim

